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In the context of an ageing global population, dementia poses a significant public 
health challenge. While there is no cure, understanding the risks for dementia and 
how these may be minimised is key to reducing the impact of the disease. As life 
expectancy improves, increasing proportions of the population are expected to 
survive into advanced old age. As such, understanding the risks for dementia in the 
oldest-old and how these may differ from earlier old age is of increasing importance. 
The existing literature specific to the oldest-old is lower in volume and many of the 
findings are inconsistent. 
The first two chapters provide a background to the thesis such that the reader may 
understand the context for the subsequent studies. The first of these chapters 
provides an overview of dementia, focussing on the impact of the disease and the 
requirement for further research. The concept of the oldest-old age group is 
described, along with a discussion regarding the complexities associated with 
studying those in advanced old age. The potential impact of diverse and complex 
health and disease profiles in this sector of the population are introduced. The thesis 
objectives are introduced within the text and summarised at the close of the chapter. 
The second chapter introduces the study cohort on which all of the studies included 
in the thesis are based – the Lothian Birth Cohort 1921 (LBC1921).  
The present thesis had three primary objectives. The first was to determine incident 
cases of dementia in a study cohort of oldest-old participants: the LBC1921. Dementia 
cases in this cohort were ascertained using existing data primarily and the dementia 
ascertainment method was developed following a systematic review of such 
methodology within the literature. While no ‘gold standard’ method was found, the 
evidence on which the methodology for this thesis was developed is presented and 
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discussed. Using this method, 22.5% of the n=489 eligible participants were found to 
have developed dementia during the follow-up period. Comparing these results with 
‘expected’ dementia rates in the cohort, the ascertainment method was determined 
to be relatively effective. 
The second objective of this thesis was to investigate potential risk factors for 
dementia in oldest age, with a focus on those that would be considered modifiable. 
The first study of risk factors considered a range of potentially modifiable health and 
lifestyle factors including hypertension, diabetes, obesity, smoking, 
hypercholesterolaemia and physical activity. The most well documented genetic risk 
factor for Alzheimer’s disease – APOE ɛ4 – was also included in the analyses. 
Contrary to other studies of dementia in the oldest-old, the presented study found that 
carrying at least one APOE ɛ4 allele continued to be a statistically significant risk 
factor for dementia in those aged over 79 years (OR: 2.23; 95% CI: 1.29, 3.86). A 
history of hypertension was shown to decrease the risk for incident dementia after 
age 79 years (OR: 0.47, 95% CI: 0.23, 0.98). This is a similar pattern to that described 
within the literature on the oldest-old but differs in direction from the association 
observed in earlier old age. The results also indicated an increased risk for dementia 
with greater lifetime leisure-based physical activity (OR: 1.17, 95% CI: 1.04, 1.32). 
This finding was again contradictory to the findings of studies of dementia in earlier 
old age. A history of statin-use was also observed to increase risk for dementia (OR: 
3.39, 95% CI: 1.04, 11.02), while increased height reduced the risk for dementia (OR: 
0.72, 95% CI: 0.55, 0.95). Overall, the findings suggested that the risk factor profile 
for dementia in the oldest-old, as observed in the LBC1921, differs from the risk factor 
profile in earlier old age. The second study of risk factors examined the association 
between physical fitness and dementia. The published study presented within the 
chapter considered three specific measures of fitness in oldest age: grip strength, 
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walking speed and lung function (FEV1). These analyses did not demonstrate an 
association between any of the fitness measures at age 79 years and subsequent 
dementia; FEV1 (HR per unit increase 1.30, p = 0.37), grip strength (HR 0.98, 
p = 0.35), walking speed (HR 0.99, p = 0.90). The findings were again different to 
those described in studies of younger participants and supported the possibility of a 
changed risk factor profile for dementia in oldest-age. The final study of risk factors 
considered whether DNA methylation-based measures of accelerated ageing may be 
associated with dementia risk. Such measures of accelerated ageing may be 
considered, in simplest terms, as whether someone’s ‘biological age’ is more 
advanced than their chronological age. The results did not demonstrate any 
consistent association between recognised age acceleration measures and 
dementia.   
The third objective of the thesis was to revisit previous studies of non-pathological 
cognitive ageing in the LBC1921 and determine whether previously unidentified cases 
of dementia had influenced the findings. The study looked at five previous studies, 
and four factors reported to be associated with poorer cognitive ageing: smoking, 
APOE ɛ4, reduced fitness and lower vitamin B12. After excluding those participants 
who had gone on to develop dementia, the analyses were repeated. The overall 
findings were unchanged from the original studies, with all four factors continuing to 
be associated with poorer cognitive ageing (p<0.05).  
The final chapter of the thesis provides an overview and summary of the findings from 
the included studies. The general limitations, with regard to methodology and the 





Dementia is, without question, a devastating disease. It has a profound effect on the 
individual, their family and friends, and society. It is a disease that is associated with 
ageing, and as the number of people surviving to old age increases across the world, 
the impact of the disease will be considerable. There is no cure currently available for 
dementia and the available treatments do not work for everyone. It is therefore vitally 
important to identify any factors that may increase or decrease one’s risk of 
developing dementia. It is possible that the risk factors for dementia are different, 
depending on a person’s age. Within the field of dementia research, there is less 
known about the very oldest in the population. The limited number of studies probably 
reflects the difficulties in recruitment and retention of study participants in this oldest 
age group. The study of the oldest-old age group is complex for additional reasons. 
Those in advanced old age are more likely to have accrued a number of health 
conditions or diseases. Similarly, the longer one lives, the greater the possibility of 
being exposed to external factors that might affect health and wellness. The result is 
that the health and disease profile of this sector of the population is complex and 
diverse. There is also the potential for significant overlap between features of health 
conditions and risk factors of interest, making the study of such risk factors in this age 
group more complicated. Given the improvements in health and social care, life 
expectancy is improved and as a result a larger proportion of the population is 
surviving to advanced old age. Understanding the risks for disease in this age-group 
has therefore grown in importance. The focus of this thesis was therefore to examine 
risk factors for developing dementia after age 79 years of age. All of the studies 
included in this thesis described the same group of people, a study group called the 
Lothian Birth Cohort 1921 (LBC1921). The participants were all born in 1921, live(d) 
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in the Lothian area of South-East Scotland and were enrolled in the study at age 79 
years. 
This thesis had three aims. The first was to identify those people within the study 
cohort who went on to develop dementia after enrolling in the study – incident cases 
of dementia. Existing studies were collected and reviewed in order to design a method 
for identifying dementia cases in the cohort. Using this method, it was discovered that 
22.5% of those who were included in the study went on to develop dementia. A 
thorough examination of the findings suggested that the method was suitably 
effective, and the results could be used to investigate the risk factors for dementia in 
this cohort.   
The second aim of the thesis was to investigate whether any risk factors for 
developing dementia after age 79 years could be identified; by comparing those who 
developed dementia with those who did not, several factors were investigated. The 
first study of risk factors demonstrated that a well-recognised genetic risk factor for 
dementia (APOE ɛ4) in earlier old age continued to be a risk factor for dementia in 
oldest age. The same study investigated several health and lifestyle factors that have 
been shown to be important risk factors for dementia in earlier old age and found that 
a history of high blood pressure and increased height both reduced one’s risk for 
dementia after age 79 years, while increased levels of physical activity across 
adulthood and use of cholesterol-lowering drugs (statins) both increased risk for 
dementia. All of the findings from this study suggested that the risk factor profile for 
dementia in oldest-age differs from that in early old age. Some of the findings support 
the findings of other study groups, but others do not. These differences reinforce the 
importance of further study of dementia in this age group, so that a more conclusive 
picture can be drawn. The second study of risk factors examined physical fitness in 
more detail; whether physical fitness at age 79 years affects one’s risk for developing 
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dementia. Fitness is an important target for intervention and as such it is of clear value 
to understand its role in dementia risk. The study considered three measures of fitness 
– grip strength, lung function and walking speed – but found that none were related 
to dementia risk. These findings would suggest that while physical activity promotion 
may improve other aspects of health, it would have little effect on dementia risk in this 
age-group. The third risk factor study considered epigenetic age acceleration. 
Epigenetic age may be thought of as a biological age – put simply, epigenetic age 
acceleration is a measure of whether one’s body is ageing better or worse than one’s 
actual age. This study investigated whether those who were ageing better (had a 
lower epigenetic age when compared with chronological age) were at a lower risk of 
developing dementia. Once again, the results suggested that there was no clear link 
between epigenetic measures of age acceleration and dementia.  
The final aim of this thesis was to use the identified cases of dementia to re-examine 
the findings of previous studies of the Lothian Birth Cohort 1921. The cohort had 
originally been set up to investigate differences in ‘normal’ cognitive ageing – how 
different people’s thinking and memory change with age, when there is no disease 
affecting the same (no dementia, for example). Several factors had been identified as 
risk factors for poorer normal cognitive ageing, but without knowing who went on to 
develop dementia it had not previously been possible to rule out that these findings 
were simply risk factors for dementia cases that had not yet been detected. The study 
looked at five previous studies, and four factors that were linked to less successful 
cognitive ageing: smoking, APOE ɛ4, reduced fitness and lower vitamin B12. When 
the studies were repeated – without those subjects who had gone on to develop 
dementia – the previous findings were unchanged. This showed that the original 
findings were likely to be correct and hadn’t been affected by unidentified early cases 
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1: Introduction: What is dementia? 
1.1  Introduction to the chapter 
The aim of this introductory chapter is to provide an overview of dementia such that 
the reader can understand the basis and context for the research questions posed in 
this thesis. The chapter therefore opens with a definition of dementia and an overview 
of the dementia statistics for the United Kingdom (UK). Whilst global dementia 
statistics are considered later in the chapter, it is important to outline the statistics for 
the country in which the examined study cohort is based. In doing so, the dementia 
statistics for the study cohort can be compared and contrasted with the population 
from which the participants are sampled, with any notable differences given 
appropriate consideration. By reflecting on such differences, one might make 
reasonable suggestions as to the relevance of the findings to the wider population. 
To provide a person-centred context to the introduction, the impact of dementia 
across the population hierarchy is explored – from the individual to society. 
Appreciating the impact of dementia is central to understanding why prevention, 
management and treatment are important, and necessary. If one considers the 
positive effect such strategies could have – on a personal and population level – one 
can acknowledge the requirement and justification for further research aimed at 
advancing knowledge and evidence in this field. The subsequent section of the 
introduction examines the scale of the challenge that addressing dementia poses 
across the world and explores the avenues by which the challenge may be 
approached. Included within this section is a general discussion regarding the role of 
ongoing dementia research. The current diagnostic methods for dementia are then 
outlined, along with a discussion regarding dementia within the spectrum of cognitive 
decline. This is an important consideration if one is to appreciate the potential 
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limitations of current dementia ascertainment methodology, including the possibility 
of misclassification. Not only is this relevant in dementia research, but also in the 
study of non-pathological cognitive ageing. Finally, the concept of the oldest-old age 
group is introduced and the complexities of studying this section of the population are 
discussed.  
Across the chapter, the research questions considered in this thesis are introduced. 
Each of the final study questions aimed not only to provide research relevant to this 
thesis, but also to have value within the wider literature and the field of dementia 
research. The context of each study question within the literature will be considered 
within the individual study chapters. The chapter closes with a specific list of research 
objectives.  
1.2  Dementia: an overview 
1.2.1  Dementia: a definition and overview 
The term dementia does not refer to a specific disease but is an umbrella term that 
describes a collection of symptoms, caused by a number of neurodegenerative and 
cerebrovascular conditions.(Alzheimer's Association Report, 2020) The most 
common of these conditions is Alzheimer’s disease, which accounts for approximately 
60-80% of dementia cases.(Alzheimer's Association Report, 2020) Other dementia 
subtypes include vascular dementia, dementia of mixed vascular and Alzheimer’s 
aetiology, dementia with Lewy bodies, frontotemporal dementia, Parkinson’s disease 
dementia and others. This thesis will consider all-cause dementia, i.e. it would not 
focus on any individual dementia subtype or aetiology. Dementia is characterised by 
a chronic or progressive cognitive decline that is of sufficient severity that activities of 
daily living are impaired. Whilst memory impairment is the most recognised cognitive 
deficit, other cognitive domains – such as attention, orientation, judgement, language, 
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abstract thinking and executive function – are often also affected. Depending on the 
type of dementia, changes in social behaviours may also be a prominent feature. 
Dementia is not limited to older persons, but the vast majority of cases arise in those 
aged over 65 years.  
1.2.2  Incidence and prevalence of dementia in the UK 
1.2.2.1 Overall incidence and prevalence 
Based on evidence from a large UK study of dementia incidence –  the Medical 
Research Council Cognitive Function and Ageing Study (MRC CFAS) II – it has been 
estimated that 209,600 people aged over 65 would be expected to develop dementia 
in the UK each year.(Matthews et al., 2016) This number is to equivalent one new 
case of dementia every 3 minutes in the UK alone.(Matthews et al., 2016) 
An estimated 850,000 people were living with dementia in the UK in 2015, a number 
that equated to 1.3% of the total population, one in seventy-nine of the total population 
or one in fourteen of those aged over 65 years.(Prince et al., 2014) The percentage 
of the population living with dementia varies between different regions. In Scotland, 
the NHS Health Board with the highest proportion of the population living with 
dementia is NHS Western Isles (1.13 per 100 population), while in NHS Lothian – 
where our study cohort is based – rates are lower (0.75 per 100 population); dementia 
rates in NHS Lothian are close to those recorded for NHS Scotland as a whole (0.77 
per 100 population).(Public Health Scotland, 2020) Prevalence rates are likely to 
correlate with the age profile of a region; those regions with the most older people 
would be expected to be those with the higher prevalence of dementia. Differences in 
dementia rates are likely to reflect not only the age distribution within a geographical 
area, but also the proportion of people with dementia that have a formal diagnosis 
within each area. Despite improvements, relatively high rates of undiagnosed 
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dementia persist across the UK; the dementia diagnosis rate for the Scotland for the 
has been reported to be 64-67%.(Scottish Government, 2013; Alzheimer's Research 
UK, 2018a). A number of factors may affect the diagnosis rate within a population; 
access to specialist services, public awareness, cultural beliefs, contact with health 
services, local interest of clinicians, and support or isolation in the community may all 
affect whether cognitive change is detected, reported and diagnosed. 
1.2.2.2 Incidence and prevalence by age group and sex 
The estimated prevalence of late-onset dementia, in the UK, increases for each five-
year age group, from 60-64 years (0.9%) to 90-94 years (29.9%), and even further in 
those aged over 95 years (41.1%).(Prince et al., 2014) These estimates – produced 
for the Alzheimer’s Society Dementia UK Update – are based on the outcome of an 
Expert Delphi Consensus, with access to the available literature.(Prince et al., 2014) 
The overall age-standardised prevalence determined by the consensus (7.1%) lay 
between those found by the MRC CFAS I study (7.5%) and the MRC CFAS II study 
(6.4%).(Prince et al., 2014) The pattern of exponentially increasing prevalence with 
increasing age observed within UK-based studies is consistent with that described in 
larger European and global studies.(Perera et al., 2018) In the UK, the estimated 
prevalence was higher for women than men for every age group over 75 years: 75-
79 years, 6.6% for women, 5.3% for men; 80-84 years, 11.7% for women, 10.3% for 
men; 85-89 years, 20.2% for women, 15.1% for men; 90-94 years, 33% for women, 
22.6% for men; 95+ years, 44.2% for women, 28.8% for men.(Prince et al., 2014) 
From age 60 to 74 years, the prevalence was similar for both sexes.(Prince et al., 
2014) It is likely that the greater life expectancy in women translates to a higher 
prevalence of dementia in the oldest age groups.  
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Despite the increasing mortality associated with advancing age, MRC CFAS II has 
demonstrated that, in the UK, more than 40,000 incident cases arise annually in each 
age group over 80 years, reflecting the increasing incidence rates associated with 
increasing age.(Matthews et al., 2016) The same study reported higher incidence in 
women aged over 65 years, with approximately 135,000 cases occurring in the UK 
each year, compared with 74,000 cases per year in men aged over 65 
years.(Matthews et al., 2016) 
1.2.2.3 Trends in dementia incidence and prevalence in the UK 
Evidence from population-based studies has suggested that both incidence and 
prevalence of dementia within the UK may be decreasing over time. On comparing 
the findings from the MRC CFAS I and the MRC CFAS II studies, a 20% drop in 
dementia incidence (95% CI: 0-40%) was observed in those aged over 65 
years.(Matthews et al., 2016) In all but one age and sex group (women aged 80 to 84 
years), the incidence rate was lower in the latter MRC CFAS II study.(Matthews et al., 
2016) The overall reduction in incidence was however shown to be driven by a larger 
reduction in incidence in men, across all age groups.(Matthews et al., 2016) In 2020, 
the Alzheimer Cohorts Consortium produced a paper that reported that the incidence 
rate of dementia had declined by 13% (95% CI: 7-19%) per decade between 1988 
and 2015.(Wolters et al., 2020) The analyses were based on the aggregated data 
from seven cohort studies based in Europe and the United States, including the MRC 
CFAS.(Wolters et al., 2020) A reduction in dementia prevalence was also observed 
between MRC CFAS I and MRC CFAS II (OR: 0.7, 95% CI: 0.6-0.9, 
p=0.003).(Matthews et al., 2013) Prevalence estimates for the UK based on MRC 
CFAS II suggested that the number of persons living with dementia was 24% less 
than that which would have been predicted based on MRC CFAS I estimates and 
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population ageing.(Matthews et al., 2013) The reduction in prevalence was driven by 
decreased rates in the non-care setting.(Matthews et al., 2013)  
A number of suggestions have been made as to why dementia incidence and 
prevalence may be stabilising or reducing. Societal changes in early age such as 
improved nutrition, increased levels of education, and improved living conditions are 
likely to have improved physical and mental health in early and middle life.(Matthews 
et al., 2013; Wu et al., 2016) Such improvements may in turn have reduced dementia 
occurrence in later life.(Matthews et al., 2013; Wu et al., 2016) The improvements and 
changes in those mentioned societal factors were often dramatic in the early years of 
those studied in older age due to the impact of war, disease epidemic or famine.(Wu 
et al., 2016) Greater access to and availability of medical treatments across the life 
course for participants in the latter studies is also likely to have had an impact on 
reducing dementia prevalence.(Matthews et al., 2013; Wu et al., 2016) In particular, 
the prevention and treatment of vascular conditions has advanced considerably; as a 
recognised risk factor for dementia, the reduction in vascular disease may have had 
a role in reducing or stabilising dementia prevalence.(Matthews et al., 2013; Wu et 
al., 2016) As highlighted within the Lancet Commission Report 2020, we must 
consider the potential for this trend to reverse in the future as a result of increasing 
obesity, diabetes and physical inactivity within high-income countries.(Livingston et 
al., 2020)  
1.2.2.4 Dementia and mortality 
In England, since 2001, deaths from dementia have doubled in women, and increased 
by 60% in men.(Public Health England, 2017) In Scotland, since 2000, deaths from 
dementia or Alzheimer’s disease have doubled for women, and almost tripled for 
men.(National Records of Scotland, 2017) In 2015, dementia and Alzheimer’s disease 
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was the leading cause of death in women (accounting for 15.3% of deaths) and the 
second most common cause of death in men (accounting for 8.0% of deaths) in 
England.(Public Health England, 2017) In Scotland, deaths from dementia are now 
more frequently recorded than deaths from cerebrovascular disease.(National 
Records of Scotland, 2017) Whilst it is true that the number of deaths attributed to 
other conditions – such as heart disease or stroke – have reduced, deaths from 
dementia are known to have increased and these reductions cannot therefore explain 
why dementia has become a leading cause of death.(National Records of Scotland, 
2017; Public Health England, 2017) The increase in deaths from dementia may be 
attributable to the ageing of the population, but it is likely that increased awareness of 
dementia and increased frequency of diagnosis have also played a role.(Public Health 
England, 2017) 
1.3  What is the impact of dementia? 
The impact of dementia is experienced not only by the individual, but also by carers, 
families, and the wider community. The effects can be physical, psychological, social 
and economic.  
1.3.1  Impact on an individual 
A diagnosis of dementia affects each individual differently. The effects depend on the 
impact that the symptoms have on the person and each individual’s personality and 
situation prior to disease onset. In thinking about the impact on the individual, one 
might consider the potential for dementia to disrupt functionality in each area of a 
person’s life including physical health, psychological health, employment, 




A change in living situation may be necessary as a direct result of the symptoms of 
dementia. As a dementia syndrome increases in severity, a number of safety issues 
may arise meaning that it is no longer appropriate for a person to remain at home. 
Such issues may include wandering or becoming lost, leaving the house unlocked or 
the doors open, unreliable concordance with prescribed medication (including the 
possibility of accidental overdoses), or leaving on household items such as cookers, 
taps, microwaves or irons. There may also be concerns regarding a person with 
dementia’s vulnerability due to their decision-making. Opening their home to 
strangers or agreeing to sign inappropriate contracts may be two such concerns. 
Some of these difficulties may be minimised using simple measures. Ovens can be 
disconnected to prevent unsupervised cooking, medications can be locked away and 
call screening systems can be used to prevent cold-calling. In the UK, a legal 
document termed ‘Lasting Power of Attorney’ (LPA) can be used to appoint another 
person or persons to make finance or welfare decisions on behalf of 
another.(Government of the United Kingdom) The nominated ‘attorney’ is typically a 
family member or close friend.(Government of the United Kingdom) The document 
would come into effect when the person was determined to lack capacity to make 
specific decisions.(Government of the United Kingdom) While the LPA and strategies 
described above are aimed at protecting the person and increasing the time that they 
are able to remain in the home, it is possible that this will be perceived as a loss of 
independence and could be emotionally detrimental. This is just one of a number of 
aspects of dementia that can affect a person’s psychological and emotional wellbeing. 
Symptoms of depression are common in dementia and it can be difficult to diagnose 
a major depressive disorder given the overlap of symptoms. It is not only 
psychological health that can be impacted by a diagnosis of dementia; studies 
indicate that physical health is adversely affected by dementia. For example, a Danish 
study of survival after early-stage breast cancer patients demonstrated an increased 
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risk of death from breast cancer for those with a diagnosis of dementia.(Ewertz, Land, 
Dalton, Cronin-Fenton, & Jensen, 2018) An American study demonstrated that, when 
compared with controls, persons with Alzheimer disease had more co-morbid medical 
conditions, a higher burden of illness, greater costs of healthcare, greater use of 
hospital services and inpatient admissions.(Zhao, Kuo, Weir, Kramer, & Ash, 2008)  
Receiving a diagnosis of dementia is likely to have significant implications regarding 
a person’s ability to continue in employment. While employment is unlikely to be a 
concern for those in oldest-old age, this is likely to have an increased significance in 
early old age in the coming years. Increased retirement age and changes to pensions 
might be expected to lead to an increased number of people working beyond 65 years 
of age, resulting in more people developing dementia while still in employment.  
1.3.2  Impact on friends and family 
A sizeable proportion of the UK population – 24.6 million people or 38% of the total 
population – know a family member or close friend who is living with 
dementia.(Alzheimer's Research UK, 2018b) All of those with a connection to a 
person living with dementia will have a difference experience, but most will experience 
a change in the relationship as a result of the diagnosis. How profound such changes 
are is likely to be dependent on the closeness of the relationship, the severity of the 
impairment and related symptoms and the involvement that a person has in the day-
to-day care and support of the person with dementia. The experience of caring for a 
person with dementia has been shown to differ considerably to caring for a person 
with another condition.(Ory, Hoffman, Yee, Tennstedt, & Schulz, 1999) Dementia 
caregivers spend a greater number of hours providing care and assist with a greater 
number of activities of daily living. Dementia caregivers also report comparatively 
more negative effects including greater caregiver stress, mental health and physical 
10 
 
health problems, and family conflict.(Ory et al., 1999) A study of carers of persons 
aged under 65 years with dementia showed that 59% of those in employment reduced 
their hours or left employment after the diagnosis.(Luscombe, Brodaty, & Freeth, 
1998) With reducing income, it is not surprising that most participants of this study 
(89%) also reported financial difficulties after diagnosis.(Luscombe et al., 1998) 
Caregiver stress or strain is increased by the presence of certain behavioural and 
psychological symptoms of dementia. Symptoms such as wandering may require 
closer supervision while other symptoms, including disinhibition and aggression may 
be more difficult to manage – both physically and emotionally. Apathy, depression 
and anxiety are also likely to place emotional strain on the caregivers. Furthermore, 
one cannot underestimate the potential physical and psychological fatigue that may 
arise from the close monitoring that might be required to provide care and prevent 
harm or accident.   
The strain on a caregiver and the emotional difficulties of watching a loved one in the 
final stages of dementia is illustrated by a US study that showed 72% of carers felt 
relief following the death of the patient, and over 90% believed that death would be a 
relief for the patient.(Schulz  et al., 2003) In the same study, carer symptoms of 
depression were shown to decrease significantly within three months of the 
death.(Schulz  et al., 2003) It is not only those with a carer’s role who are affected by 
the diagnosis of dementia. Whilst the practical difficulties such as finances and 
employment may be less significant, emotional and psychological difficulties will 
remain. The person with dementia will usually have multiple roles within their social 
network, such as partner, parent, sibling, child, friend or colleague. The reciprocity in 
these relationships will likely decrease as the disease progresses and, as a result, 
each of these relationships will be changed.(Millenaar et al., 2016) While a friend 
might grieve the gradual loss of a friendship, a partner will find it increasingly difficult 
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to keep the person with dementia involved, becoming solely responsible for all major 
life decisions.(Millenaar et al., 2016) As the dementia process advances, changes in 
the reciprocity of a relationship can result in carers experiencing loneliness.  
1.3.3  Impact on society 
The financial impact of dementia on society is considerable, with a total cost in the 
UK of £26.3 billion, or an annual cost of £32,250 per person; £4.3 billion is spent on 
healthcare costs, while £10.3 billion is spent on social care costs.(Prince et al., 2014) 
Of the social care costs, £4.5 billion is publicly funded and £5.8 billion is privately 
funded.(Prince et al., 2014) Almost half of the total cost of dementia in the UK - £11.6 
billion – is attributed to the cost of unpaid care. As the general population ages, there 
is likely to be increased pressure on hospitals, emergency departments and 
ambulance services. Those with dementia have been shown to utilise such services 
more frequently than those without dementia, after adjusting for comorbidities, 
resulting in even further strain on services.(Voss et al., 2017) Increased pressures on 
services such as housing – specialist care homes in particular, home support 
services, community healthcare services and day care services – would also be 
expected. Aside from the monetary implications, increasing the capacity of such 
services will also depend on the availability of adequately trained staff, hospital 
transport systems and the potential for increasing space within appropriate building 
structures.  
1.3.4  Public perception 
A research poll conducted by YouGov has revealed that more people are concerned 
about developing dementia than cancer.(YouGov UK, 2017) Dementia was the most 
feared condition with 38% naming it as their biggest fear. A second poll – carried out 
by Alzheimer’s Research UK – reported that 42% of participants agreed that dementia 
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was the condition that they most feared getting in the future.(Stevens, 2018) The 
public concern regarding dementia is evidenced by the prominence of the condition 
within media. Striking headlines include “The dementia timebomb” (BBC: Science, 
2014), “Study shows dementia is biggest killer in affluent areas” (BBC News: Wales, 
2017) and “The nine lifestyle changes that could save you from dementia” (The 
Telegraph: Knapton, 2017). The use of emotive language, such as “save you”, “killer” 
or “timebomb”, reflects the way in which dementia is often perceived and discussed 
within society. The media also highlights the potential social problems facing those 
with dementia – such as vulnerability to crime (BBC News: Glasgow & West, 2018) 
and carer abuse (BBC News: Northampton, 2018). In opposition to the negative press 
regarding dementia are the reports describing the positivity and drive of researchers 
and society to make advances in the understanding and treatment of dementia and 
in the care of persons with dementia. It is likely, that by raising the profile of dementia 
through news stories, charitable fundraising, celebrity endorsement of campaigns and 
advertising, awareness of the condition will increase, leading to improved rates of 
presentation and diagnosis.  
1.4  Addressing dementia 
1.4.1  The scale of the challenge within the global population 
As fertility declines and life expectancy increases, the global population is ageing. 
Global projections estimate that the number of people aged over 60 years will have 
increased from 13% of the population (962 million) in 2017 to 22% of the population 
(2.1 billion) in 2050.(United Nations, 2017) In 2017, Europe had the highest 
percentage of population aged over 60 years (25%), but the ‘squaring‘ of the 
population pyramid will continue over the coming decades and by 2050 all major 
areas of the world, save Africa, will have approximately one quarter or more of their 
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population aged over 60 years.(United Nations, 2017) In 2017, the number of persons 
aged over 80 years was 137 million and this number is projected to triple to 425 million 
by 2050.(United Nations, 2017) 
As a disease closely associated with ageing, the number of dementia cases is also 
expected to increase. In 2015, 46.8 million people worldwide were estimated to be 
living with dementia, and the number rose to 50 million by 2018.(Patterson, 2018; 
Prince et al., 2015) This number is expected to reach an estimated 152 million by 
2050.(Patterson, 2018) The number of people living with dementia is highest in Asia 
(22.9 million), followed by Europe (10.5 million), the Americas (9.4 million) and Africa 
(4 million).(Prince et al., 2015) This pattern is the same with regard to 
incidence.(Prince et al., 2015) There were estimated to be almost 10 million new 
cases globally in 2015, the equivalent of one new case every three seconds.(Prince 
et al., 2015) Projected estimates indicate that approximately one in three people 
(32%) born in 2015 will develop dementia in their lifetime.(Lewis, 2015) These 
estimations do not however take into consideration the potential for life expectancy to 
improve further in the future and do not include cases arising before sixty years of 
age; as such, these figures are likely to be an underestimation.(Lewis, 2015) 
Dementia is therefore one of the greatest public health challenges facing the ageing 
global population.  
The monetary cost of providing care and support to those with dementia worldwide in 
2015 was estimated to be US$818 billion, rising to US$1 trillion by 2018, and as 
dementia rates continue to increase, the worldwide costs are expected to reach $2 
trillion by 2030.(Patterson, 2018; Prince et al., 2015) To provide a frame of reference 
for these values, the cost for global dementia care in 2015 was more than the market 
value of Apple and more than double the market value of Google in the same 
year.(Prince et al., 2015) If the cost of global dementia care in 2015 was a country, it 
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would have been the 18
th
 largest in the world.(Prince et al., 2015) It is estimated that 
by 2050, 68% of persons with dementia will live in low or middle-income countries. 
With fewer resources to both provide and fund care in such countries, the impact of 
increasing dementia will only compound the burden of disease among people aged 
over 60 years in low- and middle-income countries, which is already greater than in 
high income countries.(Prince et al., 2015)  
1.4.2  The importance of dementia research 
Currently, dementia is not curable, and the treatments are not universally effective or 
universally tolerated.(Birks, 2006; Lanctôt et al., 2003; Tricco et al., 2018) Dementia 
research is therefore critical in order to develop strategies and treatments that will 
reduce the impact of this condition. Further dementia research may be considered in 
three broad categories: understanding dementia, developing treatments for dementia 
and, caring for those with dementia. Each area of dementia research is vitally 
important, and all are connected. Understanding dementia involves a vast number of 
scientific fields as the disease process is investigated across the system hierarchy. 
As examples, this includes investigating genetics, biomarkers, neuropathology, risk 
factors and environmental effects. The research included in this thesis would fall 
under the category of furthering the understanding of dementia. Further details 
regarding the specific areas of research for this thesis are outlined in the latter 
sections of this introduction. 
The more that is understood about dementia – including aetiology, susceptibility, 
pathophysiology, and the relationship between pathology and symptomology – the 
more accurately and specifically studies can be directed in order to develop 
treatments or establish preventative measures. There is a worldwide push to move 
forward with drug development for dementia and the discovery of any disease-
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modifying drug effective in the treatment of dementia would have an impact on the 
care of those with dementia, either by preventing the onset of new cases or by limiting 
the effect of the disease on those already diagnosed. Since 1998, only four drugs 
have been approved for the treatment of dementia, despite over 100 attempts being 
made to produce an effective drug.(Patterson, 2018) Furthermore, these drugs are 
symptomatic treatments as opposed to disease-modifying agents. Developing a new 
drug involves several stages of research, costing an estimated £1.15 billion and taking 
approximately 12.5 years.(Paul et al., 2010; The Association of the British 
Pharmaceutical Industry, 2018) Only 0.02% of researched new compounds will 
eventually receive licensing approval from a regulatory agency.(The Association of 
the British Pharmaceutical Industry, 2018) Despite the cost and difficulty in bringing 
an effective drug to market, the value and importance of drug discovery in dementia 
is reflected in the fact that the number of clinical trials in Alzheimer’s disease has has 
increased in recent years.(Cummings, Lee, Ritter Sabbagh & Zhong, 2019) Other 
types of research are also of considerable importance in furthering knowledge and 
developing strategies for addressing dementia. For example, through research that 
evaluates care strategies for dementia, resources might be best utilised and the best 
possible experience for the person with dementia might be achieved.  
The scale of the challenge posed by dementia is reflected in the launch of several 
large, collaborative research centres and by the amount of funding required to make 
such centres viable. One such centre is the UK Dementia Research Institute (UK 
DRI), set up using a £250 million investment from the Medical Research Council, 
Alzheimer’s Society and Alzheimer’s Research UK.(Hesse & Henstridge, 2018) The 
UK DRI aims to bring together expertise from various fields in order to advance the 
understanding of how dementia develops and progresses.(Hesse & Henstrideg, 
2018) The primary objective of the institute is to discover novel means by which 
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dementia can be diagnosed, treated and prevented, and to bring these new strategies 
to the clinical domain more quickly.(Hesse & Henstridge, 2018) In 2014, the Medical 
Research Council also set up the £53 million Dementias Platform UK, a private-public 
partnership between universities and drug companies, with the primary aim of 
accelerating progress in dementia research.(Bauermeister et al., 2020) The 
importance of investing in dementia research has been acknowledged by the UK 
Government, with funding doubling between 2012 and 2015, to over £60million per 
year.(Department of Health, 2016) The importance of dementia research is also 
recognised by the wider community. In 2018, Join Dementia Research – a service 
that allows people to register their interest in taking part in dementia research – had 
34,982 volunteers across the UK who had registered interest, and 9,637 volunteers 
who had been enrolled in studies through the service.(Join Dementia Research, 2018)  
1.4.3  Dementia ascertainment 
From this point on, the introduction focuses on topics that are more specifically 
relevant to this thesis. In doing so, the background and rationale for each of the thesis 
objectives are introduced. 
Central to many dementia research studies is the identification of dementia cases. In 
this thesis, the ascertainment of dementia cases within a specific study cohort (the 
Lothian Birth Cohort 1921) would be a crucial first step. It would not only provide a 
measure of dementia incidence for the cohort but would also determine the dementia 
outcomes on which all of our subsequent studies were based. Dementia 
ascertainment in dementia research falls into two broad categories: 1. ascertainment 
for the purposes of selecting a cohort of persons with dementia, and 2. dementia 
ascertainment as an outcome measure of the study. Ascertainment methodologies 
vary depending on the specific requirements of the study. For example, clinical drug 
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trials will often require participants to meet detailed and specific eligibility criteria that 
are best established through clinical evaluation. Similarly, drug trials aimed at 
preventing the development, or progression of dementia are likely to require detailed 
clinical follow up in order to quantify the level of impairment and the potential benefit 
of the drug. While clinical assessment may be considered the gold-standard in 
dementia ascertainment, it is not without limitations. Multiple examiners may interpret 
signs or symptoms differently, resulting in differences in ascertainment.(Martin-Khan 
et al., 2012) Furthermore, different studies are likely to utilise different diagnostic 
criteria or have different requirements for eligibility, making comparisons between 
studies difficult. Clinical dementia ascertainment for each participant in a large study 
would involve considerable time and funding. This is of particular relevance in 
longitudinal studies, or studies across the life course where repeat assessments over 
long periods would be necessary. Studying subjects prior to dementia onset, through 
the life course, is essential for the thorough investigation of risk factors, causation and 
early detection. Prospective longitudinal studies using a clinical ascertainment 
procedure have the disadvantage that the results would only be available a 
considerable time after the commencement of the study.  
One way to reduce the cost and time taken to achieve results is to use existing data. 
Accessing previously recorded data also limits the potential inaccuracies that would 
arise if information were collected using participant or carer recall and allows data to 
be collected for those participants who are lost to follow-up. The value of existing data 
is illustrated by the growing interest in the use of informatics in health research. As 
records become increasingly computer-based, accessing large volumes of linked data 
is ever more feasible. The Farr Institute of Health Informatics Research in the UK was 
established in 2013, with the purpose of enabling safe and secure access to health 
records in order to maximise the use of existing data and enable research on a 
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national scale.(Hemingway et al., 2020)  The Farr institute made significant progress 
in beginning to grow the field of data science in health. The value of such an institute 
was demonstrated by the formation of the Health Data Research UK (HDRUK) 
institute, which became the successor to the Farr institute; the HDR UK was an 
expansion of the previous Farr institute, with additional research centres and longer-
term funding.(Hemingway et al., 2020)  
Existing data can take many forms, including both routinely collected data and data 
collected for the purposes of research. Research data, such as imaging results, may 
include information that can be used for a purpose other than that for which it was 
originally collected. Routinely collected data are not limited to those persons enrolled 
in a study and can therefore offer datasets on a large scale. Examples of such data 
include death certificates – completed for every deceased person in the UK, and 
discharge diagnoses for acute hospital admissions – completed following any 
discharge from an NHS hospital in the UK. Whilst health record data are often 
anonymised for the purposes of research, centres offering data linkage allow more 
than one record – such as General Practice records and hospital records – to be 
supplied for the same person, using an identifying key. 
Existing data were key in performing dementia ascertainment for the study cohort 
included in this thesis. Having been recruited and enrolled in the study several years 
prior to the commencement of any dementia ascertainment procedure, prospective 
clinical assessment of each participant was not possible. However, both routinely 
collected data and research data were available for the purposes of ascertainment 
and subsequent analyses. The first crucial step in achieving the research aims 
addressed within this thesis was the development of a dementia ascertainment 
procedure for the cohort. In order to achieve the most effective possible procedure, 
the methodologies described within the literature were considered along with the data 
19 
 
sources available for use in this study. The first objective of this thesis was therefore 
the investigation and evaluation of dementia ascertainment procedures using existing 
data within the literature; the evidence gathered was then used to guide the 
development of an ascertainment procedure for use in the cohort discussed in this 
thesis. The second objective was to utilise this procedure to perform dementia 
ascertainment for the cohort.  
1.4.4  How dementia might be addressed 
When planning any research, it is important to consider the potential usefulness of 
the proposed study. Findings that could provide some insight into how dementia may 
be addressed might be considered to be most valuable. As such, the objectives within 
this thesis were chosen following careful consideration of their value in providing 
evidence that may be of use in reducing the impact of dementia.    
When considering how to reduce the impact of dementia, it is necessary to outline the 
broad areas that must be addressed. Such areas include prevention, diagnosis, 
treatment, reducing the impact of existing disease, monitoring and reporting. Integral 
to developing preventative strategies is a comprehensive understanding of those 
factors that either increase or decrease the risk for dementia. For this reason, risk 
factors and protective factors associated with dementia are frequently investigated 
within the literature. While such studies have produced a significant body of evidence 
describing the risk factor profile for dementia in older persons, studies describing risk 
factors in the oldest-old are much fewer in number.(Sibbett, Russ, Deary, & Starr, 
2017) It is important to understand whether risk factors for dementia are equally 
relevant across the life-course, such that preventative strategies can be implemented 
in order to achieve optimal effectiveness. The primary aim of this thesis was therefore 
to perform research studies that would provide further evidence to the literature, such 
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that we might further our understanding of dementia in the oldest-old. A more 
comprehensive overview of the concept of the ‘oldest-old’ age group is provided in 
section 1.5. The included studies focus on the investigation of risk factors for dementia 
in a specific cohort of participants aged over 79 years at baseline; the cohort is 
introduced in Chapter 2. Here, we outline the types of risk factor that are considered 
within this thesis, in order for that the reader may appreciate the rationale for our 
selections.  
Risk factors and protective factors may be subdivided into those with a genetic basis, 
and those that might be considered to be environmental or lifestyle factors. Genetic 
factors are recognised to play an important role in dementia and a number of genetic 
factors have been proposed as being associated with risk for developing the 
condition. Genetic factors may be genetic variants or genetic mutations. Specific 
mutations in the amyloid precursor protein (APP), presenilin 1 and presenilin 2 genes 
result in a relatively rare autosomal dominant early onset dementia, termed familial 
Alzheimer’s dementia. The more common late onset Alzheimer’s dementia is not a 
genetic disease, but genetic factors have been shown to play a significant role. The 
most consistently reported genetic variant is Apolipoprotein E (APOE). The APOE ɛ4 
allele has been shown to be associated with an increased risk for Alzheimer’s disease, 
while the APOE ɛ2 allele is associated with a decreased risk. As a genetic risk factor, 
as opposed to a disease-causing mutation, the presence of an APOE ɛ4 allele does 
not reliably predict dementia and similarly, the absence of the allele does not eliminate 
the possibility of dementia. While APOE ɛ4 is widely accepted to be a risk factor for 
dementia in those aged over 65 years, its importance as a risk factor in those in very 
oldest-age has been challenged.(Corrada, Paganini-Hill, Berlau, & Kawas, 2013) The 
third objective of this thesis was to evaluate the role of APOE ɛ4 in the development 
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of dementia in our study cohort; thus adding to the evidence for this risk factor in 
oldest-age.  
An environmental factor may be defined as an identifiable element in a subject’s 
environment that influences the survival, function, regulation or growth of that subject; 
and in this instance, one that affects the likelihood of developing dementia. Factors 
can include: 
• elements within the geographical environment – such as pollutants or 
occupational toxins, 
• physical health factors – such as health diagnoses, medications, or 
physiological measures, and 
• lifestyle measures – such as alcohol intake, smoking status, body mass index 
and participation in physical exercise.  
Many such risk factors may be deemed modifiable and are therefore of considerable 
interest regarding the potential for risk reduction in dementia. A considerable number 
of studies have investigated potentially modifiable risk factors for dementia, but fewer 
studies have looked specifically at the oldest-old. Investigating potentially modifiable 
risk factors for dementia, and how these may differ in advanced old-age, is the primary 
focus of this thesis. The fourth objective of this thesis was to explore the associations 
between previously reported modifiable risk factors and dementia, in our study cohort 
of the oldest-old. The potentially modifiable risk factors for dementia selected for 
inclusion were based on current evidence within the literature, and this is discussed 
in the fourth chapter of the thesis.  
Within those risk factors considered to be modifiable, some are more readily 
modifiable. For example, lifestyle factors such as fitness and body weight can be 
targeted with relatively simple measures. Furthermore, given the recognised 
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association between physical fitness and medical diagnoses such as hypertension 
and diabetes (Shook et al., 2012), targeting fitness could reduce any impact of such 
conditions on dementia rates. The fifth objective of this thesis was to explore in further 
detail, the association between specific fitness measures and the risk for incident 
dementia in oldest age.    
While several risk factors have been proposed as having a role in dementia, there is 
no known single factor, or combination of factors that can accurately predict which 
persons in the population will go on to develop dementia. It is therefore likely that the 
aetiology of dementia involves a complex interaction between multiple factors, both 
genetic and environmental. Of particular research interest is the investigation of how 
environmental factors and genetic factors may be linked in dementia pathogenesis. 
Epigenetics is the study of changes in the phenotype that result from alterations in 
gene expression rather than alterations in the genetic code. Epigenetic modifications 
provide a means by which environmental factors can influence the development of 
dementia in persons who inherit the same genetic variants; as such, epigenetics may 
be thought of as a bridge between genetics and environment.(Foraker et al., 2015) 
One might therefore consider epigenetics to be the manner by which one could alter 
gene expression by making a change to one’s environment – hence changing one’s 
‘fixed’ genetics to a potentially modifiable risk factor.  The two most commonly studied 
epigenetic markers are DNA methylation and histone modification. DNA methylation 
results from the addition of a methyl group to the DNA molecule, often at a cytosine 
nucleotide that is adjacent to a guanine base (CpG dinucleotides). DNA methylation 
results in the activation, or more typically the repression of gene transcription.(Wen 
et al., 2016) Post-translational histone modifications can include the methylation and 
acetylation of lysine or arginine groups. The resulting changes in chromatin structure 
give rise to the observed alterations in gene expression.(Wen et al., 2016) 
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Previous studies have explored the potential for using measures of DNA methylation 
to predict age, and originally, the most consistently reported were those published by 
Hannum and Horvath in 2013.(Hannum et al., 2013; Horvath, 2013) The resulting 
estimates of age have been suggested to reflect one’s biological age. Hannum 
described a method, based on a single cohort, by which age could be predicted based 
on measures of DNA methylation within whole blood; Horvath described a predictor 
of age based on measures of DNA methylation from several studies and multiple 
tissue types.(Hannum et al., 2013; Horvath, 2013; Marioni, Shah, McRae, Chen, et 
al., 2015) From these two ‘epigenetic clock’ measures, two measures of age 
acceleration have been described: extrinsic epigenetic age acceleration (EEAA) and 
intrinsic epigenetic age acceleration (IEAA).(Chen et al., 2016; Dugué et al., 2017) 
IEAA was based on Horvath’s estimate of epigenetic age and estimates epigenetic 
ageing effects that are not influenced by differences in blood cell counts; EEAA was 
based on an epigenetic age calculated using the method described by Hannum and 
captured both intrinsic changes in methylation and extracellular blood cell composition 
changes.(Chen et al., 2016)  
More recently, two novel DNA methylation-based measures of epigenetic age have 
been described: DNAm PhenoAge and DNAm GrimAge.(Levine et al., 2018; Lu et al., 
2019) DNAm PhenoAge was developed by using “phenotypic age” as a reference, 
rather than chronological age, and was produced by regressing a phenotypic measure 
of mortality risk on CpGs.(Levine et al., 2018)  DNAm GrimAge was developed by 
regressing time-to-death on DNA methylation-based biomarkers of mortality and 
morbidity (including several plasma proteins and smoking pack-years), producing a 
single composite biomarker of lifespan.(Lu et al., 2019) The observed discrepancies 
between chronological age and methylation-predicted age have been proposed as a 
potential explanation for the variability in risk for age-related diseases and 
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mortality.(Marioni, Shah, McRae, Chen, et al., 2015) Studies have provided evidence 
in support of this hypothesis: Marioni et al. concluded that measures of accelerated 
ageing, based on DNA methylation, can predict all-cause mortality after accounting 
for genetic, health and lifestyle factors (Marioni, Shah, McRae, Chen, et al., 2015), 
while Dugué et al. – using a pooled analysis of seven studies – demonstrated an 
association between DNA methylation-derived measures of accelerated ageing and 
increased cancer risk, after adjusting for relevant risk factors.(Dugué et al., 2017)  
Given the importance of dementia as an age-related disease, the sixth objective of 
this thesis was to consider the association between DNA methylation–derived 
measures of accelerated aging and incident dementia, and determine whether this 
may be a valuable predictor of risk. If increased age acceleration was found to be 
associated with an increased risk for dementia, one might suggest that by discovering 
the underlying causes for age acceleration, risk for dementia could be reduced via 
targeted interventions.  
1.4.5  Distinguishing dementia within the spectrum of cognitive decline 
This topic is of particular relevance with regard to the study cohort on which all of the 
research included in this thesis is based. As a study cohort that was originally 
recruited to investigate non-pathological decline, dementia outcomes were not 
available until dementia ascertainment was completed for this thesis. As such, early 
studies were unable to exclude the possibility that preclinical or prodromal dementia 
was mistaken for ‘normal’ cognitive ageing and had influenced the findings.   
Differentiating dementia from other types of cognitive decline is essential in dementia 
research to avoid erroneous conclusions. While this is a simple statement, the reality 
of achieving the same is more complex. Dementia exists within a spectrum of 
cognitive decline and differentiating dementia from other types of cognitive decline 
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can be difficult. This has implications for both dementia research and research into 
other types of age-related cognitive decline.  
Current diagnostic techniques for dementia are based on the observation of clinical 
symptoms, which are typically compared with a set of well-recognised criteria. The 
most recognised of these criteria are those described in the Diagnostic and Statistical 
Manual of Mental Disorders (DSM), published by the American Psychiatric 
Association (APA) and those described in the International Classification of Diseases 
(ICD), published by the World Health Organisation (WHO). These classification 
manuals have been revised several times since their inception, with the DSM and ICD 
now in their fifth and eleventh revisions, respectively. Each of these classification 
systems relies on a patient reaching a threshold, at which point a diagnosis of 
dementia can be made. This threshold typically corresponds to a decline in cognitive 
function with associated decline in functionality such that activities of daily living are 
impaired. In most cases – such as in the presence of Alzheimer’s disease – the patient 
will not reach this threshold in a sudden or abrupt manner, but rather, cognitive 
function and general functionality will follow a more gradual downward trajectory. Prior 
to reaching the severity of the disease warranted for a clear diagnosis a degree of 
impairment is likely to be present. In this earlier phase, it is not always clear whether 
such a cognitive impairment will advance to the point where a diagnosis of dementia 
is made, or whether subtle cognitive changes will persist or even reverse.  
Further to this, studies have indicated that the pathogenesis of Alzheimer’s disease 
may begin long before any symptoms become clinically apparent. The concept of a 
‘preclinical’ phase in dementia is described within the literature and is widely 
accepted.(Nitrini, 2010; Sperling et al., 2011) The term preclinical dementia describes 
the earliest period of the dementia process, where underlying pathological changes 
are present, but symptoms are either completely absent or are not of sufficient 
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severity ever to meet recognised criteria for mild cognitive impairment (MCI). In simple 
terms, cognitive function would be indistinguishable from normal variation or expected 
cognitive ageing. Studies have suggested that the period between the onset of 
pathological change and clinically identifiable symptoms could be as long as a 
decade, or even more.(Dubois et al., 2016; Sperling et al., 2011) While studies have 
shown early pathological changes in those who went on to develop dementia, as a 
result of death before dementia it is less clear whether these early changes will always 
lead to a clinical syndrome of dementia in the absence of death. Neuropathological 
studies have demonstrated dementia-type changes in the post-mortem brains of 
individuals who did not display clinically detectable cognitive impairment prior to 
death, but it is impossible to know whether these persons would have developed 
clinical dementia if they had lived longer.(Sperling et al., 2011) Another study has 
demonstrated that the proportion of study subjects without dementia with evidence of 
amyloid plaque build-up in the brain (one of the neuropathological changes 
associated with Alzheimer’s disease) resembles the proportion diagnosed with 
dementia a decade later.(Sperling et al., 2011) One might hypothesize that such 
studies could be evidence for the preclinical phase of dementia. It is also possible, 
however, that these pathological changes are necessary, but not sufficient on their 
own to produce the clinical syndrome of dementia.(Sperling et al., 2011) Other factors 
– such as cognitive reserve or environmental exposures – may influence or reduce 
susceptibility or may alter the time taken for the emergence of clinical 
symptoms.(Sperling et al., 2011) 
Disappointing results from clinical trials for dementia drugs may indicate that by the 
time the clinical symptoms are identifiable, the pathological process is too far 
advanced for therapeutic intervention.(Nitrini, 2010) The preclinical phase of the 
dementia process has been identified as a potentially crucial period for intervention 
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and is therefore of considerable interest to researchers.(Nitrini, 2010; Sperling et al., 
2011) If a single marker were identified to have a firm connection with the 
development of clinical dementia, this would be a clear target for intervention, either 
directly or indirectly as an identifier for those persons who may benefit from other 
interventions. It would also be a valuable tool in selecting participants for studies of 
non-pathological cognitive ageing, limiting the potential influence of incipient 
dementia on findings.  
While autopsy studies are informative with regard to early pathological changes in the 
brain tissue, in vivo markers of preclinical dementia would be required to identify 
susceptible patients clinically and target interventions. Identifying such a marker 
would have the additional advantage in research studies of being able to identify those 
persons who would have gone on to develop dementia when death occurs before 
criteria for a clinical diagnosis were met. Imaging techniques such as positron 
emission tomography (PET) and studies of cerebrospinal fluid (CSF) have shown 
promising results with regard to identifying in vivo markers for preclinical 
dementia.(Dubois et al., 2016; Mak et al., 2017; Sperling et al., 2011) A proposed 
hypothetical model suggests that early biomarkers are followed by biomarkers of 
neuronal damage, structural brain changes and finally, clinical symptoms.(Dubois et 
al., 2016) It has been suggested that the preclinical phase of dementia may be 
classified as different states; those who have a developing pathology but remain 
asymptomatic, and those who are asymptomatic but at risk of subsequent 
dementia.(Dubois et al., 2016) Similarly, biomarkers may be divided into those 
representing the presence of pathology at any point in the dementia process, and 
those that represent evidence of consequent damage.(Dubois et al., 2016) While the 
understanding of preclinical dementia has been much advanced in recent years, the 
challenge of identifying the most accurate and effective in vivo marker for dementia 
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pathology, and translating this into practice, remains.(Dubois et al., 2016; Mak et al., 
2017) 
Until there is a recognised and regularly utilised method, with proven reliability, by 
which study participants in the preclinical phase of dementia can be identified, it is 
likely that some such participants will be incorrectly included in studies of non-
pathological cognitive ageing. Such inclusions may have an impact on findings. To 
determine the accuracy of reported results it is vital that the potential impact of 
preclinical dementia is evaluated retrospectively, using follow-up dementia data. A 
number of factors have been demonstrated to be associated with non-pathological 
cognitive aging for the study cohort considered in this thesis. The final component – 
and seventh objective – of this thesis was therefore be to re-examine these results in 
order to establish the potential impact of preclinical dementia on the findings. Details 
of those previous studies are discussed in Chapter 7.    
1.5 The ‘Oldest-Old’ 
1.5.1 Who are the oldest-old? 
For many years, the ‘older age’ or ‘elderly’ population was widely referred to as a 
single homogenous group; those aged 65 years and above. This threshold for 
categorisation likely reflected typical retirement age, with post-retirement being 
considered to be older age.(Kydd, Fleming, Paoletti & Hvalic-Touzery, 2020) Within 
the literature, there has however been increasing interest in the group at the upper 
end of this age-bracket, often referred to as the ‘oldest-old’. The definition of the 
oldest-old group varies within the literature, but is most often described as those aged 
over 80, 85 or 90 years of age.(Bullain & Corrada, 2013; Kydd et al, 2020; Tsoi et al., 
2014) What constitutes oldest-old age is likely to have changed over time given the 
increase in the number of individuals surviving into these older age brackets. In the 
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research setting, past studies may have been limited to studying age groups with 
sufficient numbers of participants; as a result of improvements in life expectancy, 
oldest-old age thresholds may be higher in more recent studies. While the numerical 
threshold is debatable, the concept of there being an earlier old age and a later old 
age is generally accepted.  
Age 80 years and above is frequently used within the literature to denote oldest-old 
age.(Erlangsen, Bille-Brahe & Jeune, 2003; Lucca et al., 2020; Mirkin & Weinberger, 
2001) This perhaps reflects a theoretical halving of older age into 60-80 years and 
80-100 years. While this might be an overly simplistic view – as ageing and age 
related decline is unlikely to be a linear process – there is no clear evidence for 
selecting a particular age ‘cut-off’. Having been recruited to baseline testing at age 79 
years, our study cohort closely resembled the 80+ age group and we therefore reflect 
other studies within the literature and use the term oldest-old within the thesis.  
1.5.2 The complexity of the oldest-old age group 
1.5.2.1 Complex variables 
For many reasons, the study and care of those in this oldest population group can be 
complex.(Melzer et al., 2015; Studenski, 2008) Most persons reaching this age will 
have developed a number of health conditions, creating a complicated picture of 
health within an individual, and producing a diversity across the group.(Tsoi et al., 
2014) Similarly, the longer one’s life the more likely that they have been exposed to 
increasing numbers of external factors that may influence health and wellbeing, 
further complicating the ‘health and disease profile’ of this age group. While the range 
of health and lifestyle factors is likely to vary widely between individuals of this age, 
there may also be significant inter-person variation relating to a single variable. Taking 
diabetes as an example: the ‘back-story’ of a diagnosis of diabetes is likely to differ 
30 
 
significantly from one person to the next. Let us compare Person A, who developed 
type II diabetes at age 40, and maintained satisfactory control of blood sugar without 
the need for medication; Person B who developed type II diabetes at age 75 and had 
periods of poor control despite medication; and Person C who was diagnosed at age 
50 and had significant complications relating to diabetes despite adequate blood 
sugar control. We can see that ‘a history of diabetes’ is not a straightforward binary 
variable, but one that may differ according to the clinical history. Most health variables 
of interest in risk factor studies are likely to be subject to similar complexities and with 
advancing age, such complexities might be expected to increase. In parallel with the 
increased likelihood of multiple chronic and acute illnesses, the likelihood of 
polypharmacy is also increased in oldest-old age.(Tsoi et al., 2014) 
1.5.2.2 Additional complexities 
The sample size in studies of the oldest-old are always going to be more limited than 
those in earlier old age as a result of recruitment challenges in oldest age.(Mody et 
al., 2008) Furthermore, studies are going to be subject to high rates of attrition due to 
illness and death.(Mody et al., 2008) Given the increased potential for hospital 
admission in this age-group, prospective follow up may also be affected by participant 
unavailability during planned testing dates. Participants may also change residence, 
or type of residence as a result of increasing support needs. This has the potential to 
interfere with studies depending on the study criteria and follow-up procedures. The 
relatively high proportions of sensory impairment and physical disability can be a 
barrier to inclusion in studies and can make the completion of certain components of 
assessment difficult or impossible. Such impairments can also ‘cloud’ or confuse the 
functional loss associated with a cognitive decline. Studies of oldest-old age 
participants must also consider the potential effects of easy fatiguability on data 
collection.(Mody et al., 2008) Lengthy testing procedures may result in poorer results 
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towards the end of the testing period as a result of fatigue. It is therefore important to 
add studies to the literature in order to build a larger volume of data relating to specific 
study questions, to allow for collation, comparison and potential meta-analyses. 
1.5.2.3 Frailty in oldest-old age 
Studies of the oldest-old may be further complicated by the varying degrees of frailty 
observed in this age group. Frailty may be defined as a decline in the reserve or 
resilience of body systems to withstand every-day stressors or acute stress and return 
to the pre-morbid condition; this may be simply considered as the reducing ability of 
the body to ‘bounce-back’ from an insult.(Kojima, Liljas & Iliffe, 2019; Xue, 2011) A 
widely accepted definition produced by the World Health Organisation (WHO) is as 
follows: “a clinically recognizable state in which the ability of older people to cope with 
everyday or acute stressors is compromised by an increased vulnerability brought by 
age-associated declines in physiological reserve and function across multiple organ 
systems”.(World Health Organisation, 2017) Studies have considered a wide range 
of domains in the assessment of frailty, including both physical and psychological 
domains. One popular clinical definition of frailty is a phenotype model consisting of 
five physical items, produced by Fried et al.(Fried, et al., 2001) The five items include 
unintentional weight loss of ten pounds or more, slow walking speed, poor grip 
strength, self-reported exhaustion and low physical activity.(Fried, et al., 2001). It can 
therefore be seen that frailty would affect variables of interest in the study of dementia, 
including body mass index (as an assessment of obesity), grip strength and walking 
speed (as measures of fitness) and physical activity, complicating the investigation of 
the role of such risk factors in dementia. 
In addition to the individual features of frailty having the potential to affect studies of 
risk factors for dementia in the oldest-old, overall frailty may have an impact on study 
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findings. Frailty has been shown to increase the risk for incident dementia.(Li et al., 
2020) It is possible therefore that the decline in resilience puts one more at risk of 
dementia.(Li et al., 2020) One may also consider whether the association between 
frailty and dementia is explained by a shared or  similar aetiological pathway.(Li et al., 
2020) In support of this explanation, studies have shown that the rate of change in 
frailty and cognition are strongly correlated, with common neuropathological 
basis.(Buchman et al., 2014) Alternatively, one must consider whether reverse 
causation is giving rise to the observed relationship. Given that one might expect 
reduced activity and weight loss in dementia, such changes may occur as part of the 
prodromal phase of dementia, before dementia is diagnosed in a study.  
Frailty is an important feature of health in oldest age, and is much more frequent in 
this age group than any other. Studies have demonstrated an exponential increase in 
the prevalence of frailty with increasing age, from approximately 6.5% in those aged 
60-69, to 65% in those aged over 90 years.(Gale, Cooper & Sayer, 2015) As such, it 
is increasingly possible that features associated with frailty may dominate the clinical 
picture, complicating the appearance of the risk factor profile in the oldest-old. Frailty 
will therefore be considered in the later chapters, in the context of specific study 
results. 
1.5.3 A potentially changing risk factor profile in oldest-old age 
Perhaps unsurprisingly, given the various complexities of this age group, previous 
studies of risk factors for dementia in the oldest-old have not produced consistent or 
conclusive results. Studies of this age group have however produced results that 
suggest the risk factor profile for dementia in oldest-old age is changed from that in 
earlier old age. As noted in section 1.4.4, the importance of APOE e4 has been 
questioned in oldest-old age.(Corrada et al., 2013) Hypertension – which is also a 
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recognised risk factor for dementia – has also been shown to decrease in potency 
with advancing age, with a possible reversing of the association in advanced old-
age.(Corrada et al., 2017; Li et al., 2007) Another risk factor found to have a changed 
association in oldest-old age is hypercholesterolaemia. While hyperlipiaemia has 
been shown to be associated with increased risk in earlier old age, studies in the 
oldest-old have shown a lack of such an association, and possibly even a reduced 
risk for dementia.(Evans, Kawas, & Corrada, 2014; Piguet et al., 2003; Rastas et al., 
2010) 
It is not only health factors that have been suggested to differ in their association with 
dementia in oldest age; the associations between lifestyle factors and dementia in 
oldest-old age have have also been called into question. Participation in greater levels 
of vigorous exercise at approximately age 40, 70 and 90 years was not associated 
with incident dementia over 90 years.(Paganini-Hill, Kawas, & Corrada, 2016) 
A potential change in the risk factor profile for dementia in oldest-old age is supported 
by evidence from other studies of health risks in oldest age. The recognised 
associations between traditional cardiovascular risk factors – including hypertension 
and hyperlipidaemia – and mortality have been shown  to be absent, or even inverted 
in oldest-old age.(Vaes et al., 2017). 
Studies have suggested that it is not only the risk factor profile that changes in 
dementia in the oldest-old. The neuropathological features of dementia observed in 
the post-mortem examination of oldest-old individuals have been shown to differ from 
what might be expected based on features observed in earlier old age.(Bullain & 
Corrada, 2013) Such differences can cause one to question whether the disease 
process for dementia in oldest-old age is different to that in earlier old age. Based on 
the current evidence, it is difficult to make a definitive statement in answer to this. 
What we do know, is that there are differences in how dementia may need to be 
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assessed based on differences in ‘population norms’ and non-dementia related 
functional impairment; we suspect that the risk factor profile might be changed; and 
that there is evidence that the neuropathology is changed.(Bullain & Corrada, 2013) 
The only way to make a more conclusive argument either way is to increase the 
volume of evidence within the literature.  
The oldest-old age group is therefore an important area of research interest for 
multiple reasons including: the growing size of this group; the likely volume of studies 
required to produce adequately large volumes of data; and the complexity of the 
health and disease profile within the group. The studies contained within this thesis 
therefore aimed to add to the existing literature in this field. 
 
1.6  Key epidemiological concepts in the thesis 
Within this thesis a number of key epidemiological concepts are discussed; many of 
these are of particular relevance as a result of the characteristics and design of the 
study cohort, including their advanced age at recruitment. We introduce such 
concepts here and explore these further within the relevant chapters of the thesis. 
Unmeasured confounding 
The complex web of differing health conditions and lifestyle influences, the exact 
nature of which varies widely between persons, raises the possibility of unmeasured 
confounding in studies of the oldest-old; i.e. an extraneous variable has an effect on 
the independent and dependent variables being studied, resulting in an observation 
that does not reflect the actual association between the variables being 
studied.(Pourhoseingholi, Baghestani & Vahedi, 2012) Such unmeasured 
confounding has the potential to affect the results of studies of oldest-old age cohorts, 




When examining the potential for confounding in a regression analysis, one must also 
consider the potential for collinearity between variables and the potential that 
collinearity is undermining the statistical significance of an independent variable.  All 
of these issues make the design of studies and interpretation of results (both within a 
group and between groups) in the oldest-old more challenging; perhaps contributing 
to varying results between cohorts. A clearer picture of patterns of risk in the oldest-
old will therefore require increased numbers of studies and detailed studies of any 
factor flagged as potentially important. 
Reverse causation 
With studies in oldest-old age, baseline measurements have the potential to be of 
increased proximity to the dementia outcome. While this may be limited by starting 
studies earlier in the life course and following participants to oldest-old age, this is not 
always feasible. Where it is not, the potential for reverse causation should be 
considered when examining observed associations. This would be important in our 
study given that most variables were measured at a baseline age of 79 years.  
Competing risk 
Death would also be a notable competing risk for dementia in our studies, given the 
potential for death to occur before dementia in a participant who would have gone on 
to develop dementia if they had not died. Further consideration will be given to the 
competing risk of death within relevant chapters of the thesis. 
Association versus causation 
When considering the veracity and direction of associations, one must also give 
thought to the nature of an observed relationship. In particular, whether we are 
observing causation or association. If the value of one variable provides information 
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about another, one can report the observation of an association but not causation. 
Before describing causation in any findings, it is useful to consider the guidelines 
described by Bradford Hill in his 1965 paper on association and causation.(Hill, 1965) 
He described nine viewpoints that one might consider; these include the strength, 
plausibility, consistency, biological gradient and temporality of an association.(Hill, 
1965) In our study of dementia in oldest-old age, observations were unlikely to be 
described as causation; the complexities outlined previously increase the likelihood 
of there being other variables affecting the observed relationship that were not 
controlled for within the analyses. Furthermore, the inconsistencies in observations in 
studies of dementia in the oldest-old make identifying causation less likely. 
Healthy survivor bias 
Studies of oldest-old cohorts are also at risk of being affected by healthy survivor bias. 
Simply by being of oldest-old age means that those available to recruitment have 
survived several possible health or lifestyle factors that would be of interest in studies 
of risk factors. Studying only those who survive, and ignoring those who did not can 
lead to misleading conclusions. This potential for bias is revisited in the relevant 
chapters.  
Selection bias 
The study sample considered within the studies included in this thesis is potentially 
subject to selection bias as a direct result of recruitment procedures. While 
participants were not entirely self-selecting, they did need to agree to take part in 
testing. Certain characteristics – such as better physical and mental health, or an 
interest in the subject of cognitive ageing – may have introduced bias to the sample. 
Selection bias relating to sample recruitment is explored further in Chapter 2, where 




Any data that might be considered to missing not at random has the potential to affect 
study findings. If one considers a variable measuring cognition, it could be postulated 
that those with poorer cognition would be less likely to complete the measure, thus 
leading to missing data for those with the poorest cognitive ability. The resulting 
dataset would therefore not be a true representation of the sample, and the results of 
analyses using these data might be misleading. Given the potential for cognitive and 
physical impairments in advanced old age, one must recognise the potential for such 
factors to affect the completeness of data and how the missing values might affect 
the analyses. The ‘randomness’ of missing data is discussed further in Chapter 2.  
 
1.7 Core questions and statement of aims for thesis 
This thesis will consider a single study cohort in addressing each of the described 
objectives. The second chapter will introduce and describe the study cohort from 
which the data for this thesis are derived – the Lothian Birth Cohort 1921. The 
subsequent chapters will address each of the research questions in turn, as outlined 
below. 
Thesis objectives 
Objective 1: Develop a method for ascertaining dementia using existing data. This 
would include an evaluation of the potential sources of data, based on evidence from 
the literature. 
Objective 2: To use this method to perform dementia ascertainment in the study 
cohort (Lothian Birth Cohort 1921).  
Objective 3: Explore the association between the APOE ɛ4 genotype and dementia 
in the oldest old. 
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Objective 4: Explore the association between potentially modifiable risk factors and 
dementia in the oldest old. 
Objective 5: Explore the association between physical fitness in older age and 
dementia in oldest age. 
Objective 6: Explore DNA methylation-based measures of accelerated ageing – as a 
proxy for accelerated biological aging – as a potential predictive factor for incident 
dementia in the cohort. 
Objective 7: Examine the potential effect of preclinical, or prodromal, dementia on 
previous findings relating to risk factors for non-pathological cognitive ageing in the 











2: An introduction to the study cohort: The Lothian Birth Cohort 1921 
2.1  Introduction to the chapter 
The data for this thesis were drawn from the Lothian Birth Cohort 1921 (LBC1921). 
This chapter provides a detailed description of the origins, recruitment and follow-up 
of the cohort. The LBC1921 was designed as a follow-up study of the Scottish Mental 
Surveys of 1932 (SMS1932). This survey had tested the general intelligence of almost 
all Scottish school pupils born in 1921. The Lothian Birth Cohort study aimed to exploit 
the rare opportunity that these childhood intelligence data provided for examining 
cognitive ageing from childhood to old age.  
2.2  Background 
The SMS1932 was designed and implemented by the Scottish Council for Research 
in Education.(Scottish Council for Research in Education, 1933) The primary 
objectives of the study were to investigate the rates of mental deficiency in Scotland 
and describe the distribution of intelligence throughout the community. Participants 
took part in the SMS1932 across all Scottish schools simultaneously, on June 1
st
, 
1932, with only a very limited number being tested in the following days. A total of 87 
498 pupils undertook the test: 43 288 girls and 44 201 boys. The intelligence test used 
in the survey was a version of the Moray House Test No.12 (MHT). The MHT was 
developed by Professor Godfrey Thompson, Bell Professor of Education at the 
University of Edinburgh (1925-1951). The MHT comprised 75 items (71 numbered 
questions), with a maximum score of 76 marks. It has been described as a test of 
verbal reasoning and included a number of different tasks including: following 
directions (14 items), same-opposites (11), word classification (10), analogies (8), 
practical items (6), reasoning (5), proverbs (4), spatial items (4), arithmetic (4), mixed 
sentences (3), cypher decoding (2), and other items (4).(Deary, Whalley, & Starr, 
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2009) In order to determine concurrent validity for the MHT, a sample of 1000 pupils 
– 500 girls and 500 boys – underwent individual testing.(Scottish Council for Research 
in Education, 1933) The test used was the Stanford revision of the Binet-Simon Test 
(standardised by Terman).(Deary et al., 2009; Terman, 1916) The test was modified 
for Scottish use by substituting American terminology for more familiar terms.(Scottish 
Council for Research in Education, 1933) Despite aiming for a representative sample, 
the ‘Binet 1000’ sample were determined to be of slightly higher intellectual ability 
when compared with the complete sample, particularly the boys.(Scottish Council for 
Research in Education, 1933) The concurrent validity of the MHT was however high 
– with a correlation between the MHT and Stanford-Binet Scale of 0.80 for boys and 
0.76 for girls.(Deary et al., 2009) The idea for the Lothian Birth Cohort studies resulted 
from the discovery of ledgers containing the original results of the Scottish Mental 
Surveys.(Deary et al., 2009) 
2.3  Recruitment and follow-up 
From 1999, participants of the SMS1932 were identified, traced and recruited within 
the Lothian area of Scotland. Lothian is a region of South-East Scotland, in which the 
largest settlement is Edinburgh. Potential participants were identified by two means: 
through media advertisement or by the Community Health Index – area based lists of 
general practice registration. Five hundred and fifty participants attended baseline 
(wave 1) LBC1921 testing at approximately 79 years of age, almost seven decades 
after taking part in SMS1932. Surviving participants who continued to consent to 
inclusion in the LBC1921 study, attended up to four subsequent waves of follow-up 
testing, at roughly 83, 87, 90 and 92 years of age. The first aim of the LBC1921 study 
was to investigate molecular genetic influences of non-pathological cognitive ageing. 
Subsequent aims included the investigation of influences leading to variation in 
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lifetime cognitive ageing, studying the effects of single nucleotide polymorphisms and 
conducting a genome-wide association study.  
Data on a wide range of variables were collected at each test wave, by questionnaire 
and in-person testing. Appropriately trained personnel completed the in-person 
testing at a suitable clinical research facility (Welcome Trust Research Facility, 
Western General Hospital, Edinburgh). Some of the same information was collected 
at multiple test waves whereas some information was collected at only a single wave 
of follow-up testing. In general, this reflected whether a variable was fixed (such as 
APOE ɛ4 carrier status), or liable to change (medical history, for example). Additional 
information variables were also introduced according to the developing research aims 
of the study. All collected data – original copies and computerised versions – were 
stored in accordance with study approvals. Specific details on how each data variable 
included in this thesis was collected or measured will be described within the relevant 
chapter.   
2.4  Cohort demographics 
All of the N=550 participants recruited to the LBC1921 were relatively healthy and 
living independently within the community. All participants were born in 1921. 
Females formed a slight majority within the cohort, numbering n=326 (57.5%) 
compared to n=234 (42.5%) males at enrolment. Participants had a mean age of 79.1 
(SD: 0.6) years at baseline testing (in 1999), with a range of 77.7 years to 80.6 years. 
Overall, the cohort was cognitively normal at baseline, with a mean Mini-Mental State 
Examination score of 28.2 (range 18-30) for the n=548 participants with test scores 
available. A score of 23 or below is widely accepted to be suggestive of cognitive 
impairment and in the LBC1921, only n=9 participants scored less than 24 at 
recruitment. These participants were typically excluded from analyses to prevent the 
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possible inclusion of participants who were cognitively impaired at the outset of the 
study. Manual social classes were less well represented within the LBC1921: social 
class I, n=130 (23.6%); social class II, n=186 (33.8%); social class III, n=215 (39.1%); 
social class IV, n=11 (2%); social class V, n=6 (1.1%). Participants had spent a mean 
of 10.9 years (range 7 to 20.5 years) in formal, full-time education. We would note 
that in the 1930s – when the LBC1921 participants would have left school – the school 
leaving age in Scotland was 14. Age 11 IQ scores (derived from SMS1932 MHT test 
scores) and age 79 IQ scores were available for n=493 and n=540 participants, 
respectively. IQ scores were standardised, with a sample mean of 100 and standard 
deviation of 15, based on MHT scores corrected for age in days at testing. The 
standardised IQ scores at age 11 years ranged from 44.0 to 130.7, while the 
standardised IQ scores at age 79 years ranged from 35.6 to 123.9. As these scores 
were standardised on the sample, the low scores are relative to the sample, which 
had a higher mean cognitive score than the background population. To demonstrate 
how the cohort age 11 IQ scores compare with the general population more clearly, 
we can consider the raw MHT scores: 34.5 (SD: 15.5) was the mean score for 
Scotland, 37.3 (SD: 14.8) for those in Edinburgh schools, and 46.4 (SD: 12.1) for 
those recruited to LBC1921.(Deary, Gow, Pattie, & Starr, 2011; Starr, Pattie, Whalley, 
& Deary, 2008)             
2.5  Attrition and missing data 
Attrition – a loss of participants to follow-up – would be expected in any longitudinal 
study of older participants. The most obvious reason for attrition in this age-group 
would be death, but other factors – including poor physical health, poor mobility, 
cognitive decline, increased frailty, changes in living arrangements or support network 
– are also likely to feature. Although the baseline differences between returnees and 
non-returnees were relatively small, grip strength, lung function (FEV1), MMSE and 
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age 79 IQ have all been shown to be poorer in those who did not return.(Deary, Gow, 
Pattie, & Starr, 2012) A history of cardiovascular disease was more common in those 
who did not return.(Deary et al., 2012) Participants may also opt out for less specific 
reasons, such as finding that attending for follow-up is tiring, no longer enjoyable or 
simply deciding that they would prefer to stop taking part. While the number of 
participants attending wave 1 (baseline) testing was N=550, the number attending 
was reduced at all subsequent waves: n=321 were assessed at wave 2 (mean age 
(SD) 83.4 (0.5) years), n=235 at wave 3 (mean age (SD) 86.6 (0.4) years), n=129 
(plus 11 with dementia) at wave 4 (mean age (SD) 90.1 (0.1) years) and n=59 at wave 
5 (mean age (SD) 92.1 (0.3) years.(Taylor, Pattie, & Deary, 2018)  
Table 2.1 Number and age of participants at each LBC1921 test wave 
 Test Wave 
 Wave 
1 
Wave 2 Wave 3 Wave 4 Wave 
5 








90.1 (0.1) 92.1 
(0.3) 
Number assessed 550 321 235 129  
(+11 with dementia) 
59 
 
Given that one of the possible reasons for attrition may be cognitive decline or 
dementia, there is the potential for bias as those remaining in the study will have less 
cognitive impairment. For this reason, it is important to have methods of follow-up that 
do not require attendance, such as record linkage to death certificates and hospital 
records. Such sources will be discussed further in Chapter 3 where dementia 
ascertainment methods using existing data are explored. We would also note that any 
new diagnosis of dementia reported by a participant or carer resulted in a referral to 
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the Clinical Research Fellow (a registered medical doctor) for assessment in order to 
confirm the diagnosis and likely subtype classification for study purposes.   
While the LBC1921 study aimed to collect the same set of data for each participant, 
some data were missing following each wave of testing. Data may have been missing 
for a number of possible reasons. As a result, the missing data probably included that 
which was missing completely at random, missing at random and not missing at 
random. Examples of how data might be missing completely at random are: a blood 
sample lost at a laboratory, or a questionnaire lost in the post. We would note that 
data missing completely at random are less likely in this cohort given the careful data 
collection and follow-up procedures. There is a possibility that some data were 
missing at random. Sex differences are often cited as potential reasons for data to be 
missing at random; men may be less likely to complete a depression assessment and 
women may be less likely to consent to weight measurement. In the LBC1921 these 
types of missing data are again likely to be few in number; research staff made a 
particular effort to encourage test completion in order to minimise this. Data missing 
not at random is unfortunately a possibility in the LBC1921. For example, individuals 
with cognitive decline may struggle to complete cognitive testing, leaving data 
incomplete. Similarly, participants with mobility issues might be unable to complete 
tests of walking speed, meaning these data were missing. While data collection staff 
aimed to minimise missing data, some missing data is unavoidable. 
Data were more complete for some variables than for others.  For example, of the 
total cohort (N=550) attending wave 1 testing, age 11 IQ scores were available for 
n=493 (89.6%), APOE ɛ4 status was available for n=543 (98.7%), sex was available 
for n=550 (100%), height was available for n=544 (98.9%), smoking status was 
available for n=549 (99.8%) and self-reported lifetime physical activity was available 
for n=367 (66.7%). Self-reported physical activity data were collected via a postal 
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questionnaire, completed sometime after attendance at wave 1 testing. The 
implication of these missing data would be that the number of participants included in 
an analysis would be limited to those with complete data for included variables.  
2.6 Potential for bias in the cohort 
Participants in observational studies chose whether to partake, and motivation must 
therefore be taken into account when considering the potential characteristics of a 
cohort. As described above, participants were recruited through advertising and 
through general practice lists. Individuals with an interest in cognitive ageing may 
have been more likely to consent to inclusion in the study, particularly in the case of 
those who responded to media advertisements. It is possible that increased interest 
was the result of personal or family experience with cognitive decline and as a result 
there is a potential for the recruited cohort to be at a greater risk for cognitive decline. 
By agreeing to participate in the study, participants were agreeing to take part in 
regular testing that involved time, and mental and physical effort. As such, participants 
were more likely to be fitter, with less health issues. Participants with an interest in 
research may also potentially be more educated or intelligent than the general 
population average. This would appear to be the case in LBC1921, where mean age 
11 IQ was above the national and regional mean; there was also a slight restriction in 
the range of IQ scores. The main likely effect of this would be a slight lowering of the 
associations’ effect sizes. A similar pattern is seen in the LBC1936.(Johnson, Corley, 
Starr & Deary, 2011) With these considerations in mind, we must recognise the 
potential for selection bias in our studies. 
The missing data described above may also give rise to a selection bias. If data are 
not missing completely at random – for example when those with poorer physical 
health are less likely to be able to complete physical fitness tests – then the sample 
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with complete data (and therefore included in the analyses) will not represent the total 
population.    
 
2.7  Study funding and ethical approvals 
The Lothian Birth Cohort 1921 has been funded latterly by Age UK (the Disconnected 
Mind grant). Previous funding was provided by the UK Biotechnology and Biological 
Sciences Research Council (BBSRC) for wave 1 (15/SAG09977), a Royal Society-
Wolfson Research Merit award to Professor Ian Deary for wave 2, the Chief Scientist 
Office (CSO) of the Scottish Government’s Health Directorates for waves 3 
(CZB/4/505) and 4 (ETM/55) and a questionnaire study between the first two waves 
(CZG/3/2/79), and the UK’s Medical Research Council (MRC) Centenary Early Career 
Award to Dr Tom Booth for wave 5.(Taylor et al., 2018) Completed as part of this 
thesis, dementia ascertainment was funded by the Alzheimer Scotland Dementia 
Research Centre. Ethical approval for LBC1921 was provided by the Lothian 
Research Ethics Committee for test waves 1-3, and the Scotland A Research Ethics 
Committee for test waves 4 and 5. Participants attending from wave 4 provided 
informed, written consent for data linkage and access to health records. 
2.8  Other studies describing dementia in the oldest-old 
While studies investigating dementia in the oldest-old are less frequent within the 
literature, several cohort studies have been designed with this specific aim. Table 2.2 






Table 2.2 Existing studies of dementia in the oldest-old 
Name of Study Location of Study 
Participants 
Age of Participants Number of 
Participants 
Study designed to investigate dementia in the oldest-old 
90+ Study USA 90+ years 1600+ 
Leiden 85-Plus 
Study 
Netherlands 85+ years 599 
Vantaa 85+ Study Finland 85+ years 601 
WISE Study USA 85+ years 1299 
CAIDE85+ Study Finland 85+ years Estimated 
enrollment of 500 
Monzino 80-plus 
Study 
Italy 80+ years 2139 
OCTO-Twin Study Sweden 79+ years 702 (351 twin pairs) 
Study not originally designed to investigate dementia in the oldest-old 
Eurodem Study Combines data from 





Cache County Study USA 85+ years 719 
Kungsholmen 
Project 
Sweden 90+ years 502 
Canadian Study of 
Health and Aging  
Canada 85+ years 1807 
 
Initiated in 2003, The 90+ Study is based in the USA and reports to have over 1600 
persons enrolled.(Gardner, Valcour, & Yaffe, 2013; UCI MIND) The initial participants 
recruited to the study were survivors of the earlier Leisure World Cohort Study 
(LWCS), which studied a retirement community in California.(Gardner et al., 2013) A 
2017 study on hypertension and dementia in The 90+ Study cohort provided the 
following specifics regarding enrolled participants: of the 1554 participants who were 
enrolled by 17
th
 July 2013, 891 were seen for in-person assessment at baseline; of 
those 891 participants, 601 were without dementia at baseline.(Corrada et al., 2017) 
Of the 663 participants not seen in-person at baseline, 45% were determined to have 
48 
 
dementia at baseline using other sources of information.(Corrada et al., 2017) The 
Leiden 85-Plus Study is a prospective population study based in Leiden, Netherlands 
and includes 599 participants.(Rostamian et al., 2017) The 705 inhabitants of Leiden 
who turned 85 years of age between the 1
st
 of September 1997 and the 1
st
 of 
September 1999 were eligible to participate; 85% of those eligible participated in the 
study.(Rostamian et al., 2017) Also a prospective population-based study, The 
Vantaa 85+ Study included 601 inhabitants of Vantaa, Finland who were aged 85 
years or over on the 1
st
 of April 1991.(Hall et al., 2019; Gardner et al., 2013 Clinical 
examination was completed for 553 participants (214 of whom had dementia at 
baseline), and neuropathological examination was performed on 304 
participants.(Hall et al., 2019) The Monzino 80-plus Study included 2139 participants 
at baseline, of which 74% were female; participants were interviewed at home and 
resided in the Varese province of Italy.(Lucca et al., 2011) The OCTO-Twin Study 
(Origin of Variances in the Oldest-Old) was carried out between 1991 and 
2002.(Karlsson et al., 2015; Maelstrom Research, 2020) Participants included 351 
twin pairs, recruited from the Swedish population-based twin registry.(Karlsson et al., 
2015; Maelstrom Research, 2020) Participants were followed up five times, at two-
yearly intervals, with the aim of investigating aetiology of individual differences among 
twin-pairs age 80 and older, on a range of domains including health and functional 
capacity, cognitive functioning and psychological well-being.(Karlsson et al., 2015; 
Maelstrom Research, 2020) The Women Cognitive Impairment Study of Exceptional 
Aging (WISE) Study is an ancillary study to the Study of Osteoporotic Fractures, 
based in the USA.(Gardner et al., 2013; Yaffe et al., 2011) Of the 1338 participants 
who completed the cognitive test battery, 1299 were aged over 85 years.(Gardner et 
al., 2013; Yaffe et al., 2011) All five of these studies included a majority of female 
participants.(Corrada et al., 2017; Gardner et al., 2013) A relatively new study of the 
oldest-old, that is not yet complete, is the CAIDE85+ study.(NIH: U.S. National Library 
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of Medicine: ClinicalTrials.gov) The CAIDE85+ study is based in Eastern Finland and 
is the third follow up of the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) 
study, which began in 1998 with 2000 participants.(NIH: U.S. National Library of 
Medicine: ClinicalTrials.gov) These participants, in mid-life between 1972 and 1987, 
had previously taken part in the North Karelia, and FINMONICA survey studies.(NIH: 
U.S. National Library of Medicine: ClinicalTrials.gov) CAIDE85+ is due to start in May 
2019 and complete in December 2020, with an estimated enrollment of 500 
participants.(NIH: U.S. National Library of Medicine: ClinicalTrials.gov) Other studies 
– although not originally designed to investigate dementia in the oldest-old – have 
included older cohorts that have been used for this purpose.(Gardner et al., 2013) 
Such studies include the Eurodem study, the Cache County Study, the Kungsholmen 
Project and the Canadian Study of Health and Aging.(Gardner et al., 2013) The 
Eurodem study has investigated the prevalence, incidence and risk factors of 
dementia by combining data from dementia studies in ten European countries, 
(including the Leiden 85-Plus Study).(Gardner et al., 2013) In a study of dementia 
prevalence, the Eurodem Study included 1623 participants aged over 85 years, 73% 
of whom were female.(Gardner et al., 2013) The Cache County Study was 
established in 1995 with the aim of investigating risk factors for Alzheimer’s and other 
dementias. Based in Utah, USA, approximately 14% (n=719) of the participants of the 
original study group were aged over 84 years at baseline.(Tschanz et al. 2005; 
Tschanz, Norton, Zandi & Lyketsos, 2014) The majority of those in this sub-group 
were again female (66%).(Gardner et al., 2013) The Kungsholmen Project is based 
in Stockholm, Sweden and has published study results based on a sub-set of 
participants (n=502) aged 90 years and over.(Gardner et al., 2013; von Strauss, 
Viitanen, De Ronchi, Winblad, & Fratiglioni, 1999; von Strauss, Fratiglioni, Viitanen, 
Forsell, & Winblad, 2000) In a study of dementia prevalence in the very old, The 
Canadian Study of Health and Aging included 1807 participants aged over 85 years, 
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of which 72% were female.(Ebly, Parhad, Hogan & Fung 1994; Gardner et al., 2013) 
All of the studies described have been located in Northern America or Europe, which 
may be expected given that areas with greater life expectancy would yield larger 
populations of persons in advanced old age. Studies such as the 90+ Study and WISE 
are predominantly made up of white subjects of high socioeconomic status. While the 
studies described above would provide valuable evidence describing dementia in the 
oldest-old, the limitation in study location and participant demographics would suggest 
that findings might not be applicable to the broader global population. As life 
expectancy improves in other countries and regions, studies of dementia in the oldest-
old in these populations will be important in determining how applicable previous 
findings are from a global perspective. The LBC1921 demographics would be similar 
to those included in the previous studies of the oldest-old, with the cohort comprising 
mostly of white, European subjects of relatively high socioeconomic status and 
educational achievement. For this reason, results of previous studies would be 
comparable with results from study of the LBC1921 cohort, and vice versa. 
Furthermore, results from studies of the LBC1921 would add further detail to the 
existing evidence in that these studies could account for childhood intelligence.  
As described within this chapter, the LBC1921 was not originally designed to 
investigate dementia. With a considerable proportion of the cohort deceased at the 
outset of the study period for this thesis, dementia outcomes were therefore 
determined using existing data as the primary data source. The next chapter explores 
such methodology within the literature, before discussing the procedure that was 
developed for dementia ascertainment in the LBC1921.  
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3: Dementia ascertainment using existing data 
3.1  Introduction 
Developing an effective dementia ascertainment procedure was a vitally important 
first step in addressing the objectives of this thesis. It was to be the basis on which all 
subsequent analyses were built. Further to this, the dementia outcomes determined 
in this body of work were to be incorporated into the LBC1921 dataset and be 
available to other researchers. Failure to produce a dementia ascertainment method 
of sufficient effectiveness and accuracy would limit the acceptance of any future 
findings based on dementia cases derived using this method.  
Ideally, the ascertainment method would have replicated a recognised and 
consistently used method based on evidence of effectiveness. The optimal evidence 
base would have been a systematic review describing a ‘best method’ based on 
individual articles that had evaluated dementia ascertainment methodologies using 
existing data. At the commencement of this study, no such review was identified within 
the literature. Without a review of multiple articles, the next best option for determining 
a suitable methodology would have been the identification of any article describing 
the study and evaluation of dementia ascertainment methods using existing data. 
Again, a literature search revealed no such publication.  
In the absence of such an evidence base, it was important to consider the methods 
for dementia ascertainment utilised by some of the large, well-recognised UK-based 
dementia studies. The Medical Research Council Cognitive Function and Ageing 
Studies (CFAS I and II) used evidence gathered from repeated screening and 
assessment interviews to determine a study diagnosis of dementia.(Matthews et al., 
2013) For some analyses, these data were combined with death certificate 
data.(Brayne et al., 2006) Similarly, the Cambridge City over-75s Cohort (CC75C) 
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study determined consensus diagnoses using data from assessment interviews, 
informant information and death certificate data.(Brayne et al., 2009) The similarities 
between the methods of these studies is likely to be due to the fact that these cohorts 
were set-up in order to investigate dementia. They have therefore collected data in 
such a manner to optimise the accuracy of dementia ascertainment. As previously 
described, the LBC1921 study was not originally designed in order to investigate 
dementia and as such, the data collected were not optimised for this purpose. Having 
been commenced many years prior to the proposed ascertainment of dementia, 
prospectively determining cases was not possible, particularly given the large number 
of deaths that had already occurred in the cohort. Having determined that dementia 
cases would need to be ascertained using evidence from previously collected data, 
the next step was to identify any individual studies that had used such methods. From 
the previous literature searches it was apparent that no paper investigated this 
methodology as the main study topic; it was therefore necessary to identify articles 
describing this type of procedure within their reported methods. Given the number of 
dementia studies that could have potentially used existing data, either in full or in part, 
to ascertain dementia, a systematic approach was required in order to identify the 
maximum number of relevant articles. The decision was made to limit the investigation 
of methods to studies based within the UK only. Primarily, this was due to the wide 
variation in the type and availability of both healthcare and datasets across the world 
and because UK data sources would be directly relevant to this thesis. To guide the 
development of a dementia ascertainment method for LBC1921, it was necessary to 
examine the methods of any UK-based cohort or longitudinal study using existing data 
for dementia ascertainment. A systematic review was therefore designed and 
completed, with a view to describing the methods previously used, discussing the 
benefits or drawbacks of each, and finally, make recommendations for developing 
effective methods.  
53 
 
The success of the systematic review would hinge on the design of the literature 
search. The search strategy needed to include terms specific to the purpose of the 
review, including terms relevant to dementia, the UK and a longitudinal or cohort study 
type. Given that the review considered a methodology, rather than a study outcome, 
the search terms needed to be broad enough to prevent the unintentional exclusion 
of relevant articles. It was anticipated, therefore, that while the search was likely to 
return a large number of potentially relevant articles, a significant proportion would 
not be eligible for inclusion in the study. In order to design the most effective search 
strategy for identifying relevant articles the authors of the review used an iterative 
process to review and optimise the included terms, with the guidance from a librarian 
with expertise in literature search strategy.  
The systematic review was designed and completed as described in the published 
systematic review in the subsequent section of this chapter. The completed 
systematic review was published in BMC Psychiatry with the aim that this would 
provide evidence for other researchers looking to design dementia ascertainment 
methods using existing data.  
The full reference for the included paper is as follows: 
Sibbett, RA., Russ, TC., Deary, IJ. and Starr, JM (2017). Dementia ascertainment 
using existing data in UK longitudinal and cohort studies: a systematic review of 
methodology. BMC Psychiatry, 17: 239. doi: https://doi.org/10.1186/s12888-017-
1401-4 
The author of this thesis is the first author of the published paper and made the 
following contributions to the manuscript: took part in devising the review objectives, 
writing the search strategy, writing the inclusion and exclusion criteria, developing and 
utilising the quality measure, performed the literature search, took part in screening 
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for inclusion and exclusion, led the writing of the manuscript and contributed to 
revisions of the same. The contributions of each additional author is detailed within 
the paper. The additional files for the published manuscript can be viewed within 
Appendix 1 of this thesis, from page 231. The individual appendices can be viewed 
on the following pages: 
• Additional file 1 .................................................................................. page 232 
• Additional file 2: Table S1 ................................................................. page 235 
• Additional file 3: Table S2 ................................................................. page 236 
• Additional file 4: Table S3 ................................................................. page 243 
• Additional file 5: Table S4 .................................................................. page 253 
The references for this paper are included within the published manuscript, in the 
referencing style of the journal. The references can be seen on pages 69-70 of the 
thesis. 
3.2  Dementia ascertainment using existing data in UK longitudinal and 
cohort studies: a systematic review of methodology   
(The published manuscript is included from the next page) 
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RESEARCH ARTICLE Open Access
Dementia ascertainment using existing
data in UK longitudinal and cohort studies:
a systematic review of methodology
Ruth A. Sibbett1,2*, Tom C. Russ1,2,4,5, Ian J. Deary1,2,3 and John M. Starr1,2
Abstract
Background: Studies investigating the risk factors for or causation of dementia must consider subjects prior to disease
onset. To overcome the limitations of prospective studies and self-reported recall of information, the use of existing data
is key. This review provides a narrative account of dementia ascertainment methods using sources of existing data.
Methods: The literature search was performed using: MEDLINE, EMBASE, PsychInfo and Web of Science. Included articles
reported a UK-based study of dementia in which cases were ascertained using existing data. Existing data included that
which was routinely collected and that which was collected for previous research. After removing duplicates, abstracts
were screened and the remaining articles were included for full-text review. A quality tool was used to evaluate the
description of the ascertainment methodology.
Results: Of the 3545 abstracts screened, 360 articles were selected for full-text review. 47 articles were included for final
consideration. Data sources for ascertainment included: death records, national datasets, research databases and
hospital records among others. 36 articles used existing data alone for ascertainment, of which 27 used only a single
data source. The most frequently used source was a research database. Quality scores ranged from 7/16 to 16/16.
Quality scores were better for articles with dementia ascertainment as an outcome. Some papers performed validation
studies of dementia ascertainment and most indicated that observed rates of dementia were lower than expected.
Conclusions: We identified a lack of consistency in dementia ascertainment methodology using existing data. With no
data source identified as a “gold-standard”, we suggest the use of multiple sources. Where possible, studies should
access records with evidence to confirm the diagnosis. Studies should also calculate the dementia ascertainment rate
for the population being studied to enable a comparison with an expected rate.
Keywords: Dementia, Research design and methodology
Background
As the global population ages and dementia rates increase,
further research is required in order to reduce the impact
on the individual and on society [1, 2] Key aspects of
current dementia research include causation, risk factors,
early detection, and prevention. In order to investigate
such factors robustly – and avoid reverse causality – stud-
ies need to consider subjects prior to disease onset.
Whether such studies concentrate on the entire life course
or on a limited period prior to dementia onset, completing
data collection prospectively can be time-consuming and
costly. Recruiting those who already have a diagnosis in
order to consider life-course risk and protective factors is
limited by the potential inaccuracy or incompleteness of
information recalled by participants and carers.
In order to overcome such limitations, the use of previ-
ously collected data is key. The value of existing data sets is
demonstrated by the launch of The Farr Institute of Health
Informatics Research in the UK, aimed at optimising the
use of health records in research by facilitating the safe and
secure use, and linkage of, electronic patient records, re-
search data and routinely collected data [3].
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Using existing data in dementia research is not
unusual. Death certificates are often utilised to comple-
ment clinical follow-up methods where study partici-
pants are lost to follow up [4, 5]. Although studies have
used existing data for the purposes of dementia ascer-
tainment, to our knowledge no review has been pro-
duced in order to collate and consider the various
methods described. As a result, there is no clear guid-
ance or standard to follow when designing a study using
existing data for dementia ascertainment. The aim of
this systematic review is therefore to provide a narrative
account of the dementia ascertainment methods using
existing data sources described in the literature, in order
to provide evidence for potential approaches in future
research. It should be noted that this review focuses on
ascertainment from sources of existing data, rather than
on the specific dementia criteria utilised by each study.
This review is specifically aimed at providing a basis for
dementia ascertainment methods for studies based in
the UK, where there are highly developed systems allow-
ing the capture of health outcomes from a variety of
sources. This review will therefore not consider studies
based out-with the UK, as datasets vary widely between
countries and health systems. It is however likely that
some of the data sources considered in this review will
have an equivalent in other countries and so our conclu-
sions will have relevance outside the UK.
Methods
The Preferred Reporting of Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement was used to
guide the conduct and reporting of the present system-
atic review [6].
Selection criteria
The ‘PICOS’ approach (population, intervention, com-
parator, outcome, study design) was adopted in order to
define the study question and build an appropriate
search strategy. Given that this review would focus on
methodology, the intervention and comparator were not
applicable. The population (P) would be a UK-based co-
hort or population group, the outcome (O) would be the
dementia ascertainment method and sources of existing
data, and the study design (S) would be observational.
This review aimed to guide future studies performing
dementia ascertainment using existing data within the
UK. This review will not consider populations out-with
the UK as health data and systems vary from that which
is available in the UK.
Data sources
Scholarly articles for inclusion in the review were identi-
fied through searching four separate electronic databases
determined to be appropriate for dementia ascertainment
methodology. The following databases were included:
MEDLINE (from 1946), EMBASE (from 1980),
PsychINFO (from 1987) and Web of Science (from
1900). The literature search took place on the 28th
December 2015.
Search strategy
The study authors (who have expertise in dementia) de-
veloped the search strategy with input from a research
librarian experienced in systematic review methodology.
Each search included terms relating to: a) dementia; b)
the UK; and c) longitudinal or cohort study type. The
full electronic search strategy for MEDLINE is detailed
in Additional file 1. No limitation parameters were used.
The inclusion and exclusion criteria for this review
aimed to strictly limit included papers to those using
previously collected data for dementia ascertainment.
Specifically, this required the exclusion of any paper
where dementia status was used to select participants or
where dementia was determined by prospective clinical
review. The exclusion criteria needed to be extensive
given the broad terms used for the initial literature
search. Such broad search terms were required given
that the area of interest was methodology, rather than
the primary topic of a study.
The inclusion criteria for review articles were: a)
Longitudinal or cohort studies applying retrospective de-
mentia ascertainment methods; b) Dementia cases must
be ascertained from a defined larger cohort/population;
c) Ascertainment may be an outcome, or ascertainment
may be performed in order to determine a cohort of par-
ticipants with dementia; d) Dementia diagnoses were
ascertained using existing data (in part or in full). Exist-
ing data included that which was collected routinely and
that which was collected for previous research.
The exclusion criteria were: a) Study population based
outside the United Kingdom; b) Articles published in
non-English language; c) Participant self-referral/other
referral to studies following advertising for persons with
dementia; d) Participant/carer/health service response to
census/survey; e) Participants included based on known
neuropathological diagnosis of dementia; f ) Direct refer-
ral of participants from NHS/voluntary services follow-
ing advertising/request for referral of persons with
dementia; g) Study participants recruited from hospital
wards, outpatient clinics (or referrals to the same) or
other services, unless documented that records/other
existing data used to select cases; h) Study participants
selected from an existing register of dementia cases,
study/research centre, memory or old age psychiatry
clinic patients, people prescribed cholinesterase inhibi-
tors or dementia carers; i) Studies where dementia was
not the primary condition or disease of interest, or at
least of equal weight to another condition; j) Animal





models of dementia; k) Simulated cohorts; l) Ascertain-
ment not for dementia diagnosis (i.e. cognitive decline
‘suggestive of dementia’, cognitive impairment); m) Sys-
tematic reviews (any systematic review on this specific
topic would be included, but reviews producing sum-
mary data from several studies without any primary
description of dementia case ascertainment would be ex-
cluded) /meta-analyses/case reports – i.e. any non-
longitudinal or cohort study; n) Studies where dementia
cases were ascertained entirely at baseline and/or pro-
spectively in a clinical assessment setting; o) posters or
abstracts; p) unclear description, additional duplicates or
errors in citation.
Study selection
References were exported to and managed using the ref-
erence management software package Endnote X7.5.
The results from each database search were compiled
and any duplicates removed. Duplicates were identified
and removed by the ‘find duplicates’ function within the
Endnote software. Additional duplicates were then iden-
tified and removed manually. Records returned by the
literature search were excluded sequentially. In an initial
phase of screening, titles and abstracts were reviewed for
eligibility by the first author, according to the inclusion
and exclusion criteria. The threshold for inclusion at this
phase was purposefully low, to prevent the exclusion of
any relevant study. The full-texts of articles remaining
following the initial screening were obtained and inde-
pendently scrutinised by the first and second authors,
according to the same inclusion and exclusion criteria.
Any discrepancies between the final full-text lists for in-
clusion between the first and second authors were dis-
cussed and agreed upon at a meeting. It was planned
that any disagreements persisting following the meeting
would be discussed with a third author.
Where the list of eligible full-text articles included
more than one article by the same study group or au-
thor(s), and described the same ascertainment method-
ology, we included only the article with the most
comprehensive description of the methodology, and ex-
cluded all the others. This was done in order to prevent
bias in our findings. We aimed to prevent double-
counting of a single study which had given rise to mul-
tiple research outputs – where a single group or author
had published multiple articles using the same method-
ology from a single project. Including all such articles
would risk making it appear that a specific methodology
or data source was used more frequently and more
widely than in reality.
Data collection
The data extracted from the eligible full-text articles in-
cluded: the author(s), the journal reference (including
year of publication), the study topic or aim, whether de-
mentia ascertainment was the outcome or where it was
ascertained to form a cohort for further study, the
source(s) of existing data for dementia ascertainment,
the criteria for dementia ascertainment, and whether
there was any validation procedure or comparison with
expected dementia rates. Data were also extracted for
the purpose of evaluating the quality of the methodology
description, as detailed below.
Quality measure
A quality tool was developed by the authors in order to
evaluate the description of dementia ascertainment
methodology within each included article. The compo-
nents of the quality measure were based on whether the
paper contained sufficient information such that an inci-
dence or prevalence rate could be calculated and the as-
certainment rate could be compared with another
population. The components of the quality measure
considered the description of: a) the size of the baseline
population; b) the age of the baseline population; c) the
sex of the baseline population; d) the source of the base-
line population; e) the ascertainment procedure and f)
the date or time period studied. Each article was given a
quality score, with a higher score indicating a higher-
quality description of dementia ascertainment method-
ology. The maximum score was 16 and the full details of
the quality tool are shown in Table 1.
Where more than one eligible article reported results
based on the same study population and the same ascer-
tainment method, the article with the highest score for the
quality of description of dementia ascertainment method-
ology would be included and the others excluded from the
final review. These exclusions would be important in
order that studies or research groups with a high output
of articles from the same study, using the same ascertain-
ment methodology, did not bias the review findings. Spe-
cifically, we wanted to avoid certain methods appearing to
be frequently used within the UK when the same study
group was actually using them multiple times.
Results
Article selection
A total of 5031 citations were identified by the four separ-
ate database searches, including 2150 from MEDLINE,
1614 from EMBASE, 479 from PsychInfo and 788 from
Web of Science. After collating the search results, 1486
duplicates were removed. The title and abstract for each
of the remaining 3545 records was screened for suitability
and it was determined that 360 full-text articles required
full-text review. Of those selected for full-text review, it
was agreed that 63 articles met the criteria for inclusion.
A flow chart of study selection is shown in Fig. 1.




The reasons for the exclusion of papers following full-
text review differed between the first and second au-
thors, largely since several papers could have been ex-
cluded for multiple reasons. Rather than excluding
articles based on multiple exclusion criteria the authors
made exclusions based on a primary exclusion criteria.
Despite the differences, both authors excluded the same
papers. The reasons for exclusion are therefore not de-
tailed in Fig. 1, but presented in Additional file 2: Table
S1. The most frequent reasons for the exclusion of full-
text articles (combined total number excluded by both
authors) were: cases ascertained entirely through base-
line or prospective clinical assessment or new data only
(n = 103), not a longitudinal or cohort study (n = 125)
and participants recruited directly from hospitals, clinics
or other service (n = 102). It would be expected that a
large number of ineligible or irrelevant articles were
returned by the literature search owing to the broad
search parameters used in order to identify a method-
ology rather than a specific study topic. Many such arti-
cles also passed through the first phase of screening
because the title and abstract did not contain sufficient
detail regarding the study methodology in order for eli-
gibility to be determined.
A number of the eligible articles reported results based
on the same study population and the same ascertain-
ment method was described multiple times. We identi-
fied nine groups of articles reporting the same
methodology and n = 16 articles were excluded on this
basis. Details of the excluded articles are shown
alongside the articles chosen for inclusion in Additional
file 3: Table S2.
Following this process, 47 papers remained for consid-
eration in this review. An overview of the characteristics
of the included studies can be seen in Table 2. The table
includes: the topic of the article; whether dementia as-
certainment was an outcome of the study or whether as-
certainment was performed to build a cohort of subjects
with dementia upon which further study was carried
out; whether existing data was used in full or in part; the
existing data sources utilised; the diagnostic criteria
used; whether the article included a validation study of
dementia ascertainment or a comparison between ob-
served rates and expected rates; and the total score
achieved when the quality tool was applied to each art-
icle. We determined that existing data was used in part
when new data was used in any way to support
Table 1 Quality Tool
Quality tool components
1 Baseline population size
A) Exact number (score = 3)
B) Approximate number (score = 2)
C) Other description of size (score = 1)
D) Not specified (score = 0)
2 Baseline population age
AI) Exact age range specified for total population (score = 4)
AII) Broad age range specified for total population (score = 3)
BI) Exact age range specified for analyses (score = 2)
BII) Broad age range specified for analyses (score = 1)
C) Not specified (score = 0)
3 Baseline population sex
A) Specified (score = 1)
B) Not specified (score = 0)
4 Baseline population
A) Named with description (score = 2)
B) Named only (score = 1)
C) Not specified (score = 0)
5 Dementia ascertainment
AI) Sources and specific criteria clearly described (score = 3)
AII) Sources and specific criteria less clearly described (score = 2)
B) Sources named but no specific criteria described (score = 1)
C) Unclear/ not described (score = 0)
6 Dementia cases
A) Number plus comparison to expected/ documented rate
(external UK comparison) (score = 2)
B) Number only (score = 1)
C) Not specified (score = 0)
7 Time/ period/ date
A) Specified
B) Not specified/ unclear
Fig. 1 Study Flow Design


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sibbett et al. BMC Psychiatry  (2017) 17:239 Page 8 of 16
63 
 
ascertainment. New data included clinical assessment,
informant interview and contact with services for
information.
Sources of data
The sources of existing data described by the eligible ar-
ticles were numerous and included general practice re-
search databases (n = 16), case notes or records
(n = 16), death certificates (n = 14), case registers
(n = 5), national datasets (n = 6), electronic hospital in-
formation systems (n = 2), radiology records (n = 3),
hospice records (n = 1), pharmacy records (n = 1) and
missing person records (n = 1). Of the 47 included pa-
pers, 31 (66%) used only a single source of existing data
for the purpose of ascertainment (Table 2). The highest
number of different data sources used was three. The
most commonly used data source in studies using a sin-
gle data source was a research database, such as the
General Practice Research Database (GPRD), the Clinical
Practice Research Datalink (CPRD), The Health Im-
provement Network (THIN) or the Scottish Programme
for Improving Clinical Effectiveness- Primary Care
(SPICE-PC) (n = 14). The next-most used data source in
articles using a single data source was death certificates
(n = 9). When considering all included papers, the re-
search database and case records or notes were equal as
the most frequently used sources (n = 16), but in those
papers using multiple sources only, case notes or records
were the most frequently utilised source of existing data
(n = 13). Figure 2 illustrates the source or sources of
existing data used by each of the 47 articles.
Of the 36 papers using existing data only for the pur-
pose of dementia ascertainment (i.e. no clinical compo-
nent), 27 (75%) used only a single data source and the
most frequently utilised data source was the research data-
base (n = 14). Including the articles that only used existing
data and used single or multiple sources, the research
database remained the most frequently used (n = 16), but
considering those using multiple sources separately, case
notes were the most frequently used (n = 6).
The criteria utilised by the articles to determine a
diagnosis of dementia from the data sources was varied.
Most studies using death certificates for dementia ascer-
tainment extracted a diagnosis based on the condition
having been recorded on any part of the certificate.
Others stated that dementia cases were recognised by
specific ICD-10 codes listed on the certificate. Evidence
from death certificates were also used in combination
with evidence from other sources to determine cases.
Case records were in many cases reported to be exam-
ined by a specialist medical doctor with training in de-
mentia. Researchers often searched the case records for
evidence to meet a specific diagnostic criteria, such as
DSM-IV, ICD-10 or NINCDS-ADRDA criteria. In other
cases, dementia diagnosis was taken as a formal diagno-
sis or mention of a diagnosis within in the notes. Re-
searchers employed a number of different techniques
when using databases to ascertain dementia diagnoses.
These included searching the database for diagnostic
codes, Read Codes derived from Quality and Outcomes
Framework (QOF) codes, recorded diagnoses or pre-
scriptions for dementia defining drugs. Some studies ap-
plied diagnostic criteria to evidence within the records.
Other studies developed algorithms that combined a
number of different criteria. Details of the criteria uti-
lised by each study is shown in Table 2.
Quality measure
The quality measure was primarily a means of evaluating
the description of the ascertainment methodology and
the sources of data used. We identified significant dis-
crepancies between the detail provided in the method-
ology of articles and the quality measure results give an
indication of the completeness or lack of information
provided by the authors. The quality measure is there-
fore closely related to our reporting of the sources used
and how dementia was ascertained from each.
The breakdown of the quality measure results for each
article are shown in Additional file 4: Table S3. When an
article included sub-studies where dementia was included
as an outcome in one study and for a dementia cohort
study in another, the quality measure was performed on
the outcome study due to the more specific detail in-
cluded. Where only one sub-study met the inclusion cri-
teria for this review, the results listed considered only the
eligible sub-study. Overall, the quality scores ranged from
7/16 [7, 8] to 16/16 [9, 10] and the mean score achieved
across all 47 papers was 12.0 (SD: 2.6). Quality scores were
lower for studies using existing data alone for ascertain-
ment (n = 36; mean = 11.5 (SD 2.6)), compared with stud-
ies using existing data in addition to other methodologies
(n = 11; mean 13.4 (SD 2.3)) (p < 0.05). There was also a
significant difference (p < 0.001) in quality scores between
studies where dementia was either an outcome or both an
outcome and the basis of forming a cohort (n = 31;
mean = 13.0 (SD 2.1)), and studies where dementia ascer-
tainment was performed to build a cohort (n = 16;
mean = 10.2 (SD 2.6)).
The quality measure also included whether a valid-
ation study or comparison with expected dementia rate
was performed. Given the importance of validating an
ascertainment methodology in order to determine its ef-
fectiveness we have expanded on this further, as follows.
Studies reporting a validation procedure
Of the 47 papers included, relatively few performed a valid-
ation study for dementia cases or compared ascertainment
Sibbett et al. BMC Psychiatry  (2017) 17:239 Page 9 of 16
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to previously documented rates. Imfeld et al. [11] com-
pleted a validation procedure for the algorithm used to
identify cases within the General Practice Research Data-
base (GPRD), and found up to 80% of Alzheimer’s disease
cases and up to 75% of vascular dementia cases were con-
firmed by GP questionnaire responses. Seshadri et al. [12]
completed a validation of Alzheimer’s disease cases identi-
fied using code algorithms for dementia or Alzheimer’s dis-
ease within GPRD and confirmed only 48% cases as either
possible or probable Alzheimer’s disease according to
NINCDS-ADRDA criteria. Authors did however report a
much higher validation rate of 83% for those identified spe-
cifically as Alzheimer’s disease cases within the GPRD, and
for whom there was adequate data for validation [12].
Imfeld et al. [11] reported that the incidence rates of Alz-
heimer’s disease found in their study, were three to six
times lower than those found in previous European studies.
Goh et al. [13] and Qizilbash et al. [14] did not perform any
validation study, but referred to the above-mentioned work
by Seshadri et al. [12, 15]. Using the Scottish Programme
for Improving Clinical Effectiveness- Primary Care (SPICE-
PC) database, Guthrie et al. [16] found that the prevalence
of dementia was only about half of that found in epidemio-
logical studies. Recording was found to be particularly poor
in older age groups. Rait et al. [17] used The Health Im-
provement Network (THIN) database and on comparison
with incidence rates demonstrated by the EURODEM study
and Cognitive Function and Ageing Study (CFAS), the inci-
dence rates found by Rait et al. were shown to be signifi-
cantly lower than would have been expected [17]. Heath et
al. [9], who did not name the research database used, re-
ported the prevalence in their population to be close to the
middle of the range of previous estimates.
The under-reporting of dementia on death certificates
was noted in articles in this review [10, 18–20]. Doll et
al. [21] compared their findings to European statistics
(EURODEM) and determined that they had only re-
corded 30% of dementia cases from death certificates.
Russ et al. [10] found that compared to using multiple
sources, death certification alone missed approximately
16–18% of dementia cases. The same study found that
general practice records did not identify all cases identi-
fied by record linkage [10].
McGonigal et al. [22] tested the assumption that most
patients with pre-senile Alzheimer’s disease are known
to psychiatric services. After consulting further data
sources including death certificates, general hospital and
neurology service records, and opinions within the med-
ical community, the authors reported that approximately
97% of participants identified as having pre-senile de-
mentia in their study were indeed cared for within psy-
chiatric services [22]. Overall, McGonigal et al. [22]
found that the annual incidence rates of pre-senile Alz-
heimer’s disease, determined using hospital records,
within their study population were comparable to annual
incidence rates quoted by a national study using differ-
ent ascertainment methods. It should be noted that
some 11% of hospital records requested by McGonigal
et al. [22] were either lost or contained insufficient data
to apply the diagnostic criteria. If the proportion of
probable dementia in missing records was the same as
for the available records, 12% of cases would have been
missed as a result [22]. Crugel et al. [7] did not perform
any validation study but did note that it was known that
the number of dementia cases identified using their elec-
tronic record system was lower than the number known
to the hospital trust. Renvoize et al. [23], who used local
computerised medical and social records for case identi-
fication, found a prevalence rate consistent with previous
studies. Pendlebury et al. [5] state an awareness of
Fig. 2 Sources of Existing Data for all Included Articles
Sibbett et al. BMC Psychiatry  (2017) 17:239 Page 10 of 16
65 
 
under-recording of dementia diagnoses in primary care
records and Sampson et al. [24] report that dementia is
under-diagnosed in the acute hospital setting. Shah et al.
[25] also acknowledge the deficiencies in recognition
and recording in primary care, and note that the preva-
lence found in their study is lower than what might be
expected, based on epidemiological surveys. Newens et
al. [26] used hospital information systems and clinical
records to ascertain the incidence and prevalence of
early onset dementia. The authors reported a similar
prevalence rate to rates documented elsewhere.
Ryan [27] acknowledged potential diagnostic and cler-
ical errors within the Scottish Morbidity Records (SMR)
from Information Services Division (ISD) Scotland. A
validity rate of 84% is quoted from a previous work by
the same author [27]. Russ et al. [10] also note the
likelihood that SMR datasets will miss some cases of de-
mentia. Stephens et al. [28] highlight the possibility of
under-recording in Hospital Episode Statistics (HES),
particularly those with earlier or milder forms of demen-
tia. Keenan et al. [29] question the reliability of dementia
subtype diagnoses within HES. Those studies describing
a validation study or making a comparison with
expected rates are shown alongside their respective
methodologies in Additional file 5: Table S4.
Brayne et al. [30], Brayne et al. [31] and Clarke et al.
[4] made comparisons of prevalence with expected or
previously documented rates. As these studies used
existing data in part only, it is not possible to draw con-
clusions regarding the sources of existing data that were
used based on these comparisons.
Discussion
Our systematic review identified 47 articles relevant for
inclusion. 36 articles used existing data sources alone for
dementia ascertainment, whilst 11 used existing data in
conjunction with new data. The existing data sources
utilised by the 47 articles included: research databases,
death records, clinical notes, national datasets, hospital
information systems, radiology records, missing person
records, pharmacy records and hospice records. The
most commonly used sources were research databases,
clinical records and death records. The quality of the de-
scription of dementia ascertainment methodology varied
widely, with scores from 7 to 16 out of a maximum
score of 16. Most studies that completed a validation
procedure for dementia ascertainment found that
observed rates of dementia were lower than expected.
The initial literature search returned a substantial
number of articles in comparison to the number that
were included for final analysis. As this review consid-
ered a methodology rather than an outcome or specific
dementia-related topic, it was necessary to write a broad
and inclusive search strategy so as not to miss any
relevant articles. As such, it was anticipated that a high
proportion of articles would be excluded. The articles in-
cluded in the final analysis covered a wide variety of spe-
cific study topics. The results of the quality measure
varied widely, but those papers demonstrating the poor-
est scores for quality of description were, in nearly all
cases, papers in which dementia ascertainment was per-
formed in order to build a cohort for further study [7, 8,
19, 32–34]. This might be expected given that dementia
ascertainment was not the focus of these studies and
thus the descriptions of method concentrated on other
aspects of the studies.
Our assessment of methodology is primarily a narra-
tive account of the sources of existing data utilised in
the included articles. The purpose of this review does
not include repeating previous extensive literature that
compares and comments on diagnostic criteria. The aim
is to outline each source and provide some evidence re-
garding the usefulness or drawbacks of the source.
All of the research databases used by papers in this re-
view rely on the collection of anonymised patient data
contributed by participating general practices within the
UK. Databases such as the Clinical Practice Research
Database (CPRD) have been designed in order to facili-
tate data-linkage across services, including Hospital Epi-
sode Statistics [32]. General practice databases have
been used widely in medical research and it has been re-
ported that usage of the General Practice Research Data-
base (GPRD) and Clinical Practice Research Database
have resulted in over 800 and 1500 publications respect-
ively [35, 36]. Each database collects data from several
hundred general practices and provides records for mil-
lions of patients [13, 35, 37]. The volume of data avail-
able and the number of general practices involved in
such databases indicate a clear benefit to the use of these
resources. In order to determine the usefulness of gen-
eral practice research databases, we must ascertain the
validity of diagnostic coding for dementia within the da-
tabases. We might consider this in two ways: firstly, do
diagnoses contained within the database correlate with
information within the general practice records; and sec-
ondly, are dementia cases recorded within general prac-
tice records an accurate reflection of dementia rates
within the population? Using GP questionnaires, Dunn
et al. [38] completed a validation study of dementia cases
and controls drawn from the GPRD and reported a con-
firmed diagnosis in 83% of recorded cases. This rate is
similar to those reported for Alzheimer’s disease by
studies in this review: Imfeld et al. (80%) [11] and
Seshadri et al. (83%) [12]. Seshadri et al. did, however,
find a much lower validation rate when considering both
dementia and Alzheimer’s disease together (48%) [12].
Dunn et al. [38] did not consider dementia prevalence in
the study population against previously reported national
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statistics or alternative databases. In this review, Imfeld
et al. [11], Guthrie et al. [16], and Rait et al. [17] all re-
ported lower than expected ascertainment rates from
the GPRD, SPICE-PC and THIN database respectively,
when compared to previously documented incidence
and prevalence. From the findings of the articles in-
cluded in this review, we would suggest that dementia
diagnoses within a general practice research database are
not a completely accurate reflection of dementia cases
known to the GP or within a population.
A distinct advantage of using death certificates for de-
mentia ascertainment is their availability and the ease of
data collection from this source. As dementia is not al-
ways the primary cause of death, the inclusion of the
diagnosis on the death certificate relies on both the
certifying doctor’s familiarity with the patient’s medical
history and their opinion as to whether the diagnosis
merits inclusion on the certificate. Despite the import-
ance of dementia as a contributory factor or cause of
death, rates of reporting on death certificates have
historically been poor [39, 40]. A more recent Scottish
study did however illustrate an improvement, with
71.5% of deceased patients from a group with known de-
mentia having the diagnosis correctly recorded on their
death certificate [41]. In this review, both Doll et al. [42]
and Russ et al. [10] demonstrated such under-reporting.
It is clear that, despite improvements in diagnosis and
reporting, we cannot rely on death certificates to give a
completely accurate reflection of dementia cases within
a population and studies using this source alone are fail-
ing to achieve the best possible ascertainment rates.
The national datasets used by studies in this review in-
clude Scottish Morbidity Records (SMR) from the Infor-
mation Service Division (ISD) of NHS National Services
Scotland and Hospital Episode Statistics (HES). SMR are
sets of permanently linked datasets, and specifically,
SMR01 is a record of inpatient and day-case general hos-
pital admissions, whilst SMR04 is a record of inpatient
and day-case psychiatric admissions [43]. HES is a na-
tional dataset containing records of all admissions, out-
patient appointments and A&E attendances at NHS
hospitals in England [44]. In this review, Stephens et al.
[28] and Keenan et al. [29] highlight the likelihood of
under-recording or inaccuracies in the HES data, but a
recent study found that when compared with dementia
recording in CPRD and General Practitioner survey re-
sponses, HES was accurate in 85% of cases [45]. In order
to make assurances regarding the quality of published sta-
tistics, ISD Scotland complete regular assessments of col-
lected data. The report published in 2015 found an 89%
accuracy for the main diagnosis and a 77.5% accuracy for
dementia diagnoses in SMR01 [46]. In our review, Ryan
[27] reports a validity rate of 84% based on a previous
work. Out-with this review, Russ et al. [47] found that
while SMR01 only recorded 53% of known cases of de-
mentia, SMR04 recorded dementia 100% of the time in a
cohort of people with known dementia. This would sug-
gest that where a diagnosis of dementia has been made in
a psychiatric unit, it is reliably reported within the national
dataset SMR04. As most health assessment and treatment
in the UK takes place within the National Health Service
(NHS) it can be assumed that these datasets are represen-
tative of the whole population. They can also be used for
large-scale studies. The main drawbacks of these datasets
would be that any cases not seen in hospital services
would be missed, they rely on cases having been diag-
nosed, the cases having been diagnosed correctly, and they
rely on the diagnoses being recorded in the relevant rec-
ord systems.
The findings of the study by McGonigal et al. [22]
would suggest that psychiatric records and psychiatric
case registers are valuable and accurate data sources for
pre-senile dementia case ascertainment. It should how-
ever be noted that these are historical data, mostly over
30 years old, and admission policies for psychiatric
hospitals in Scotland and the UK have changed over that
period so this assumption may no longer be tenable. It is
possible that a diagnosis, although recorded within clin-
ical records, is simply incorrect. A 2012 Danish study
highlighted this issue and in a study of 195 patients reg-
istered as having a diagnosis of early onset dementia, the
authors found that the diagnosis was correct (according
to DSM-IV or ICD-10 criteria) in just 58% of cases [48].
It would therefore seem reasonable to suggest that the
most reliable diagnosis taken from written data sources
will be where the evidence for diagnostic criteria is
present as well as the diagnosis itself.
Studies aiming to evaluate the quality of source infor-
mation might compare the data collected with informa-
tion from a second source, for example paper medical
records [49]. Concordance between two sources in-
creases the likelihood of correctness, and completeness,
but it should be recognised that no source can be as-
sumed to be completely accurate – there is no true
“gold-standard” [49]. A diagnosis present in more than
one source may superficially appear to be reliable; how-
ever, we must consider the possibility that a diagnosis of
dementia was initially entered into the notes in error
and simply transcribed from one record to another. Be-
tween October 2014 and September 2015, the National
Patient Safety Agency received almost 99,057 reports re-
lating to failures in documentation from NHS organisa-
tions in England and Wales [50].
In using previously collected data for dementia case
ascertainment, we are relying on diagnoses having been
made and recorded. Using existing data is therefore most
effective when diagnostic rates are high. Any population
with a poor record for detecting dementia might yield
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different study results, particularly if undiagnosed cases
are associated with particular factors or variables. Regional
variation in rates of diagnosis have been reported previ-
ously, suggesting that the use of existing data might be
more reliable in some geographical areas [51, 52].
All of the sources described by studies included in this re-
view have value, and all are likely to provide ascertainment
data for a majority of cases within a population. It would be
prudent, however, to be cautious in accepting any docu-
mented case as correct without evidence to substantiate the
diagnosis. Similarly, if a single source is used, the possibility
of missing cases should be considered. We must establish
methods for minimising any error, but one should be realis-
tic and accept that any dementia ascertainment method will
be open to some error. The main drawback to using exist-
ing data of any kind is the potential for undiagnosed cases
being missed. For this reason, the most accurate dementia
ascertainment process is likely to include prospective
follow-up with clinical assessment. Using such methods
does however have its own limitations. Collecting prospect-
ive data in an ageing population is time-consuming and can
lead to delays in the release of findings. This is particularly
true if we are to consider influences across the life course
or premorbid risk factors. Prospective studies are subject to
attrition, due to death or other causes. Using clinical
follow-up also restricts the size of a study cohort, with finite
funding and resources available for each study. Also signifi-
cant is the variability of clinical assessment methods across
studies, making the comparison of study results less accur-
ate. Within the UK there is an ongoing drive to improve
rates of dementia diagnosis and, as such improvements are
made, existing data will become increasingly accurate and
their use for dementia ascertainment will become increas-
ingly valuable in the study of dementia.
Considerations for future studies
The evidence for the accuracy of the sources discussed may
not be comprehensive and conclusive, but we must attempt
to make suggestions for a ‘best possible’ method when per-
forming dementia ascertainment using existing data. In
order to minimise any missed cases it would be sensible to
collect data from multiple data sources. This might elimin-
ate those cases that have simply failed to be recorded des-
pite a diagnosis having been made. In accessing multiple
sources, we may also be more confident that those without
a recorded diagnosis are truly dementia free. The most use-
ful method for determining whether any diagnoses are cor-
rect would be to consider evidence for a diagnosis within
the existing data. Evidence consistent with diagnostic cri-
teria for dementia may not only confirm recorded cases,
but identify cases that have failed to be recorded.
When deciding which combination of sources to in-
clude in an ascertainment methodology it is useful to
consider the advantages and disadvantages of each
source, and which combination of sources are likely to
yield the highest number of cases. Diagnoses derived
from hospital records are of particular value given the
high rates of hospital admission for persons with demen-
tia. [53] At a given time-point, it has been estimated that
6% of inpatients in a general hospital have dementia,
while 0.6% are aged over 65 and without dementia. [53]
National datasets derived from hospital records (such as
Hospital Episode Statistics) should contain the same
diagnoses as the hospital records themselves. It is how-
ever possible that in some situations, such as when there
is increased demand on a service, only the main diagno-
sis is coded. Although the list of diagnoses might be the
same, the records could contain further detail to allow
for confirmation of the diagnoses. In this sense they may
be considered more accurate. The nature of datasets
mean that a list of diagnoses, or list of participants with
a particular diagnosis can however be made available for
a much larger population and in a more time efficient
manner. Both, therefore, have their advantages and dis-
advantages, but using both is unlikely to yield many add-
itional cases. The choice of which to use of the two
would depend on the requirements of the study. The
similarities, advantages and disadvantages between GP
records and GP research databases would be much the
same as those described for hospital records. The benefit
of GP records over hospital records are that they are
more likely to contact records from external services
such as social work and housing and contact is likely to
be more frequent. These benefits might increase the
chance of a diagnosis or symptoms having been re-
corded. Death certificates have the advantage of being
readily available and they are particularly useful as
follow-up for participants who do not provide consent
for access to records or data linkage. For these reasons,
death records would be a useful addition to any other
source being used for ascertainment. The disadvantages
are that they rely on the physician deeming the diagnosis
significant enough to warrant inclusion on the death cer-
tificate and they are of no use in identifying dementia
cases in the living. Death records and national datasets
have the advantage of not being restricted to a specific
locality or area, compared with electronic health records
that might be held on a different system in each health
board. The recording of dementia diagnoses within these
sources depends on the proportion of dementia cases
identified in the community- in the UK this has previ-
ously been shown to be less than 50%. [54].
All of the sources described are likely to identify de-
mentia cases at the more severe end of the spectrum.
Regardless of the source, the diagnosis of dementia is
more likely to have been made if the condition is more
severe and it is therefore more likely to have been re-
corded. In contrast, early cases are more likely to remain
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undiagnosed and, as such, would not appear in any
existing data. In the case of hospital or GP records or
databases, the more severe the condition, the more likely
they are to have had contact with a healthcare provider.
Similarly, the higher the number of co-morbidities, the
more likely they are to have contact with services. This
regular contact with services for management of comor-
bidities may also mean that a diagnosis is more likely to
have been made. The more severe the dementia, the
more likely it is to be considered a significant factor in
cause of death and it is therefore more likely to be re-
corded on a death certificate.
Clinical assessment is probably the best method for
identifying early cases of dementia. There are however
problems with non-random screening participation. [55]
Early cases are more likely to be recorded in existing
data if cases are being identified and diagnosed at an
early stage within the community. Diagnoses are in turn
more likely to be made if the physician is aware of the
condition, appreciates the benefits of diagnosis and is
confident in making a diagnosis, or referring for a spe-
cialist opinion. Investments in research and public health
raise the awareness of dementia among physician, and
the general population, meaning that patients are en-
couraged to present to services rather than accept that
changes are merely a consequence of ageing.
Limitations of the review
Given the variability in the quality of the description of
methodology for dementia ascertainment and, in par-
ticular, the number that did not provide sufficient infor-
mation such that an incidence or prevalence rate for
dementia could be derived, it was not possible to draw
comparisons between the ascertainment rates for differ-
ent methodologies. A future study considering dementia
ascertainment methodologies, using existing data, in in-
cidence and prevalence papers only, might provide the
opportunity for direct comparison and an assessment of
the effectiveness of different methodologies. It would
also be worthwhile for such a study to include studies
based out-with the UK. As our study did not, we may
have missed ascertainment methodologies that could be
replicated using UK sources of existing data. With the
use of existing data in dementia studies continuing, it
may be worthwhile to consider updating this review in
due course. Given that, a single author performed phase
one screening of titles and abstracts there is the poten-
tial for error. This is, however, unlikely given that the
broad search strategy returned a large number of articles
that were obviously not relevant to the review.
Conclusions
In conclusion, our review revealed a lack of consistency
with regard to dementia ascertainment methodology
using existing data in previous UK studies. Optimising
ascertainment is of essential importance in order to in-
crease statistical power, avoid selection bias and enable
comparability between studies. We described the bene-
fits of a number of sources of existing data including:
death records, national datasets, research databases, and
hospital records. Evidence suggested that although each
was useful, none was completely accurate when used
alone and we would therefore recommend that future
studies use a combination of these data sources. Where
possible, studies should access records with evidence to
confirm, query, or refute the diagnosis. Studies should
also calculate a dementia ascertainment rate for the
study population to allow for comparison to an expected
or previously documented rate. Not only would this help
in judging the findings of an individual article, but it
would also provide further evidence for guiding demen-
tia ascertainment methodology using existing data.
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3.3  Chapter discussion and conclusions 
3.3.1  Further discussion on systematic review 
Having completed an extensive review of the UK-based literature, it was clear that 
there was no previously described ‘gold-standard’ method for ascertaining dementia 
using existing data. Furthermore, there was considerable variability between studies 
in the range and number of data sources utilised for dementia ascertainment 
purposes. The information gathered would have been improved if a larger proportion 
of included articles had provided sufficient data for ascertainment rate calculation. 
One consideration for the future would be the usefulness of a study looking 
specifically at studies of incidence or prevalence using existing data, where study 
dementia ascertainment rates could be compared, thus providing further basis for the 
evaluation of optimal methods. While the review performed in this thesis was 
designed to specifically guide ascertainment methods in the UK, a future study like 
that described above, would benefit from the inclusion of studies based outside the 
UK. While data sources used outside the UK may not be directly applicable to UK-
based study design, the types of datasets used may reflect types of data available in 
the UK. While the likely increased heterogeneity of context and healthcare systems 
resulting from such inclusions might be considered to have a negative impact on a 
review, the positive effect of a broader focus and the additional evidence gathered 
may outweigh this. There could be particular value in including European studies in a 
future review as these may be expected to share more similarities with UK studies 
and systems, as opposed to studies based in the United States of America for 
example. Given the number of studies that are carried out using centres across 
Europe, study design and completion in European countries may be expected to 
share similarities with UK studies; the observed methods may therefore be applicable 
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to the UK. Potentially relevant studies would include the European Prospective 
Investigation into Cancer and Nutrition (EPIC) - Murcia study, based in Spain; the 
study was originally designed to investigate potential associations between lifestyle 
and nutritional factors and cancer, but has been extended to investigate other 
outcomes, including dementia.(Andreu-Reinon et al., 2019) Dementia outcomes were 
determined using a two-step process: by linkage of the EPIC dataset with medical 
datasets, followed by the validation of potential cases through careful study of the 
medical records.(Andreu-Reinon et al., 2019) The relevance of such a study to our 
ascertainment method is clear considering this study also used a cohort originally set-
up for other purposes and ascertained dementia using existing data. Such a study 
would add valuable evidence and information on the methods for determining incident 
dementia using existing data. Studies using existing data to support clinical 
ascertainment – such as the Rotterdam study, which has reported using medical 
records to support clinical assessment to determine cases of dementia – would also 
add valuable evidence that would be of relevance to the design of UK-based 
studies.(Ott et al., 1995)  
Health service delivery, clinical guidelines and protocols in Europe may also share 
similarities with the UK. While no two countries will share the exact same model for 
delivering healthcare, the same can be said for the UK where the individual nations 
deliver healthcare slightly differently; the broad underlying principle of the national 
health service is however the same across the UK. The NHS provides healthcare for 
all citizens and is free at the point of service, funded by the government through tax 
payments. National health systems are described as following the Beveridge model, 
named for William Beveridge who designed the NHS in the UK, and such systems 
are employed in other countries within Europe including Portugal, Spain, Denmark 
and Italy.(Gobierno de Espana, 2019; Lameire, Joffe & Wiedemann, 1999; Wallace, 
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2013) Given the potential for similarities in healthcare delivery between such 
countries, dementia ascertainment procedures based on healthcare data from these 
countries may be applicable to studies in the UK. Future systematic reviews might 
therefore consider broadening the search strategy to include studies based in 
European countries.  
In our study, we used search terms that related to dementia, longitudinal study type 
and the UK. While we used a multipurpose keyword search (searching all possible 
fields), there is a theoretical possibility that a study may not have included one or 
more of these terms in the included fields. While it is unlikely that the first two of these 
terms would not be included, there is a possibility that the UK, or some region thereof, 
was not included in one of the searched fields. If this were the case, then we would 
have accidentally omitted a study of interest. While this was a possibility, we would 
note that our search strategy identified all of the relevant studies that we were aware 
of and expected to find. Any future reviews of this kind might consider whether to omit 
these terms. 
Without any statistical quantification regarding the relative effectiveness of differing 
ascertainment methods, it was difficult to produce a solid conclusion from the review 
and make a single recommendation for future studies. As detailed within the published 
paper, a quality tool was used to describe the amount of information on dementia 
ascertainment methodology contained within included papers. This was developed to 
provide an indication of whether studies contained sufficient detail to allow for an 
ascertainment rate to be calculated and compared to another population. It was based 
on the authors’ opinion and did not replicate a previous tool from the literature. As 
such, it is accepted that this would have been approached differently by others and is 
open to criticism. If a future review were to concentrate on incidence or prevalence 
studies only, then it is likely that components of such a tool could be made more 
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specific. While the make-up and application of the tool can be questioned it is hoped 
that it satisfactorily provided the information that it was designed to do. It was included 
in order to give the reader an indication of the varying amounts of detail included in 
study methodologies and as evidence for why it was impossible to quantify results. 
Further to this, it was designed to highlight the importance of including such detail in 
future studies. Despite the limitations of the quality tool and being unable to produce 
a comparative quantification of the effectiveness of the studies, it was hoped, that 
gathering evidence from multiple previous studies into a single paper and discussing 
the potential advantages and disadvantages of the included data sources would prove 
to be a useful resource for other research teams.    
3.3.2  Dementia ascertainment in the Lothian Birth Cohort 1921 
It was determined that the most effective dementia ascertainment procedure for the 
LBC1921 study would be one that was developed based on the evidence gathered in 
the systematic review. In particular, the aim would be to maximise both sensitivity and 
specificity. Findings from the systematic review suggested that greater sensitivity 
would be obtained through the use of multiple data sources, with each data source 
ideally placed to ‘fill the gaps’ likely to be present in another. As the review highlights, 
specificity would be increased with the inclusion of a data source that would potentially 
provide details to support or refute a diagnosis. Based on the systematic review, three 
types of data source were identified as having benefits for inclusion in the LBC1921 
dementia ascertainment procedure. First, a large dataset likely to include follow-up 
data for large proportion of participants. Second, a dataset that could provide 
additional details regarding signs, symptoms and diagnosis. Third, a dataset likely to 
be specifically rich in dementia data. 
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For the LBC1921 study, three primary data sources were therefore selected. Death 
certificates, as described within the review, are a widely-utilised and accepted source 
of dementia data. Given the number of participants known to be deceased at the 
outset of this study, death certificates would be a rich source of data. Publicly 
available, access would not be limited by consent procedures. This would be of 
particular relevance in the LBC1921, where consent to data linkage and access to 
medical records was not in place until the fourth wave of testing, by which time many 
of the participants had died. Death certificates would be valuable in providing data for 
those participants lost to follow-up by death, or for those lost to follow-up who then 
subsequently died. While death certificates have received criticism in the past 
regarding the reliability of dementia reporting, evidence gathered in the review 
indicated improvements in recent years. Since all deaths would have occurred after 
recruitment in 1999, it can be assumed that these improvements were applicable. It 
is not possible to exclude the possibility that dementia was erroneously omitted from 
a proportion of death certificates. It was hoped that utilising further sources would 
minimise this possibility. The second data source selected was local electronic 
hospital records (Trak system). These would be available for participants living in the 
Lothian area, who had provided consent to data linkage at the fourth wave of follow-
up. Given the relatively late inclusion of this consent procedure in the LBC1921 study, 
the number of participants would be limited. In cases where there was access, 
electronic hospital records would provide a wealth of data including hospital 
correspondence, multi-disciplinary clinical notes, referrals from general practice, lists 
of coded diagnoses (ICD10), test results and imaging reports. This data source would 
be valuable not just in identifying cases, but also in providing evidence or detail to 
support or refute any dementia diagnoses. The final source of data would be 
psychiatric records. These would again be available for those participants who 
provided consent to data linkage. Psychiatric records would exist for those 
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participants who had been in contact with psychiatric services, meaning that these 
data would likely provide data on fewer participants than the previous data sources. 
Given, however, that dementia is frequently diagnosed and managed within 
psychiatric services, it was deemed to be of specific importance in the identification 
of cases. At the outset of this study, psychiatric records were held on a system 
separate to the general hospital records (PiMS system). At a first round of data 
collection for dementia ascertainment, a request was made to system management 
for a record of all diagnoses in this system for LBC1921 participants. Latterly, 
psychiatric records were incorporated into the general hospital system (Trak), 
meaning that in addition to lists of diagnostic codes, further details on diagnoses were 
available through psychiatric inpatient and outpatient letters. 
While there was no possibility of performing prospective clinical assessment for all 
participants as part of the ascertainment procedure, additional information would be 
available for a small number who were seen for review in either the NHS or research 
setting. In the research setting, assessments were undertaken when memory 
impairment or decline was noted during the routine LBC1921 testing, or when a new 
diagnosis of dementia was self-reported. Participants seen by members of the 
research team within NHS clinics were asked for consent to share relevant 
information with the LBC1921 study. 
Having determined the sources of data to be used in LBC1921, data was collected 
from each in repeated rounds of updated data collection, until a specific consensus 
date. The exact dates are provided within the study in section 4.2. Data included any 
evidence of dementia, cognitive impairment, or similar, along with any relevant 
additional information (for example, history of vascular disease or causes of death). 
The evidence collected for each participant was examined at a consensus meeting, 
which included the author of the thesis, a psychiatrist specialising in psychiatry of 
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older age and a medical geriatrician with substantial expertise in the field of dementia. 
Including more than one specialist with expertise in both the clinical diagnosis and 
study of dementia limited any bias that might result from individual difference in 
practice or interpretation of criteria. The consensus meeting took place within the NHS 
setting to allow for access to electronic hospital records for any (consented) 
participant where additional information was useful to make a consensus decision 
regarding dementia classification. The members of the consensus meeting discussed 
the strength of the evidence in each case and proposed an opinion as to the presence 
of dementia. Agreement was achieved for each case without the need for further 
discussion at a later date.  
Cases were determined with differing degrees of certainty based on the volume and 
detail of the evidence for dementia gathered in each case. ‘Probable’ and ‘possible’ 
gradations had been used in previous dementia criteria and dementia studies to 
illustrate confidence in the diagnosis and these same terms were therefore employed 
to group cases by the strength of evidence for a dementia diagnosis.(Huang & 
Halliday, 2013; McKhann et al., 1984) The consensus team describe their rationale 
for each of the cases in a summary of criteria. The criteria describe the type of data 
collected from each data source. We provide an overview of the criteria, and the basis 
for each here, while a summarised version is provided in Table 4.1, in Section 4.2 
(page 93). On a death certificate, dementia recording was fell into three categories. 
First, where there was no mention of dementia, second, where dementia was 
recorded as either a cause of death or contributing factor, and third, where cognitive 
impairment was recorded as a cause of death or contributing factor. Given that under-
reporting of dementia is the most common criticism of death certificates for dementia 
ascertainment, it was assumed that where dementia was recorded, it was likely 
present. Any recording of dementia on a death certificate was therefore classified as 
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‘probable’ dementia. A record of cognitive impairment on a death certificate was 
classified as ‘possible’ dementia. The rationale was that for cognitive impairment to 
warrant inclusion on the death certificate – as a cause or contributor to death – it was 
likely to be of a significant severity, rather than a subtle change in cognition.  
Similarly, cognitive impairment noted in hospital records was likely to represent a 
significant change in cognitive function and was classified as a ‘possible’ dementia 
case. This did not however include cases where cognitive impairment was noted to 
have resolved, been labelled as a delirium or if a potentially reversible cause of 
impairment was noted (a febrile illness for example). A diagnosis of ‘probable’ 
dementia was derived from one of three patterns of evidence within the hospital 
records; either recorded dementia with supporting diagnostic details, a recorded 
diagnosis of dementia without details, or no confirmed diagnosis, but sufficient data 
within records to meet ICD-10 diagnostic criteria. Where a possibility of dementia was 
raised within records, but there was insufficient evidence to confirm a diagnosis 
according to ICD-10 criteria, a case was classified as ‘possible’ dementia. A diagnosis 
of dementia confirmed on clinical review was termed as a ‘probable’ dementia case. 
It is important to note that all such diagnoses depended on the absence of evidence 
contradicting or opposing the presence of dementia. For example, where cognitive 
impairment was recorded in hospital records, but psychiatric correspondence detailed 
a likely diagnosis of mild cognitive impairment, the criteria determined that dementia 
was not present. While it was preferred that dementia cases were supported by details 
of diagnoses, the inability to access linked hospital records for every participant meant 
that this was not possible.    
Given the paucity of articles exploring and quantifying the success of dementia 
ascertainment procedures in the systematic review, it was important that the 
outcomes of the method designed for use in the LBC1921 study be evaluated. It was 
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therefore planned that the results of the LBC1921 dementia ascertainment procedure 
would be compared with expected or predicted dementia rates for the cohort. This 
would not only allow LBC1921 researchers and readers of the study to gauge the 
reliability of the dementia outcome, but also provide evidence of the relative success 
or inadequacy of the method for those designing an ascertainment methodology. After 
dementia cases had been determined, the methodology would be further evaluated 
through the consideration of the usefulness of the included data sources. Specifically, 
the data sources providing evidence for each dementia case would be identified, such 
that the sources contributing most highly to the ascertainment procedure could be 
recognised. Similarly, any redundant data sources providing no unique data could be 
highlighted, with the suggestion that there is no need to include these in future 
ascertainment procedures. The results of these evaluations of effectiveness and 

























4: Modifiable risk factors for dementia in the Lothian Birth Cohort 1921 
4.1  Introduction 
As highlighted in the main introduction, understanding the risk factors or protective 
factors for dementia is pivotal to the development of preventative strategies. 
Evidence-based medical, social and lifestyle strategies have been shown to reduce 
the impact of other significant health conditions, such as coronary heart disease, 
stroke and diabetes.(Law, Wald, & Rudnicka, 2003; World Health Organisation, 2010) 
The research behind such evidence has guided the development of risk assessment 
measures, monitoring techniques and risk reduction strategies.(Department of Health 
Physical Activity Health Improvement and Protection, 2011; National Institute for 
Health and Care Excellence, 2015, 2017) With increased understanding and 
evidence, a similar approach could potentially be designed for dementia syndromes, 
with strategies aimed at preventing or delaying the onset or progression of the 
disease.  
Without a clear understanding of how, when or why the pathological processes for 
dementia begin, a life course approach to considering risk factors is particularly 
valuable. A life course approach would not only take into account those factors acting 
in later life, at a time close to dementia onset, but also mid-life factors – such as health 
conditions or fitness, and early-life factors – such as educational attainment.   
Identifying potentially modifiable factors associated with dementia would be key to the 
design of preventative strategies. As such, a number of studies have attempted to 
identify any factor that could be targeted in order to decrease risk for dementia. 
Several factors have been further evaluated through the meta-analyses of results 
from multiple reports. Previous estimates suggest that up to fifty percent of Alzheimer 
disease cases occurring worldwide may be attributable to potentially modifiable risk 
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factors, thus, reinforcing the potential impact of risk reduction strategies.(Barnes & 
Yaffe, 2011) A recent report considered the impact of nine potentially modifiable risk 
factors for dementia – education, midlife hypertension, midlife obesity, midlife hearing 
loss, late life smoking, late life depression, late life physical activity, late life social 
isolation and late life diabetes.(Livingston et al., 2017) The findings suggested that 
35% of dementia was attributable to these nine factors but the study authors 
acknowledge that this could be higher if other factors were included in the 
analyses.(Livingston et al., 2017) A second report used relative risks from existing 
meta-analyses to estimate the population-attributable risk of Alzheimer’s disease for 
seven potentially modifiable risk factors – diabetes, midlife hypertension, midlife 
obesity, physical inactivity, depression, smoking and low educational 
attainment.(Norton, Matthews, Barnes, Yaffe, & Brayne, 2014) While the combined 
worldwide population-attributable risk for the seven factors was reported to be 49.4% 
(95% CI: 25.7-68.4), when the results were adjusted for associations between the risk 
factors the estimate reduced to 28.2% (95% CI: 14.2-41.5).(Norton et al., 2014) 
Therefore, after accounting for the non-independence between risk factors, it would 
appear that approximately thirty percent of cases of Alzheimer’s disease worldwide 
may be attributable to potentially modifiable risk factors (as opposed the fifty percent 
of cases previously reported).(Norton et al., 2014)  
A 2015 systematic review and Delphi consensus study collected and reviewed 
evidence from two-hundred and ninety-one epidemiological studies, with the purpose 
of evaluating the evidence for potentially modifiable risk factors for dementia.(Deckers 
et al., 2015) By considering the results of the systematic review alongside the results 
from the first round of the Delphi study, a panel of experts ranked the risk factors in 
order of importance with respect to primary prevention of dementia.(Deckers et al., 
2015) The study highlighted depression, midlife hypertension, physical inactivity, 
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diabetes, midlife obesity, hyperlipidaemia and cigarette smoking as important factors 
associated with increased risk for dementia.(Deckers et al., 2015) A number of other 
factors including coronary heart disease, renal dysfunction, diet and cognitive activity 
were identified as requiring further study.(Deckers et al., 2015) The authors reported 
a considerable overlap between the factors identified in this study and those reported 
in previous reviews.(Deckers et al., 2015) As described within the next section of this 
chapter, this study forms the basis for our selection of risk factors to be considered in 
the first study of risk factors for dementia in the LBC1921.   
We note that although several risk factors for dementia have been identified with some 
consistency within the literature, addressing such factors has been shown to be 
ineffective in prevention trials.(Andrieu, Coley, Lovestone, Aisen & Vellas, 2015) For 
example, while hypertension has been highlighted as a risk factor for dementia, in the 
Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG) 
study and the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) 
the reduction in risk for dementia associated with antihypertensive treatment did not 
reach statistical significance (hazard ratio [HR] 0·86, 95% CI 0·67 to 1·09, p=0·21 and 
relative risk reduction 12%, 95% CI  8% to 28%; p=0·2).(Andrieu et al., 2015) A 2016 
paper by Moll van Charante et al. reported the results of a 6 year randomised control 
trial of a nurse-led multidomain intervention for cardiovascular risk factors - preDIVA. 
(Moll van Charante et al., 2016) Based in the Netherlands, the intervention consisted 
of 4-monthly nurse assessments where the following risks were assessed: smoking, 
blood pressure, diet, weight and physical activity; blood lipids and blood glucose were 
measured every 2 years.(Moll van Charante et al., 2016) Following assessment, 
tailored lifestyle advice was given according to cardiovascular risk management 
guidelines and drug treatment was prescribed where indicated.(Moll van Charante et 
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al., 2016) The intervention did not result in a reduction in all-cause dementia (hazard 
ratio [HR] 0·92, 95% CI 0·71 to 1·19; p=0·54).(Moll van Charante et al., 2016)  
Dementia is a disease associated with ageing and dementia studies are therefore 
typically completed using older-age populations. Classically, studies of older age have 
included those aged over 65 years. Many of the articles included in previous reviews 
examined participants aged over 65 years.(Deckers et al., 2015) As a result of 
increasing longevity, the over-65 years age bracket is widening. Factors such as 
advancements in healthcare, changes in employment type and lifestyle habits have 
led to increased life expectancy in the UK. The Office of National Statistics (ONS) 
reported that in 1980 to 1982, five percent of males and fourteen percent of females 
could expect to live to at least ninety years of age.(Office for National Statistics, 2017) 
By 2014 to 2016, twenty-one percent of males and thirty-two percent of females could 
expect to reach at least ninety years.(Office for National Statistics, 2017) In 1987, the 
total number of persons aged over 90 years and living in the UK was 212,067; by 
2017, this figure had risen to 579,776.(Office for National Statistics, 2018) As the 
number of persons surviving beyond ninety years increases, it is expected that the 
oldest-old will also represent an increasing proportion of those aged over 65 
years.(Bullain et al., 2013)  
With an increased proportion of the population surviving into oldest-age, it is 
necessary that studies consider whether risk factors for dementia are the same in 
early old age and more advanced old age. Understanding any differences in the risk 
factor profile for dementia with advancing age would allow for the appropriate 
targeting of preventative strategies and make the best use of available resources. The 
oldest-old has been varyingly defined as those aged over 80, 85 or 90 years of age.(U. 
Lucca et al., 2015) The fact that studies of this age group are less frequently 
documented within the literature may reflect the potential difficulties in recruiting and 
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retaining participants of advanced age. Co-morbid health conditions, physical frailty, 
cognitive decline, changes in living circumstances and mortality may all contribute to 
reduced recruitment and increased attrition. Despite such difficulties, studies including 
the 90+ Study, based in North America, and the Monzino 80-plus Study, based in 
Italy, have been designed to examine dementia in oldest-old populations.(Corrada, 
Sonnen, Kim, & Kawas, 2016; Ugo Lucca et al., 2015) Studies investigating dementia 
in the oldest old have proposed changes to the risk factor profile in oldest-age, when 
compared with earlier old-age.(Kawas, 2008)  
As can be seen from our discussion thus far, there are already a number of studies 
that investigate risk factors for dementia in oldest-old age, and even more in earlier 
old age or older age in general. We therefore summarise our rationale for performing 
another study of risk factors in oldest-old age as follows:  
1) Studies in this age-group are less numerous and a larger volume of data is 
required to make conclusions about the risk factor profile in oldest-old age; 
2) As described in the introduction, the oldest-old age group is complex with 
regard to their health and disease profile – large numbers of studies are 
therefore likely to be required to decipher which risk factors are important; 
3) Studies of the oldest-old typically have smaller sample sizes than earlier old 
age and a greater number of studies are therefore required in order to collect 
a volume of evidence equivalent to studies in earlier old age; 
4) Trials designed to address risk factors identified in observational studies have 
been shown to be ineffective in reducing dementia risk, suggesting a 
complexity to these risk factors that is not yet understood and a requirement 
for further study to promote understanding. 
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We therefore suggest that further studies in this field and age-group are required. The 
subsequent section of the thesis therefore explores the risk factors for dementia in 
the LBC1921, an oldest age cohort. In doing so, the aim was to obtain further evidence 
that would either support or oppose the literature describing a changed risk factor 
profile for dementia in oldest age. The risk factors selected for consideration were 
drawn from the existing literature, as described within the study, and had a particular 
focus on those that could be described as potentially modifiable.   
The study included in this chapter is an amended version of a peer-reviewed article, 
published during the course of this PhD.(Sibbett et al., 2017) In the original published 
version, a number of participants were included for whom it was later discovered that 
there were incomplete follow-up data. As soon as this was detected, the analyses 
were repeated, and the journal contacted and supplied with the new results. The 
amended version is included in place of the original to provide clarity between the 
correctly reported results and the further discussion within the thesis. The original 
published version however is supplied, along with the original supplementary 
materials, and the submitted corrigendum, as Appendices 2i (page 258), 2ii (page 
269) and 2iii (page 276) respectively. The complete reference for the original 
publication is as follows: 
Sibbett RA, Russ TC, Deary IJ, Starr JM: Risk factors for dementia in the ninth decade 
of life and beyond: a study of the Lothian birth cohort 1921. BMC Psychiatry 2017, 
17(1):205. 
The author of this thesis was the first author of the study and made the following 
contributions to the published work: assisted with study design, completed data 
collection for dementia diagnoses, completed the statistical analyses, interpreted the 
results, led the writing of the paper and contributed to revisions of the same. The 
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contributions made by the additional authors are detailed within the manuscript. The 
supplementary materials for the amended manuscript are provided in Appendix 2iv, 
from page 285. The individual appendices are provided on the following pages: 
• Additional file 1: Table S4.1 .............................................................. page 285 
• Additional file 2: Table S4.2 .............................................................. page 286 
• Additional file 3: Table S4.3 .............................................................. page 287 
• Additional file 4 .................................................................................. page 288 
• Additional file 5: Table S4.4 .............................................................. page 291 
 The references for this study are included within the main reference section for the 































4.2  Risk factors for dementia in the ninth decade of life and beyond: A 
study of the Lothian Birth Cohort 1921 
Ruth A. Sibbett, MBChB, Tom C. Russ, PhD, Ian J. Deary, PhD,
 
John M. Starr, 
FRCPEd 
From the Alzheimer Scotland Dementia Research Centre (R.A.S., T.C.R, I.J.D., 
J.M.S.), Centre for Cognitive Ageing and Cognitive Epidemiology (R.A.S., T.C.R., 
I.J.D., J.M.S.), Department of Psychology (I.J.D.), Division of Psychiatry (T.C.R.), The 
University of Edinburgh, Edinburgh, UK. 
Abstract 
Background: With increasing numbers of people surviving beyond eighty years, this 
section of the population demands attention to reduce the impact of dementia. In order 
to develop effective preventative strategies, it is essential to understand age-specific 
risk factor profiles for dementia: do risk factors for dementia in those in their sixties 
and seventies persist into oldest age? The aims of this study were to determine 
incident dementia and to investigate the risk profile for dementia from age 79 to 95 
years in a well-characterised cohort. 
Methods: Participants underwent intelligence testing at age 11 and were followed-up 
from at 79 years of age. Variables included: age, sex, age 11 IQ, APOE ɛ4, education, 
diabetes, hypertension, statin use, physical activity at leisure and in occupation, 
symptoms of depression, height, number of teeth, body mass index, blood pressure, 
cholesterol and HbA1c. Dementia cases were ascertained from death certificates, 
electronic patient records and clinical reviews. Logistic regression analysis 
determined the degree of risk for dementia associated with each variable. Analyses 
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were completed both with and without the physical activity variables due to the 
significant number of missing data for these variables.  
Results: Of the eligible cohort, n=379 participants remained dementia-free and 
n=110 had developed probable dementia. When logistic regression analyses 
contained all variables, complete data was available for n=221 (n=48 with dementia). 
Results demonstrated that greater lifetime physical activity (OR: 1.17, 95% CI: 1.04, 
1.32) and the use of statins (OR: 3.39, 95% CI: 1.04, 11.02) increased the risk for 
dementia. A reduction in risk for dementia was seen for hypertension (OR: 0.47, 95% 
CI: 0.23, 0.98). When physical activity variables were excluded, the number with 
complete data increased to n=355 (n=80 with dementia). Positive APOE ɛ4 carrier 
status was found to increase the risk for dementia (OR: 2.23; 95% CI: 1.29, 3.86), 
while increased height (OR: 0.72, 95% CI: 0.55, 0.95) was shown to be associated 
with a decreased risk. 
Conclusions: Dementia incidence was consistent with expected rates. The risk 
profile for dementia in this cohort of participants aged 79-95 confirmed previous 
findings that risk factors differ for those over 79 years.  Further evidence is 
recommended in order that the risk profile for this age group can be accurately 
determined. 








Without clear means of prevention or cure, dementia is recognised to be one of the 
greatest public health challenges facing the ageing global population. Dementia rates 
are known to increase exponentially with age, from 5.5 per 1000 person-years in 
those aged 70-74, to 30.5 per 1000 person-years in those aged 80-84.(Fratiglioni et 
al., 2000) With increasing numbers of people surviving into the ninth decade of life 
and beyond (Norton, Matthews, & Brayne, 2013), this section of the population 
demands attention in order to reduce the impact of dementia.(Knapp et al., 2007)
 
Despite studies such as the 90+ Study (MiND) (North America) and the Monzino 80-
plus Study (U. Lucca et al., 2015) (Italy) the oldest in the population remain less well 
represented in dementia research.  
In order to develop effective preventative strategies for dementia and ensure that 
these are directed appropriately, it is essential to identify potentially modifiable risk 
factors and understand whether these persist into oldest age. Significant modifiable 
risk factors for dementia demonstrated by replication within the literature include: 
diabetes (Lu, Lin, & Kuo, 2009), hypertension (Rönnemaa, Zethelius, Lannfelt, & 
Kilander, 2011), hypercholesterolaemia (Anstey, Lipnicki, & Low, 2008), depression 
(Diniz, Butters, Albert, Dew, & Reynolds, 2013), smoking (Anstey, Sanden, Salim, & 
O'Kearney, 2007; Gelber et al., 2012), obesity (Gelber et al., 2012) and physical 
inactivity (Deckers et al., 2015; Gelber et al., 2012; Rovio et al., 2005). Previous 
studies have proposed that the risk factor profile for dementia changes with age, but 
the evidence is not conclusive.(Bullain et al., 2013; Kawas, 2008)   
The present study draws on prospectively collected longitudinal data from the Lothian 
Birth Cohort 1921 (LBC1921). Participants were predominantly cognitively normal at 
baseline (aged 79 years) and underwent detailed follow-up from to age 95 years. As 
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a result, this study can add further evidence to the literature regarding risk factors for 
dementia in the oldest-old. Most participants in this cohort had also taken part in 
childhood intelligence testing at age 11 years. This is an unusual and valuable feature 
of the data for a study cohort of the oldest-old, given that lower childhood IQ has been 
shown to be a putative risk factor for dementia (McGurn, Deary, & Starr, 2008) and is 
associated with several modifiable risk factors.(Corley, Gow, Starr, & Deary, 2010; 
Corley, Gow, Starr, & Deary, 2012; Mõttus, Luciano, Starr, & Deary, 2013) Dementia 
ascertainment had not previously been performed in LBC1921 and, although a 
number of participants would have developed dementia during the study period, there 
had not been any clear means of identifying all such participants. Mini-Mental State 
Examination (MMSE) (Folstein, Folstein, & McHugh, 1975) was performed at each 
wave of follow-up and a small number were seen for clinical review following concerns 
raised regarding their cognitive function. Some participants self-reported a new 
diagnosis of dementia. This would have identified only a proportion of cases. There 
was no previous follow-up regarding dementia ascertainment for those who had died 
or left the study. Given the likelihood that participants with incident dementia were 
less likely to attend for follow-up, death records would be a valuable source of data 
for dementia ascertainment, particularly where a diagnosis of dementia failed to be 
recorded in the secondary care records. 
The primary aims of this study were: i) to determine cases of incident dementia within 
the LBC1921 study cohort from age 79-95, and ii) to investigate whether recognised 
modifiable risk factors for dementia (diabetes, hypertension, hypercholesterolaemia, 
depression, smoking, physical inactivity, obesity) remained risk factors for dementia 
in the ninth decade and beyond. These modifiable risk factors were considered 
together with key non-modifiable factors including; age 11 IQ, APOE ɛ4 status, and 
measures associated with socio-economic status. 
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The present study primarily drew on existing data for dementia ascertainment. Given 
the variability in methodology for using routinely collected data in the literature, we 
aimed to quantify the effectiveness of our dementia ascertainment method as a 
secondary outcome.  
4.2.2 Methods 
4.2.2.1 Study population 
The LBC1921 is described in detail elsewhere (Deary et al., 2011), and is outlined 
briefly here. Almost all Scottish school pupils born in 1921 had their general 
intelligence tested at age ~11 years as part of the Scottish Mental Survey 
1932.(Scottish Council for Research in Education, 1933) Beginning in 1999, the 
LBC1921 was designed in order to follow up some of the same participants in later 
life with the primary aim of investigating non-pathological cognitive ageing.(Deary, 
Whiteman, Starr, Whalley, & Fox, 2004) The LBC1921 includes 550 participants 
recruited from the Lothian area of Scotland, as relatively healthy, community-dwelling 
volunteers, most of whom had taken part in intelligence testing in 1932. Lothian is an 
area in southeast Scotland in which the largest settlement is the city of Edinburgh. 
Participants underwent the first wave of testing at approximately 79 years of age. 
Those participants surviving and continuing to consent to inclusion in the study were 
re-tested at regular intervals, at mean ages of about 83, 87, 90 and 92 years of age. 
The data were collected by questionnaire and one-to-one testing and included 
measures of socio-demographic, psychological, cognitive, medical, physiological, and 
genetic factors. Those participants self-reporting a history of dementia or scoring less 
than 24 on the MMSE at baseline were excluded from our study (n=11), as were those 
who were missing baseline MMSE data (n=2). Deaths were ascertained 
prospectively, with records for participants supplied by the General Registrar’s Office, 
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Scotland.(Starr & Deary, 2011) Ethical approval was provided by the Lothian 
Research Ethics Committee (test waves 1-3) and the Scotland A Research Ethics 
Committee (test waves 4-5). Participants attending from wave 4 provided written 
consent for data linkage and access to health records.  
4.2.2.2 Dementia ascertainment 
Surviving participants who continued to take part in the LBC1921 study were seen for 
routine follow-up as described previously. Follow-up for the purposes of detecting 
dementia diagnoses included the retrospective collection of evidence from the 
sources described below, from enrolment to age 95 years. Dementia cases were 
determined at a final consensus meeting on 15th December 2016. Death records for 
deceased participants were examined for evidence of cognitive impairment or 
dementia. Data from death records were collected from those available by 30
th
 June 
2016. For consenting participants, data were collected from medical and psychiatric 
electronic patient records for services in Lothian. Patients were located in the system 
using their Community Health Index (CHI) number, a unique number given to each 
patient within Scotland, recorded at every health service contact. Each hospital record 
accessed was read in full and examined for evidence of dementia or cognitive 
impairment since enrolment in the study. This included gathering both recorded 
confirmed diagnoses and evidence for diagnoses. Until 2014, general and psychiatric 
records were held on separate systems (Trak and PIMS respectively), but all records 
were subsequently incorporated into the Trak system. The final date for data 
collection from this source was 16
th
 May 2016. For 26 participants, additional 
information was available as a result of clinical assessments undertaken by the 
authors (JMS or TCR) in the NHS or research setting. In the research setting, 
assessments were undertaken when impairment or decline was noted during the 
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routine LBC1921 testing, or when a new diagnosis of dementia was self-reported. 
Data from these sources were collected until the consensus date. 
Each case with evidence of cognitive impairment or dementia was considered at a 
consensus meeting (RAS, TCR, JMS) which included both a geriatrician and a 
psychiatrist. The meeting agreed upon whether the evidence supported a diagnosis 
of dementia and determined the subtype of dementia. Depending on the strength of 
the evidence, the diagnosis and subtype were deemed either ‘probable’ or ‘possible’. 
The criteria for probable and possible diagnoses utilised by the consensus are shown 
in Table 4.1. Any disagreement on diagnosis was resolved through discussion.  
Table 4.1 Consensus criteria for dementia case ascertainment 
CONSENSUS CRITERIA FOR DEMENTIA CASE ASCERTAINMENT 
PROBABLE DEMENTIA POSSIBLE DEMENTIA 
ANY of the following (without opposing 
evidence from same/ other source): 
-dementia diagnosis on death certificate 
(any part) 
-dementia diagnosed on clinical review 
(ICD-10/ DSM-IV) 
-dementia diagnosis in electronic general 
medical records (Trak) 
-dementia diagnosis in electronic psychiatric 
records (PIMS) 
-ICD-10 criteria for dementia diagnosis met 
by data within any existing records 
ANY of the following (without opposing 
evidence from same/ other source): 
-recorded cognitive impairment on death 
certificate 
-cognitive impairment/ decline recorded in 
notes, but incomplete evidence to meet ICD-
10 diagnostic criteria 
-possibility of dementia recorded in notes but 
no formal diagnosis/ incomplete evidence to 






Dementia subtype diagnoses were made on a similar basis. Any dementia case with 
insufficient evidence to make a subtype diagnosis was classified as ‘unknown’ 
subtype. In order to minimise the risk of misclassification bias, probable dementia 
cases would be used as our primary outcome and possible cases would be excluded 
from the analyses. We would however repeat our analyses including possible 
dementia cases and include the results as supplementary information.  
4.2.2.3 Variables 
Modifiable risk factors assessed in the present study were identified by matching 
those consistently reported in the literature (diabetes, hypertension, depression, 
hypercholesterolaemia, smoking, obesity, and physical inactivity) (Deckers et al., 
2015) with data collected at LBC1921 test waves. We also included the following 
variables: age, sex, APOE ɛ4 status, age 11 IQ, number of teeth (as a post-retirement 
measure of socio-economic status (Starr et al., 2008)), height, and years in full-time, 
formal education. The full list of included variables is detailed in Appendix 2iv, 
Additional file 1: Table S4.1.  
Age at baseline was calculated according to the number of days between birth date 
and date attending wave 1 testing. The presence of at least one APOE ɛ4 allele was 
determined using genomic DNA isolated from venous blood.(Schiepers et al., 2011) 
Venous blood was also used to measure total serum cholesterol and HbA1c.(Deary 
et al., 2011) Any previous history of diabetes or hypertension, years in formal 
education, use of statins, and smoking status (previous, current or never) were self-
reported by participants.(Schiepers et al., 2011) Body mass index (BMI) was 
calculated from height and weight, measured using a SECA stadiometer and digital 
SECA scales, respectively.(Starr et al., 2010) A trained research nurse measured 
sitting blood pressures (systolic and diastolic) using an Omron 705IT monitor.(Starr & 
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Deary, 2011) Remaining teeth were counted during the general physical 
assessment.(Starr et al., 2008) Symptoms of depression were evaluated using the 
self-reported Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983) 
(HADS) at wave 1.(Gale et al., 2010) Only the scores for the depression sub-scale 
were considered. Physical activity was self-reported by participants as part of a 
retrospective questionnaire at wave 2 follow-up (~age 83).(Gow, Pattie, & Deary, 
2017) Based on the methodology described by Hirvensalo and colleagues 
(Hirvensalo, Lampinen, & Rantanen, 1998), responses were scored on a six-item 
scale according to increasing levels of physical activity. Responses predominantly 
related to leisure-based activity: necessary movement, walking, walking/ outdoor 
exercises, exercising until sweating, exercising several times per week, keep fit/ 
heavy exercise.  Participants indicated their perceived level of physical activity at 
three age ranges: 20-35, 40-55 and 60-75 years.(Gow et al., 2017) A lifetime score 
was calculated by the sum of the three scores. The physical effort required in a 
participant’s previous occupation was assessed using a single item [Q21] from the 
Job Content Questionnaire (JCQ) by Karasek (Karasek et al., 1998)
 
which was 
included, with permission, in the wave 2 questionnaire.   
Age 11 IQ was derived from the results of the Moray House Test (MHT) no. 12, 
undertaken by participants in 1932.(Schiepers et al., 2011) Following correction for 
age at testing, the cohort MHT scores were converted to IQ scores, with a 
standardised sample mean score of 100 and SD of 15.(Schiepers et al., 2011) To 
demonstrate how the cohort IQ compares with the general population, we consider 
the raw MHT scores: 34.5 (SD: 15.5) was the mean score for Scotland, 37.3 (SD: 
14.8) for those in Edinburgh schools, and 46.4 (SD: 12.1) for those recruited to 
LBC1921.(Starr et al., 2008) 
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4.2.2.4 Statistical analyses 
Statistical analyses were performed using IBM SPSS Statistics software version 21. 
The primary outcome of the study was the development of dementia. The analyses 
were completed for an outcome of probable dementia, with possible cases excluded. 
Univariate analysis was completed for each predictor variable, using either the 
Pearson chi-square or t-test. At this stage, a p value of <0.05 was used to demonstrate 
significant difference between those who developed dementia and those who did not. 
Binary logistic regression analysis was used to determine the risk for dementia 
associated with each predictor variable. For the purposes of logistic regression, the 
data for height and age 11 IQ were standardised so that a unit increase represented 
one standard deviation increase on the original scale. The following logistic regression 
models were completed using the ‘backward conditional’ function. The input for model 
1 included all variables. The analyses for model 2 included all variables except lifetime 
physical activity and physical activity in occupation, which were excluded since data 
were missing for around one-third of eligible participants (33.4 to 39.3% missing, with 
zero to 14.1% missing for all other variables). The analyses for models 1 and 2 were 
repeated to include both probable and possible dementia in the outcome, and the 
results are made available in the supplementary information. 
4.2.3 Results 
4.2.3.1 Main findings 
550 participants recruited to the LBC1921 attended the first wave of data collection. 
We excluded 9 participants with an MMSE score of less than 24 at baseline, 2 
participants missing MMSE results at baseline, 2 participants who self-reported a 
diagnosis of dementia at baseline and 41 participants with no follow-up data available. 
The eligible cohort (n=496) included 285 (57.5%) females and 425 (85.7%) were 
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known to be deceased by the 30
th
 of June 2016. The mean age in years at wave 1 
was 79.1 years (SD: 0.6). APOE ɛ4 carrier status was available for 490 participants 
(98.8%), with 132 (26.6%) recorded as carriers. The mean (standardised) age 11 IQ 
score was 100.3 (SD: 14.9), calculated from the 447 scores available (90.1% of the 
eligible cohort). The mean MMSE score for the eligible cohort was 28.3 (SD: 1.5). 
Descriptive statistics for those eligible for inclusion, and those excluded are shown in 
Table 4.2. 
Table 4.2 Descriptive statistics for those included & excluded from the 
study 
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129 participants were found to have evidence of cognitive impairment or dementia in 
their records. A consensus diagnosis of probable dementia was agreed for 110 
participants (38 probable Alzheimer disease, 25 probable vascular dementia, 9 
probable mixed-type dementia, 1 probable progressive supra-nuclear palsy, 6 
possible vascular dementia, 1 possible dementia in Parkinson’s disease, and 30 of 
unknown subtype) and a diagnosis of possible dementia was determined for 7 
participants (1 possible vascular dementia, 6 unknown subtype). The remaining 12 
cases considered had either insufficient information for diagnosis or evidence 
contradictory to a diagnosis of dementia (for example, the evidence supports a 
diagnosis of delirium rather than dementia). Figure 4.1 illustrates the number of 
probable cases ascertained by each data source, or combination of data sources. 
Almost two thirds of cases of probable dementia (63.6%) were determined based on 
a single source of information with the largest proportion of these single source 











Figure 4.1  Number of probable dementia cases ascertained, by data source 
 
All 7 cases of possible dementia were identified based on evidence from a single 
source (death certificate or electronic medical record). Of the 12 cases that did not 
meet the criteria for probable or possible dementia, 9 were determined based on a 
single data source, whilst the remaining 3 used two sources. The sources were as 
follows: 9 used evidence from the electronic medical records only, 1 used evidence 
from both the electronic medical records and the electronic psychiatric records and 2 
used evidence from the electronic medical records and from clinical review. 
Univariate analysis demonstrated significant differences between the group with 
probable dementia and the group without dementia for the following variables: positive 
APOE ɛ4 carrier status (p<0.001), lower BMI at age 79 (p=0.027), lifetime physical 
activity (p=0.045) and current smoking status at age 79 (p=0.036) (Table 4.3).   
100 
 
Table 4.3 Univariate analyses: comparisons between groups with and 
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Following the exclusion of possible cases of dementia (n=7), n=489 participants were 
included in the logistic regression analyses, of which n=110 had developed probable 
dementia. The results for these analyses are shown in Table 4.4. A history of 
hypertension was associated with a decreased risk for dementia in model 1 (OR: 0.47, 
95% CI: 0.23, 0.98), while the same relationship approached significance in model 2. 
A higher lifetime leisure-based physical activity score (OR: 1.17, 95% CI: 1.04, 1.32) 
and use of statins (OR: 3.39, 95% CI: 1.04, 11.02) were both associated with an 
increased risk of dementia in model 1. The presence of an APOE ɛ4 allele increased 
the risk of dementia in the second model (OR: 2.23, 95% CI: 1.29, 3.86). Increased 
height was associated with a decrease in risk for incident dementia in model 2 (OR: 
0.72, 95% CI: 0.55, 0.95). Although current smoking was included in both models, the 
relationship with dementia did not reach significance. Age did not demonstrate an 
effect in any model, as might be expected in this narrow-age cohort.  
To investigate the relationship with physical activity further, analysis for a third model 
was completed in which three individual age groups scores (20-35, 40-55, 60-75 
years) replaced the lifetime physical activity score. All other variables were also 
included. Increased physical activity at age 40-55 years was significantly associated 
with incident dementia (OR: 1.52, 95% CI: 1.12, 2.06). The results of this model are 
shown in Appendix 2iv, Additional file 2, Table S4.2.   
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Results for logistic regression analyses (models 1 and 2), repeated with possible 
cases included in the outcome, can be seen in Appendix 2iv, Additional file 3, Table 
S4.3. 
Table 4.4 Logistic Regression Results 
 Odds Ratios (95% CI) for Probable Dementia 
 Model 1 (n=221) Model 2 (n=355) 
APOE ɛ4 - 2.23 (1.29,3.86) 
Height (z score) - 0.72 (0.55, 0.95) 
Hypertension 0.47 (0.23,0.98) 0.63 (0.36,1.08) 
Current smoking 0.14 (0.02, 1.17) 0.24 (0.05, 1.05) 
Lifetime physical activity 1.17 (1.04,1.32) - 
Statin use 3.39 (1.04,11.02) - 
Years in education 0.86 (0.73, 1.01) - 
Note. The variables entered into the analyses for each model were as follows: Model 
1- age, sex, APOE ɛ4 carrier status, age 11 IQ (z score), number of teeth, height (z 
score), years in education, history of diabetes, HbA1c, history of hypertension, 
systolic blood pressure, diastolic blood pressure, cholesterol, use of statins, HADS 
depression score, BMI, smoking status, physical activity in occupation, lifetime 
physical activity (‘backward conditional’ method); Model 2- as model 1, but physical 
activity in occupation and lifetime physical activity excluded (‘backward conditional’ 
method).  
 
4.2.3.2 Validation study 
In order to validate our case ascertainment method using existing data sources, we 
completed a validation study comparing diagnoses extracted from existing data with 
diagnoses made on clinical review. Clinical reviews were performed for 26 
participants. Of the 24 who were diagnosed as having dementia on clinical review, 23 
had a diagnosis of dementia in at least one source of existing data. This would 
suggest that we would miss 4% of cases using existing data alone. Two participants 
seen for clinical review were not diagnosed as having dementia, but both had a 
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diagnosis of dementia in the electronic medical records. This discrepancy might 
reflect the use of different diagnostic criteria, or the use of clinical judgement in clinical 
practice, particularly where evidence is ambiguous. Despite this discrepancy, our 
method would identify dementia in 88% of cases, with 4% being false negatives and 
8% being false positives. Of the 17 cases identified as Alzheimer’s disease (AD) on 
clinical review, 14 (82%) had AD listed as a diagnosis within at least one data source. 
Of the 14 cases, 5 (36%) also had a different subtype diagnosis recorded in existing 
data, 7 (50%) also had dementia of an unspecified subtype recorded, while 2 (14%) 
cases listed only AD. Of the 2 cases identified as vascular dementia on clinical 
assessment, 1 had vascular dementia listed as a diagnosis within the existing data. 
Of the 3 cases identified as mixed Alzheimer’s and vascular dementia on clinical 
assessment 1 had a diagnosis of mixed dementia in the existing data. These findings 
demonstrate the usefulness of accessing records to find evidence that will support a 
subtype diagnosis based on recognised criteria. Our finding that overall dementia 
diagnoses were confirmed in 88% of cases is comparable, if not better than, validation 
procedures performed for other existing data sources or methodologies. 
4.2.4 Discussion 
This study found that 22.5% of eligible, initially cognitively normal participants from 
the LBC1921 developed dementia from age 79 to 95 years. At the time of this study, 
420 of 489 eligible participants had died, including 89 who had died with dementia. A 
total of 21 participants with dementia were alive at age 95. Our analyses indicated 
that the presence of an APOE ɛ4 allele, greater lifetime leisure-based physical activity 
and statin-use increased the risk for dementia. A history of hypertension and 
increased height were found to reduce the risk for dementia.  
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The results of this study reinforce the importance of the APOE ɛ4 allele as a risk factor 
for the development of dementia.(Corrada, Paganini-Hill, Berlau, & Kawas, 2012; 
Keage et al., 2009) A number of studies have suggested a decline in the importance 
of APOE ɛ4 as a risk factor for dementia with advancing age.(Corrada et al., 2012; 
Juva et al., 2000)
 
Somewhat to the contrary, our study has determined that APOE ɛ4 
continues to be a risk factor for incident dementia from age 79 to 95.  
Our results also indicated that a history of hypertension by age 79 was associated 
with a reduction in risk for dementia. This result supports the findings of previous 
studies that have demonstrated that the association of hypertension with dementia 
changes towards later life.(Li et al., 2007) We might hypothesize that persons 
surviving and remaining dementia-free at the ninth decade of life, are no longer 
subject to any increased risk as a result of vascular factors such as hypertension.  In 
simple terms, such risk factors have been used up and those with hypertension who 
were at the highest risk for dementia are more likely to have died from hypertension-
related diseases prior to the onset of dementia. As a result, we might expect a 
paradoxical effect, much like that seen in this study. This hypothesis is supported by 
the direction of relationship for physical activity. Previous studies have hypothesized 
that a reduction in blood pressure is a consequence of the development of dementia 
and, although this mechanism is not fully understood, several processes have been 
proposed.(Iadecola et al., 2016; Li et al., 2007) Blood pressure may decline in early 
dementia due to the direct effect of neurodegeneration at the brainstem and 
hypothalamic nuclei – where arterial pressure is regulated – or it may be related to 
systemic changes such as weight loss, or any disease effecting the ability of the 
cardiovascular system to maintain perfusion pressures throughout the body.(Iadecola 
et al., 2016) Another possible explanation for the reduced risk is the potentially 
protective effect of antihypertensive agents, particularly as it is reported that 
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antihypertensive use in hypertension is higher in older age.(Forette et al., 2002; 
Johnson et al., 2012; NHS Digital, 2012; Scottish Government, 2013)  
The findings relating to physical activity were more unexpected with higher levels of 
overall leisure activity throughout adulthood being linked with an increased risk of 
developing dementia. As a consequence of missing data, the findings relating to 
physical activity were obtained for a smaller sample size and we must therefore be 
cautious in drawing inferences from these findings, particularly as they contradict 
studies that have previously indicated a link between midlife inactivity and 
dementia.(Gelber et al., 2012; Rovio et al., 2005)
 
The discrepancy between our 
findings and those of previous studies may be related to the method of data collection 
for these variables. Self-reporting physical activity levels throughout life at 79 years is 
likely to be subject to recall bias and variability between participants. 
In this cohort, one standard deviation increase in height corresponded to 9.4cm which 
was associated with an approximately 28% reduction in odds of probable dementia 
(OR: 0.72, 95% CI: 0.55, 0.95). Our results are supported by the finding of a 2014 
individual participant meta-analysis, that increasing height was related to a lower rates 
of death from dementia.(Russ, Kivimäki, Starr, Stamatakis, & Batty, 2014) As 
concluded by the authors, since height is regarded as a marker of factors in early life, 
it may be these that are related to risk of dementia.(Russ et al., 2014) Like APOE ɛ4, 
we have demonstrated that decreased height continues to be a significant risk factor 
for dementia in oldest age. By demonstrating that certain recognised dementia risk 
factors are unchanged in oldest age, we can be more confident in our findings that 
the risk associated with other factors is changed in oldest age.  
The results also suggested an association between the use of statins and dementia, 
with statin-use increasing risk. This is contrary to the results of a Cochrane review of 
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two randomised control trials that found no evidence that statin-use was associated 
with dementia or cognitive decline.(McGuinness, Craig, Bullock, & Passmore, 2016) 
Similarly, a systematic review of the literature indicated that statin use in later life did 
not prevent cognitive decline or dementia in subsequent years.(Power, Weuve, 
Sharrett, Blacker, & Gottesman, 2015) Given these contradictions, we must consider 
whether this was a spurious finding, with the statin-use variable being subject to a 
confounding factor – such as indication – that was not included in our analyses.  
Contrary to much of the existing literature, no other factor considered in this study 
was found to be associated with dementia. We should consider however, that the 
prevalence of some conditions, including diabetes and depression, in our cohort was 
low and as a result, we were unlikely to detect anything except large effects, higher 
than those estimated by meta-analyses.(Diniz et al., 2013; Lu et al., 2009)
   
Power 
calculations determined that with binary logistic regression, setting alpha=0.05 and 
the group sizes fixed at n= 379 (participants without dementia) and n=110 
(participants with dementia) with a base proportion of 5.8% (as for diabetes 
prevalence) in the n=379, a minimum prevalence of 15.2% would be required in the 
n=110 to detect a statistical difference with 80.0% power. Further investigation using 
case-control studies or much larger cohort studies are therefore required.  
Moreover, given n=110 people with dementia, the number of participants with each 
subtype of dementia was too few for analysis by individual subtype: combining cases 
of different aetiology may have affected the analysis. As previously noted, some of 
the data collected relied on recollection by the participant and was therefore subject 
to potential variability in reporting. The associations between our variables may also 
have affected our analyses. We attempted to minimise this as far as possible, but 
such bias could not be eliminated without excluding important variables. By examining 
many different possible predictors for dementia, in more than one model, there is also 
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the potential for false positive findings. We limited the number of models in our 
analyses to two to reduce the chance of such false findings insofar as possible. A 
valuable strength of the study cohort is the presence of an intelligence test score from 
age 11.(Corley et al., 2012; Deary et al., 2011; McGurn et al., 2008) Each participant 
also underwent careful background assessment and thorough follow-up, providing a 
wealth of longitudinal data for the assessment of modifiable risk factors. The LBC1921 
is a narrow-age cohort comprising ethnically, geographically and culturally 
homogenous participants, which means that we can rule out a number of potential 
confounding effects. Follow-up data were available for a satisfactory proportion of the 
original cohort to allow for analyses. The cohort demographics for those excluded 
from the analyses were similar to those included and it can therefore be assumed that 
the eligible cohort was a successful representation of the whole cohort. With a mean 
baseline MMSE of 28.1 (SD: 1.7) for those participants who subsequently developed 
dementia, we can be confident that we have identified truly incident, as opposed to 
prevalent, cases.  
To assess the effectiveness of our dementia detection methodology, we sought to 
compare the incidence rate found against the rates determined by previous studies. 
Without knowing the age at diagnosis for a high proportion of dementia cases, the 
expected overall incidence over the study period had to be estimated (see Appendix 
2iv, Additional file 4). Had all cases of dementia been ascertained, we would have 
expected approximately 148.7 cases (see Appendix 2iv, Additional file 5, Table S4.4). 
The 110 cases of dementia detected in this study therefore equates to 74.0% of the 
estimated number of cases arising over the same time period. This proportion is fairly 
consistent with a 2012 study of dementia diagnosis rates, which found that, within 
Lothian (the Health Board where the LBC1921 is resident), 68.3% of the expected 





sought to establish whether cases identified as possible dementia would be confirmed 
with additional follow-up. Of the 7 possible dementia cases, 5 were deceased at the 
time of the consensus meeting and no further follow-up could be completed. 
Electronic hospital records for the 2 other cases were accessed on 10
th
 January 2017 
and both contained evidence from that confirmed a formal diagnosis of dementia. It 
should be noted that neither case was seen for clinical review by ourselves and we 
did not therefore influence the diagnosis having been made. 
This study has demonstrated the benefits of using multiple data sources for 
ascertainment. Our study returned the greatest number of cases from death 
certificates, which identified 68.2% of all cases of probable dementia, and 84.3% of 
all deceased participants with probable dementia. This finding would be in line with a 
previous Scottish study that found 71.5% of patients who die with dementia have the 
diagnosis on their death certificate.(Russ, Batty, & Starr, 2012) Death certificates as 
a source of data benefit from their availability, but it is clear that the potential for 
missed cases remains. Many published UK studies utilising existing data for dementia 
ascertainment use only a single data source.(Doll, Peto, Boreham, & Sutherland, 
2000; Imfeld, Bodmer, Schuerch, Jick, & Meier, 2013) As is the case with any 
dementia ascertainment procedure, the emphasis must be on achieving the most 
accurate representation of dementia incidence or prevalence within the population. 
Where possible, we would recommend that future studies consider inconsistencies 
between sources on a case-by-case basis. If there is reliable and consistent evidence 
in one source, the absence of a diagnosis in another source should not be assumed 
to equate to an absence of the disease. Where there is contradictory evidence, of 
similar weighting, from two or more sources, external evidence can be sought to clarify 
the diagnosis. This may take the form of a clinical review. Where no external evidence 
is available or possible, cases with contradictory evidence should be classified as 
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possible cases and excluded from the analyses due to the risk of misclassification. 
Using existing data offers savings in terms of researcher and participant time and the 
associated financial costs. This method also allows for large population studies, 
where clinical diagnostic work-up is not feasible due to scale.  
4.2.5 Conclusions 
In summary, the results of this study suggest that the presence of an APOE ɛ4 allele 
is a risk factor for incident dementia from age 79-95. A previous diagnosis of 
hypertension and increasing height were found to reduce the risk of incident dementia 
in the same age group. Statin-use was also found to increase risk for incident 
dementia after age 79 years. Increased leisure-based physical activity in adulthood 
was found to increase the risk for incident dementia but including this variable in the 
analyses reduced the study sample size and we must therefore be cautious in drawing 
inferences from this finding, particularly as it contradicts previous studies. Our findings 
would support the hypothesis that the risk profile for dementia alters with age, 
however, further evidence would be required before the risk profile for the ninth 
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4.3  Chapter summary and conclusions 
Using the dementia ascertainment method developed in the previous chapter, we 
found that 22.5% of eligible participants of the Lothian Birth Cohort 1921 had 
developed dementia during the follow-up period. Assessments of validation for the 
methodology suggested that the ascertainment method was effective, and the results 
were therefore reliable enough to be used in the analyses of risk factors for dementia 
in the study cohort.  
The analyses included in the study suggested a changed risk factor profile for 
dementia in oldest age when compared with that described within the literature for 
those in earlier old age. Specifically, our study found that a previous history of 
hypertension and increasing height reduced the risk for dementia in the cohort, while 
increased leisure-based physical activity in adulthood and the use of statins increased 
the risk for incident dementia. The presence of at least one APOE e4 allele also 
increased the risk for dementia. None of the other factors considered in the study 
were found to be associated with an increase or decrease in risk for dementia. As 
noted in the study discussion, we have to contemplate whether a lack of power to 
detect an association contributed to some of the null findings. Other limitations of the 
study must also be taken into account when examining the findings. As described 
within the introductory chapters, the nature of the cohort and recruitment to the study 
may have affected our findings. Selection bias may have led to a reduced number of 
dementia cases when compared with national rates, as a result of increased 
intelligence and education within the cohort.  
Considering health and lifestyle variables as individual risk factors may be misleading 
in this age-group given the likely levels of co-morbidity. Perhaps if one was able to 
produce a ‘health profile’ for each individual and compare these within the cohort, this 
113 
 
might be useful in the investigation of dementia risk in this age-group. In doing so, 
one would however have to address the potential oversimplification of variables within 
our study. We must think about whether the ‘back story’ to individual variables 
complicated our results. While we looked at health and lifestyle factors as simple 
binary variables (with a yes/ no response), in reality the background to a diagnosis is 
much more complex. Considering hypertension, there will be wide variability in age at 
diagnosis, treatment method, effectiveness of treatment. In oldest-old age this may 
be further complicated by additional considerations such as a purposeful under-
treatment as a result of falls risk, or medication reduction due to the adverse effects 
of polypharmacy. While the majority of evidence from earlier in the life course 
suggests that increased blood pressure is associated with increased risks for 
cardiovascular disease, cognitive decline and mortality, the picture is less clear in the 
oldest-old.(Muller, Smulders, de Leeuw & Stehouwer, 2014) It has been suggested 
that increased blood pressure in those aged over 80 years may be a compensatory 
mechanism, by which organ perfusion is maintained and functional decline and 
morbidity are prevented. Muller, et al. 2014)  
If we consider statin-use, this may be affected by age at starting, specific drug, dosage 
and compliance. In oldest-old age this may be further complicated by those who have 
had their statins discontinued, or if they were never started due to contraindications 
or side effects. Side effects such as memory impairment or confusion, increased risk 
of falls and weight loss have all been reported to be increased in those aged over 75 
years. Statins can also interact with other medications and polypharmacy in the 
oldest-old age group might be expected given the levels of comorbidity in this section 
of the population. Statins may however be discontinued as medications are 
rationalised to prevent adverse outcomes relating directly to polypharmacy. The 
nature of and proportions of persons within the ‘statin-user’ group are therefore likely 
to be significantly different to those in earlier old age. Even those variables that may 
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initially appear to be simple, may be complicated in oldest-old age. While height is 
likely to be determined by genetic factors, absence of disease and childhood nutrition, 
height at age 79 years is potentially affected by changes in skeletal structure and 
general body composition. Osteoporosis, arthritis, kyphosis and decreased muscle 
mass can all reduce height and all are increasingly common with advancing age. 
Background factors are relevant in most health and lifestyle variables and we must 
consider whether this affected both our positive and null findings.  
In our study, we note the likely collinearity between the height and BMI variables, 
given that the BMI calculation includes height; collinearity in a regression model 
reduces the ability of each variable to independently predict an outcome. We therefore 
suggest that future studies examine the collinearity between these variables and 
between other variables included in analyses.  
We must also consider whether the changed direction of some associations from 
earlier old age are the result of reverse causation. As we note within the study 
discussion, it is possible that hypotension is caused by some dementia-related 
change within the brain, hence the association between absence of hypertension and 
dementia. Similarly, reduced physical activity in older age (and hence part of the 
lifetime assessment of physical activity) may be part of the prodromal phase of the 
dementia process. Other factors such as depression and weight loss have also been 
described as being part of the dementia prodrome, thus complicating the observed 
associations in oldest age.(Livingston et al., 2020) As a result of the advanced age at 
participant recruitment and the reported long duration of prodromal or preclinical 
dementia, the relative proximity of baseline testing and incident dementia potentially 
increases the possibility of detecting an association that is explained by reverse 
causation. While the data on  LBC1921 participants were detailed, they were collected 
over a limited time period – from the age of 79 years. Aside from childhood IQ scores 
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and retrospective reports from participants, there were no data from across the life 
course. The suspected long duration of preclinical dementia and the previously 
reported effects of factors in midlife with regard to dementia risk reinforce the 
importance of collecting longitudinal data. The increasing availability of digital health 
records will make this a valuable resource for conducting longitudinal data analyses 
for the investigation of dementia in the oldest-old in future studies; electronic health 
data from across the life-course will enable the completion of larger studies, with 
better cost efficiency, incorporate data from different time points and thus allow for 
the analyses of data over time.(Zhao et al., 2019) To be utilised most effectively, so-
called big data needs to be analysed and interpreted appropriately. Traditional 
statistical models may oversimplify the complex and non-linear interactions between 
variables, and as such, approaches that incorporate multiple risk factors and identify 
more subtle differences in relationships between variables and outcomes may be 
more effective at determining risk for dementia.(Obermeyer & Emanuel, 2016; Weng, 
Reps, Kai, Garibaldi & Qureshi, 2017)  Newer statistical tools from the field of machine 
learning provide such an approach, addressing the limitations of standard models and 
exploiting the complex interactions between variables to improve accuracy in outcome 
prediction.(Obermeyer & Emanuel, 2016; Weng et al., 2017) Algorithms ae designed 
to learn rules from data; using patient-level observations at a starting point, the 
algorithm is able to search through a huge number of variables, combining them in a 
wide variety of non-linear and highly interactive ways, identifying the combinations 
that best predict the outcome.(Obermeyer & Emanuel, 2016) In doing so, machine 
learning is able to complete a vast number of analyses, using enormous volumes of 
data, the likes of which would have been impossible previously.(Obermeyer & 
Emanuel, 2016) Machine learning algorithms have been shown to improve the 
accuracy of cardiovascular risk prediction and it may follow therefore that such 
methods will improve the predictability of dementia outcomes.(Weng et al., 2017) 
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Machine learning algorithms may be of particular use in the study of dementia in the 
oldest-old given the potential complexities in the relationships between variables, as 
described within this thesis.  
Based on several features of our findings and our cohort, such as the relatively low 
strength of association, the lack of plausibility for some variables and a lack of 
specificity (as described by Bradford Hill (1965)) and a the lack of consistency with 
other studies within the literature, we describe the observations as associations and 
do not make inferences with regard to causation.(Hill, 1965) 
As detailed within the study, we recognise another potential inaccuracy of our findings 
relating to physical activity – the limitations in collecting retrospective historical 
physical activity data. Further to this, the relatively high levels of missing data for these 
variables made the accuracy of the results unclear.  
Missing data may be particularly significant in studies of the oldest-old age group as 
physical and cognitive impairments limit the completion of specific assessments or 
testing.(Hardy, Allore, & Studenski, 2009) It may be expected that those 
demonstrating the greatest change in physical condition or cognition who are lost to 
follow-up, resulting in missing data and leading to inaccuracies in 
findings.(Sommerlad et al., 2020) In this study we chose to approach missing data 
using a complete case analysis methodology where only those cases with complete 
data were included in analyses; this method is used in other studies of risk factors for 
dementia within the literature.(Mukadam, Sommerlad, Huntley & Livingston, 2019) 
Alternative approaches to missing data, such as multiple imputation or maximum 
likelihood methods, are described within the literature, but none are without 
limitations.(Kang, 2013) We must however consider the possibility that by using an 
alternative approach to missing data, our findings may have been altered. A previous 
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study of variation in blood pressure and subsequent risk for dementia demonstrated 
that large variation in blood pressure over a period of years increased the risk for 
dementia; these findings were unchanged after imputing missing data using a multiple 
imputation method.(Ma et a., 2019) A second study exploring the potential association 
between participation in leisure-based physical activity and dementia found that using 
multiple imputation to account for missing data found results that were consistent with 
the primary analyses.(Sommerlad et al., 2020)  While such findings might suggest 
that using an alternative approach in our study was less likely to result in significant 
differences in the findings, differences in the type and volume of missing data might 
give rise to differences in the effect that alternative approaches has on the findings of 
a study. If one chose to repeat a similar study to our own in the future, consideration 
should therefore be given to the use of an alternative approach, particularly where 
there are greater numbers of missing data. 
With regard to the physical activity variable, we must also discuss the potential 
variability in the make-up of these scores. The lifetime activity score was the sum of 
the activity scores from three age periods; it follows that different participants could 
have a different pattern of activity across the lifetime, but arrive at the same total 
score. For example, one person may be very active in early age, fairly active in middle 
age and less active in older age, whereas another may be fairly active across the 
lifetime. It is possible that particular trends in activity are associated with differing 
levels of risk for dementia, and if this were the case then our analyses would not have 
identified this.  
Given the close association between physical activity and physical fitness, we aimed 
to gather further evidence regarding this potential association by examining physical 
fitness at baseline and subsequent dementia. Details of this study are given in the 
Chapter 5.  
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5: Physical fitness in old age and subsequent dementia 
5.1  Introduction 
5.1.1  Physical activity and physical fitness 
A number of different measures may be utilised in order to determine physical fitness. 
Such measures may include – among others – grip strength, walking velocity, gait 
assessment, lung function, exercise tolerance and timed sitting-to-standing. Levels of 
achievement on measures of physical fitness are likely to reflect participation in 
physical activity. In support of this hypothesis, previous evidence has demonstrated 
that physically active individuals aged over 65 years have greater cardio-respiratory 
fitness.(Department of Health Physical Activity Health Improvement and Protection, 
2011) While activity and exercise may not be directly interchangeable when 
considering the findings of studies, there is likely to be a link between the two. A 
subject who partakes in regular activity is likely to perform better on tests of physical 
performance compared to a similar subject who does not. Where there is a physical, 
health or functional issue that may limit fitness, this is also likely to limit physical 
activity. One issue with examining the effect of physical activity across the life course 
– as noted in the previous chapter – is the potential for inaccuracy when asking 
participants to self-report exercise participation. How a participant will respond to 
questions regarding physical activity will depend on their perception of their physical 
activity; it will likely reflect how their exercise regimen compares to their peers or their 
own expectations. For example, a participant who walks for 30 minutes five days a 
week may consider this a low level of exercise if their peers take part in regular 
distance running, whilst a participant who follows the same walking regimen may 
consider their level of activity to be higher if their peers do not take part in any 
exercise. Similarly, if an individual was very active in early years, they may believe 
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that their activity level in older age is comparatively low, but an individual was 
relatively inactive in early life, may view the same level of activity in later life differently. 
It may be therefore that measures of physical fitness are a useful proxy for physical 
activity, and more accurate than self-reported physical activity.   
5.1.2  Fitness as a modifiable risk factor in health 
Physical activity and physical fitness are widely recognised to be important modifiable 
risk factors for multiple diseases. As such, increased physical activity is a key target 
for public health promotion.(Department of Health Physical Activity Health 
Improvement and Protection, 2011) The Department of Health for the UK describes a 
number of health benefits as a result of participation in regular physical activity. In 
adults, improved physical fitness through exercise has been proposed to reduce the 
risk for type II diabetes by up to 40%, cardiovascular disease by up to 35%, colon 
cancer by 30%, depression by up to 30%, hip fractures by up to 68% and breast 
cancer by 20%.(Department of Health Physical Activity Health Improvement and 
Protection, 2011) Reducing the prevalence of such conditions would reduce demand 
on health and social services, and the related costs. Based on five conditions linked 
to inactivity, the direct cost of physical inactivity for the NHS is approximated at £1.06 
billion; this is however likely to be an underestimation given the positive impact of 
physical inactivity on a wide range of conditions.(Department of Health Physical 
Activity Health Improvement and Protection, 2011) Physical activity may also improve 
life expectancy and reduce overall mortality by up to 30%.(Department of Health 
Physical Activity Health Improvement and Protection, 2011) Physical inactivity is 
estimated to be responsible for one in six deaths in the UK (equal to the impact of 
smoking on UK mortality) and 6% of deaths globally (equal to the impact of elevated 
blood glucose on global mortality).(Department of Health Physical Activity Health 
Improvement and Protection, 2011) 
120 
 
Those health conditions described above are of particular relevance in older age. 
Individuals aged over 65 years are at greater risk of metabolic and cardiovascular 
disease, injury due to falls, malignancy, depression and cognitive 
deterioration.(Department of Health Physical Activity Health Improvement and 
Protection, 2011) Evidence from studies of adults and older adults has shown that 
partaking in either moderate or vigorous physical activity gives rise to similar health 
benefits in both adult age groups. The scientific evidence for adults aged over 65 
years shows reductions in mortality, coronary heart disease, stroke, hypertension, 
type II diabetes, colon and breast cancer, for those who are more physically active or 
physically fit.(Department of Health Physical Activity Health Improvement and 
Protection, 2011; Farrell, Cortese, LaMonte, & Blair, 2007; Schmid et al., 2015; 
Sherrington et al., 2008; World Health Organization, 2010)  
5.1.3  Fitness and cognitive impairment 
A number of studies have also shown a relationship between lower physical fitness 
and poorer cognitive function in old age.(Auyeung et al., 2008; Deary, Whalley, Batty, 
& Starr, 2006; Rosano et al., 2005) A previous study of the Lothian Birth Cohort 1921 
revealed similar findings: better overall physical fitness – as defined by a latent trait 
of grip strength, forced expiratory volume in one second (FEV1) and six metre walking 
time – was associated with more successful cognitive ageing, contributing 3.3% 
additional variance to cognitive ability after adjusting for childhood cognitive 
ability.(Deary et al., 2006) Studies have also demonstrated an association between 
lower fitness levels and increased risk of dementia.(Kueper, Speechley, Lingum, & 
Montero-Odasso, 2017; Wang, Larson, Bowen, & van Belle, 2006) In the Adult 
Changes in Thought (ACT) Study, the age-specific incidence rate of dementia was 
53.1 per 1000 person years for those who achieved poorer scores on a baseline test 
of physical function, while the age specific incidence rate for those who achieved 
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better scores was 17.4 per 1000 person years.(Wang et al., 2006) In this study, lower 
performance scores were shown to be associated with increased risk for dementia in 
both Alzheimer’s disease and all-cause dementia.(Wang et al., 2006) While the 
results are not always consistent, studies have demonstrated associations with 
increased risk for dementia for a variety of fitness measures, including reduced global 
physical function, grip strength, balance and velocity of gait.(Kueper et al., 2017) 
While much of the evidence within the literature describes the association between 
fitness and dementia in earlier old age, some studies have considered this 
relationship in advanced old age. Notably, findings from the 90+ Study indicated an 
association between poorer physical performance and increased odds of dementia in 
the oldest-old.(Bullain, Corrada, Perry, & Kawas, 2016; Bullain et al., 2013) In these 
studies, strong associations with increased odds of dementia were seen for poorer 
performance in each of the following tasks: walking speed, repeated rising from a 
chair, grip strength and standing balance.(Bullain et al., 2016; Bullain et al., 2013)    
These previous findings would indicate that physical fitness continues to be an 
important risk factor for dementia in oldest age. The aim of the subsequent study was 
to explore this association within the LBC1921, adding evidence to the literature on 
this less well-studied age group. Confirming the relationship between physical fitness 
and dementia in oldest-age – and how this may differ from other age groups – will be 
key to determining whether health strategies aimed at improving fitness and exercise 
participation has the additional benefit of reducing one’s risk of developing dementia 
in oldest age. 
The study included in this chapter was published in BMC Psychiatry and the complete 
reference is as follows: 
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Sibbett, RA., Russ, TC., Allerhand, M., Deary, IJ., Starr, JM. Physical fitness and 
dementia risk in the very old: a study of the Lothian Birth Cohort 1921. BMC Psychiatry 
2018, 18: 285.  
The author of this thesis was the first author and made the following contributions to 
the manuscript: assisted with study design, completed data collection for dementia 
ascertainment, took part in the dementia ascertainment consensus meeting, 
contributed to statistical analyses, led the writing of the manuscript and contributed to 
revisions of the same. We note that the Cox regression models and cumulative 
incidence graphs were completed by a contributing author – Mike Allerhand. The 
thesis author completed all other aspects of the statistical analyses. Supplementary 
materials for this publication are provided in Appendix 3, from page 292. The 
individual appendices are provided on the following pages: 
• Additional file 1: Table S1 ................................................................. page 293 
The references for this paper are included within the published manuscript, in the 
referencing style of the journal. The references can be seen on pages 132-133 of the 
thesis. 
5.2  Physical fitness and dementia risk in the very old: a study of the 
Lothian Birth Cohort 1921 
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Overall physical fitness may be considered as the capacity
of an individual’s body to undertake varying degrees of
physical activity. As such, physical fitness can reflect a per-
son’s ability to undertake the physical activities required to
achieve day-to-day function. Overall physical fitness is
comprised of a number of factors; the most important of
which are probably muscular strength, muscular endur-
ance, and cardiorespiratory or cardiovascular endurance.
In the investigation of associations between fitness and
disease, test measures should therefore reflect at least one
of these components. Within the literature, tests of lung
function, walking speed and grip strength are frequently
used to measure physical fitness. Such measures reflect
the components of physical fitness described above, with
lung function tests providing a measure of cardiorespira-
tory function, grip strength providing a measure of mus-
cular strength and walking speed providing a measure of
both muscular endurance and cardiorespiratory endur-
ance. A latent trait representing physical fitness can be
extracted from these variables which is significantly
associated with non-pathological cognitive change in this
cohort of older adults at age ~ 80 years [1].
By examining the relationship between such physical
fitness measures and disease, studies can determine
whether fitness levels may be considered as a risk factor
for disease. With widely recognised risk factors for
dementia – such as age and APOE ε4 allele status – be-
ing fixed and unchangeable, identifying potentially modi-
fiable risk factors would be of considerable value in
contributing to the development of strategies aimed at
reducing disease incidence. Such strategies are of par-
ticular importance in dementia, given the lack of cure or
universally effective treatments. Several previous studies
have therefore explored the potential association be-
tween physical fitness and dementia. Such studies have
demonstrated that reduced pulmonary function [2–8],
slow walking speed [9–13] and weak handgrip [9, 10, 14,
15] are associated with an increased risk of dementia.
One might hypothesise that these findings reflect the
importance of maintaining an optimal blood supply to
the brain [16]. Specifically, if an individual has poor lung
function, it is possible that blood oxygenation levels are
below those required to maintain brain health. Further-
more, slow walking speed may be due to cardiovascular
deficiencies and if the heart and circulatory system are
struggling to meet the requirements of other areas of
the body, it is possible that the brain is experiencing
similar deficiencies. While none of these deficiencies
may be dramatic enough to result in immediate clinical
concern, it is possible that slight inadequacies that are
present over a period of time could result in changes to
brain structure or function. It is also possible that with
increased fitness comes a reduction in other potential
risk factors for dementia, such as hypertension, diabetes
and increased body mass index [16]. The documented
association between physical fitness and normal cogni-
tive ageing [1], together with evidence that physical
activity – which correlates with physical fitness – is a
risk factor for dementia in generally younger populations
[17], suggests that there is good a priori rationale to
investigate whether such risk persists into the ninth
decade and beyond.
Only a minority of participants included in the afore-
mentioned studies were aged over 80 years. Those studies
with an older mean participant age may involve partici-
pants from a wide age range (for example: mean age
80.3 years, age range 54–100 years) [14] and it is not
therefore possible to draw any inferences regarding the
relationship between fitness and dementia in oldest age
given the potential influence of those younger participants
included in the analyses. Based on current evidence, it
remains unclear whether the patterns of association iden-
tified in early old age persist into oldest age. Within the
literature, studies looking specifically at the oldest-old are
typically fewer in number, likely as the result of difficulties
in recruitment and retention of study participants, for
reasons including co-morbidity and mortality. Under-
standing how the risk factor profile for dementia changes
with age is vital in designing successful preventative strat-
egies. In 2017, the number of persons aged 79 years or
older in the UK was estimated to be 3,635,993; 5.5% of the
total population [18]. As life expectancy increases and the
global population ages, the number of persons reaching
oldest-age are expected to grow, reinforcing the import-
ance of understanding patterns of disease in this growing
section of the population through further research.
This study considers the participants of the Lothian
Birth Cohort 1921 (LBC1921), who were recruited at age
79 years and have undergone follow-up for dementia
into their 90s. While a previous study of the LBC1921
had identified an association between superior physical
fitness at age 79 years and improved cognitive aging [1],
the effect of fitness at age 79 years on the development
of dementia had not been investigated in this cohort.
Measures of fitness collected at baseline (grip strength,
time to walk 6 m and forced expiratory volume in 1 s
(FEV1)) reflected those commonly used within the litera-
ture and would therefore allow for comparisons with
previous findings. As such, the study of physical fitness
measures and dementia within this detailed, narrow-age
cohort would be well-suited to add evidence, specific to
the oldest-old, to the literature. Given the frequency of
death within a cohort of advanced age we recognised the
possibility that this may influence our findings. Such
consideration was particularly important given that asso-
ciations between reduced grip strength, reduced pul-
monary function, reduced walking speed and increased
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risk of death have been well documented [19, 20]. We
therefore planned to consider death as a competing risk
in our analyses.
The primary aim of this study was therefore to explore
the association between three measures of physical fit-
ness – grip strength, lung function and walking speed –
and subsequent dementia in persons aged over 79 years.
Methods
Participants
Participants were members of the Lothian Birth Cohort
1921 (LBC1921), which is described more fully else-
where [21]. Most had taken part in general intelligence
testing at age 11, as part of the Scottish Mental Survey
1932 (SMS1932) [22]. Childhood cognitive test scores
were available for 89.6% of those LBC1921 participants
who attended baseline testing. Missing childhood cogni-
tive data was likely to have resulted from school absence
on the day of testing (due to sickness, for example), or
be because the test results for some schools in Fife (a re-
gion neighbouring Lothian) were not found. From 1999,
SMS1932 participants were traced and recruited for
follow-up in later life, with the aim of investigating
normal cognitive ageing [23]. Five-hundred and fifty
participants, mostly from the Lothian area of Scotland,
enrolled in the study and attended the first wave of test-
ing. Participants were aged approximately 79 years at
baseline. Surviving participants who continued to take
part in the study were re-tested at four subsequent test
waves; at ~ 83, 87, 90 and 92 years of age (approximately
3-yearly intervals). This interval was planned as the
period over which the authors expected to be able to
detect significant changes in some cognitive test scores,
while balancing this against attrition. At each wave, data
were collected by questionnaire and in-person testing.
Participant deaths were ascertained prospectively, at
regular intervals, with details supplied by the General
Registrar’s Office, Scotland. The Lothian Research Ethics
Committee (test waves 1–3) and the Scotland A
Research Ethics Committee (test waves 4–5) provided
ethical approval for the study. From wave 4, attending
participants provided consent for data linkage and access
to health records.
Fitness variables
The three fitness measures included in this study were
6-m walk time, grip strength and forced expiratory vol-
ume in 1 s (FEV1) [1]. Walking speed, grip strength and
FEV1 have all been shown to be valuable in evaluating
physical and functional capacity [24–27]. Six-metre walk
time was taken as the time in seconds for a participant
to walk a measured length of 6 m, at a normal walking
pace. Subjects were permitted to utilise any habitually
used walking aid, while those who were unable to walk
six metres would not participate in the test. A Jamar
Hydraulic Hand Dynamometer was used to measure grip
strength in kilograms, in the dominant hand; the best of
three trials was recorded. FEV1 was measured using a
microspirometer, in units of litres per second; the best of
three attempts was recorded. Taking three measure-
ments is in line with guidance for clinical practice [28].
Additional variables
The analyses would also include variables deemed to be
of potential importance with regard to their association
with either physical fitness or dementia. In a previous
study of the risk factors for dementia in LBC1921, posi-
tive APOE ɛ4 carrier status was found to increase risk,
whereas a history of hypertension was found to reduce
risk [29]. These variables were therefore included, along
with the following important control variables: age, sex,
height, age 11 IQ, smoking status, history of cardiovas-
cular or cerebrovascular disease and history of diabetes.
Age, sex and height are all key control variables given
the direct impact on physical strength and fitness.
Similarly, a history of cardiovascular or cerebrovascular
disease and diabetes history were included given the po-
tential association with physical fitness and dementia.
When such conditions impact a person’s ability to par-
take in exercise, fitness is likely to be adversely affected.
The inclusion of age 11 IQ as a control variable is im-
portant given the known association with dementia [30]
and other fitness-related factors [1, 31]. We also consid-
ered the potential impact of smoking status given the
likely association with physical fitness, and lung function
in particular. Whilst other factors were potentially asso-
ciated with fitness, we could not include all possible risk
factors, as this would have led to multiple hypotheses
testing. We therefore adopted the hypothesis-driven
approach described above, based on previous findings.
Data collection procedures
APOE ɛ4 status was determined using genomic DNA
isolated from participants’ venous blood. Any history of
hypertension, diabetes, cerebrovascular or cardiovascular
disease, smoking status (ex-, current-, or never-) and sex
were self-reported by participants at the first wave of
testing. A positive history of cerebrovascular or cardio-
vascular disease included those reporting previous
stroke, transient ischaemic attack, myocardial infarction,
angina, coronary artery bypass graft and angioplasty pro-
cedures and those who reported a positive history but
did not specify the specific nature. A positive history of
diabetes included those reporting any history of diabetes
(any type or type unspecified). Age at baseline was taken
from the number of days between date of birth and date
of attendance at wave 1 testing. Age 11 IQ was calcu-
lated based on the results of the Moray House Test
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(MHT) no.12, the general intelligence test taken by par-
ticipants at age 11 as part of SMS1932 [21]. MHT scores
were corrected for age at testing, then converted to
IQ-type scores with a standardised mean score of 100
(SD 15). Height in centimetres was measured using a
SECA stadiometer.
Dementia ascertainment
Follow-up for the purpose of dementia ascertainment
has been described previously and involved the retro-
spective collection of evidence, from enrolment to age
95 years [29]. Data were collected from death certifi-
cates, electronic hospital records, and clinical reviews.
Each death record available by 30th June 2016 was ex-
amined for evidence of dementia or cognitive impair-
ment. Electronic hospital records and psychiatric
records were accessed for participants who were willing
and able to consent to data linkage. Any evidence for de-
mentia or cognitive impairment since enrolment in the
study – whether a confirmed diagnosis or evidence for a
diagnosis – was recorded. Data were collected from elec-
tronic medical records to the 16th May 2016. Additional
information was available for 26 participants who under-
went clinical review by the authors (TCR, JMS), either in
the NHS or research setting. Information from such re-
views was collected up to 15th December 2016, when all
of the evidence from each source was considered at a
final dementia diagnosis consensus meeting (RAS, TCR,
JMS). The evidence was examined against a previously
described list of criteria for ‘probable’ or ‘possible’ de-
mentia diagnosis [29]. Using these criteria, the meeting
agreed upon the presence of a diagnosis and the subtype.
Any disagreement was resolved through discussion.
Event variables
The events considered in these analyses would be de-
mentia and death. Determination of these outcomes was
as described above. Time to death was taken as the
number of days between the date of attendance at wave
1 testing and date of death. For those who did not die,
the censoring time was taken as the number of days
between wave 1 testing and a date beyond that last date
of data collection for any participant. Time to dementia
was taken as the number of days between the date of
attendance at wave 1 testing and the first date that a
dementia diagnosis was noted in any of the available
sources. If dementia was recorded on a death certificate
only, and no duration was noted, the diagnosis was pre-
sumed to predate death by 6 months. If the duration
was not given on the death certificate, but a diagnosis
was recorded in another source, the earliest such date
was used to determine the time to dementia. If sources
had recorded cognitive decline, mild cognitive impair-
ment and dementia, the date was taken as the earliest
recording of a dementia diagnosis. If dementia was
ascertained based on evidence within the records that
did not include a formal diagnosis of dementia, the earli-
est mention of cognitive impairment was used to date
dementia (as long as this did not specifically note the
absence of a dementia syndrome). For those who did not
develop dementia, the time to dementia variable was
recorded as either the time to date of death or to a date
beyond that last date of data collection for any surviving
participant.
Participant exclusions
Any participant reporting a history of dementia or scoring
23 or less on the Folstein Mini Mental State Examination
[32] (MMSE) at baseline was excluded from our analyses.
Those without a valid MMSE score at baseline were also
excluded, as were those without any follow-up data avail-
able. To minimise the potential for classification error,
possible dementia cases were excluded from the analyses
and probable dementia was used as the primary outcome
in this study.
Statistical analysis
We first performed simple comparison analyses between
the group who developed dementia and the group who
did not, for each of the included variables. Univariate ana-
lyses were completed using either a Pearson chi-square
(for categorical variables) or independent samples t-test
(for continuous variables) (IBM SPSS, Version 21). A p
value of < 0.05 was used to demonstrate a statistically
significant difference. All subsequent steps in the analyses
were completed using the R statistical software (version
3.3.3) [33].
The second stage of the analyses used binary logistic
regression to examine the potential risks for dementia
associated with the fitness measures. In a first model (lo-
gistic regression model 1) we included the fitness vari-
ables along with those factors known to be associated
with dementia in our cohort and the other important
control variables (FEV1, grip strength, 6-m walk time,
APOE ɛ4 carrier status, height, age, sex, history of hyper-
tension, smoking status and age 11 IQ). The develop-
ment of probable dementia was the outcome. In the
second model (logistic regression model 2), the same
variables were included, with the addition of a history of
cardiovascular or cerebrovascular disease and a history
of diabetes. A history of hypertension was considered
separately to these other health variables as a statistically
significant association with dementia had previously
been observed within this cohort.
The main analyses used Cox regression models with
death being included as a competing risk for dementia;
in doing so, the influence of fitness on earlier death in
the analysis of dementia development due to fitness was
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considered. The models were completed using standard
software for Cox regression with right-censored data
and treating death as censored, (R package survival).
The first and second Cox regression models (Cox regres-
sion models 1 and 2) included the same covariates as
those described for logistic regression models 1 and 2.
Both models fitted the data acceptably with concordance
of 64%. Analysis of the scaled Schoenfeld residuals (R
function cox.zph), showed all covariates complied with
the proportional hazards assumption. As is recommended
practice, we supported the results of Cox regression with
graphs demonstrating cumulative incidence for each com-
peting event; illustrating the time-varying risk of dementia,
between covariate levels. The unbiased estimate of cumu-
lative incidence was calculated using the Aalen-Johansen
estimator [34], (R packages prodlim and mstate).
Results
Participant eligibility
A total of N = 550 participants recruited to LBC1921
attended baseline testing at age 79 years. We excluded
the following participants from the analyses: participants
with an MMSE score of less than 24 at baseline (n = 9),
participants without a valid MMSE score at baseline
(n = 2), participants reporting a history of dementia at
baseline (n = 2), and participants with no follow-up
data available for the purpose of dementia ascertainment
(n = 41). One additional participant was excluded as the
calculated time to dementia suggested that dementia pre-
dated attendance at wave 1 testing. From the remaining
participants (n = 495), a consensus diagnosis of probable
dementia was agreed for n = 109. Those participants with
a possible diagnosis of dementia were excluded from the
analyses (n = 7).
Participant demographics (Table 1)
The resulting eligible cohort (n = 488) included 280
females (57.4%) and 419 participants (85.9%) were
known to be deceased [29]. This included 331 who died
with no diagnosis of dementia. Descriptive statistics for
those eligible for inclusion (both with and without
dementia), and those excluded are shown in Table 1.
Event variables
The mean time to death for the n = 419 participants who
were known to be deceased was 3144.5 days (SD:
1517.5). For those who survived, the time to death was
taken as an arbitrary point beyond the last date of data
collection for any participant; 6500 days. The mean time
to dementia for the n = 109 who developed dementia
was 3535.7 days (SD: 1283.3). A total of n = 379 partici-
pants remained dementia free; for these participants,
time to dementia was taken either as the time to death
for those who died (n = 331, mean = 2863.0 days, SD:
1469.4), or an arbitrary point beyond the last date of
data collection for any participant (n = 48, 6500 days).
Dementia group comparison (Table 1)
Also included in Table 1 are the results of the group
comparison analyses. Univariate analyses demonstrated
little difference between those participants who devel-
oped dementia and those who did not. Only smoking
status (p < 0.001) and APOE ɛ4 (p < 0.001) carrier status
demonstrated statistically significant difference (p < 0.05).
Univariate analyses were also performed to compare
those who died with those who survived. Lower FEV1
and greater 6-m walk time were both associated with an
increased risk of death (p = 0.02 and p = 0.01, respect-
ively). The results for these univariate analyses are avail-
able in Additional file 1: Table S1.
Logistic regression results (Table 2)
The results of both logistic regression analyses demon-
strated that APOE ɛ4 remains an important risk factor
for dementia after age 79 years (logistic regression model
2: Odds Ratio (OR) 2.52 (95% confidence interval: 1.50,
4.22), p < 0.001). Both initial models also suggested that
increased FEV1 at age 79 increased the risk for subse-
quent dementia (logistic regression model 2: OR 1.93
(1.07, 3.57), p = 0.03). The only other variable that
reached statistical significance was height, and only in
the second model; increased height was shown to
decrease risk for subsequent dementia (OR 0.95 (0.91,
1.00), p = 0.04).
Cox regression analyses (Table 2)
In both Cox regression models, APOE ɛ4 continued to
be an important predictor for dementia (Cox model 2:
Hazard Ratio (HR) 2.85 (95% confidence interval: 1.85,
4.41), p < 0.001). The results did however demonstrate
that once death was considered within the analyses, the
association between FEV1 and dementia did not reach
statistical significance in either model (Cox model 2: HR
1.30 (0.74, 2.30), p = 0.37). Neither grip strength (Cox
model 2: HR 0.98 (0.94, 1.02), p = 0.35) nor walking
speed (Cox model 2: HR 0.99 (0.87, 1.13), p = 0.90) was
associated with dementia in either model. No other vari-
able was demonstrated to be associated with dementia.
Cumulative incidence graphs
For the purposes of calculating cumulative incidence,
FEV1 results were divided into two groups, at a value of
1.8 l per second. This value was close to both the sample
mean and median. The stacked cumulative incidence
plot shown in Fig. 1 demonstrated that increased FEV1
was associated with decreased risk of death but not
dementia (Fig. 1). A second cumulative incidence plot
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confirmed that the presence of an APOE ɛ4 allele was
associated with an increased risk for dementia (Fig. 2).
Discussion
Contrary to the existing evidence within the literature
[2–15 ], this study found that decreased fitness beyond
age 79 was not a risk factor for subsequent dementia.
More specifically, FEV1, grip strength and walking
speed at age 79 years were not found to be associated
with dementia. Indeed, considering those who survive,
greater FEV1 is associated with an increased risk of
dementia: that is, if you survive, having better respira-
tory function (a measure of fitness) when you are
younger makes it more likely that you will develop
dementia. Even when the effect of poor respiratory
function on mortality risk is taken into account, being
fitter as a younger adult does not confer any benefit
with regards to dementia risk once you reach your
ninth decade. This raises an important distinction be-
cause better physical fitness was associated with
higher cognitive scores in oldest age, even after
adjusting for childhood IQ, in this same cohort [1].
That is, having better physical fitness at age 79 was
good for a person’s cognitive ability but did not re-
duce the risk of developing dementia. As was ob-
served in a previous study of the LBC1921, the
presence of an APOE ɛ4 allele was however associated
with an increased risk for dementia [29].
Table 1 Study Sample Demographics and Group Comparison
Eligible Participants (n = 488) Group Comparison p value
(chi-square or t-test)
Excluded Participants
(n = 62)Dementia (n = 109) No Dementia (n = 379)
Age n = 109 n = 379 n = 62
-mean age in years (SD) 79.04 (0.55) 79.08 (0.59) 0.54 79.09 (0.53)
Sex n = 109 n = 379 n = 62
-% female 62.4% 55.9% 0.23 58.1%
Living or deceased n = 109 n = 379 n = 62
-% deceased 80.7% 83.3% 0.08 29.0%
MMSE score at baseline n = 109 n = 379 n = 60
-mean score (SD) 28.10 (1.64) 28.33 (1.46) 0.16 27.27 (2.67)
Height n = 106 n = 378 n = 60
-Mean height in cm (SD) 162.11 (9.21) 163.59 (9.45) 0.15 163.83 (8.53)
APOE ɛ4 carrier status n = 109 n = 373 n = 61
-% carrier APOE ɛ4 41.3% 22.5% < 0.001 27.4%
Age 11 IQ (standardised) n = 101 n = 339 n = 53
-Mean score (SD) 100.19 (16.18) 100.22 (14.53) 0.98 98.21 (15.63)
FEV1 n = 106 n = 378 n = 60
-mean rate in litres per second (SD) 1.95 (0.59) 1.84 (0.62) 0.12 2.03 (0.68)
Grip strength n = 106 n = 378 n = 60
-mean strength in kilograms (SD) 25.89 (10.17) 26.46 (8.87) 0.57 28.18 (8.59)
6 m walk time n = 105 n = 377 n = 59
-mean time in seconds (SD) 4.56 (1.53) 4.84 (2.11) 0.20 4.37 (1.29)
Smoking status n = 108 n = 379 n = 62
-% ever smoker 42.6% 61.7% < 0.001 50.0%
History of cardiovascular or cerebrovascular disease n = 104 n = 373 n = 58
-% positive history 28.9% 28.2% 0.89 24.2%
History of hypertension n = 108 n = 375 n = 61
-% positive history 35.2% 41.9% 0.21 41.0%
History of diabetes n = 109 n = 379 n = 62
-% positive history 4.6% 5.8% 0.62 1.6%
Italicized results demonstrate significance of p<0.05
Sibbett et al. BMC Psychiatry  (2018) 18:285 Page 6 of 11
129 
 
Table 2 Regression Results

















(n = 425) (n = 425) (n = 416) (n = 416)
Sex (female) 0.77 (0.31, 1.85) 1.26 (0.56, 2.83) 0.86 (0.34, 2.11) 1.42 (0.63, 3.23)
Age (days) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
Height (centimetres) 0.96 (0.92, 1.00) 0.97 (0.94, 1.01) 0.95 (0.91, 1.00) 0.97 (0.93, 1.01)
APOE ɛ4 carrier 2.47 (1.49, 4.08) 2.72 (1.78, 4.14) 2.52 (1.50, 4.22) 2.85 (1.85, 4.41)
Age 11 IQ 1.00 (0.98, 1.02) 0.99 (0.98, 1.01) 1.00 (0.98, 1.02) 1.00 (0.98, 1.01)
History of hypertension 0.64 (0.38, 1.05) 0.79 (0.51, 1.23) 0.64 (0.38, 1.06) 0.78 (0.50, 1.22)
Smoker (ever) 0.63 (0.38, 1.04) 0.92 (0.60, 1.40) 0.62 (0.37, 1.03) 0.94 (0.61, 1.45)
FEV1 (l/s) 2.05 (1.15, 3.75) 1.43 (0.82, 2.48) 1.93 (1.07, 3.57) 1.30 (0.74, 2.30)
6 m walk time (s) 0.93 (0.79, 1.07) 0.99 (0.87, 1.13) 0.94 (0.79, 1.08) 0.99 (0.87, 1.13)
Grip strength (kg) 1.00 (0.96, 1.05) 0.98 (0.94, 1.02) 1.01 (0.96, 1.05) 0.98 (0.94, 1.02)
History of cardiovascular or cerebrovascular
disease
– – 1.08 (0.61, 1.86) 1.14 (0.72, 1.81)
History of diabetes – – 0.86 (0.19, 2.88) 1.39 (0.41, 4.66)
Logistic regression model 1 and Cox regression model 1: included FEV1, grip strength, 6-m walk time, APOE ɛ4 carrier status, height, age, sex, history of
hypertension, smoking status and age 11 IQ, with the development of probable dementia as the outcome. Logistic regression model 2 and Cox regression model
2: as logistic regression model 1 plus history of cardiovascular or cerebrovascular disease and history of diabetes. Results for Cox regressions show the hazard
ratios and 95% confidence intervals. Statistically significant results are italicized
Fig. 1 Cumulative incidence of dementia and death (stacked) at 2 levels of FEV1. Note. FEV1 groups were split at 1.8 l per second
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Previous studies have repeatedly shown that poorer
lung function, grip strength and walking speed are asso-
ciated with increased risk for dementia [2–15]. The pri-
mary reason for this inconsistency may be that most
previous studies have investigated the association in a
younger population, or a population with a broader age
range than the LBC1921 [2, 7]; the results of this study
may differ simply because the results are specific to the
oldest-old. We might also consider the impact of death
on our finding. In our cohort, increased lung function at
age 79 was associated with a reduce risk of death. We
can therefore hypothesize that our null findings may be
due to the fact that those with poorer fitness, who would
have been more likely to develop dementia, would have
died from another cause before developing dementia.
Taking lung function as an example, in addition to death
directly related to lung disease, death before dementia
may occur because of diabetes, atherosclerosis or coronary
heart disease, all of which are known to be associated with
poorer lung function [5]. Given that our competing risks
analyses accounts for this possibility, we would not expect
to have found an increased risk of dementia for those with
low FEV1 if these people had survived.
In examining the potential influences on our findings
it is worthwhile considering the fitness levels of the par-
ticipants of the study, when compared with population
norms. While predicted values for FEV1 are less well
established for those aged over 70 years, formulae
published by the British Thoracic Society can be used to
calculate the expected results for our study population
[28]. Females included in our study achieved, an average,
94.5% of the predicted FEV1 value, while males achieved
88.8% of the predicted value, based on mean age and
height. Both of these were above the 80% cut-off used to
demonstrate abnormality, and below the 100% threshold
that would demonstrate better than expected lung function.
The mean walking speed recorded for male and female
study participants (137 cm per second and 118 cm per sec-
ond, respectively) were similar to published normative
values for persons aged in their 70s (133 cm per second
and 127 cm per second for males and females respectively)
[35]. Previously published expected median values for grip
strength – measured using a Jamar Hydraulic Hand
Dynamometer – also closely resemble those achieved in
the present study [36]. For males, the expected median
was 34.9 kg, and the achieved median and mean were
34 kg and 34.5 kg respectively. For females, the ex-
pected median was 20.9 kg, and the achieved median
and mean were 20 kg and 20.3 kg respectively. One
might expect the values for grip strength and walking
speed to be slightly below expected levels because the
reference values were for individuals aged 70–79 years
and the participants of this study were at the upper-
most limit of this age bracket. Based on these results
one might assume that, with respect to grip strength,
walking speed and FEV1, this study cohort were not
Fig. 2 Cumulative incidence of dementia for APOE ɛ4 carriers and non-carriers. Note. Predicted cumulative incidence of dementia (Aalen-Johansen
estimator) for men aged 79 of average height, fitness (FEV, 6 m walking time, and grip strength), and age 11 IQ
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of unusually high or low fitness and reflected a typ-
ical population of this age.
It is also possible that the lack of association observed
in our results is the result of some type of resilience to
disease. It is acknowledged within the literature that
some individuals do not appear to be susceptible to the
negative effects of certain lifestyle habits. For example,
some heavy smokers do not develop lung disease [37].
Studies – including a large Medical Research Council
funded study of UK Biobank data – have suggested that
DNA variants may explain why some individuals can have
relatively good lung health despite smoking [38, 39]. It is
possible that there is a similar unidentified genetic resili-
ence for dementia, such that those who are more suscep-
tible to developing dementia because of certain risk
factors will do so prior to oldest age, while those who are
genetically resilient will continue to be resilient in oldest
age, resulting in a lack of observed association.
The null findings of this study should not be overlooked
as unimportant. If these associations are indeed only
present in earlier old age, the fact that lung function, grip
strength and walking speed were not significantly associ-
ated with dementia in our cohort, demonstrates an
important difference between the risk profile for dementia
in early old age and late old age.
Since the median age of dementia diagnosis in the UK,
for example, is now over 80, if our findings are repli-
cated, it means that for the majority of people who will
develop dementia seeking to improve physical fitness is
unlikely to have any effect on preventing the disease.
Although our findings do not concur with previous re-
ports, our findings are supported by other health-related
analyses in this cohort that identified changes in the risk
factor profile for dementia in advanced old age [29]. In
the LBC1921, a history of hypertension was associated
with a decreased risk of dementia, and increased phys-
ical activity in early adulthood was associated with an in-
creased risk for dementia after age 79 years [29].
Whereas the relationship between physical activity and
dementia was novel, other studies have described a change
in the relationship between hypertension and dementia in
the oldest old [40]. The results of the present study,
together with these previous findings, would indicate that
there is different risk profile for dementia in the oldest
old, when compared with those in earlier old age.
Our findings therefore highlight two important differ-
ences. Firstly, it seems increasingly likely that the risk
profile for dementia in oldest age differs from the risk
profile in earlier old age. Secondly, that the risk profile for
dementia in oldest age differs from the risk profile for less
successful non-pathological cognitive ageing in the oldest
old. Understanding the risk profiles for each of these
separate processes and how they differ is important, as
this knowledge will aid in the design and development of
appropriate prevention and management strategies. Given
that dementia is set to be one of the greatest public health
challenges facing the ageing population, successful
cost-effective prevention strategies are of vital importance.
Strengths and limitations
A significant strength of this study lies in the suitability of
the cohort for these analyses. The minimal cultural, ethnic
and geographical variability within the narrow-age cohort
minimises confounding errors and means that the results
are specific to the oldest old. We recognise, though, that
this limits the generalisability of the results, and so
additional studies are required in other groups. The avail-
ability of a childhood IQ score is a rare strength of the
study, as is the detailed follow-up completed since enrol-
ment in the study. The high mean baseline MMSE score
(28.3, SD: 1.5) for those included in the analyses increases
the likelihood that we identified incident cases of demen-
tia, rather than prevalent cases. By including multiple
measures of fitness it was possible to consider several
components of fitness. Whilst this was a strength of our
study, it could be argued that additional tests could have
provided a more comprehensive assessment of fitness. We
selected the additional variables for inclusion in the ana-
lyses based on the available evidence, but it is possible that
there was some residual confounding due to a variable not
considered in this study. It is not however possible to
exclude all such possibilities without negatively affecting
the analyses through multiple hypotheses testing. The
dementia ascertainment method in this study has previ-
ously been shown to be effective and comparable with
expected rates [29]. Having determined dementia cases
retrospectively using existing data, it was not possible to
accurately date the onset of dementia. For this reason, we
cannot be entirely confident in the accuracy of the time to
dementia variable. The method used to determine date of
onset in this study, is however conservative and it is likely
that dementia onset preceded our assigned date by some
time. As such, the true competing risk of death is almost
certainly less than we are adjusting for in the model.
While we recognise this limitation of our study, it is not
unique to our method; it is notoriously difficult to pin-
point the exact date of dementia onset, even in studies
using prospective clinical follow-up. This is particularly
true given that the most common form of dementia –
Alzheimer’s disease – has a gradual onset. A further limi-
tation of our study is the possibility of missed cases. Our
results could also have been affected by using an outcome
of probable dementia of any subtype. The number of
participants with each subtype of dementia was too few to
perform individual analyses. It is also possible that the
overall size of our study cohort had an impact on our find-
ings, and that a larger sample size would have produced
differing results.




The results of this study suggest that increased physical
fitness at age 79 years does not reduce the risk for subse-
quent dementia. The early death of participants with
poorer fitness, who would have been more at risk of
dementia dying before developing dementia, might explain
why the findings differ from studies of earlier old age.
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5.3  Chapter summary and conclusions 
The study described in Section 5.2 did not demonstrate any association between 
fitness at age 79 years and subsequent dementia. Contrary to previous findings, lower 
fitness – as described by grip strength, walking speed and lung function – did not 
result in an increased risk for dementia in this age-group. Once again, our findings 
provide further evidence for a changed risk factor profile for dementia in oldest-old 
age.  
If our findings were repeated in other studies, it would demonstrate that the strategies 
or interventions aimed at reducing dementia risk should differ according to age. 
Understanding the role of physical exercise in dementia risk reduction in this age-
group is important given that advancing age may give rise to an increasing number of 
barriers to participation in physical activity. As age advances it might be expected that 
co-morbid conditions which could affect exercise capability – such as increased 
general frailty and diseases affecting mobility or cardiorespiratory function – might be 
more common. If our findings are correct, one might suggest that the factors that 
constitute a ‘healthy lifestyle’ for dementia risk reduction are different in the oldest-
old.  
We do however have to consider the limitations of our study that might have resulted 
in the null finding; potential limitations such as the size of our study cohort and the 
uncertainty regarding the optimal fitness measures for consideration as discussed 
within the included paper. An important consideration in risk factor studies is the 
potential for observing a reverse association (or reverse causation), where the 
reported association actually arises as a result of features of the dementia 
prodrome.(Sommerlad et al., 2020) Physical inactivity is proposed to be part of the 
prodrome of dementia and as such, one might expect reduced levels of activity in the 
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years preceding diagnosis. This hypothesis is strengthened by the findings of a study 
by Sommerlad et al. (2020) who only found an association between reduced activity 
and increased risk for dementia where leisure activity was assessed at older ages, 
with less than ten years between activity assessment and dementia.(Sommerlad et 
al., 2020) As we note within our introduction to the chapter, physical activity and 
physical fitness are likely to be closely related and reduced physical fitness may 
therefore also be expected to be present in this prodromal phase. In support of this 
hypothesis, physical fitness has been shown to be lower in those with recently 
diagnosed mild cognitive impairment and dementia.(Hesseberg, Bergland, Rydwik & 
Brovold, 2016)  
In this study, three measures of physical fitness were investigated. It is possible that 
if different measures, or further measures were examined, different results would 
have been observed. Regardless of which fitness measures were chosen, all are 
likely to be influenced by additional factors in oldest-old age. As discussed previously 
within the thesis, those in the oldest-old age group are likely to have a more 
complicated health and disease profile, and this will likely complicate the investigation 
of fitness in this age group. The prevalence of cardiovascular disease is known to 
increase with advancing age. The Scottish Health Survey 2019 reported that 44% of 
persons aged 75 years and over had at least one cardiovascular condition (excluding 
hypertension or diabetes), compared with 26% in those aged 65-74 years.(The 
Scottish Government, 2019) Rates were higher in males (The Scottish Government, 
2019), and would be expected to be higher if hypertension was included in the 
prevalence statistics. Cardiovascular disease is likely to have an impact on the overall 
health status of an individual, but may also have a direct impact on most individual 
measures of fitness. In our study, grip strength and walking speed are most likely to 
be negatively impacted by cardiovascular illness. Appreciating how these conditions 
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affect fitness is not as simple as grouping participants by the presence or absence of 
a condition; each condition is likely to affect an individual differently, and thus affect 
fitness differently. The impact of disease on fitness will also be influenced by 
premorbid fitness and an individual’s resilience or reserve. As discussed within the 
main introduction to the thesis, resilience or reserve is central to the concept of frailty. 
Frailty may be determined using different methods; the most common methods are i) 
a frailty index based on a measure of accumulated deficits, or ii) a clinical assessment 
criteria based on a proposed clinical phenotype of frailty.(Rockwood, Andrew & 
Mitnitski, 2007) The phenotype criteria include measures such as unintentional weight 
loss, low physical activity, slowness of gait, exhaustion and weakness.(Fried, 2001) 
The crossover between this frailty measure and our assessment of fitness is clear; 
two of our measures of fitness – grip strength and walking speed – are two of the five 
recognised phenotypic criteria for frailty. A frailty index, such as that developed for 
use in the Canadian Study of Health and Aging, is constructed using a large number 
of variables – many of which might also be viewed as measures of physical 
fitness.(Rockwood et al, 2005) Like the phenotype criteria, many variables have direct 
overlap with, or have influence on, the fitness assessment measures used in our 
study.(Rockwood et al., 2005) Examples would include – poor muscle tone in limbs, 
bradykinesia, impaired mobility, musculoskeletal problems, lung problems and 
respiratory problems.(Rockwood et al., 2005) It is clear that there is a complex 
relationship between fitness and frailty, and given the frequency of frailty in old age, 
this will affect the study of, and interpretation of results from, studies of physical fitness 
and dementia in the oldest-old age group.  
In our study, we also note the potential for a healthy survivor bias to affect the findings. 
By studying those who reached age 79 years and remained relatively healthy, we 
might be obscuring an association by excluding participants who had died or were too 
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unwell to enrol. If we look at smoking and lung function in particular, smoking related 
lung disease may have restricted an individual’s ability to enrol, and likewise it may 
have caused death prior to age 79. By selecting healthy survivors at age 79 for our 
study, we may inadvertently be introducing a selection bias to the study sample when 
investigating the association between lung function and dementia.  
When reviewing the study findings, one must give consideration as to whether there 
was sufficient statistical power to detect an association, or whether insufficient power 
may have contributed to the failure to reject the null hypotheses.(Hoenig & Heisey, 
2001) It is important to recognise that a study with a small sample size may not be 
able to detect an important difference, resulting in a Type 2 error. It would be useful 
to be able to show whether truthful conclusions could be based on the non-significant 
results observed in this study. Power calculations are generally recommended to take 
place prior to data collection, to determine the minimum size of a study sample 
required to detect an association. In our case, recruitment and data collection had 
already taken place, resulting in a fixed sample size. Expert opinion within the 
literature states that retrospective power analyses are not reliable or meaningful, and 
are not therefore reported to be good practice.(Gilbert & Prion, 2016; Goodman & 
Berlin, 1994; Hoenig & Heisey, 2001) Retrospective or observed power is calculated 
using the collected data and as such, the power analysis assumes that the observed 
effects are true – which may not be the case.(Hoenig & Heisey, 2001) For example, 
if a non-significant test result is used to calculate power, one would expect a low 
power, leading to the potentially false assumption that the original analyses lacked 
sufficient power to detect a positive association.(Hoenig & Heisey, 2001) Even if 
calculations of observed power were not subject to such limitations, the specific 
modelling methods used in this study complicate the calculation of statistical power, 
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and make it less likely that we could produce a realistic or meaningful value for 
statistical power.  
While these issues mean that we do not report a specific value for statistical power, 
we can make general comments about the potential impact of statistical power in our 
study. In general, it can be assumed that the larger the sample, the greater the power. 
Given the relatively small size of our study sample, the possibility of there being 
inadequate power to detect associations in this study is recognised. Obviously, larger 
sample sizes are required to have sufficient power to detect smaller effects. For 
example, Cohen (1992) offers guidance for Pearson's (product-moment) correlation 
coefficient r.(Cohen, 1992) With alpha fixed at 0.05 and power at 0.80, with an effect 
size (r) of 0.1, the necessary sample size is at least 783.(Cohen, 1992) When r is 
medium (0.3) or large (0.5), the necessary sample size is smaller, at 85 and 28, 
respectively.(Cohen, 1992) If the alpha is .01, which might be adopted to avoid a 
greater Type 1 error rate, the respective numbers are 1163, 125, and 41.(Cohen, 
1992) Broadly speaking, then, in the area of cognitive ageing, where associations 
tend to be small, the typical necessary numbers are in the several to high hundreds. 
Most analyses in cognitive ageing will be more complex than just a correlation, of 
course and, therefore, the minimum Ns needed will also depend on other factors, 
such as how many and which covariates are in the model, and what strategy for 
correction for multiple testing is implemented. 
We can therefore state that, based on our non-significant findings, we failed to reject 
the null hypotheses, but not that we accept the null hypothesis to be true. The 
limitations in statistical power of our study reinforce the importance of larger studies 
to further investigate our finding that increased physical fitness at age 79 years does 
not reduce the risk for subsequent dementia.  
139 
 
The past two chapters have considered individual potentially modifiable risk factors 
for dementia. It has however been suggested that the aetiology of dementia may be 
a complex interaction between genetic and environmental or lifestyle factors. The 
study of epigenetic modifications explores how changes in the environment can give 
rise to changes in how DNA is expressed. Epigenetic modifications may therefore be 
key to understanding interactions between genetics and environment. The 
subsequent chapter will therefore explore how one type of genetic modification might 














6: DNA methylation-based measures of accelerated ageing and  
dementia in the Lothian Birth Cohort 1921 
6.1  Introduction 
The study of epigenetics considers the effect produced by interactions between 
genetics and external factors. The prefix ‘epi-‘ is of Greek origin and translates to 
mean upon, on, above or in addition to. One may therefore consider a simplified 
representation of the concept of epigenetics as follows: additional external information 
is layered on top of the genetic code and changes the expression of this underlying 
code. In essence, the addition of this external information alters how the same DNA 
sequence is ‘read’ and expressed within the individual: a change in phenotype without 
a change in genotype. Such modifications have been shown to be transmitted to 
daughter cells in a non-genetic heritable pattern.(Weinhold, 2006)  
Epigenetics is not a new term, nor is it a novel field of research. Since the term first 
appeared in print, researchers have endeavoured to uncover evidence that gene 
function could be altered by more than just changes in gene sequence.(Weinhold, 
2006) The history of the field of epigenetics predates the creation of such terminology 
and it could be argued that the possibility of such a phenomenon began with the 
evolutionary theories of Charles Darwin.(Shields, 2019) In 1956, Conrad Waddington 
– often referred to as the father of epigenetics – published a paper in which he 
successfully demonstrated an inherited characteristic that was acquired in response 
to an environmental stimulus.(Noble, 2015; Waddington, 1956) Coining the term 
‘epigenetic landscape’, Waddington showed that by changing the chemical 
composition or temperature of the environment, embryo fruit flies could be persuaded 
to show different thorax and wing structures; the adult could display a different 
phenotype from the same genotype.(Noble, 2015) Modern day epigenetic research 
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has been much advanced by the progression in technology and experimental 
procedure. Multiple types of epigenetic modifications have been identified and 
described thus far. The most commonly studied epigenetic markers involve 
modifications of DNA (methylation) or histone proteins (methylation, phosphorylation, 
acetylation, ubiquitylation and sumolyation).(Ptashne, 2007) Histone modification 
influences gene expression via two mechanisms: by changing chromatin structure or 
by regulating the binding of effector molecules.(Bannister & Kouzarides, 2011; Wen 
et al., 2016) The majority of studies of histone modification focus on their role in the 
regulation of transcription, but histone modifications can also affect the regulation of 
other DNA processes, such as repair, replication and recombination.(Bannister & 
Kouzarides, 2011; Wen et al., 2016) DNA methylation also affects gene transcription, 
through activation or more typically repression. This chapter will not focus on histone 
modification but will explore how measures of DNA methylation may be used in the 
assessment of risk for dementia.   
As discussed within the previous chapters of this thesis, the risk factor profile and 
aetiology of dementia is not completely understood. While several individual genetic 
and environmental factors have been identified to play a role in the development of 
dementia, it is thought that interactions between the two may be of key importance. 
Such interactions may offer some explanation as to the variation in penetrance of 
genes associated with dementia. For these reasons, the study of epigenetics is 
therefore of considerable interest in dementia research.   
Within the main introduction to the thesis, we described how measures of DNA 
methylation have been used to estimate an individual’s age: DNAm age. More 
specifically, DNAm age is described as an estimate of one’s biological age. As a 
result, DNAm age has been suggested to be a better measure of risk regarding 
mortality and age-related disease than chronological age. Differences between 
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DNAm age and chronological age have been used to give a measure of accelerated 
ageing, with accelerated biological ageing being provided as a potential explanation 
as to why some individuals age more successfully than others. This may be the 
avoidance of age-related conditions or the persistence of features of less advanced 
age.  
Given that age is the most important risk factor for dementia, measures of biological 
age are of clear interest in understanding dementia risk. If accelerated biological 
ageing were associated with dementia risk, any factors identified to affect biological 
ageing would be clear targets for intervention. The study in Section 6.2 therefore 
aimed to examine the association between well-recognised DNA methylation-based 
measures of accelerated ageing and incident dementia within the LBC1921. 
The study included in Section 6.2 entitled “DNA methylation-based measures of 
accelerated biological ageing and the risk of dementia in the oldest-old: A study of the 
Lothian Birth Cohort 1921” by RA Sibbett et al. was published in BMC Psychiatry in 
February 2020. The complete reference is as follows: 
Sibbett, RA., Altschul, DM., Marioni, RE., Deary, IJ., Starr, JM., Russ, TC. DNA 
methylation-based measures of accelerated biological ageing and the risk of 
dementia in the oldest-old: a study of the Lothian Birth Cohort 1921. BMC Psychiatry 
2020, 20: 91. 
The author of this thesis was the first author and made the following contributions to 
the manuscript: contributed to study design, performed data collection for dementia 
ascertainment, took part in the dementia ascertainment consensus, contributed to 
statistical analyses and the interpretation of results, led writing of the manuscript and 
contributed to revisions of the manuscript. 
143 
 
We would note that Drew Altschul contributed to the writing of the statistical methods 
and results and Riccardo Marioni contributed to the writing of the DNA methylation 
calculation methods. The competing risk regression models and cumulative incidence 
graph were completed by the second author – Drew Altschul – with the thesis author 
completing all other aspects of the statistical analyses. The supplementary materials 
for this manuscript can be viewed in Appendix 4, from page 294. The individual 
appendices are provided on the following pages: 
• Additional file 1: Figure S1 ................................................................ page 295 
• Additional file 2: Table S1 ................................................................. page 296 
• Additional file 3: Table S2 ................................................................. page 298 
• Additional file 4: Table S3 ................................................................. page 299 
• Additional file 5: Table S4 ................................................................. page 300 
The references for this paper are included within the published manuscript, in the 
referencing style of the journal. The references can be seen on page 158 of the thesis. 
6.2 DNA methylation-based measures of accelerated biological ageing and 
the risk of dementia in the oldest-old: A study of the Lothian Birth Cohort 1921 
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As the global population ages, diseases closely associated
with advancing age are projected to increase in number as
a result. Dementia is one such disease, the most common
cause for which is Alzheimer’s disease (AD). As the num-
ber of dementia cases increases, so will the economic and
social care requirements [1]. Managing the impact of
dementia will therefore pose a significant public health
challenge. Gaining a comprehensive understanding of the
risk factors for dementia is a vital step in addressing this
challenge.
It is recognised that both genetic and environmental fac-
tors contribute to the development of dementia. There is,
however, considerable variability in the risk that one will
develop the disease. It is thought therefore, that the aeti-
ology is likely to be a complex interaction between genetic
and environmental factors. Epigenetics could be considered
to be a bridge between genes and the environment, with
exposure to environmental factors giving rise to alterations
in gene expression, via epigenetic mechanisms [2]. Unsur-
prisingly, the study of epigenetics is an area of considerable
research interest and it may prove to be important in un-
derstanding dementia risk.
Older age is widely recognised to be the most signifi-
cant risk factor for dementia. However, it is clear that
some individuals age more successfully than others, in
that, for some, advancing age has less effect on physical
robustness, health (and disease) status and cognitive
function [3, 4]. The explanation for individual differ-
ences in the effect of ageing is also likely to be multifac-
torial, with genetic, lifestyle and health factors all playing
a role [3]. It has been suggested that each individual has
a biological or physiological age that may differ from
chronological age and is the result of such factors. Fur-
thermore, studies have shown that each individual may
have a series of biological ages, depending on the bio-
marker used to estimate age, suggesting that the biological
ageing process may not just vary between individuals, but
also within each individual [5].
Patterns of a specific epigenetic modification within the
DNA sequence – DNA methylation – have been used in
previous studies to calculate estimates of biological age.
DNA methylation is one of the most frequently-studied
epigenetic marks and occurs with the addition of a methyl
group to the DNA molecule, typically at a cytosine nucleo-
tide that precedes a guanine nucleotide – CpG sites [2].
Such estimates of age are typically referred to as the
‘epigenetic age’ or ‘DNAm (DNA methylation) age’ and are
suggested to reflect both an individual’s biological age and
their susceptibility to age-related health outcomes [6].
DNA methylation-based estimates of age have been shown
to be consistent across biological sample types, including
blood and various tissues [6]. Whereas epigenetic age has
been shown to correlate highly with chronological age,
significant discrepancies between the two are noted at the
individual level [6]. Studies comparing chronological age
with epigenetic age found that there was an increased risk
of all-cause mortality for those exhibiting accelerated
ageing – i.e. those who had higher epigenetic age than
chronological age – after adjusting for related genetic,
health and lifestyle factors [6, 7]. Furthermore, the off-
spring of persons surviving to 105–109 years of age have
been shown to have a lower epigenetic age than age-
matched controls [8]. A number of suggested risk factors
for dementia have also been shown to be associated with
greater age acceleration; poorer physical fitness, lower
cognitive ability, lower socioeconomic status, greater body
mass index, higher total cholesterol to high-density lipo-
protein cholesterol ratios, hypertension and smoking
(greater pack-years) have all been shown to be associated
with greater age acceleration (calculated using DNA
methylation-based measures) [9, 10]. Based on these previ-
ous findings, we hypothesized that measures of accelerated
biological ageing based on DNA methylation would be a
valuable predictor of dementia risk.
This study would consider four recognised DNA
methylation-based measures of accelerated ageing: the
two first-generation measures of age acceleration – in-
trinsic epigenetic age acceleration (IEAA) and extrinsic
epigenetic age acceleration (EEAA) – and the two novel
estimates of age acceleration – AgeAccelPheno (based
on PhenoAge) and AgeAccelGrim (based on GrimAge).
The rationale for including the older measures was that
these have been the most consistently reported in the lit-
erature and there is therefore more evidentiary basis that
these measures were valid and appropriate for inclusion
in our study. The novel measures were included on the
basis that these have been shown to be more accurate
predictors of mortality, time-to-death and other morbid-
ities than the earlier measures [11, 12].
The earlier measures – IEAA and EEAA – were based on
methods for estimating epigenetic age described by Hor-
vath [13] and Hannum et al. [14], respectively, in 2013 [6].
Horvath’s epigenetic age estimate is based on DNA methy-
lation at 353 CpGs, while Hannum’s epigenetic age esti-
mate is based on DNA methylation at 71 CpGs. Both age
acceleration measures compare epigenetic age estimates
with chronological age in order to define age acceleration.
The age acceleration measures also differ however, in that
IEAA is independent of changes in blood cell composition,
whereas EEAA incorporates age-related changes in blood
cell composition [6]. Whereas the epigenetic age estimates
produced using these measures have demonstrated statisti-
cally significant associations with age-related conditions,
the effect sizes seen have been relatively small [11].
Levine et al. proposed that a new, more successful
DNA methylation-based measure of epigenetic age may
be developed by using “phenotypic age” as a reference,






rather than chronological age [11]. So-called “phenotypic
aging measures” are based on clinical biomarkers (albumin,
creatinine, serum glucose, C-reactive protein, lymphocyte
percent, mean cell volume, red cell distribution width, alka-
line phosphatase, white blood cell count) and age, and had
previously been shown to be associated with differences in
risk for mortality, physical and cognitive function, facial
ageing and life expectancy [11]. In 2018, Levine et al. pub-
lished the novel measure for epigenetic age, produced by
regressing a phenotypic measure of mortality risk on CpGs:
DNAm PhenoAge [11].
More recently, Lu et al. published another novel measure
of epigenetic age, termed DNAm GrimAge [12]. In a two-
step process, the authors began by identifying DNA
methylation-based biomarkers of mortality and morbidity
including several plasma proteins and smoking pack-years;
time-to death was then regressed onto these biomarkers,
producing a single composite biomarker of lifespan: DNAm
GrimAge [12]. By adjusting the measure for chronological
age, the authors produced a measure of age acceleration:
AgeAccelGrim [12]. Each of the four measures are in units
of year.
Given the differences in how each measure arrives at a
calculation of epigenetic age acceleration, and the differ-
ences between measures in the accuracy of prediction
for other outcomes shown in previous studies, one
would not necessarily expect our results to be consistent
between age acceleration measures. Because the novel
methods have been shown to be more accurate predic-
tors of morbidity and mortality in previous studies, we
might expect that these measures would be more accur-
ate in predicting incident dementia.
In summary, we explore the associations between four
DNA methylation-based measures of accelerated ageing
and n = 109 cases of incident dementia from a cohort of
n = 488 individuals, who were healthy when recruited at
age 79 years, and followed-up for approximately 16 years.
Given the known association between accelerated ageing
and mortality, we recognised the potential for death to
affect our findings. Death is therefore considered as a
competing risk in our analyses.
Methods
Participants
Participants were members of the Lothian Birth Cohort
1921 (LBC1921), recruited from 1999, with baseline test-
ing at mean age 79 years. The cohort has been described
in detail within the literature and an overview will be
provided here [15, 16]. All participants were born in
1921, and most had taken part in a general intelligence
test at age 11 years – the Scottish Mental Survey 1932
(SMS1932) [17, 18]. The survey was completed within
Scottish schools and used a validated test of intelligence.
SMS1932 participants were recruited for follow-up in
later life, with the aim of investigating the possible deter-
minants of non-pathological cognitive ageing [19]. Five-
hundred and fifty relatively healthy and independently
living participants, residing mostly in and around the
Lothian area of Scotland, enrolled in the study and
attended baseline testing. Surviving participants who
remained in the study were re-tested at four subsequent
test waves; at approximately 83, 87, 90 and 92 years of
age [16]. Test waves used questionnaires and in-person
testing and collected medical, physiological, genetic,
cognitive, psychological and socio-demographic data.
Information regarding participants who had died was
provided at regular intervals by the General Registrar’s
Office, Scotland.
Only those participants scoring 24 or higher on the
Folstein Mini Mental State Examination (MMSE) [20] at
baseline (n = 539) were included in the present study.
Similarly, those reporting a history of dementia at base-
line (n = 2) were not included. These exclusions were
made in order to minimise the possibility that we were
including prevalent cases of dementia in our analyses.
Without such exclusions there is the possibility that we
could falsely identify an association between epigenetic
age acceleration and risk for incident dementia – when
we were in fact identifying an association between epi-
genetic age acceleration and existing dementia. Ethical
approval for the study was provided by the Lothian Re-
search Ethics Committee (test waves 1–3) and the Scotland
A Research Ethics Committee (test waves 4–5). From wave
4 onwards, participants were asked to provide consent for
data linkage and access to health records.
Measures of DNA methylation
Blood samples extracted at wave 1 (mean age 79) were
used in the present study. DNA was extracted from
whole blood samples at MRC Technology, Western
General Hospital, Edinburgh, UK. Methylation typing
was performed at the Welcome Trust Clinical Research
Facility, Western General Hospital, Edinburgh. DNA
samples were bisulphite converted and hybridised to the
12 sample Illumina HumanMethylation450BeadChips
using the Infinium Methylation protocol and Tecan
robotics.
Extensive quality control was conducted, as reported
in Zhang et al., [21] to leave a dataset consisting 470,278
CpG sites from 436 LBC1921 participant observations.
Briefly, one sample from each duplicate pair (same sam-
ple from the same wave) was removed, along with one
sample from each replicate pair (same sample, different
analysis set). Samples and CpG sites with low call rates
(95% of CpGs and samples with P < 0.01) were excluded,
as were XY probes.
Following this initial screening process, the raw IDAT
files for these 436 individuals underwent a separate






quality control analysis. This was conducted in accordance
with the recommended analysis procedure in Hovarth’s
epigenetic clock tutorial (https://dnamage.genetics.ucla.
edu/), to help reduce missing CpG values. Raw DNAm
IDAT files were read into R, using minfi, and were nor-
malised using the noob (normal-exponential convolution
using out-of-band probes) method, implemented by the
preprocessNoob() function. This method estimates back-
ground noise from out-of-band probes and removes it for
each individual sample; and performs dye-bias normalisa-
tion whereby a subset of control probes estimate the dye
bias. The getBeta() function of minfi was used to obtain
noob-normalised methylation beta values.
Measures of epigenetic age
The online calculator developed by Hovarth (https://dna
mage.genetics.ucla.edu/) was used to determine measures
of epigenetic age (Intrinsic Epigenetic Age, Extrinsic Epi-
genetic Age, DNAm GrimAge, and DNAm PhenoAge)
from the beta values described above. The age calculator
performed a further normalisation process on the LBC1921
methylation data entered into the algorithm. Age acceler-
ation measures were obtained for PhenoAge and GrimAge
by extracting residuals from the model of epigenetic age on
chronological age.
Intrinsic epigenetic accelerated aging (IEAA), and ex-
trinsic epigenetic accelerated ageing (EEAA) have been
described in detail within the literature by Chen et al. [6]
IEAA is defined as the residual that resulted from a
multivariate regression of epigenetic age – calculated
using the Hovarth epigenetic age measure – on chrono-
logical age and measures of blood cell counts [6]. EEAA
was based on the epigenetic age calculated using the
measure described by Hannum et al., with a weighted
average of Hannum’s age estimate being produced in
order to increase the contribution of certain blood cell
types (known to change with age) on the age estimation
[6]. The resulting age estimate was regressed on chrono-
logical age in a univariate model, with EEAA represent-
ing the resulting residual variation [6].
Additional variables
Covariates included in the main statistical models were as
follows: age, sex, APOE ɛ4 carrier status, ever-smoking
status, history of hypertension, history of diabetes and his-
tory of either cardiovascular or cerebrovascular disease.
Genomic DNA was isolated from participants’ venous
blood in order to determine APOE ɛ4 status. Participants
were classified as carriers if they possessed one or more
APOE ɛ4 alleles. Date of birth, sex, smoking history and
history of hypertension, diabetes, cerebrovascular, and car-
diovascular disease were self-reported by participants at
the first wave of testing. Age was calculated as the number
of days between date of birth and date of attendance at
wave 1 testing. Additional analyses were performed to fur-
ther investigate the component parts of AgeAccelGrim;
additional covariates therefore included the DNAm-based
surrogates for seven proteins and smoking pack years
(beta-2 microglobulin (DNAm B2M), cystatin-C (DNAm
Cystatin C), growth differentiation factor 15 (DNAm
GDF-15), plasma activator-inhibitor 1 (DNAm PAI-1),
Leptin (DNAm Leptin), adrenomedullin (DNAm ADM),
and tissue inhibitor metalloproteinase 1 (DNAm TIMP-1)
and DNAm PACKYRS.
It was important to determine the association between
chronological age and dementia, before exploring whether
DNA methylation-based measures of accelerated aging
could be of greater predictive value in assessing dementia
risk, hence the inclusion of chronological age in the ana-
lyses. Given the narrow-age nature of our cohort, there is
little variance in age and we would not expect to observe a
statistically significant association between age and de-
mentia; the chronological age variable would not therefore
be included in subsequent statistical models if this
assumption was confirmed. APOE ɛ4 carrier status was in-
cluded because of the known association with dementia,
particularly as this association had been replicated in earl-
ier studies of this cohort [22]. Smoking status was intro-
duced given the recognised effect that smoking has on
DNA methylation [23], and the potential for this to affect
the findings. Furthermore, whereas smoking had not been
found to be associated with dementia in previous studies
of this cohort, it has been reported to be an important risk
factor within the literature. A history of hypertension, dia-
betes and cardiovascular or cerebrovascular disease were
included given the potential association with earlier death
and dementia. Furthermore, such health outcomes in-
crease with advancing age and so greater epigenetic age
could be associated with susceptibility to these conditions
[24, 25]. An interaction term for sex and measure of accel-
erated ageing was included as sex is strongly linked to
both AgeAccelPheno and AgeAccelGrim. Whereas other
factors – such as age 11 IQ – could be proposed to be as-
sociated with dementia [26], such variables have not been
shown to be important with regard to dementia risk in
this cohort and were not therefore included [22, 27]. Our
hypothesis-driven approach, based on previous findings
aimed to minimise the inclusion of variables that would
not be relevant in this sample, and reduce the possibility
of multiple hypotheses testing.
Dementia ascertainment
Dementia case ascertainment in LBC1921 has been de-
scribed previously in detail [22]. Briefly, cases were
ascertained retrospectively, up to age 95 years, based on
evidence collected from death certificates, medical re-
cords, and a small number of clinical assessments [22].
Death certificates available by the end of June 2016 were






examined for any recording of either dementia or cogni-
tive decline, in any position. For each participant who
consented to data linkage and access to records, local
electronic hospital records were reviewed and any evi-
dence for dementia or cognitive decline was collected.
Prior to 2014, psychiatric records were held on a separ-
ate electronic system and diagnoses were supplied to the
study in the form of ICD-9 and ICD-10 codes for those
who had been in contact with psychiatric services. ICD-9
and 10 codes that were relevant to the dementia ascertain-
ment process are shown in Additional file 1: Figure S1.
Latterly, psychiatric records were merged with the general
hospital system and accessed as previously described. Data
for each consenting participants were accessed using their
Community Health Index (CHI) number, a unique identi-
fier specific to each NHS patient in Scotland and recorded
at each contact. The last date for data collection from
medical records was the 16th of May 2016. Additional evi-
dence was available for a small proportion of participants
(n = 26) who underwent clinical review by one of the
authors (TCR, JMS), either in the NHS or research setting.
Any participant who reported a new diagnosis of dementia
at routine LBC1921 follow-up, or any participant for
whom a concern was raised regarding cognitive decline,
was referred for such clinical assessment. Data from such
reviews were collected up to 15th December 2016, when
all of the evidence gathered was reviewed and discussed at
a final dementia diagnosis consensus meeting (RAS, TCR,
JMS). The meeting agreed upon the presence of a diagno-
sis and the subtype, using a previously described list of
criteria for ‘probable’ or ‘possible’ dementia diagnosis [22].
Any disagreement was resolved through discussion. To
minimise the potential for introducing classification error
to the results, possible dementia cases were excluded from
the analyses.
Time-to-event variables
The events included in this study are dementia and
death, determined as described above. The number of
days between the date of attendance at wave 1 testing
and date of death gave the ‘time to death’. For those
who did not die, the censoring time was taken as the
number of days between wave 1 testing and a date be-
yond that last date of data collection for any participant
(6500 days after baseline testing). The number of days
between the date of attendance at wave 1 testing and the
first date that a dementia diagnosis was noted in any of
the available sources gave the ‘time to dementia’. Where
dementia was recorded on a death certificate and no
duration was given, and dementia was not recorded in
another source, the diagnosis was presumed to predate
death by six months. Where the duration was not given,
but a diagnosis was recorded in another source, the
earliest such date was used to determine the date of
onset. If sources recorded both cognitive impairment
and dementia, the date of dementia onset was taken as
the earliest recording of a dementia diagnosis. If demen-
tia diagnosis was determined based on evidence that did
not include a formal diagnosis of dementia, the earliest
mention of cognitive impairment was used to date onset
(as long as the same record did not specifically note the
absence of a dementia syndrome). For participants who
remained dementia-free, the ‘time to dementia’ variable
was taken as either the time to date of death or to a date
beyond that last date of data collection for any surviving
participant (6500 days after baseline testing).
Statistical analysis
The first step in analysing the data was to demonstrate
any statistically significant differences (p < 0.05) between
the group who developed dementia and the group who
did not. Univariate analysis – using either the Pearson
chi-square or t-test (IBM SPSS, Version 21) – was com-
pleted for each variable that would be included in the
main analyses. The same software was used to calculate
the level of correlation between the measures of epigen-
etic age acceleration. R statistical software, (package
‘cmprsk’ in R version 3.5.1) was used to perform all sub-
sequent steps in the analyses.
The main analyses were completed using competing risk
regression (CRR) models, in which death was considered a
competing risk for dementia. Having been considered in a
number of previous studies, the association between age
acceleration measures and death would not be a primary
focus of this study; incident dementia after age 79 years
was the primary outcome to be reported. Death and de-
mentia compete for risk in that they non-independently
occur. This changes the risk function that a given variable
may have with an outcome. For example, older individuals
are likely to both die and get dementia. Two individuals
might both die at the same time, before being diagnosed
with dementia. One of these individuals would have devel-
oped dementia in a few months had they lived, the other
would not have developed dementia for several years. In a
more standard logistic or Cox model predicting only de-
mentia diagnosis, both individuals would be censored out
of the analysis at the time of death, and the information
on the competing risk of death is ignored. Competing risk
regression models take into account the information from
a competing risk and reweights the primary outcome risk
in light of competing outcomes. The first CRR regression
model (CRR 1) explored the association between age and
dementia, with chronological age (at baseline testing)
being the only variable included. Chronological age was
excluded from subsequent models as it did not prove to
be statistically significant in this first model. The second
model (CRR 2) examined measures of accelerated aging as
a marker of biological ageing; the covariates included in






the model were the given DNA methylation measure of
accelerated ageing, sex, APOE ɛ4 carrier status, and a
DNA methylation age acceleration and sex interaction
term. The interaction term was to be excluded from sub-
sequent models if it did not reach statistical significance.
The third model (CRR 3) included these same variables,
with the addition of ever-smoking status. The final model
(CRR 4) included three additional health outcome vari-
ables – history of hypertension, history of diabetes, and
history of cardiovascular or cerebrovascular disease. Ac-
celerated ageing, sex and APOE ɛ4 are also included in
this model. Smoking status is included if it was statistically
significant in model 3.
The main findings of the CRR analyses were supported
with cumulative incidence plots for each competing
event (dementia and death); these illustrate the time-
varying risk of dementia, between covariate levels. The
Aalen-Johansen estimator was used to calculate the un-
biased estimate of cumulative incidence. In addition to
the CRR models, logistic regression models would be
completed to establish the associations between variables
and dementia, when death outcomes are not considered.




The complete LBC1921 cohort included N = 550 partici-
pants who were recruited and attended baseline testing
at age 79 years. The participants eligible for these ana-
lyses did not include those who had an MMSE score of
less than 24 at baseline (n = 9), those without a valid
MMSE score at baseline (n = 2), those who reported a
history of dementia at baseline (n = 2), and those with
no follow-up data available for the purpose of dementia
ascertainment (n = 41). For one participant, the calcu-
lated time to dementia suggested that dementia predated
attendance at wave 1 testing and they were also excluded
from the study sample. Of those who were eligible for
inclusion in this study (n = 495), a consensus diagnosis
of probable dementia was agreed for n = 109 and a con-
sensus diagnosis of possible dementia was agreed for
n = 7. Those with possible dementia were excluded from
the analyses, resulting in a final study sample of n = 488
participants. Exclusions were made on a step-wise basis
as shown in Fig. 1, with a total of n = 62 participants ex-
cluded from these analyses. Over half of the included
participants were female (57.4%, n = 280) and over
three-quarters were known to be deceased by the 30th
of June 2016 (85.9%, n = 419). Of those who were de-
ceased, 79.0% (n = 331) had died without a diagnosis of
dementia. Descriptive statistics for those included and
excluded are shown in Table 1, alongside group com-
parison statistics for those with and without dementia.
Dementia group comparison
Univariate analyses demonstrated little difference between
those eligible participants who developed dementia and
those who did not. Positive ever-smoking status (p <
0.001), greater smoking pack years (p = 0.016), increased
DNAm GrimAge age acceleration (AgeAccelGrim) (p <
0.001) and increased extrinsic epigenetic accelerated age-
ing (EEAA) (p = 0.047) reduced the risk for dementia,
while positive APOE ɛ4 (p < 0.001) carrier status increased
the risk for dementia.
Time-to-event variables
The mean time to dementia and the mean time to death
for the eligible study sample were 3371.0 (SD: 1724.7)
Fig. 1 Flowchart for participant exclusion process






days and 3618.9 (SD: 1829.3) days, respectively. The
mean time to death for deceased participants (n = 419)
was 3144.5 days (SD: 1517.5). For the participants who
survived, the ‘time to death’ variable value was taken as
the number of days between baseline testing and a date
beyond the last date of data collection for any partici-
pant; 6500 days. The mean time to dementia for those
who developed dementia (n = 109) was 3535.7 days (SD:
1283.3). For the participants who remained free of de-
mentia (n = 379), ‘time to dementia’ variable value was
taken either as the time to death for those who died
(n = 331, mean = 2863.0 days, SD: 1469.4), or time to a
date beyond the last date of data collection for any par-
ticipant for those who survived (n = 48; 6500 days).
Main analyses
The first competing risk model (CRR 1), included a sin-
gle variable – chronological age (at baseline). In our
study cohort (n = 488), chronological age at baseline did
not demonstrate a statistically significant association
with incident dementia (HR 1.00 [95% CI 1.00, 1.00],
p = 0.61). Chronological age was not, therefore, included
in subsequent competing risks models. The variables in-
cluded in each model are shown in Fig. 2.
Table 1 Study sample demographics and univariate analyses







Dementia (n = 109) No Dementia (n = 379)
Age n = 109 n = 379 n = 62
-mean age in years (SD) 79.04 (0.55) 79.08 (0.59) 0.540 79.09 (0.53)
Sex n = 109 n = 379 n = 62
% female 62.4% 55.9% 0.230 58.1%
Living or deceased n = 109 n = 379 n = 62
% deceased 80.7% 87.3% 0.081 29.0%
MMSE score at baseline n = 109 n = 379 n = 60
mean score (SD) 28.10 (1.64) 28.33 (1.46) 0.156 27.27 (2.67)
APOE ɛ4 carrier status n = 109 n = 373 n = 61
% carrier APOE ɛ4 41.3% 22.5% < 0.001 27.9%
Age 11 IQ (standardised) n = 101 n = 339 n = 53
mean score (SD) 100.19 (16.18) 100.22 (14.53) 0.982 98.21 (15.63)
Smoking status n = 108 n = 379 n = 62
% ever smoker 42.6% 61.7% < 0.001 50.0%
Lifetime smoking packs* n = 108 n = 376 n = 58
mean total packs (SD) 4359.83 (8016.04) 6616.27 (8740.85) 0.016 3880.78 (6609.45)
History of hypertension n = 108 n = 375 n = 61
% positive history 35.2% 41.9% 0.212 41.0%
History of diabetes n = 109 n = 379 n = 62
% positive history 4.6% 5.8% 0.624 1.6%
History of cardiovascular or
cerebrovascular disease
n = 104 n = 373 n = 59
% positive history 28.9% 28.2% 0.889 22%
EEAA n = 88 n = 295 n = 53
mean (SD) 0.37 (7.27) 2.35 (8.41) 0.047 −0.27 (6.68)
IEAA n = 88 n = 295 n = 53
mean (SD) −0.64 (5.60) 0.80 (6.84) 0.074 0.59 (5.13)
AgeAccelGrim n = 88 n = 295 n = 53
mean (SD) −1.30 (4.14) 0.66 (4.64) < 0.001 −0.39 (4.91)
AgeAccelPheno n = 88 n = 295 n = 53
mean (SD) 0.21 (6.56) 1.75 (7.63) 0.087 0.53 (6.55)
Note. *Lifetime smoking packs calculated by number of packs (20 cigarettes) smoked per year multiplied by the number of years smoking






All subsequent models included a measure of acceler-
ated ageing and each was completed four times – using
EEAA, IEAA, AgeAccelPheno and AgeAccelGrim, in turn,
as the measure of accelerated ageing (CRR models XEEAA,
XIEAA, XAgeAccelPheno and XAgeAccelGrim respectively). The
results for models 2–4 (for each age acceleration measure)
are shown in Table 2. CRR 2 included four covariates:
measure of accelerated ageing, sex, APOE ɛ4 carrier status
and a sex by measure of accelerated ageing interaction
term. In CRR 2AgeAccelGrim, where AgeAccelGrim was used
as the measure of accelerated ageing, greater accelerated
ageing was associated with lower risk of incident dementia
(HR 0.89 (0.81, 0.97), p = 0.009). In the same model, carry-
ing no APOE ɛ4 alleles was associated with a lower risk
for incident dementia (HR 0.45 (0.30, 0.69), p < 0.001). A
relationship between sex and incident dementia was not
demonstrated (HR 0.84 (0.53, 1.34), p = 0.46). Similarly,
the association between the sex by AgeAccelGrim inter-
action term and dementia did not reach statistical signifi-
cance (HR 1.05 (0.94, 1.18), p = 0.38). When model 2 was
repeated, using IEAA, EEAA and AgeAccelPheno (CRR
2IEAA, 2EEAA and 2AgeAccelPheno respectively), the associ-
ation between accelerated ageing and dementia did not
reach statistical significance. APOE ɛ4 negative carrier sta-
tus associated with a lower risk for incident dementia in
each of the three models. CRR 3 included the same covari-
ates as model 2, with the addition of smoking status (ever
smoker versus never smoker). Given its lack of statistical
significance, the sex by age acceleration interaction term
was dropped from subsequent models. In CRR 3AgeAccel-
Grim, the association between accelerated ageing (AgeAc-
celGrim) and dementia no longer reached statistical
significance (HR 0.95 (0.89, 1.01), p = 0.09). Lifelong non-
smoking (never smoking status) was associated with a
higher risk of incident dementia (HR 1.69 (1.06, 2.71), p =
0.03). Negative APOE ɛ4 status continued to be associated
with a lower risk of dementia (HR 0.44 (0.29, 0.67), p <
0.001). In CRR 3IEAA, 3EEAA and 3AgeAccelPheno there was
no statistically significant relationship between accelerated
ageing and dementia. Lifelong non-smoking status was as-
sociated with a higher risk of incident dementia in all
three models; negative APOE ɛ4 carrier status was again
associated with a lower risk of incident dementia in the
three models. In CRR 4AgeAccelGrim – which included his-
tory of hypertension, diabetes, cardiovascular or cerebro-
vascular disease as covariates – only APOE ɛ4 carrier
status (HR 0.41 (0.27, 0.64), p < 0.001) and smoking
status (HR 1.69 (1.05, 2.73), p = 0.03) reached statis-
tical significance, with negative APOE ɛ4 carrier
status reducing risk for incident dementia and never-
smoking status increasing the risk for incident demen-
tia. The same two variables reached statistical significance
for the models including EEAA, IEAA and AgeAccel-
Pheno as measures of accelerated ageing.
Fig. 2 Competing Risk Regression Models. α Each model was repeated four times, each time substituting a different DNA methylation-based
measure of accelerated ageing: EEAA, IEAA, AgeAccelPheno, AgeAccelGrim


































































































































































































































































































































































































































































































































































































































































































































































































































































Each model was repeated as a logistic regression model,
with probable dementia as the outcome. In these analyses
– where death was not considered – the association be-
tween AgeAccelGrim and dementia reached statistical sig-
nificance in models 2 and 3 (p < 0.05) and approached
significance in model 4 (p = 0.06). In each case, greater
age acceleration reduced the risk for subsequent dementia.
The association between AgeAccelPheno, EEAA, IEAA
and dementia was not statistically significant in any model.
Being a non-carrier for the APOE ε4 allele was associated
with a reduced risk for dementia in every model (p <
0.001). Being a never-smoker increased the risk for de-
mentia in every model where it was included (p < 0.05).
The complete results for the logistic regression are avail-
able in Additional file 2: Table S1.
Components of AgeAccelGrim
Given that the association observed between AgeAccel-
Grim and dementia was the only significant finding regard-
ing the age acceleration measures when examined using
competing risk regression analyses (CRR 2AgeAccelGrim), and
that the direction of association was opposite to what we
might have expected, we wished to investigate it further.
Based on the change in statistical significance observed
following the introduction of a smoking variable, we hy-
pothesized that the association seen had been related to
the smoking component of the age acceleration measure.
By separating out the individual components of AgeAccel-
Grim, we were able to look at the association between the
DNA methylation-based surrogate biomarker for smoking
pack years and dementia on its own to see if any associ-
ation we were seeing for the measure overall was mirrored
in what was observed for this component. The components
on which the AgeAccelGrim measure was based were
therefore considered in turn. Model 2 was repeated
eight times, each time substituting a component of the
measure for AgeAccelGrim. The components included
DNA methylation-based surrogate markers for smoking
pack years (DNAm PACKYRS) and seven plasma proteins
– beta-2 microglobulin (DNAm B2M), cystatin-C (DNAm
Cystatin C), growth differentiation factor 15 (DNAm GDF-
15), plasma activator-inhibitor 1 (DNAm PAI-1), Leptin
(DNAm Leptin), adrenomedullin (DNAm ADM), and tis-
sue inhibitor metalloproteinase 1 (DNAm TIMP-1). Each
was entered into a competing risk regression model along
with APOE ɛ4 carrier status and sex. An interaction term
was not included given that it was not previously found to
be statistically significant. Only the association between the
DNAm PACKYRS component and dementia reached stat-
istical significance (HR: 0.97 [0.95, 0.99], p = 0.007). The
complete results for these component analyses are provided
in Additional file 3: Table S2.
These analyses were again repeated as logistic regression
analyses. The association between DNAm PACKYRS and
dementia once again reached statistical significance (p <
0.05). The complete results for these analyses are provided
in Additional file 4: Table S3.
Cumulative incidence graphs
Figure 3 shows cumulative incidence plots for the two
competing events: dementia and death. The general direc-
tion of the cumulative incidence plot does seem to sup-
port the direction of the association observed between
AgeAccelGrim and dementia in CRR 1AgeAccelGrim, with
increased risk for dementia for those with lower levels of
age acceleration. Based on the figure, it would appear that
the reversal and divergence of the association between age
acceleration and dementia begins 10 years after baseline,
when subjects are aged approximately 89 years. In contrast
with the unclear pattern demonstrated for dementia, the
cumulative incidence plot indicated a greater risk for
death for those with highest levels of accelerated ageing
(calculated using AgeAccelGrim in our study) compared
with those with lowest levels of age acceleration. This re-
sult reinforced the patterns of association shown in previ-
ous studies, where higher age acceleration was associated
with a greater risk of mortality [7].
Correlation between measures of age acceleration
In this study cohort, positive correlations were shown be-
tween each of the four measures of epigenetic age acceler-
ation (0.259 ≤ r ≤ 0.439) (Additional file 5: Table S4). The
strongest correlation was seen between EEAA and AgeAc-
celGrim (r = 0.439), but this was only marginally greater
than the correlations observed between EEAA and AgeAc-
celPheno (r = 0.424), AgeAccelPheno and AgeAccelGrim
(r = 0.416) and AgeAccelPheno and IEAA (r = 0.403). The
weakest correlation was seen between IEAA and AgeAccel-
Grim (r = 0.259); this may reflect the fact that IEAA is
based on Horvath’s original measure which was developed
using multiple tissue types, while AgeAccelGrim was devel-
oped using blood methylation data alone [12].
Discussion
This study aimed to determine whether DNA methylation-
based measures of accelerated ageing were associated with
risk for dementia in the oldest-old. The results did not dem-
onstrate any consistent relationship between DNA-based
measures of accelerated ageing and incident dementia. The
initial findings suggested that increased AgeAccelGrim may
be associated with decreased risk for incident dementia in
those aged over 79 years. However, on subsequent test-
ing the results indicated that smoking might explain
this association, and more specifically, that it was likely
to be the collinear relationship between GrimAge and
smoking that had given rise to this finding.





Comparison with previous findings
Whereas a number of studies have suggested an increased
risk for dementia associated with DNA methylation pat-
terns at specific loci or with increased DNA methylation
age, we are not aware of any studies that specifically exam-
ined the relationship between methylation-based measures
of accelerated ageing and dementia [28–31]. For this rea-
son, it is not possible for us to directly compare our find-
ings. We can however consider previous notable findings
relating DNA methylation and dementia.
Investigating how a change in the expression of DNA
alters the risk of developing the dementia is of clear
value in both furthering our understanding of the patho-
genesis of the disease and in guiding the development of
effective treatments. To this end, several studies have
considered how specific changes in DNA methylation
affect one’s risk of developing dementia, with notable
epigenetic changes being observed between subjects with
dementia and controls [30]. Recent studies have indi-
cated that DNA methylation may indeed contribute to
the pathogenesis of dementia. For example, the APOE
gene (variants of which are recognised to be important
in dementia risk) has been shown to be differently meth-
ylated in Alzheimer’s disease (AD) [32]. Specifically,
reduced methylation levels at a well-defined CpG island
within the fourth exon of the APOE gene in brain tissue
were observed in AD subjects when compared with
controls; these differences in methylation levels were ob-
served in both the hippocampus and frontal lobe regions
of the brain, where AD pathophysiological changes were
abundant [32]. Furthermore, DNA methylation levels
were increased in the presence of an APOE ɛ4 allele in
controls, but not in AD subjects [32]. Studies have also
reported changes in DNA methylation, in relation to
AD, at several other genes [30]. In 2014, De Jager et al.
and Lunnon et al. published the results of two large-
scale epigenome-wide association studies (EWAS) in
Alzheimer’s disease [33–35]. Differences in methylation
were reported at a number of loci, including four that
were independently identified in both studies: ANK1,
RPL13, C10orf54-CDH23 and RHBDF2 [33–35]. A 2016
systematic review by Wen et al. described studies report-
ing higher methylation levels of several genes (observed
in peripheral blood cells or brain tissue of AD patients)
Fig. 3 Cumulative incidence plots for AgeAccelGrim: death and dementia. Note. The two groups for each event (death and dementia) were
formed from the half of participants with higher age acceleration levels who experienced that event and the half with lower age acceleration
levels that experienced that same event. A steeper rising line indicates that individuals in this group were at greatest risk for the event, e.g., in
general, individuals were more at risk for death than dementia






including OPRK1, BDNF, UQCRC1, HTERT, TREM2,
TBX2AR, SORBS3, SPTBN4, and CREB promotors and the
synaptophysin gene [30]. Lower levels of methylation of a
number of other genes were reported in the blood or brain
tissues of AD subjects, including PIN1, FAAH, ALOX5,
DR4, TNFA, COX-2, NF-kβ, CRTC1 and S100A2 [30].
Other studies have also suggested differences in global
DNA methylation – i.e. the overall level of methylcytosine
within the genome – between AD subjects and controls
[30]. While the results described are not consistent across
all studies, the evidence would seem to support the hypoth-
esis that DNA methylation plays an important role in
dementia.
Findings relating to DNAm age and dementia are of
particular relevance here given the direct relationship
between DNA methylation-based age and measures of
accelerated ageing. Levine at al. (2018) tested for an
association between pathologically determined AD and
DNAm PhenoAge in the dorsolateral prefrontal cortex
[11]. They found that when comparing same-age indi-
viduals, the dorsolateral prefrontal cortex appeared more
than one year older in those with AD [11]. Furthermore,
DNAm PhenoAge was associated with typical neuropatho-
logical signs of AD including neurofibrillary tangles, amyl-
oid load and neuritic plaques [11]. A previous Swedish
longitudinal study examined the association between
DNAm age (calculated using Hovarth’s epigenetic clock)
and dementia and the authors reported that increased
DNAm age was a statistically significant predictor for de-
mentia (β = 0.16, p = 0.019) [28]. This was however a small
study, with n = 11 dementia cases, and the logistic regres-
sion analyses were adjusted for gender only [28]. DNAm
age was calculated at a time when n = 6 of these cases were
already diagnosed, and n = 5 were diagnosed in the follow-
ing four years [28]. We must therefore consider whether
this study describes an association between advanced
DNAm age in existing dementia, as opposed to increased
DNAm age predicting dementia.
Based on these previous findings, one might have ex-
pected that the present study would have identified a
similar association between accelerated ageing and de-
mentia. There may be a number of reasons why this was
not the case, and these are discussed within the context
of the mechanisms and limitations of the study below.
Mechanisms
Whereas chronological age is widely recognised to be
associated with dementia, this was not the case in our
study cohort. It is probable that the absence of such an
association in this study can be attributed to the use of a
narrow-age cohort. In studies of methylation age and de-
mentia using participants of a wider age-range, chrono-
logical age would likely be an important covariate for
inclusion. As has been shown previously in this study
cohort [22, 27], the presence of at least one APOE ɛ4
allele was related to an increased risk of incident demen-
tia. As such, it remains an important covariate for inclu-
sion in studies of dementia in those aged over 80 years.
The results of the analyses included in this study did
not find any consistent relationship between DNA-based
measures of accelerated ageing and incident dementia.
Only one model yielded a result for accelerated ageing
that reached statistical significance at conventional
levels. Indeed, this result contradicted the hypothesised
results, with increased accelerated ageing (AgeAccel-
Grim) being associated with a reduced risk for incident
dementia. This finding would contradict those previous
studies that have shown an association between in-
creased methylation age and greater risk for developing
age-related health outcomes [6, 7]. Given the unexpected
direction of this association, one must consider the ro-
bustness of this finding. Given that the magnitude of the
association was relatively small and was not observed in
any subsequent model it may be that this was a chance
finding that does not demonstrate a true association. In
this study, the introduction of a smoking variable meant
that the association between AgeAccelGrim and demen-
tia no longer reached statistical significance. Such a find-
ing might be expected given that GrimAge is built, in
part, on smoking related data and the two are extremely
collinear, correlating at approximately 0.9. We note that
the direction of association between smoking and dementia
in this study is the same as that for AgeAccelGrim and de-
mentia. We therefore suggest that an association between
smoking and dementia seems to explain the observed rela-
tionship between AgeAccelGrim and dementia. Our finding
that the DNA methylation-based marker for smoking pack
years was the only component of AgeAccelGrim associated
with dementia in this cohort provided further evidence for
this explanation.
In these analyses, a lifelong history of non-smoking was
associated with an increased risk for dementia. While the
direction of this association may defy the expected and
contradict previous studies, it is in line with a general pat-
tern observed in this cohort of individuals aged over 79
years [22]. A previous study of the LBC1921 has also dem-
onstrated an increased risk for dementia after age 79 years
with greater lifetime physical activity, and a decreased risk
for dementia for those with a history of hypertension at
age 79 years [22]. Similarly, other factors that have previ-
ously been shown to increase risk for dementia in studies
of earlier old age have been found to have no effect on risk
in this cohort of participants aged over 79 years [22, 27].
In a previous study of physical fitness and dementia in the
LBC1921, a positive history of ever-smoking was observed
to decrease risk for dementia, but in that study the associ-
ation did not reach statistical significance [27]. It would
therefore appear that the statistical significance of the






association between ever-smoking and dementia within our
cohort is dependent on the covariates included in the ana-
lyses. It is possible that the direction of the association be-
tween age acceleration and dementia observed in these
analyses simply reflects of the direction of the association be-
tween smoking and dementia in this this cohort, but we ac-
knowledge that the inconsistency in statistical significance
means that we must treat the association observed in this
study with caution. We must also consider whether survival
to age 79 years or recruitment at age 79 years have influ-
enced our smoking-related findings. It is possible that those
individuals who were most likely to have experienced greater
risk for dementia as a result of previous or current smoking
had died earlier to age 79 years, leaving only those who
would remain unaffected or in some way ‘resistant’ to the
negative effects of smoking. Similarly, we must consider the
possibility that those who would have been more likely to de-
velop dementia a result of their smoking history had done so
prior to recruitment age and would not therefore have been
eligible to enrol in the LBC1921 study. Given that suscepti-
bility for lung disease is variable between persons [36], one
might suggest that there is a similar variability in susceptibil-
ity for dementia and those who remained dementia free at
age 79 would be those with a reduced susceptibility, giving
rise to an apparent reduction in risk for smokers.
Implications
Without any consistent results it is difficult to draw any
comparisons between the age acceleration measures
considered in this study, and how useful each might be in
establishing risk for incident dementia. Furthermore, the
lack of positive findings regarding dementia in the present
study limits the clinical implications specific to dementia.
There is a clear requirement for further study in this field; a
full appreciation of the role of DNA methylation and DNA
methylation-based measures of accelerated ageing in de-
mentia could be of considerable value in furthering our
understanding of the risks for dementia and identifying po-
tential targets for risk reduction. Our null finding might ini-
tially suggest that future similar studies were not required.
Given some of the limitations of our study cohort however,
we cannot assume that our study answers this research
question conclusively, particularly given that this has not
been investigated previously within the literature. Our sug-
gestion for larger studies would be to overcome the poten-
tial limitations of our study that may have given rise to the
null finding. A stand-alone study can rarely be taken as
conclusive evidence and additional studies would therefore
either add strength to, or refute, our null finding.
Strengths and limitations
The study cohort used in these analyses has a number of
strengths. The LBC1921 is a narrow-age cohort of persons
aged 79 years of age at baseline; this means that the study
does not suffer from the major confounding effect of
chronological age. As such, the cohort is suited to the
study of dementia in the oldest-old. Given the homoge-
neous nature of the cohort participants, confounding er-
rors resulting from age, ethnic, cultural and geographical
variability would be unlikely. Participants have taken part
in a detailed longitudinal follow-up procedure, and death
ascertainment for the cohort is complete. Previously pub-
lished assessments of validation have shown the dementia
ascertainment methods used in this study to be effective
and incidence rates to be comparable with expected rates
for the cohort [22]. We cannot however exclude the possi-
bility of missed or misclassified cases of dementia in our
cohort. In particular, a limitation of our study is the
potential that we missed cases of preclinical or prodromal
dementia in participants who died prior to developing
clinical dementia. In addition to this, it is possible that
cases of preclinical or prodromal dementia present at the
time we concluded our ascertainment would have gone
on to develop dementia after that date.
The indication of a possible reverse association (to
that which was expected) for AgeAccelGrim, combined
with the surprising association with never smoking (in
addition to those unusual associations observed in pre-
vious manuscripts), could suggest a cohort effect; it is
possible that something specific about this study sam-
ple – such as a survivor bias, or something else about
the nature of recruitment – may have influenced the
results.
A p value of 0.05 was used to determine significance
for all models. We did not therefore specifically compen-
sate for potential erroneous inferences arising from mul-
tiple testing.
Whereas the LBC1921 is a detailed cohort, it is however
limited in size. Studies of DNA methylation-based mea-
sures of accelerated ageing and dementia within larger co-
horts are required to provide further evidence in this field.
As noted above, there were insufficient numbers of eligible
study subjects to further investigate whether DNA methy-
lation age mediates the risk of smoking. This study cohort
did not have a sufficient number of confirmed cases of
dementia of the Alzheimer’s type to allow for a specific
analysis of this outcome. Again, larger studies with sub-
jects who had confirmed dementia aetiology would allow
for such analyses.
Another strength of this study was the inclusion of
death as a competing risk. We hypothesised that death
could affect the results, given the recognised association
between age acceleration and mortality. When we repeat
model 2AgeAccelGrim as a simple Cox regression analysis
(without death as a competing risk), the effect size for
AgeAccelGrim was reduced and did not reach statistical
significance (HR 0.99 (0.93, 1.06)).






In order to complete our study using a competing
risks type analyses, it was necessary to have ‘time to
event’ variables, including a ‘time to dementia’ for those
who developed the condition during the follow-up
period. We have described within the methods the man-
ner by which such estimates were determined for these
analyses. We must however recognise the uncertainty
that exists regarding the accuracy of this estimate. The
nature of dementia and the often gradual onset mean
that it is difficult to pin-point an exact date of onset.
Furthermore, the variability in how each individual per-
ceives their own symptoms and the differing stages at
which one may present for cognitive assessment mean
that when diagnoses are ascertained from records, time
of onset may be even harder to determine. Depending
on the source of data available for dementia ascertain-
ment, the date of diagnosis was not always listed, making
it even more difficult to calculate a time to dementia
estimate. In this study, the methods for calculating the
time to dementia aimed to provide the most accurate
estimate that was possible using the available informa-
tion, but the potential for inaccurate estimates to have
affected the results is acknowledged.
Finally, while we must consider the potential for in-
accuracy in self-reported smoking data. This is however
less relevant in this study given the accuracy of the DNA
methylation based marker for smoking.
Conclusion
In conclusion, the present study did not demonstrate
any consistent association between DNA methylation-
based measures of accelerated ageing and dementia in
subjects aged over 79 years. Further, larger studies – in-
cluding analyses of separate dementia subtypes – are re-
quired to further investigate the potential association
between DNA methylation-based measures of acceler-
ated ageing and dementia.
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6.3  Chapter summary and conclusions 
Our study did not find any consistent association between DNA methylation-based 
measures of accelerated ageing and dementia in those aged over 79 years. Increased 
age acceleration (AgeAccelGrim) – based on the GrimAge estimate of epigenetic age 
– was observed to be associated with a reduced risk for dementia in a single model 
but following further examination we concluded that this result was likely to be 
explained by an association between smoking and dementia. In this study, a history 
of never-smoking was found to be associated with an increased risk for dementia. 
Once again, this is a change from the pattern of risk for smoking that is described in 
younger cohorts. It is however, in line with other risk factors for dementia in LBC1921 
that have shown a reversal in the direction of association, from those described in 
early old age.  
As outlined within the study discussion, our study was subject to a number of 
limitations, such as our having inadequate numbers of dementia cases of specific 
aetiologies in order to do separate analyses for each. We also note that in our 
analyses investigating AgeAccelGrim, we included a smoking variable. Within the 
study, we report the high levels of correlation between the two and by including both 
in the model we therefore introduce collinearity. This is perhaps unsurprising given 
that smoking related data is one component of GrimAge. As noted in previous 
chapters, by including collinear variables in a regression model, the statistical 
significance of those colinear variables is undermined and one cannot trust the 
observed p values for each. With this in mind, we might question whether the 
introduction of a smoking variable allows us to make inferences regarding the nature 
of the association as we do within the paper. While this particular analysis may have 
this limitation, we follow it up with analyses examining the components of 
AgeAccelGrim (without an additional smoking variable), and this confirms our 
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suspicion that the association between AgeAccelGrim and dementia is explained by 
smoking status. 
Our study considered measures of age acceleration at a single time point – at age 79. 
As such, we consider the DNA methylation-based measures of biological age 
acceleration as a static entity, whereas in reality it is subject to change with time and 
age.(Bjornsson et al., 2008; Wang et al., 2018) Studies of monozygotic twins have 
demonstrated the increasing divergence in methylation patterns with advancing 
age.(Fraga et al., 2005) Observed long-term differences in epigenetic modifications 
are suggested to be explained by internal and external factors such as smoking, diet 
and physical activity.(Fraga et al., 2005) It follows that as one ages, the more time 
there is for an individual to be influenced by factors affecting the epigenome. While 
one might consider epigenetic modifications in advanced age to be an accumulation 
of influences and events from across the life course, one must also consider the 
possibility for acute changes to result in short-term changes in DNA methylation. For 
example, one previous study has indicated that alcohol intoxication can give rise to 
short-term changes in DNA methylation.(Koller et al., 2019) Another study 
demonstrated an increase in DNA methylation ten minutes after a social stress test, 
followed by a decrease in methylation ninety minutes later.(Unternaehrer et al., 2012) 
Such findings might therefore suggest that it is possible for short-term changes close 
to baseline testing to have affected DNA methylation-based measurements in 
LBC1921. While most studies of DNA methylation-based epigenetic clocks have 
examined epigenetic age using cross-sectional data, a 2019 meta-analysis of 
longitudinal cohort data investigated how the difference between chronological age 
and epigenetic age changes over time, between childhood and old age.(Marioni et 
al., 2019) This study used data from five separate cohorts (including LBC1921 and 
LBC1936) and showed that epigenetic age increases more slowly than chronological 
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age, particularly in the oldest population.(Marioni et al., 2019) With all of these findings 
in mind, one might consider whether repeating DNA methylation-based measures of 
accelerated biological ageing at more than one time point might lead to a clearer 
appreciation of an individual’s biological ageing. Future studies might wish to consider 
monitoring DNA methylation-based measures of accelerated ageing over several time 
points in order to establish a pattern or trend over time and determine whether this is 
a more accurate predictor of dementia risk in the oldest-old.  
There is a clear requirement for further studies to clarify the presence or absence of 
any association between DNA methylation-based measures of accelerated ageing 
and dementia, particularly given the current lack of any similar studies within the 
literature.  
Considering the potential limitations of any study is an essential step in interpreting 
the results and appreciating the validity of the conclusions. The LBC1921 was 
originally designed to investigate non-pathological cognitive ageing, with a number of 
factors being identified as having an association with poorer cognitive ageing 
outcomes. As dementia ascertainment had not been confirmed at the time of these 
studies, it had not been possible to exclude the possibility that the results had been 
affected by the inclusion of people with preclinical or prodromal dementia. In the 
subsequent chapter of the thesis we therefore revisit a number of these previous 
studies in order to examine the potential impact of preclinical/ prodromal dementia on 






7: The impact of preclinical dementia in Lothian Birth Cohort 1921 
studies of non-pathological cognitive ageing 
7.1  Introduction: Previous findings of the LBC1921 
As outlined in the second chapter of this thesis, the LBC1921 study was originally 
designed to investigate differences in the non-pathological cognitive ageing process. 
Changes in cognition – even in the absence of dementia – have been shown to be 
associated with a decline in independence, health, quality of life, decision-making and 
well-being.(Corley, Cox, & Deary, 2017) The impact of such declines would be 
experienced not only by the individual, but also by society. The resulting increase in 
demand on social care and health care – and the associated costs – would be 
particularly challenging to address in the context of an ageing population. 
Understanding the determinants of improved cognitive ageing is therefore of key 
importance to both individuals and society. Studies identifying factors that predispose 
individuals to an accelerated rate of non-pathological decline may guide strategies 
and interventions aimed at maintaining cognitive health, much like the studies that led 
to the widely recognised strategies aimed at improving cardiovascular health. Since 
the start of the LBC1921 study in 1999, researchers have explored a number of 
potential determinants of cognitive ageing including genetic factors, social factors, 
lifestyle factors, health diagnoses and physiological measures. While the LBC studies 
(LBC1921 and the younger LBC1936 cohort) have indicated that the primary 
determinant for cognitive ability in older age is cognitive ability in childhood, 
differences in childhood cognitive ability have not been shown to influence the rate of 
change in cognitive ability between childhood and older age.(Corley et al., 2017) 
Several other factors have however been implicated in influencing non-pathological 
age-related cognitive change in LBC1921. For example, the presence of an APOE ɛ4 
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allele, lower physical fitness, smoking, the use of neuro-active medications, 
polypharmacy, lower serum vitamin B-12 have all previously been shown to be 
associated with less successful cognitive ageing in the LBC1921.(Deary et al., 2003; 
Deary et al., 2006; Deary et al., 2002; Deary, Whiteman, Pattie, et al., 2004; Starr et 
al., 2004; Starr, Pattie, Whiteman, Deary, & Whalley, 2005) The availability of 
childhood intelligence data for participants in the Lothian Birth Cohorts has been 
shown to be particularly valuable in the study of cognitive ageing. Factors that were 
initially found to be associated with poorer cognitive function in older age were not 
associated after controlling for age 11 IQ.  
Prior to the dementia ascertainment described in the earlier chapters of this thesis, it 
was not possible for analyses of LBC1921 data to account for incipient dementia. As 
highlighted within previous LBC1921 articles, a potential limitation of these studies 
was the possible impact of unrecognised dementia cases on the findings.(Deary et 
al., 2002) While such an effect was reduced as far as feasible – by excluding those 
with a low Mini Mental State Examination (MMSE) score and those self-reporting 
dementia, it was not possible to guarantee that the findings were not erroneously 
representing associations with dementia. This limitation was shared with other 
published studies of normal age-related cognitive changes.  
The design of the LBC1921 study means that this limitation was of particular 
relevance in early studies of the LBC1921. With details of childhood cognitive ability 
being available at the commencement of the study, cognitive change could be 
calculated following a single round of testing at baseline (at age 79 years). While this 
was clearly advantageous in producing results quickly, it meant that analyses could 
be performed early in the study and without results from further follow-up, and 
importantly, before future diagnoses of dementia could be determined. For this 
reason, it was important to revisit early-published results demonstrating significant 
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associations between different factors and cognitive ageing, using those ascertained 
cases of dementia to explore the potential impact of preclinical dementia on the 
original findings. Reviewing any article describing a variable that has a documented 
association with dementia would be crucial given the particular risk that these 
analyses erroneously identified a relationship with incipient dementia, and not non-
pathological cognitive ageing. With this in mind, we looked back at the LBC1921 
research studies published since the establishment of the study cohort in 1999; in 
total, five previous articles were selected for review. The four variables identified as 
having an association with cognitive ageing in these articles were APOE ɛ4 genotype, 
physical fitness, serum vitamin B-12 and smoking status. The findings from these 
original reports, the methods by which each was re-examined, and the results of these 
new analyses are described in the subsequent section of this chapter.   
The following study was published by Psychology and Aging in 2018. The complete 
reference is as follows: 
Sibbett, R. A., Russ, T. C., Pattie, A., Starr, J. M., & Deary, I. J. (2018). Does 
incipient dementia explain normal cognitive decline determinants? Lothian birth 
cohort 1921. Psychology and Aging, 33(4), 674-684. 
The author of this thesis was the first author of the published paper and made the 
following contributions: contributed to study design, completed data collection for 
dementia ascertainment, took part in the dementia ascertainment consensus meeting, 
completed statistical analyses, interpreted the results of the analyses, led the writing 
of the manuscript and contributed to revisions of the same. The supplementary 
materials for this manuscript can be viewed in Appendix 5, from page 301. The 
individual appendices are provided on the following pages: 
• Supplementary material: file A .......................................................... page 302 
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• Supplementary material: file B .......................................................... page 309 
 The references for this paper are included within the published manuscript, in the 
referencing style of the journal. The references can be seen on pages 174-176 of the 
thesis. 
7.2  Does incipient dementia explain normal cognitive decline 
determinants? Lothian birth cohort 1921. 
(The published manuscript is included from the next page) 
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Does Incipient Dementia Explain Normal Cognitive Decline Determinants?
Lothian Birth Cohort 1921
Ruth A. Sibbett, Tom C. Russ, Alison Pattie, John M. Starr, and Ian J. Deary
University of Edinburgh
The presence of an apolipoprotein E (APOE) ε4 allele, lower physical fitness, smoking, and lower serum
vitamin B-12 have been reported as contributing to poorer cognitive function in LBC1921 at age 79, after
adjusting for childhood intelligence. Because incident dementia was not previously ascertained within
LBC1921, it is possible that preclinical or unrecognized cases at age 79 influenced findings. Dementia
cases arising over approximately 16 years of follow-up were determined by a consensus using evidence
from electronic medical records, death certificates, and clinical reviews. The analyses from the original
reports were repeated after the exclusion of those who had developed dementia. In a subsequent set of
analyses, the authors considered the potential impact of terminal decline, excluding those participants
who died within 4 years of baseline testing. Positive APOE ε4 status was found to be associated with
poorer Logical Memory (Wechsler, 1987) at age 79 (F(1, 355) ! 8.16, p ! .005, "p2 ! 0.022; n ! 359)
and lower Moray House Test (Scottish Council for Research in Education, 1933) score at age 79 (F(1,
357) ! 4.27, p ! .04, "p2 ! 0.012; n ! 363). Lower age 79 IQ was associated with smoking (F(2, 360) !
3.67, p ! .026, "p2 ! 0.020; n ! 367), lower vitamin B-12 (S# ! 0.11, p ! .014; n ! 367), and poorer
physical fitness (S# ! 0.21, p $ .001; n ! 359). Only the relationship with physical fitness remained
significant after excluding those who died within 4 years of baseline (S# ! 0.203, p $ .001; n ! 310).
Unrecognized dementia had little or no effect on determinants of lifetime cognitive ageing in LBC1921.
Terminal decline may have accounted for the associations with age 11 to age 79 cognitive change.
Keywords: dementia, cognitive ageing, cognitive ability, risk factors, cognitive decline
Supplemental materials: http://dx.doi.org/10.1037/pag0000241.supp
Cognitive function in older age is a critical factor in maintaining
independence and well-being (Fillit et al., 2002). Some aspects of
cognitive ability are known to decline with advancing age, even in the
absence of dementia (Robert S. Wilson et al., 2002). As the global
population ages, it is therefore increasingly important to understand
the determinants of differences in normal cognitive ageing. Further-
more, with an improved understanding of normal cognitive ageing it
might be possible to distinguish it more clearly from pathological
ageing. This will become increasingly important as the diagnosis of
neurodegenerative conditions shifts earlier and earlier to prodromal
and preclinical states. Evidence for the association between many
different factors and nonpathological cognitive ageing are docu-
mented within the literature. A 2010 systematic review highlighted
smoking and the apolipoprotein E (APOE) ε4 genotype as risk factors
for greater cognitive decline, whereas better physical health was
identified as a protective factor (Plassman, Williams, Burke, Hols-
inger, & Benjamin, 2010).
The interpretation of findings relating to normal cognitive age-
ing is, however, often limited by the difficulty in distinguishing
whether observed associations might be explained by the presence
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of the early stages of neurodegeneration (preclinical or prodromal
Alzheimer’s disease, for instance) in some participants. This is
particularly important when investigating factors such as depres-
sion and impaired physical fitness that might themselves be early
symptoms of neurodegenerative disease (Plassman et al., 2010).
Articles describing normal cognitive ageing typically exclude par-
ticipants with known or suspected dementia at baseline or at the
time of analysis. In most cases, studies perform dementia ascer-
tainment in parallel with monitoring cognitive change, either using
a planned dementia assessment protocol or recording the diagnosis
as an incidental finding (Packard et al., 2007). A lag period
between collecting the cognitive function results and determining
dementia status is, however, necessary to reduce the number of
incipient cases missed. Studies that retrospectively exclude partic-
ipants who went on to develop dementia during an extended period
of follow-up are rarer (Bretsky, Guralnik, Launer, Albert, & See-
man, 2003; Feng et al., 2012; Fillenbaum et al., 2001; Fitzpatrick
et al., 2007; Praetorius, Thorvaldsson, Hassing, & Johansson,
2013; Small, Dixon, McArdle, & Grimm, 2012; Yaffe et al., 1999).
Previous prospective studies have confirmed a subtle cognitive
decline in nondemented participants of older-age, who went on to
develop dementia (Bäckman, Jones, Berger, Laukka, & Small,
2005; Lange et al., 2002). A meta-analysis of previous studies has
shown that APOE ε4 is significantly associated with adverse
effects on a number of domains of cognitive function in nonde-
mented older-adults (Wisdom, Callahan, & Hawkins, 2011).
APOE ε4 carriers performed significantly poorer on tests of epi-
sodic memory (d ! "0.14 ("0.21, "0.07), p # .01), global
cognitive ability (d ! "0.05 ("0.10, "004), p # .05), executive
functioning (d! "0.06 ("0.12, "0.004), p# .05), and perceptual
speed (d! "0.07 ("0.13, "0.01), p# .05; Wisdom et al., 2011).
One of the studies included in the meta-analysis did, however,
indicate that the association between APOE ε4 and cognitive
function did not remain when those with preclinical dementia were
excluded from the sample (Bondi, Salmon, Galasko, Thomas, &
Thal, 1999; Lange et al., 2002). Such studies highlight the impor-
tance of evaluating the impact of preclinical dementia when in-
vestigating the determinants of nonpathological cognitive ageing.
Like most studies of their kind, early studies of possible determi-
nants of normal cognitive ageing between age 11 and age 79 in the
Lothian Birth Cohort, 1921 (LBC1921) did not have a follow-up
period in which to determine incident dementia. We address and
correct this limitation in the present report, providing further
evidence regarding the potential effect of preclinical dementia on
studies of nonpathological cognitive ageing.
LBC1921 is a narrow-age cohort (N ! 550), mostly recruited from
the City of Edinburgh and its surrounding area. Most participants had
taken part in a Scottish national intelligence test aged 11 years (Deary,
Gow, Pattie, & Starr, 2012). Participants were recruited at a mean age
of 79 years and have been followed-up into their 90s. Studies of this
cohort have reported four factors associated with almost-lifetime
cognitive ageing, from age 11 to age 79 years (i.e., factors associated
with cognitive function at age 79 years after adjusting for childhood
IQ): smoking, lower physical fitness, APOE ε4 status, and vitamin
B-12 levels. Smoking was associated with greater relative cognitive
decline from age 11 to age 79 within the LBC1921 (Deary et al.,
2003). A lower level of overall physical fitness at 79 years was
associated with less successful cognitive ageing (Deary, Whalley,
Batty, & Starr, 2006). Specifically, a higher mental test score at age
79, after adjustment for intelligence at age 11, was correlated with
increased FEV1 (forced expiratory volume in 1 second; a measure of
lung function), decreased 6-metre walk time, and increased grip
strength after adjusting for intelligence at age 11 (Deary et al., 2006).
Possessing an APOE ε4 allele was associated with both poorer Log-
ical Memory Test scores at age 79, and cognitive decline from age 11
to age 79 in this cohort (Deary, Whiteman, Pattie, & Starr, 2004;
Deary et al., 2002). Lower serum vitamin B-12 levels at age 79 was
associated with greater relative cognitive decline from age 11 to age
79 (Starr, Pattie, Whiteman, Deary, & Whalley, 2005).
In these previous studies, LBC1921 was treated as a homoge-
neous group with regard to cognitive ageing, but the cohort might
have contained at least two separate groups: that is, one group with
“normal” or nonpathological cognitive ageing, and another group
who are subject to accelerated cognitive change because of a
pathological process, most likely dementia. This is of particular
importance given the recognized associations between APOE ε4,
smoking, physical fitness, and dementia, in addition to the asso-
ciations with cognitive ageing mentioned above. A systematic
review and Delphi consensus study published in 2014 concluded
that both smoking and physical inactivity were important modifi-
able risk factors for dementia (Deckers et al., 2015). The review
included a meta-analysis of eight studies that found that current
smoking was associated with a 59% increase in risk for Alzhei-
mer’s disease (Deckers et al., 2015; Peters et al., 2008). Further to
the evidence linking physical inactivity and dementia, there is
evidence within the literature specifically linking poorer grip
strength, lung function, and walking speed with dementia (Ca-
margo et al., 2016; Yoon et al., 2015). The oldest in the population
are less well represented in dementia research and as such, the
majority of the evidence for smoking and physical inactivity as
risk factors for dementia is taken from studies involving partici-
pants in either earlier old age or from a wide age range. Some
studies have refuted the importance of these risk factors with
advancing age (Piguet et al., 2003; Verghese et al., 2003; Wang,
Fratiglioni, Frisoni, Viitanen, & Winblad, 1999), but the paucity of
studies investigating such factors in the oldest-old mean that it is
not possible to conclusively rule out the possibility that these risk
factors had an effect on the findings of the original articles con-
sidered in this study. Possession of an APOE ε4 allele has been
shown to increase the risk of dementia, and Alzheimer’s dementia
in particular (Corder et al., 1993). While the potency of APOE ε4
as a risk factor has been shown to reduce in oldest-age, the same
meta-analysis confirms that it continues to increase the risk for
dementia in oldest-age cohorts (Farrer et al., 1997). The presence
of at least one APOE ε4 allele has also been shown to increase the
risk for dementia after age 79 in LBC1921 (Sibbett, Russ, Deary,
& Starr, 2017b). Therefore, it remains an important consideration
in this study. The relationship between vitamin B-12 and dementia
is less clear, with studies demonstrating inconsistent findings
(Agnew-Blais et al., 2015). A 2012 systematic review found no
association between serum vitamin B-12 levels and risk of demen-
tia, but did demonstrate an association between poor vitamin B-12
status and increased risk of dementia in studies using alternative
biomarkers of vitamin B-12 status (holotranscobalamin and meth-
ylmalonic acid; O’Leary, Allman-Farinelli, & Samman, 2012).
Low levels of serum B-12 and elevated total homocysteine—that
may be caused by vitamin B-12 deficiency—have been linked
with increased risk of dementia in the oldest-old (Kivipelto et al.,
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2009; Wang et al., 2001). Notwithstanding the inconsistencies
between studies, and in particular between studies of early old age
and the oldest-old, it is important to test whether the apparent
associations of vitamin B-12, physical fitness, smoking, and APOE
ε4 genotype with nonpathological cognitive ageing in LBC1921
were driven by a subgroup who subsequently developed dementia.
The LBC1921 findings listed above were based on analyses
conducted soon after the sample was recruited aged around 79
years. At that time, people with possible dementia were excluded
if they scored !24 on the MMSE or reported a dementia diagnosis
at baseline. After the participants had been followed up for ap-
proximately 16 more years, it was possible to ascertain incident
dementia cases and to repeat the previous analyses excluding
people who subsequently developed dementia to isolate any group
with true “normal” cognitive ageing.
In addition to performing these sensitivity analyses, we also
planned to use the available follow-up data to investigate the
possible impact of so-called “terminal decline” on the original
findings. Cognitive decline has been found to accelerate in the
years before death, with one particular study demonstrating accel-
erated cognitive decline 43 months from death (R. S. Wilson,
Beckett, Bienias, Evans, & Bennett, 2003). The original LBC1921
findings that are reconsidered in this article were produced shortly
after recruitment, and any effect of terminal decline was not,
therefore, examined. To investigate the possible role of terminal
decline we, therefore, repeat the previously reported analyses after
excluding those eligible participants who died within 4 years of
baseline testing at 79 years.
Method
Participants
Participants were members of the LBC1921. Most had taken
part in the Scottish Mental Survey of 1932 (SMS1932), completing
a validated test of general intelligence, the Moray House Test No.
12, at age 11 years. The LBC1921 is described in detail elsewhere,
and, at recruitment, comprised 550 community-dwelling, generally
healthy older people, mostly from the Lothian area of Scotland,
who were recruited to follow-up at mean age 79.1 years (SD: 0.6;
Wave 1; Deary et al., 2012). Surviving participants underwent four
subsequent waves of follow up at mean ages of 83, 87, 90, and 92
years (Waves 2 to 5). Study data included measures of sociode-
mographic, psychological, cognitive, medical, physiological, and
genetic factors, collected by questionnaire and clinical testing.
Dates and causes of death were supplied prospectively by the
National Records of Scotland (previously General Registrar’s Of-
fice, Scotland). The Lothian Research Ethics Committee (test
Waves 1–3) and the Scotland A Research Ethics Committee (test
Waves 4–5) provided ethical approval for the studies. From Wave
4, participants provided written consent for data linkage and access
to health records. In line with the previous cognitive ageing arti-
cles, only participants with an age-79 Mini-Mental State Exami-
nation (MMSE; Folstein, Folstein, & McHugh, 1975) score of 24
or higher and no self-reported history of dementia at Wave 1 were
included in these sensitivity analyses (Deary et al., 2003, 2004,
2006; Starr et al., 2005). We considered repeating our analyses
using a stricter MMSE cut-off to identify those who might subse-
quently develop dementia, but a receiver operator characteristic
(ROC) curve determined that the discriminating power of the
MMSE was insufficient to determine future dementia outcomes
(area under curve " 0.54) in this cohort, and it was in fact little
better than random allocation. It is possible that the variation in
cognitive reserve between individuals limits the use of the MMSE
as a predictive tool.
Dementia Ascertainment
Dementia ascertainment methodology for this cohort has been
described previously (Sibbett et al., 2017b), and will be outlined
briefly here. Evidence for subsequent dementia or cognitive im-
pairment after recruitment was collected from death records, and
medical and psychiatric electronic records. For a small number of
participants, additional information was available as a result of
clinical assessments, performed in the research or NHS setting by
the authors (JMS and TCR). Data were collected up to June 2016,
when participants were aged approximately 95 years. Each case
with any evidence suggestive of dementia or cognitive decline was
considered at a consensus meeting that included both a geriatrician
and a psychiatrist. The meeting agreed whether the evidence
supported a diagnosis of dementia. Dementia cases were deter-
mined to be possible or probable cases according to a standard set
of criteria (see Table 1). For the purposes of these sensitivity
analyses, both probable and possible cases were considered de-
mentia cases and, therefore, excluded from the main analyses.
Cognitive Testing
Participants took a validated test of general mental ability (the
Moray House Test (MHT) No. 12) at age 11 and age 79 (Scottish
Council for Research in Education, 1933). The test consisted of 75
items, completed over 45 min and the maximum achievable score
was 76. The MHT scores were corrected for age (in days) and
converted to IQ-type scores (Mean " 100, SD " 15). At age 79,
an additional battery of cognitive tests was administered to assess
some major domains of cognitive function. Verbal declarative
Table 1
Consensus Criteria for Dementia Case Ascertainment (Adapted
From Sibbett et al., 2017b)
ANY of the following
(without opposing evidence from same/other source)
Probable dementia
Dementia diagnosis on death certificate (any part)
Dementia diagnosed on clinical review (ICD-10/DSM-IV)
Dementia diagnosis in electronic general medical records (Trak)
Dementia diagnosis in electronic psychiatric records (PIMS)
ICD-10 criteria for dementia diagnosis met by data within any existing
records
Possible dementia
Recorded cognitive impairment on death certificate
Cognitive impairment/decline recorded in notes, but incomplete
evidence to meet ICD-10 diagnostic criteria
Possibility of dementia recorded in notes but no formal diagnosis/
incomplete evidence to meet ICD-10 diagnostic criteria
Note. ICD-10 " International Statistical Classification of Diseases and
Related Health Problems-Tenth Revision; DSM-IV " Diagnostic and
Statistical Manual for Mental Disorders-Fourth Edition; Trak " TrakCare;
PIMS " Patient Information Management System.
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memory was assessed using the Logical Memory subtest from the
Wechsler Memory Scale-Revised (Wechsler, 1987). Participants
were read a short story (story A) containing 25 memory items and
immediately after this they were asked to recall as much as
possible. This was repeated for a second story (story B). After a
delay of approximately 30 min, participants were asked to recall as
much detail as possible from both stories. Immediate and delayed
test scores were summed to form a single score ranging from 0 to
100. The phonemic Verbal Fluency test (Lezak, 1995) was used as
a measure of one facet of executive function. Participants were
required to name as many words as possible beginning with the
letter C in 1 min. This process was repeated for the letters F and
L and the total number of correct words given is the overall test
score. Raven’s Standard Progressive Matrices (Raven & Court Jr,
1977) was used as a measure of nonverbal or abstract reasoning.
The test comprised 60 items, with each item representing a pattern
that required completion. The score was given by the number of
items completed correctly within the 20-minute time limit.
Exposures Associated With Cognitive Decline in
Previous Studies
LBC1921 participants provided samples of venous blood at
baseline, aged 79. Venous blood was used for DNA extraction.
APOE ε4 status was determined by polymerase chain reaction
(PCR) amplification of a 227 base pair fragment of the APOE gene
containing two polymorphic sites that account for three alleles: ε2,
ε3, and ε4 (Wenham, Price, & Blundell, 1991). These alleles were
distinguished by restriction digest with the enzyme Cfo1, followed
by electrophoresis in 4% NuSieve gel. Venous blood samples
collected at a clinical research facility were used to measure serum
vitamin B-12.
Grip strength in the dominant hand was measured using a Jamar
Hydraulic Hand Dynamometer, and the best of three trials was used.
Lung function was recorded as forced expiratory volume in 1 s
(FEV1), measured using a microspirometer; the best of three attempts
was recorded. The time taken to walk 6 m at a normal pace was
recorded. Grip strength, FEV1, and 6-m walk-time were correlated
and were combined using principal component analysis to obtain a
summary fitness trait (we use the term trait, though strictly speaking
this is a score from a first unrotated component). Smoking status was
reported by participants, and coded as never-, ex-, or current-smoker.
Time from enrolment to death was calculated by subtracting the age
in days at baseline testing from the age in days at death.
Statistical Analyses
For each of the original cognitive ageing reports (Deary et al.,
2002, 2003, 2004, 2006; Starr et al., 2005), the most significant
findings were selected to be investigated in these sensitivity anal-
yses. We included two articles that investigated the effect of APOE
ε4 on cognitive ageing (Deary et al., 2002, 2004). The first (named
Article 1 hereafter) demonstrated that possessing an APOE ε4
allele was significantly associated with greater cognitive decline
from age 11 to age 79 using the same test of mental ability at both
ages (Deary et al., 2002). In the second APOE ε4 article (named
Article 2 hereafter), the main finding was that the presence of at
least one APOE ε4 allele contributed significantly to lower Logical
Memory test scores at age 79 (Deary et al., 2004). It was important
to consider both articles given the relevance of memory decline in
dementia and general cognitive decline.
Current smoking was significantly associated with a lower score
on age 79 IQ (age-adjusted MHT scores at age 79, though it was
stated in the report as age 80) compared with ex-smokers and
never-smokers (Deary et al., 2003). Lower serum vitamin B-12 at
age 79 was associated with greater relative cognitive decline
between age 11 and 79 (Starr et al., 2005). The main finding from
the physical fitness article was that lower general physical fitness
component—derived from principal component analysis of three
individual measures—was significantly associated with greater
relative cognitive decline from age 11 to age 79 (Deary et al.,
2006).
Each exposure (APOE ε4 status, smoking, vitamin B-12, and
general physical fitness) was considered separately in the first in-
stance; in each case, the analytical approach used repeated that of the
previous reports. We then conducted analyses that included all four of
these exposure variables simultaneously. The method and model for
each analysis was as follows. APOE ε4 (Article 1): General linear
modeling, with MHT score at age 79 (standardized as an IQ-type
score) as the outcome or dependent variable, MHT score at age 11
(standardized as an IQ-type score) as covariate and sex and APOE ε4
carrier status as fixed factors; APOE ε4 (Article 2): General linear
modeling, with Raven’s Standard Progressive Matrices, Logical
Memory subtest, and Verbal Fluency test scores as dependent vari-
ables, sex and APOE ε4 status as fixed factors, and age 11 IQ as
covariate; Smoking: General linear modeling, with age 79 IQ as the
dependent variable, sex and smoking as fixed factors, and age 11 IQ
as covariate; Vitamin B-12: Linear regression, with age 79 IQ as the
dependent variable and vitamin B-12, age 11 IQ, sex, APOE ε4 status,
smoking status, use of statins and number of prescribed drugs as
independent variables; Physical fitness: Linear regression, with age 79
IQ as the dependent variable and sex, age 11 IQ, fitness trait, smoking
status, APOE ε4 status and social class as independent variables;
Combined analyses: (a) Linear regression including the four main
variables simultaneously (APOE ε4 status, smoking status, vitamin
B-12, and fitness trait), plus age 11 IQ and sex, with IQ at age 79 as
the outcome variable; (b) Multivariate general linear modeling, with
Raven’s Matrices, Verbal fluency and Logical Memory as dependent
variables, APOE ε4 status, sex, and smoking status as fixed factors
and fitness, vitamin B-12 and age 11 IQ as covariates. To improve the
clarity of the effect size, we also present estimated marginal means
(95% confidence interval [CI]) with related effect size (Cohen’s d) for
categorical risk factors. For comparison, this is given alongside the
same statistics for the study cohort when dementia cases were in-
cluded. After each of the individual analyses, we completed a subse-
quent analysis in which participants with probable dementia, or no
dementia were included. Forming a between-groups variable, we
included an interaction term with the risk factor to determine whether
it varied as a function of the inclusion group. Finally, we repeated the
each of the main individual analyses after the exclusion of those
participants who had died within 4 years of baseline testing. The
methods and models were as shown above. Statistical analyses used
IBM SPSS, Version 21.
Results
There were 550 participants attended the baseline wave of data
collection at age 79 years. For each analysis, we excluded 130
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participants: 2 participants had reported a diagnosis of dementia at
Wave 1; 9 participants scored less than 24 on the MMSE at Wave
1; 2 participants were missing MMSE scores at baseline; and there
were 117 participants for whom we had ascertained a diagnosis of
dementia in about 16 years of follow up, to age 95 years. Each
analysis then repeated the other exclusion criteria and require-
ments as recorded in the original reports and, as a result, the
number of participants with complete data for each analysis varied
slightly between the separate outcomes. The numbers providing
full data for each analysis were as follows: APOE ε4, (Article 1)
n ! 363 (Article 2) n ! 359; smoking, n ! 367; vitamin B-12, n !
367; and physical fitness, n ! 359.
APOE !4
APOE !4 Article 1: MHT score as outcome (Deary et al.,
2002). Of 363 participants with complete data, 210 (57.9%) were
female and 79 (21.8%) possessed at least one APOE ε4 allele. On
general linear modeling, a lower MHT score at age 11 years was
associated with a lower MHT score at age 79 (F(1, 357) ! 239.4,
p " .001, #p2 ! 0.401). Sex was also associated with MHT score
at age 79 (F(1, 357) ! 4.76, p ! .03, #p2 ! 0.013) as was the
presence of an APOE ε4 allele (F(1, 357) ! 4.27, p ! .04, #p2 !
0.012; see Table 2). These results were consistent with those of the
original study, which found a similar effect size for each of the
three variables (see Table 1). The exclusion of dementia cases had
very little impact on the effect size (d ! $ 0.23 ($ 0.44, $ 0.03);
d ! $ 0.26 ($ 0.51, $ 0.01) and estimated marginal means (see
Table 3). The complete results for each of the main sensitivity
analyses and those for the combined analyses are shown in sup-
plementary material File A, Tables S1–S7.
APOE !4 Article 2: Logical Memory, Raven’s Matrices, and
verbal fluency as outcomes (Deary et al., 2004). Of the 359
participants with full data for these analyses, 208 were female (57.9%)
and 78 were carriers of at least one APOE ε4 allele (21.7%). On
univariate analyses (t test) there was no significant difference between
those with and without an APOE ε4 allele in age 11 IQ, p ! .50, or
age 79 MMSE, p ! .48. On general linear modeling, positive APOE
ε4 status was found to contribute to a lower Logical Memory test
score at age 79 years (F(1, 355) ! 8.16, p ! .005, #p2 ! 0.022), but
not to Raven’s Matrices (F(1, 355) ! 3.56, p ! .06, #p2 ! 0.010), or
to Verbal Fluency (F(1, 355) ! 26.52, p ! .664, #p2 ! 0.001) tests’
scores. The findings from this analysis replicate those found in the
original article (see Table 2). In both the original and new analyses,
age 11 IQ contributed significantly to all three measures whereas sex
contributed to Raven’s Matrices only. The effect size (Cohen’s d)
relating to Logical Memory test score remained relatively stable after
the exclusion of those participants who went on to develop dementia
(d ! $ 0.35 ($ 0.56, $ 0.14); d ! $ 0.36 ($ 0.61, $ 0.11); see
Table 3).
Smoking
Of the 367 participants with data available for these analyses,
211 were female (57.5%). There were 189 participants were ex-
smokers (51.5%), 30 were current smokers (8.2%), and 148 were
never smokers (40.3%). The mean age at starting smoking was
18.4 years (SD: 5.5) years (range of 7–60 years), and only four
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modeling, smoking was found to be associated with a lower IQ at
age 79 years (F(2, 360) ! 3.67, p! .026, "p2 ! 0.020; see Table
2). Age 11 IQ was also found to be significant, whereas sex was
not. As shown in Table 2, the original article also found a signif-
icant association between smoking and age 79 IQ. The effect size
(Cohen’s d) was relatively unaffected by the exclusion of dementia
cases when current smoking was compared with ex-smoking
(d ! # 0.44 (# 0.8, # 0.08); d ! # 0.45 (# 0.84, # 0.06)) and
similarly, when current smoking was compared with never smok-
ing (d ! # 0.43 (# 0.79, # 0.06); d ! # 0.53 (# 0.92, # 0.13); see
Table 3). IQ at age 79 was significantly lower for current smokers,
compared with both ex-smokers (p! .024, mean difference ! # 5.0,
95% CI [# 9.3 to # 0.7]) and never-smokers (p ! .007, mean dif-
ference ! # 6.2, 95% CI [# 10.6 to # 1.7]), and again, this repli-
cated findings from the original article.
Vitamin B-12
Of the 367 participants eligible for inclusion in these analyses, 211
were female (57.5%) and 326 had serum vitamin B-12 levels avail-
able (88.8%). The mean vitamin B-12 level was 388 (SD 162) ng/L.
To prevent bias from participants with very high serum levels that
were the result of treatment for vitamin B-12 deficiency, those with a
serum level more than 3 SDs higher than the mean were excluded
(n ! 8). The resulting mean level for included cases was 374.0 (SD
134.5) ng/L. Serum vitamin B-12 levels were standardized and stored
as z scores for the purposes of analyses. As in the original article, the
linear regression results demonstrated a significant association be-
tween lower vitamin B-12 and lower age 79 IQ (S$ ! 0.124, p!
.006, R2 change ! 0.015). After adjusting for sex, APOE ε4 status,
smoking status, use of statins, and number of prescribed drugs, vita-
min B-12 continued to be associated significantly with age 79 IQ
(S$ ! 0.110, p! .014, R2 change ! 0.012; see Table 2). This was
again the same outcome of the analysis in the original article (S$ !
0.095, p! .011). We replicate the association between vitamin B-12
and age 79 IQ by repeating our analysis without excluding dementia
cases (S$ ! 0.087, p! .022, R2 ! 0.007).
Physical Fitness
A total of 359 participants met the inclusion criteria for these
analyses, of which 208 were female (57.9%). The sex and height
adjusted fitness measures—grip strength, 6-m walk time, and
FEV1— were all significantly correlated (p! .01). Principal compo-
nent analysis identified a single component that accounted for 48% of
the total variance. The loadings on this first unrotated component—
termed “fitness”—were as follows: grip strength ! 0.75; 6-m walk
time ! # 0.65; FEV1 ! 0.68. In the present analyses, age 11 IQ was
not significantly associated with FEV1 (0.097, p! .067) as it was in
the original report (p ! .03; Deary et al., 2006). IQ at age 79
correlated significantly with all three individual fitness measures (grip
strength ! 0.154, p! .003; 6-m walk time ! # 0.193, p% .001;
FEV1 ! 0.174, p! .001) and with the combined fitness trait (0.231,
p % .001). Linear regression analyses showed that the variables
contributing significantly (p! .05) to variance in IQ scores at age 79
were: age 11 IQ (38.3% of variance); fitness (4.7%), sex (0.8%), and
social class (1.8%). Fitness accounted for a higher percentage of
variance in this analysis when compared with the original analysis
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ing variables were found to contribute to age 79 IQ: age 11 IQ (42.4%
of variance); fitness (3.1%), social class (1.2%), sex (0.7%), and
APOE ε4 (0.6%). Smoking status did not demonstrate a significant
contribution to variance in either analysis (p ! .05).
We repeated each of the main analyses with the study sample
comprising of participants with probable dementia, or no dementia.
Dementia status was included as a between-groups variable and we
included an interaction term with the risk factor to determine whether
the effect varied as a function of the dementia group. The interactions
between dementia and APOE ε4 status, dementia and smoking status,
dementia and vitamin B-12 level, and dementia and fitness were not
significantly associated with standardized MHT test score or IQ at age
79. The APOE ε4 carrier status by dementia status interaction was
associated with Raven’s Matrices test score at age 79 (p " .006), but
not Logical Memory or Verbal Fluency test scores. Further details of
these results can be seen in supplementary material File B.
Combined Analyses
Linear regression including the four main exposure variables
(APOE ε4 status, smoking status, vitamin B-12, and fitness trait)
showed that age 11 IQ (34.2%), fitness (5.6%), vitamin B-12 (2.1%),
and sex (1.7%) contributed significantly (all p # .01) to variance in
age 79 IQ. When dementia cases (n " 103) were included in the
analysis, age 11 IQ (39.9%), fitness (3.4%), vitamin B-12 (1.1%), and
sex (1.1%) continued to contribute significantly to variance (p# .01).
APOE ε4 status and smoking did not enter into the models.
Multivariate general linear modeling showed positive APOE ε4
status to be associated with lower Logical Memory test scores at age
79 years (F(1, 301) " 5.5, p " .02, $p2 " 0.018). Lower levels of
general physical fitness at age 79 years was associated with both
lower Verbal Fluency (F(1, 301) " 12.3, p " .001, $p2 " 0.039) and
lower Raven’s Matrices (F(1, 301) " 18.0, p# .001, $p2 " 0.056) test
scores. When dementia cases (n " 103) were included in the same
analysis, the same associations were found: APOE ε4 and Logical
Memory (F(1, 392) " 5.5, p " .02, $p2 " 0.014); fitness and Verbal
Fluency (F(1, 392) " 12.8, p # .001, $p2 " 0.032); fitness and
Raven’s Matrices (F(1, 392) " 13.6, p # .001, $p2 " 0.034). In
addition, lower vitamin B-12 was associated with lower Raven’s
Matrices test scores (F(1, 392) " 5.6, p" .02, $p2 " 0.014). Smoking
did not contribute significantly to any of the three outcomes.
Terminal Decline
The number of participants who died within 4 years of baseline
testing and were, therefore, excluded from the “terminal decline”
analyses were as follows: APOE (Article 1), n " 52; APOE (Article
2), n " 50; smoking, n " 52; vitamin B-12, n " 52; fitness, n " 49.
After the exclusion of these participants—and those who had devel-
oped dementia—the resulting cohort size for reanalyses ranged from
n " 309–315. The main individual analyses were repeated and the
association between fitness and age 79 IQ remained significant (S% "
0.203, p # .001). The results for APOE ε4 (Article 1: F(1, 306) "
1.30, p # .255, $p2 " 0.004; Article 2: F(1, 304) " 2.95, p " .087,
$p2 " 0.010), smoking (F(2, 308) " 1.97, p " .141, $p2 " 0.013) and
vitamin B-12 (S% " 0.087, p " .075) did not reach significance (see
Table 2). The estimated marginal means and effect sizes (Cohen’s d)
for the categorical variables are shown in Table 3. The complete
results for the terminal decline analyses are shown in supplementary
material File A, Tables S1–S5.
Power Calculations
We completed post hoc power calculations to describe the
statistical power of the new analyses, relative to the original
analyses. The statistical power to detect an effect of the same
magnitude at p # .05, as was observed for the complete study
sample, was reduced after the exclusion of dementia cases in each
analyses. The reduction in power ranged from 3% (from 0.99 to
0.96 for the physical fitness analysis) to 18% (0.60 to 0.49 for the
smoking analysis). The statistical power was reduced further after
the additional exclusion of those participants who died within 4
years of baseline testing; with reductions in power ranging be-
tween 6% (from 0.96 to 0.93 for physical fitness) and 28% (from
0.58 to 0.42 for APOE ε4 Article 1 and from 0.60 to 0.43 for the
smoking analysis).
Discussion
These sensitivity analyses, completed by repeating analyses
conducted in five of our team’s previous reports after excluding
participants who subsequently developed dementia, verified pre-
vious findings of LBC1921 studies. The presence of an APOE ε4
allele, smoking, lower physical fitness, and lower vitamin B-12
were all associated with greater relative cognitive decline between
age 11 and 79 years even after excluding those who had developed
dementia in the next 16 years. The effect sizes were similar in
magnitude to the previous findings and, therefore, we can be more
confident that prodromal or undiagnosed dementia had little influ-
ence on the original findings. However, our analyses did suggest
that terminal decline could have influenced the results, with only
physical fitness remaining significant after the exclusion of those
who died within 4 years of baseline testing. With a smaller sample
size, we had less power for these analyses and, therefore, we are
cautious when considering the results.
Comparison With Previous Literature
Like the original articles that investigated the relationship be-
tween APOE ε4 and cognitive ageing, we found that the presence
an APOE ε4 allele contributed to poorer performance on a Logical
Memory test at age 79 years, and contributed to general cognitive
decline from age 11 to age 79. Using a robust method to exclude
dementia cases we have minimized the possibility that dementia
had caused some of the effect seen previously. Our findings agree
with a previous meta-analysis, which found that APOE ε4 carriers
performed poorer on tests of episodic memory, global cognitive
ability, executive function and perceptual speed (Wisdom et al.,
2011). The effect sizes for episodic memory and global cognitive
ability were noted to increase with advancing age (Wisdom et al.,
2011). Our results did not remain significant after accounting for
possible terminal decline. Several studies have considered the
effect of APOE ε4 on mortality and although a relationship is
described, it is typically explained by the presence of dementia. If
we accept our results as correct, despite the reduced sample size,
it is possible that the participants who demonstrated a link between
APOE ε4 and cognitive decline in our main analyses would in fact
have gone on to develop dementia had they survived.
The findings for smoking and cognitive decline from the present
analyses were consistent with the original article (Deary et al., 2003).
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Our findings also agree with the conclusions of other previous studies
identifying smoking as a risk factor for cognitive decline (Yaffe et al.,
2009), and recording an increased risk of decline in current smokers
when compared with never-smokers and ex-smokers (Sabia et al.,
2012). The potential for underestimating the effect of smoking on
cognition as a result of higher rates of death and dropout among
smokers is noted from the results of a previous study (Sabia et al.,
2012). If risk of death is increased among smokers, this may explain
why the relationship between smoking and cognition becomes non-
significant after the exclusion of participants who die within 4 years
of baseline testing—if a terminal decline in cognitive ability means
that you are more likely to be closer to death, then perhaps you are
simply also more likely to be closer to death if you are a smoker. In
addition to failing to reach significance, the effect size for the rela-
tionship is reduced. Our final set of analyses included all of the main
variables considered in this article, and smoking status did not reach
significance in either. This is probably because of the inclusion of the
fitness variable and the likely link between smoking and fitness.
We found that a 134.8 ng/L (1 SD) decrease in serum vitamin
B-12 level at age 79 was associated with lower IQ scores at the
same age. This relationship is in line with that found in the original
article. Our results provide weight to the evidence for this rela-
tionship that exists within the literature, which is of particular
importance given the conflicting evidence for this association
(O’Leary et al., 2012). Although the effect size is relatively un-
changed after the exclusion of those participants dying within 4
years of enrolment, the association between vitamin B-12 and
cognition is no longer significant. Reduced dietary intake or re-
duced absorption can contribute to lower levels of serum vitamin
B-12 and those who are unwell are therefore at an increased risk.
It may be therefore, that cognitive function and vitamin B-12 both
decline toward death and are not truly associated.
We must consider whether the consistency between the results
when dementia cases were included and when cases were excluded
is related to the possibility that the factors examined in this article
are no longer associated with an increased risk for dementia after
age 79. There is evidence to support this within the literature, with
studies reporting no association between risk factors (vitamin-B-
12, smoking, physical fitness) and dementia (Crystal et al., 1994;
Piguet et al., 2003; Verghese et al., 2003; Wang et al., 1999), or at
least a declining strength of association (APOE ε4; Corrada,
Paganini-Hill, Berlau, & Kawas, 2013; Farrer et al., 1997). These
findings have not, however, been comprehensively reinforced, and
as a result, there is no widely accepted risk factor profile for
dementia in the oldest-old. This likely relates to the difficulties in
recruiting healthy persons in oldest age, and the potential for high
rates of attrition because of morbidity and mortality in such co-
horts (Sumic, Michael, Carlson, Howieson, & Kaye, 2007). Until
there is a sufficient body of evidence disputing any risk factor for
dementia in the oldest-old that is an accepted risk factor for
dementia in earlier old-age, studies must continue to evaluate the
effect of preclinical dementia in studies of nonpathological cogni-
tive ageing.
We acknowledge the possibility that terminal decline has influ-
enced our findings for vitamin B-12, smoking and APOE ε4, but
we consider these results with caution given the reduced sample
sizes (n ! 309–315) for each of these analyses. The statistical
power was reduced after these exclusions, relative to the original
analyses, meaning that we were less likely to detect any associa-
tion. We note that for physical fitness—the only finding that
remained significant in these analyses—the reduction in power
(relative to the complete sample) was only 6%, compared with a
reduction in power of between 18 and 28% for the other analy-
ses—none of which demonstrated a significant association. Fur-
thermore, excluding a group likely to be experiencing cognitive
decline reduces the amount of decline in remaining participants. If
there is less variability in cognitive decline among those who
remain in the sample, the likelihood of identifying factors associ-
ated with cognitive decline is diminished. Larger studies are re-
quired to reduce the impact of such an effect. A potentially
effective way of reducing this effect when selecting dementia
cases would be to identify probable cases of incipient dementia
using ante-mortem neuroimaging data or postmortem neuropatho-
logical data. This could, however, lead to the potential misclassi-
fication of some participants, because pathological features of
Alzheimer’s disease have been found in persons who died without
cognitive impairment (Savva et al., 2009). Given the possible
impact of terminal decline, we would suggest that studies inves-
tigating risk factors for cognitive decline in older age account for
death occurring after 4 years or less within their analyses.
Fitness was found to be significantly associated with age 79 IQ
in this article and the original article (Deary et al., 2006). After the
exclusion of those participants who died within 4 years of testing,
this was the only relationship that remained significant (p " .001).
These results are in line with previous studies that have identified
a relationship between increased fitness or exercise and decreased
cognitive decline (Fitzpatrick et al., 2007; Taniguchi, Yoshida,
Fujiwara, Motohashi, & Shinkai, 2012; Wendell et al., 2014). The
results of our four main analyses go further than simply reinforcing
previous findings—they add some validation to those studies with-
out dementia follow-up (Bretsky et al., 2003; Fillenbaum et al.,
2001; Sabia et al., 2012; Taniguchi et al., 2012). Given that the
lack of follow-up for dementia ascertainment is so often a major
criticism of studies investigating normal cognitive ageing, our
findings are valuable in demonstrating the minimal impact of
incident dementia in these follow-up analyses.
Strengths and Limitations
The accuracy of the findings is limited by the possibility that
participants who might otherwise have developed dementia could
have died from other causes before the onset of dementia. By
definition—as a result of excluding those who later developed
dementia—fewer participants were included in each analysis than
in previous studies. With the exception of not having knowledge of
incipient dementia, the limitations present in the original studies
persist. For example, we might expect the smokers in our cohort to
be biased to being particularly fit, given that by age 80 they were
relatively unaffected by serious smoking-related illness or death.
We did not have sufficiently frequent cognitive assessments to
investigate terminal decline fully and we, therefore, simply omit-
ted those participants who died within 4 years of cognitive assess-
ment at age 79 years. We cannot be confident in our findings
relating to the effect of terminal decline because of reduced sample
size, but given the possibility of an effect, we recommend that
future studies account for death in their analyses. Our dementia
ascertainment procedure did not include neuropathological exam-
ination after death. Whereas we could not exclude the presence of
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pathological findings typically associated with dementia syn-
dromes, current evidence has shown that such findings are fre-
quently observed within the brain tissues of older persons who
died without cognitive impairment (Savva et al., 2009). Such
findings demonstrate that, whereas pathological findings can con-
firm the etiology of dementia, their presence alone does not nec-
essarily equate to the presence of a clinical dementia syndrome.
This study aimed to determine the presence of the clinical syn-
drome of dementia; we would not, therefore, have expected this
limitation to affect our results. As described in an earlier study
(Sibbett et al., 2017b), our robust dementia ascertainment proce-
dure included evidence gathered from multiple sources of data—
including clinical assessment—and, as such, we were able to limit
the number of potential missed cases. There will, however, always
be limitations in the accuracy of such a methodology (Sibbett,
Russ, Deary, & Starr, 2017a), primarily because the quality and
quantity of available data will vary between participants. As such,
we cannot entirely exclude the possibility that using a procedure
with optimized sensitivity to identify cases may have found further
cases and had an effect on the findings. A significant strength of
our study is that we were able to include age 11 IQ in all
analyses—both original and new—and so protect from the possi-
bility of reverse causation by the influence of childhood IQ; in
effect, we were able to have near-lifetime cognitive change as the
outcome variable in these analyses. Using the LBC1921 as our
study population also has a number of other benefits. Possible
confounding effects are limited because of their ethnically, cultur-
ally, and geographically homogeneous nature, general good health,
and narrow-age of the cohort. We recognize, though, that this also
limits generalizability.
Conclusions
These sensitivity analyses verify previous findings and demon-
strate that preclinical or prodromal dementia had little influence on
five LBC1921 studies that examined influences on nonpathologi-
cal cognitive ageing. The presence of an APOE ε4 allele, smoking,
lower physical fitness and lower vitamin B-12 were all associated
with greater relative nonpathological lifetime cognitive decline.
These findings allow us to suggest that the impact of incipient
dementia would be minimal in studies with a similar methodology
of excluding from analyses participants who self-report a diagnosis
of dementia and/or score below an appropriate cut-off on a brief
cognitive screening test.
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7.3  Chapter summary and conclusions 
The described study revisited and repeated the primary analyses of five individual 
previous studies and included an analysis combining all of the studied factors 
together. In addition to these repeated analyses, our study included a further repeat 
of each of the five analyses, in which the potential impact of terminal decline was 
examined. As such, the described study was an extensive and thorough re-evaluation 
of the previous findings, in the context of dementia and death outcomes occurring 
since the completion of these early studies.  
In repeating the primary analyses of the previous studies, we found that our analyses 
verified the findings of the original reports, suggesting that incipient dementia had 
minimal influence on the conclusions of the original papers. Not only did the patterns 
of association remain the same, but the magnitude of the effect sizes were much 
unchanged from the original results. These findings were important, not only in 
reinforcing the veracity of these findings, but they also suggest that incipient dementia 
is unlikely to have influenced findings from other LBC1921 studies. Beyond this, the 
findings offer some level of validation to findings from other study groups without 
adequate follow-up for dementia ascertainment. We must however recognise the 
possibility that we did not identify every case of dementia and that unrecognised 
cases continued to influence the findings. It is also possible that some other cause for 
cognitive decline was influencing those associations seen in the original and repeat 
analyses. Previous studies have demonstrated an acceleration in non-pathological 
cognitive decline in the years preceding death – so-called terminal decline.(Karr, 
Graham, Hofer, & Muniz-Terrera, 2018) While the exact onset of this decline in 
relation to time of death has been reported with some variability, the rate of decline 
has been shown to increase markedly in the 3 to 4 years before death.(Wilson, Beck, 
Bienias, & Bennett, 2007) Given the high numbers of deaths in our cohort, it was 
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important to consider if such decline had influenced the original findings. Our 
additional analyses found that the original findings for smoking, APOE e4, vitamin B-
12 may indeed have been influenced by such terminal decline. When we excluded 
those participants who died within 4 years of baseline testing and repeated the 
analyses, only the association between physical fitness and cognitive decline reached 
statistical significance. While it was possible that a reduction in sample size had an 
impact on our findings, the results suggest that future studies of cognitive decline in 
advanced old age should – where possible – account for possible terminal decline in 
their analyses, given the elevated risk of imminent death that is associated with 












8.1  General findings 
This presented thesis had three primary aims. The first of these was to determine 
dementia incidence within the study cohort – the Lothian Birth Cohort 1921. With 
dementia cases identified, the next aim was to investigate potential risk factors 
associated with dementia in this cohort of the oldest-old, with a particular focus on 
potentially modifiable risk factors. The final aim was to re-examine previous findings 
of the Lothian Birth Cohort 1921 study. Previously published studies had identified 
factors associated with non-pathological cognitive ageing, and by excluding the 
people who had gone on to develop dementia (and who presumably had preclinical/ 
prodromal dementia when tested) the aim was to reduce the possibility that the 
original studies had erroneously identified an association with preclinical dementia. 
This final chapter provides an overview and discussion of the findings within this 
thesis, and how these relate to both the existing literature and the original objectives. 
The potential strengths or limitations of the work resulting from methodology or 
sample selection will be considered alongside recommendations for future research.   
8.1.1  Dementia ascertainment methodology 
The first objective of this thesis was to ascertain dementia cases and therefore 
determine dementia incidence for the Lothian Birth Cohort 1921. In order to identify 
dementia cases within the study cohort, it was necessary to either identify a previously 
described effective ascertainment methodology, or to develop one for this purpose. 
No such ‘gold-standard’ methodology had been previously published within the 
literature and it was therefore necessary to gather evidence to guide the development 
of an ascertainment method for the Lothian Birth Cohort 1921. The evidence gathered 
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and subsequent development of ascertainment methodology are described in full 
within Chapter 3.   
Based on the findings of the study described in Section 4.2, the dementia 
ascertainment method designed for the LBC1921 cohort was found to be relatively 
effective. As such, one can be confident in using the identified cases for further study, 
both within this thesis and in LBC1921 studies completed by other researchers. 
Furthermore, the methods described may be considered by others who are designing 
their own dementia ascertainment methodologies. Having previously investigated the 
ascertainment methodologies utilised in other studies and found a lack of detail in 
many published papers, it was important that this study described the ascertainment 
method clearly. By providing details of the methodology, together with a description 
of the assessments used to determine validity, the relative effectiveness of the 
methods used may be easily compared with the results of future ascertainment 
studies. While the likelihood of there being missed cases is recognised, this would be 
anticipated with any study using existing data as the primary source for dementia 
ascertainment, and it can be said that these were minimised as far as possible in this 
cohort.  
8.1.2  Dementia incidence in the Lothian Birth Cohort 1921 
Our study found that 22.5% of eligible participants developed dementia during the 
follow-up period (approximately sixteen years). As shown within the study included in 
Section 4.2, the number identified equated to approximately 74% of cases that would 
have been predicted for a cohort of this size and age; predictions were based on the 
findings of a large study that pooled data on dementia incidence from eight 
population-based studies in seven European countries.(Fratiglioni et al., 2000) The 
discrepancy between expected cases and identified cases was likely to be 
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multifactorial. It is widely recognised that a number of persons with dementia are not 
diagnosed; in the Lothian region of Scotland dementia diagnosis rates have been 
previously reported as 68.3%.(Alzheimer's Society, 2012) Our ascertainment 
procedure would have been less likely to identify undiagnosed cases given the 
relative paucity of detailed clinical data that was the result of the number of 
participants who were unable to provide consent to access medical records. This 
would be particularly true for those participants who were lost to routine follow-up, as 
changes in cognition may have been identified during repeated cognitive test 
batteries. We would however have identified those persons with dementia, but without 
a diagnosis, who continued to attend study waves for follow-up as a decline in 
cognitive ability would have resulted in a referral for clinical assessment as described 
previously. Another potential explanation for dementia rates to be lower than expected 
in this cohort is the relatively high levels of education and socioeconomic class.      
8.1.3  Risk factors for dementia 
8.1.3.1 Comparisons with previous studies of the oldest-old 
As noted within the main introduction and in each relevant Chapter of this thesis, 
existing studies of risk factors for dementia in oldest-age have produced inconsistent 
findings. While the studies based on the LBC1921 described in Chapters 4 to 6 are 
unlikely to provide any definitive clarity, it is hoped that the results will add to the 
volume of research on this topic and will aid in producing a more conclusive risk factor 
profile in the future. Here, we provide an overview of our findings and how these 





APOE ɛ4 genotype 
Based on a large volume of previous research, the APOE ɛ4 genotype is recognised 
to be an important risk factor for dementia, and Alzheimer’s disease in 
particular.(Corrada, et al., 2013) All of our risk factor studies found that the presence 
of at least one APOE ɛ4 allele continues to be an important risk factor for dementia 
over age 79 years. The study detailed in Chapter 4 looked specifically at APOE ɛ4 as 
a risk factor for dementia in the LBC1921 and found that the presence of at least one 
APOE ɛ4 allele more than doubled the risk for incident dementia (OR: 2.23 ; 95% CI: 
1.29, 3.86). This pattern of risk was also shown in the studies of other risk factors 
included in Chapters 5 and 6. Other studies specific to the oldest-old have however 
questioned the importance of APOE ɛ4 in the oldest-old. Results from the 90+ Study 
suggested that the association between APOE ɛ4 and dementia was age dependent, 
and that APOE ɛ4 is no longer a risk factor for dementia in oldest-age.(Corrada et al., 
2013) Findings from other studies have supported this conclusion.(Juva et al., 2000) 
Our results would therefore seem to disagree with much of the existing literature on 
dementia in the oldest-old. While it is not possible to modify one’s risk with regard to 
APOE ɛ4 status, it is important to understand its role in dementia risk in oldest age.  
Hypertension 
Contrary to the observed association between midlife hypertension and dementia in 
studies of younger subjects, several studies have shown that hypertension in later life 
is not a risk factor for dementia in oldest-age. The 90+ Study showed that onset of 
hypertension after age 80 years reduced the risk of subsequent dementia.(Corrada 
et al., 2017) Risk was reduced further with hypertension onset after 90 years of 
age.(Corrada et al., 2017) The results of the study also suggested a trend for 
decreasing risk with increasing severity of hypertension.(Corrada et al., 2017) Other 
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studies have also reported a reduced risk for dementia with increased systolic blood 
pressure in those aged over 85 years.(Li et al., 2007; Ruitenberg et al., 2001) In the 
Adult Changes in Thought (ACT) Study, a systolic blood pressure over 160 mmHg 
was associated with a non-significant reduction in dementia risk (HR: 0.64, 95% CI: 
0.32, 1.30).(Li et al., 2007) A pooled analysis of the Rotterdam and Gothenburg H-70 
Studies demonstrated a reduced risk for dementia with increasing systolic blood 
pressure (HR: 0.89, 95% CI: 0.82, 0.97 per 10 mmHg) in those aged over 
85.(Ruitenberg et al., 2001) While the significance of these relationships varied, the 
pattern demonstrated was consistent. Our finding that a history of hypertension 
reduces risk for dementia (OR: 0.47, 95% CI: 0.23, 0.98 (Chapter 4)) would be in line 
with this pattern of evidence. 
Smoking 
Ever-smoking 
The study included in Section 6.2 found an association between never smoking and 
an increased risk for subsequent dementia (HR 1.69, 95% CI: 1.06, 2.71, p=0.03). 
While the direction of this relationship may seem unusual and disagree with the results 
of other studies of dementia, it is in line with the patterns seen in this cohort for other 
health and lifestyle factors such as physical activity and hypertension; it may be that 
this finding therefore represents part of the changed risk factor profile in oldest-age. 
We would however be cautious in accepting this finding without further evidence as 
the same pattern of association did not reach statistical significance in the study 
detailed in Section 5.2, where the association between ever-smoking and dementia 
did not reach statistical significance  (HR: 0.94, 95% CI: 0.61, 1.45). Furthermore, we 
must consider whether selection bias or survival bias has influenced this finding. The 
90+ Study found no association between a history of ever-smoking at enrolment and 
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incident dementia (HR: 0.95, 95% CI: 0.74, 1.21).(Paganini-Hill et al., 2016) The 
discrepancy between the findings of the 90+ Study and previously reported findings 
in earlier old age may reflect a change in the risk associated with advancing age, but 
it may also be related to the 90+ Study having very few participants who were current 
smokers at recruitment.(Paganini-Hill et al., 2016)  
Current smoking 
The study detailed in Section 4.2 found that in the LBC1921, the association between 
current smoking and dementia did not reach statistical significance (OR: 0.14, 95% 
CI: 0.02, 1.17). A previous systematic review and meta-analysis that included studies 
of participants aged 65 years and over demonstrated an increased risk for Alzheimer’s 
disease for current smokers compared with never or non-smokers (summary ratio 
1.59, 95% CI: 1.15, 2.20), but not for ex-smokers compared with never smokers 
(summary ratio 0.99, 95% CI: 0.81, 1.23).(Peters et al., 2008) It is possible that our 
results differed from those of the meta-analysis due to a change in the risk factor 
profile with advancing age. We would however note that the meta-analyses 
considered Alzheimer’s disease rather than all-cause dementia and this may also 
have altered the findings.     
Overall, our findings add evidence to the literature suggesting that current smoking or 
ever-smoking do not increase the risk for dementia in this age-group. Further 
investigation of the role of smoking (ever and current) is required to better understand 
the role of this risk factor in dementia in oldest-age.   
Hypercholesterolaemia  
A Finnish study of the oldest-old – the Vantaa 85+ Study – found no statistically 
significant difference between the baseline blood lipid (HDL cholesterol, LDL 
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cholesterol and triglyceride) levels of those who went on to develop dementia during 
follow-up, and those who did not.(Rastas et al., 2010) A study of the 90+ Study 
participants also found no association between blood cholesterol and dementia in the 
oldest-old.(Evans et al., 2014) Similarly, our study from Section 4.2 did not find any 
association between blood cholesterol levels at age 79 years and subsequent 
dementia. The Sydney Older Persons Study however – a study of participants aged 
over 75 years – concluded that hypercholesterolaemia reduced the risk for cognitive 
decline and dementia (p<0.05).(Piguet et al., 2003) While this finding differs from that 
of the Vantaa 85+ Study, the 90+ Study and the LBC1921 study, all add evidence for 
the changing role of cholesterol in dementia risk with advancing age.  
Previous studies in earlier old age have however noted that raised cholesterol at 
specific periods in the life course might be more significant with regard to dementia 
risk in later life.(Alonso et al., 2009; Anstey et al., 2008) One meta-analysis concluded 
that raised cholesterol in midlife was associated with increased risk for dementia but 
raised cholesterol in later life was not.(Anstey et al., 2008) In the LBC1921, statin-use 
was observed to increase risk for dementia (OR: 3.39, 95% CI: 1.04, 11.02) (Section 
4.2). This is contrary to a paper reporting that within the 90+ Study, a history of statin-
use decreased the risk for dementia (HR: 0.58, 95% CI: 0.39-0.85, p=0.005).(Evans 
et al., 2014)      
Physical activity and physical fitness 
The 90+ Study also explored the potential associations between different exercise 
types – active exercise, less-active exercise and vigorous exercise – and incident 
dementia.(Paganini-Hill et al., 2016) Participation in active or other exercise at 
recruitment to the 90+ Study was not associated with incident dementia.(Paganini-Hill 
et al., 2016) Furthermore, active or other exercise 20 years prior to the 90+ Study 
(1980s) was not associated with incident dementia.(Paganini-Hill et al., 2016) The 
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90+ Study was a follow-up from the Leisure World Cohort Study, which had collected 
data on vigorous exercise participation at age 40 years, then in 1983 and 
1998.(Paganini-Hill et al., 2016) Vigorous activity in midlife (age 40) was not 
associated with dementia in oldest-age (HR: 1.12, 95% CI: 0.84, 1.50); neither was 
greater participation in vigorous activity in older age (1983 HR: 0.81, 95% CI: 0.58, 
1.12; 1998 HR: 1.22, 95% CI: 0.83, 1.78).(Paganini-Hill et al., 2016) The absence of 
a relationship between midlife physical activity and dementia contradicts previous 
findings for those in earlier old age – including a meta-analysis that found physical 
inactivity increased the risk of dementia by 39% - once again suggesting a changing 
risk factor profile with advancing age.(Deckers et al., 2015) The findings of the 90+ 
Study also contradicts the findings of the Oregon Brain Ageing Study which found an 
association between increased exercise and decreased risk of cognitive decline 
(defined by MMSE < 24 or CDR ≥ 0.5 on two consecutive assessments) in healthy 
women aged over 85 years.(Sumic, Michael, Carlson, Howieson, & Kaye, 2007) The 
study included in Section 4.2 suggested that increased physical activity across 
adulthood increased the risk for dementia after age 79 years (OR: 1.17, 95% CI: 1.04, 
1.32). While we might question how robust our findings are with regard to physical 
activity – as a result of reduced participant numbers for these analyses – it is possible 
that we are observing a change in the risk associated with previous physical activity, 
much like that which was observed in the 90+ Study. Unlike the 90+ Study that had 
detailed assessments of participation in physical activity from different points in the 
life course, our study relied on retrospective reporting of the same by study subjects. 
It was therefore necessary to use a more ‘concrete’ variable to examine the potential 
relationship between physical activity and dementia, hence the study included in 
Section 5.2 that examined measurable fitness levels at age 79 years. While we did 
not observe any association between measures of physical fitness at age 79 years 
and subsequent dementia (FEV1 (HR: 1.30, p=0.37); grip strength (HR: 0.98, p=0.35); 
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walking speed (HR: 0.99, p=0.90)), other studies have demonstrated findings that are 
more in line with those seen in earlier old age. As noted in the introduction to Chapter 
5, the 90+ Study has demonstrated an association between poorer performance on 
fitness tasks (walking speed, chair stands, grip strength and standing balance) and 
increased risk for dementia in those aged over 90 years.(Bullain et al., 2016; Bullain 
et al., 2013) Our lack of any observed association in the LBC1921 would therefore 
contradict both the findings of studies in earlier old age and of other studies in oldest 
age.   
Cardiovascular and cerebrovascular disease 
The study in Section 4.2 did not demonstrate any elevated or decreased risk for 
dementia with a history of cardiovascular or cerebrovascular disease, but we must 
consider whether this was because we included a history of a number of conditions 
together. The prevalence of individual conditions within LBC1921 would not have 
been sufficient to allow us to investigate these factors individually. Identifying the role 
of vascular factors in dementia risk in the oldest-old is of considerable importance and 
value given the overlap with preventative strategies for cardiovascular and 
cerebrovascular disease and the potential for risk modification. The 90+ Study 
examined a number of vascular diseases and their association with all-cause 
dementia. The authors of the study found an increased risk of dementia was 
associated with a history of congestive heart failure, stroke and heart valve.(Corrada, 
Mozaffar, et al., 2016) Again, hypertension was shown to decrease risk.(Corrada, 
Mozaffar, et al., 2016) Previous myocardial infarction, transient ischaemic attack, 
arrhythmia, coronary artery disease, hypercholesterolaemia and diabetes were not 
found to be associated with either an increased or decreased risk for 
dementia.(Corrada, Mozaffar, et al., 2016) The study draws an important distinction 
between hypertension and other vascular risk factors. In finding that the direction of 
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the association differs between hypertension and other vascular factors, it suggests 
that survival bias is less likely to explain the pattern observed for hypertension and 
dementia.(Corrada, Mozaffar, et al., 2016) The fact that the 90+ Study found different 
levels of association with dementia for different vascular conditions might explain why 
when considered together, as they were in our study, the association failed to reach 
significance and why our results differed from those previous findings.    
Diabetes 
The Vantaa 85+ Study explored the association between diabetes and dementia in 
the oldest-old and found that the incidence of dementia was twice as high in those 
with diabetes, when compared to those without (HR: 2.09, 95% CI: 1.34, 
3.25).(Ahtiluoto et al., 2010) The same study found that dementia incidence was 
doubled for those with diabetes compared to those without for both Alzheimer’s 
disease (HR: 2.45, 95% CI: 1.33, 4.53) and vascular dementia (HR: 2.15, 95% CI: 
1.06, 4.36).(Ahtiluoto et al., 2010) The WISE study did not however find diabetes to 
be a risk factor for dementia. The study included in Chapter 4 of this thesis considered 
diabetes as a possible risk factor, but like the WISE study, we found no statistically 
significant association between history of diabetes and subsequent dementia.       
Education and childhood intelligence 
While the 90+ Study and WISE both found that lower levels of education were 
associated with an increased risk for dementia in oldest age, the same was not found 
for the LBC1921 (OR: 0.86, 95% CI: 0.73, 1.01).(Corrada, Brookmeyer, Berlau, 
Paganini-Hill, & Kawas, 2008; Yaffe et al., 2011) We would however note that the 90+ 
Study found that this was true for women, but not men and WISE only includes female 
participants.(Corrada et al., 2008) Furthermore, the study in Section 4.2 of this thesis 
found no association between childhood IQ and dementia in oldest age. The LBC1921 
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cohort is fairly unique in that it has childhood cognitive data available for most 
participants. Given how unusual this is, it is not possible to consider our results in the 
context of other such studies of oldest age. The childhood intelligence scores 
gathered by the SMS1932 have however been used previously to investigate the link 
with future dementia. The childhood intelligence scores used in the LBC1921 were 
also derived from those gathered in the SMS1932. A large follow-up study of 16,097 
girls and 16,370 boys found that those in the lowest intelligence group had a greater 
risk of dementia (from age 65 to 92 years) when compared with those in the highest 
intelligence group.(Russ et al., 2017) As with the findings for education, this 
association was stronger in women (HR: 1.51, 95% CI: 1.29, 1.76) than men (HR: 
1.19, 95% CI: 0.98, 1.44).(Russ et al., 2017)  
8.1.3.2 A changing risk factor profile for dementia in oldest-age 
As described within the conclusions of the papers included in Sections 4.2, 5.2 and 
6.2, the results of these studies suggest that the dementia risk factor profile specific 
to the oldest-old differs from that described within the literature for early old age, or 
across old age. While we found that the presence of an APOE ɛ4 allele (OR: 2.23, 
95% CI: 1.29, 3.86) and reduced height (0.72, 95% CI: 0.55, 0.95) continued to be 
associated with an increased risk for dementia in oldest age, a number of other risk 
factors were no longer important with regard to dementia risk; in some cases, the 
direction of association was actually shown to reverse from that described in earlier 
old age. Unlike the findings of previous studies and meta analyses, our studies did 
not find a statistically significant association between measures of physical fitness, 
symptoms of depression, body mass index, hypercholesterolaemia, a history of 
diabetes, cardiovascular disease or cerebrovascular disease (at age 79 years) and 
dementia. While the findings for smoking were somewhat inconsistent, we 
demonstrated a possible reversal in the direction of association between ever-
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smoking and dementia, with a history of never-smoking being associated with an 
increased risk for dementia (HR 1.69, 95% CI: 1.06, 2.71, p=0.03) (Section 6.2). 
Similarly, our results suggested that higher levels of leisure-based physical activity 
across the lifetime was associated with a greater risk for dementia (OR: 1.17, 95% 
CI: 1.04, 1.32), thus demonstrating another reversal from the pattern of risk described 
in earlier old age. Finally, we found that a history of hypertension reduced the risk for 
dementia (OR: 0.47, 95% CI: 0.23, 0.98). This reversal from earlier old age is 
supported by other studies in oldest age, as detailed in the previous discussion 
section.  
The evidence within the literature and from our studies is however inconsistent 
regarding the risk factor profile in oldest-age, and the mechanisms by which the 
effects of certain factors are altered are also unclear. One suggested mechanism by 
which factors known to increase risk for dementia in early old age may not appear to 
be risk factors in oldest-old is a survival effect; those who survive and remain 
dementia-free despite the effect of the risk factors may be in some way resilient to 
them.(Gardner et al., 2013) Or in simple terms, those who were at increased risk of 
dementia or death may have already died or developed dementia at an age earlier 
than that being studied.  
While other potential mechanisms have been proposed for the differences observed, 
none have been accepted conclusively. For example: the effect of anti-hypertensives 
has been suggested as a possible explanation for the reversal of the association with 
hypertension in oldest age, but the 90+ Study did not find any such association, and 
results demonstrating an association between hypertension and reduced dementia 
risk were much unchanged after controlling for antihypertensive use.(Corrada et al., 
2017) It has been suggested that hypertension is associated with reduced risk for 
dementia as higher blood pressure in oldest-age may compensate for age-related 
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vascular change and result in the maintenance of adequate cerebral perfusion; 
cognitive decline and dementia have been shown to be more frequent in individuals 
with low cerebral perfusion.(Corrada et al., 2017) Alternatively however, it is also 
possible that low blood pressure is a consequence of incipient or preclinical dementia, 
resulting from pathological changes in areas of the brain involved in blood pressure 
regulation.(Ruitenberg et al., 2001) This hypothesis is supported by studies that have 
demonstrated declining blood pressure in the years prior to, and the years following 
dementia diagnosis.(Ruitenberg et al., 2001) Other types of selection bias have also 
been proposed as an explanation for the findings. It is possible that those participants 
with hypertension who would develop dementia, would either have done so prior to 
age 80 years, or would have died from another hypertension-related condition prior 
to developing dementia. The result would be the underestimated incidence in those 
surviving with hypertension.(Corrada et al., 2017) One can therefore see that while 
the reversal of risk relating to hypertension and dementia is supported by a number 
of studies, the mechanisms by which this change comes about are unclear.  
8.1.3.3 DNA methylation-based measures of accelerated ageing 
Given the reported association between DNA methylation-based measures of 
accelerated ageing and age-related health outcomes and mortality, we hypothesised 
that the same measures may also be associated with an increased risk for dementia 
(as another age-related health outcome). The study detailed in Section 6.2 did not 
however find any consistent association between DNA methylation-based measures 
of accelerated ageing and dementia. Without any previous studies – either in earlier 
old age or in oldest age – it is not possible to make comparisons with the previous 
literature or with any changes in the impact of this factor with advancing age. Further 
research is needed to examine this potential risk factor, establish whether it may be 
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a useful indicator of risk and if so – which factors or mechanisms give rise to this 
elevated risk. 
8.1.4  Impact of preclinical dementia on previous findings 
With evidence showing that the preclinical phase of dementia may be more than a 
decade long and with no recognised manner by which such participants should be 
identified and excluded from studies, a short duration of follow-up for dementia 
ascertainment may not be sufficient to accurately identify those who were in this early 
phase of dementia at recruitment or testing. With approximately sixteen years of 
follow-up the LBC1921 study was suited to performing such analyses. While the 
LBC1921 study may have longer follow-up for dementia ascertainment than some 
other studies, follow-up in this age group is limited by death. At present, there is no 
manner by which those participants with preclinical dementia at recruitment, but died 
before developing clinical symptoms, can be identified. It is therefore impossible to 
exclude the possible impact of incipient dementia, only limit this as far as is feasible 
with the available resources. While some studies use post-mortem neuropathological 
signs to determine the presence of dementia, evidence within the literature is unable 
to confirm that such changes will always lead to clinical dementia. If such methods 
were used to identify preclinical dementia – for the purposes of exclusion – studies 
risk excluding normal variants from their analyses, resulting in another potential bias. 
Our study in Chapter 7 used follow-up data in order to assess the potential impact of 
preclinical dementia on early studies of non-pathological cognitive decline in the 
LBC1921. The results suggested that preclinical dementia had little or no effect on 
the original findings. The long duration of follow-up of the LBC1921 cohort also 
allowed us to investigate the potential impact of imminent death on the original 
findings. The results of these additional analyses did suggest that death within 4 years 
influenced the results. When those participants who died within 4 years were excluded 
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from the repeat analyses, most associations no longer reached statistical significance. 
Our results highlight the importance of using follow-up data in order to establish the 
potential impact of both subsequent dementia and imminent death.    
8.2 Implications 
One might consider the implications of this thesis in two broad categories – 
implications for epidemiology and implications for clinical practice. More specific 
descriptions of the potential implications are discussed below. 
8.2.1 Ascertainment and dementia incidence 
As discussed previously, we determined that our ascertainment methodology was 
relatively effective in identifying incident cases of dementia within the cohort. We 
therefore suggest that this method is also suitable for use in other studies. By 
including sufficient detail on how our ascertainment was carried out, and subsequently 
comparing our findings with expected rates, our ascertainment studies are a useful 
addition to the literature in that they may help guide ascertainment methods in future 
studies. Our robust analysis of dementia ascertainment in LBC1921 has led to a 
similar dementia ascertainment approach being adopted in the larger LBC1936 study. 
The incidence study detailed in Chapter 4 adds further evidence to the literature 
regarding dementia incidence in this age group. Given the difficulties associated with 
recruiting and retaining study participants of this age, each addition to the literature is 
valuable. While ours is not a large study of incidence, the data could be used in 
combination with that from other studies to complete a larger study of incidence. When 
the younger Lothian Birth Cohort 1936 has completed dementia ascertainment it may 




The main implications and uses of the ascertainment and incidence section of the 
thesis would therefore be: 
1) To guide future ascertainment methods using existing data (particularly in 
LBC1936), 
2) To add to the evidence regarding dementia incidence in the oldest-old, and 
3) To provide details of dementia cases in LBC1921 to be used in other studies 
of the LBC1921 
8.2.2 Risk factors 
The studies within this thesis supplement the growing awareness that dementia is a 
life-course condition which develops over many decades. Thus, when in the life 
course particular factors are harmful is crucial to guiding the health and lifestyle advice 
given to those within different age groups; for example, you might not give the same 
advice to a fifty year-old and an eighty year-old.  
The clinical and public health implications of our risk factor studies are however less 
straightforward than we might have expected. Studies of earlier old age have 
produced evidence for a range of modifiable risk factors that may be addressed in 
order to prevent dementia. As detailed within the Lancet Commission report 2020, as 
many as 40% of dementia cases may be preventable if 12 factors – including 
hypertension, smoking, low education, low physical activity and head injury – are 
addressed.(Livingston et al., 2020) It would have been relatively straightforward if our 
studies had produced similar findings as those in earlier old age, thus enabling us to 
propose modifications that might prevent dementia in this age group.  
The majority of variables considered in this thesis produced null findings. Such 
variables included those that were previously identified as being important in early old 
age (diabetes, obesity, education, depression, physical fitness), and others that to our 
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knowledge had not yet been investigated (DNA methylation-based measures of 
accelerated biological ageing). While the null findings mean that it is not possible for 
us to state that addressing these factors would any potential positive effect on 
dementia, we do not dismiss them as unimportant findings. Positive and negative 
findings regarding risk for dementia are both key in developing risk profiles for 
dementia. Risk profiling on an individual level is key to developing personalised 
medicine whereby clinicians can provide someone with specific advice about their 
own risk profile and how they might address individual factors in order to reduce risk. 
The importance and potential impact of such an approach is highlighted by Brain 
Health Scotland, an initiative that focuses on improving brain health on a national 
level.(Alzheimer Scotland & Scottish Government, 2020) The primary objective of 
Brain Health Scotland is to reduce dementia incidence over the next decade, by 
increasing public awareness of the principles for maintaining brain health, and by 
providing access to the necessary interventions for dementia prevention.(Alzheimer 
Scotland & Scottish Government, 2020) 
We do however note that there are limitations to our studies that might have affected 
our null findings. Similar limitations mean that we must be cautious in reporting the 
clinical implications of our positive findings. It is possible that some of these limitations 
have given rise to erroneous results. If we consider the positive association between 
never smoking and increased risk for dementia observed in Chapter 6, we must be 
mindful that the same pattern was not seen in our other studies of the same cohort. 
This might lead us to suspect the veracity of this association. If this finding were to be 
replicated in other studies in this age group, the possibility of a healthy survivor bias 
would remain. As we note within Chapter 4, we are also cautious in accepting the 
finding that increased physical activity across the lifetime increases the risk for 
dementia. Regardless of how robust the evidence for these two associations, it is 
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unlikely that it would result in any change to public health advice given the elevated 
risks for morbidity and mortality associated with smoking and physical inactivity. 
Our study in Chapter 4 found that a history of hypertension is associated with a 
reduction in risk for dementia. We are not confident in proposing the clinical 
implications of this finding, as a result of the limitations described elsewhere in the 
thesis. Given that this finding is supported by some other reports within the literature, 
we might cautiously suggest that the patterns observed between hypertension and 
dementia add evidence for the potential protective effect of hypertension in oldest-
old. It is however unlikely that the protective effect outweighs the risks associated with 
hypertension in all persons simply because they are over a certain age. For this 
reason, it is unlikely that there would be standardised guidance for the under-
treatment of hypertension; it does however support the suggestion that there should 
not be a standardised approach to treat all hypertension to the same degree in this 
oldest-old age group. It is more likely that treatment will continue be determined on 
an individual basis, primarily based on the presence of frailty or the adverse effects 
of antihypertensive treatment. 
The APOE e4 allele was identified as being associated with an increased risk for 
dementia throughout our risk factor studies. It is not a modifiable factor, but we would 
suggest that it is included in studies of dementia in the oldest-old age group. 
While is clear that the clinical and public health implications of our risk factor studies 
are lacking, we propose that our studies add to the body of literature regarding 
dementia in the oldest-old and as such, may prove to be useful in the future.  
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 8.2.3 Studies of cognitive ageing in LBC1921 
The implications of the study detailed in Chapter 7 would primarily relate to other 
studies of cognitive ageing. Firstly, studies of cognitive ageing already completed in 
LBC1921, but without knowledge of dementia outcomes, can show that dementia 
outcomes did not affect these early studies, and are therefore more unlikely to have 
affected other studies. Similarly, studies of cognitive ageing in other study cohorts, 
also without dementia follow-up, can be more confident in their findings given our 
results. Future studies of LBC1921 can now incorporate our dementia outcomes into 
their studies to minimise the potential effect of preclinical or prodromal dementia on 
their findings.  
Our study did however demonstrate that terminal decline might have influenced the 
findings. We would therefore suggest that this is an important consideration in similar 
studies. It is difficult however to exclude terminal decline from studies in the oldest-
old age group. The more advanced the age of a cohort, the more likely they are closer 
to death and as such, excluding those who died within a certain number of years 
further limits the size of what is unlikely to be a large sample. 
8.3  Limitations 
The potential limitations of each study are described within the relevant chapters. In 
this section, there will be a broad overview of limitations arising from the study design 
or the cohort itself. 
8.3.1  Methodology 
With dementia being the outcome of interest throughout this thesis, it is important to 
acknowledge any limitations related to how cases were identified. Incorrectly 
classifying individuals as having developed dementia, or vice versa, could have 
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implications for all analyses. Most likely, such errors would dilute any association. The 
potential limitations of our ascertainment methodology are detailed within Chapter 4. 
We highlight the potential for missed cases and in particular, any potential deficiencies 
in the availability of follow-up information that might have led to the same. Our 
methods aimed to reduce this possibility as far as possible, but we recognise this 
possibility remains as a result of our methodology. Further to the possibility of missing 
diagnosed or diagnosable cases of dementia, we must also consider the possibility 
that unrecognised cases of preclinical dementia affected our findings, and in particular 
the study described in Chapter 7. With no means by which to identify preclinical 
dementia, any subject with preclinical dementia who died prior to developing the full 
clinical syndrome required for diagnosis would not be identified. This limitation is not 
however unique to this study or methodology. Until there is clear evidence for a 
recognised biomarker for the preclinical stage of dementia participants who are in the 
very early stages of the condition would not be identified by clinical assessment or by 
recordings in existing data.  
While every effort was made to include appropriate covariates in each study design, 
it could be suggested that additional variables should have been included in each of 
the included studies. The potential for having missed a necessary variable and the 
effect this could have had on the findings is acknowledged. It is however not possible 
to include every potential variable without affecting the analyses and the inclusions 
were therefore based on the available evidence, with reasoning described within each 
individual study.  
8.3.2  The Lothian Birth Cohort 1921 
The first limitation to consider is the size of the study sample. With N=550 participants 
enrolled at baseline, the cohort size is clearly not of the magnitude of some large 
199 
 
population studies. The study sample sizes for analyses described within this thesis 
are often further reduced as a result of missing data. As such, the power to detect 
small effects is limited. While the cohort size may be considered to be relatively small, 
it is a very detailed cohort with a considerable volume and variety of data available 
for participants. The availability of childhood intelligence data is particularly unusual 
for an older-age study group. 
In a study cohort of this size, the number of dementia cases identified would also be 
limited. The number of cases of different subtypes of dementia were expected to be 
too few to allow for analyses specific to each subtype of dementia. This was 
compounded by the fact that a large proportion of cases lacked sufficient detail or 
evidence to be classified by subtype. It is possible that any lack of findings in our 
studies may be attributable to our having a single outcome of all-cause dementia. It 
is noted that many of the previous findings relating DNA methylation to dementia have 
been specific to Alzheimer’s disease, and it is possible that by including cases of other 
aetiology has influenced the results. In LBC1921 the prevalence of some conditions 
– such as specific types of vascular disease – was not sufficient to allow for individual 
analyses.   
We might also consider the potential limitations of the data collection methods used 
in the LBC1921. While many variables were prospectively collected in a detailed and 
thorough manner, the fact that participants were not recruited until age 79 years 
meant that information pre-dating recruitment relied on participant recall. Some of 
those variables included in this thesis – such as reporting of lifetime physical activity 
or details of smoking pack-use or cessation – would be subject the typical 
inaccuracies related to the retrospective recollection of information. Inaccuracies may 
arise for a number of reasons, including simple errors in recall or by minimising 
potentially harmful behaviours or maximising good behaviours. Self-report of 
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behaviours such as smoking have been shown to vary in their accuracy.(Andersen, 
Philibert, Gibbons, Simons, & Long, 2017) Another limitation of recruiting at an 
advanced age is the potential for a healthy survivor bias; where only those surviving 
certain risks, diseases or conditions are recruited. The surviving sample might 
demonstrate changed or unexpected associations, through the unintentional 
exclusion of those who were unable to be recruited due to the adverse effects of the 
same conditions survived by participants. As participants volunteered or consented 
to participate, there may also be an element of self-selecting bias. Those with a family 
history or particular concern regarding cognitive decline may have been more inclined 
to take part in the study. A selection bias may also occur as those who volunteer to 
participate are typically those who are generally physically and mentally healthier, 
more well educated and those with fewer social concerns. With baseline testing at 
age 79 years, some of the dementia outcomes might be expected to occur following 
a fairly short window of time. While cases of dementia at baseline were excluded, 
preclinical or prodromal cases of dementia might have remained. For this reason, we 
note the possibility of observing associations that are the result of reverse causation. 
While our dementia ascertainment method was shown to be suitably effective, further 
detail would likely have been available if more participants had survived to wave 4 of 
testing and had consented to access to records and to data linkage. The younger 
LBC1936 cohort provided this consent from baseline and will therefore likely have a 
richer source of data from which dementia cases can be identified and confirmed.  
Finally, we must reflect on the potential limitations in generalisability of any findings 
based on data from the Lothian Birth Cohort 1921. By design, the cohort includes 
participants of a single birth-year and all resided within a small geographical area.  
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8.3.3 Complexities of the Oldest-Old Age Group 
Several characteristics of the oldest-old age group might have led to limitations in our 
studies. As noted throughout the thesis, the increased likelihood of complex health 
and lifestyle profiles in this age group may have affected our findings. 
Within the studies of risk factors, we included many variables that we treated in a 
somewhat simplified fashion; this is particularly true in section 4.2 where we 
considered a larger number of factors in one set of analyses. While we looked at 
factors such as smoking and hypertension as simple yes/no binary type variables, in 
reality, these variables are much more complex and require further thought. It could 
be suggested that such variables increase in complexity with advancing age given the 
increased likelihood of comorbidity and the divergent effects of various life influences. 
If one considers hypertension, there are a number of factors that one might need to 
consider; is it treated with antihypertensives, how long was it present before it was 
treated, what was the age of onset, is it ongoing? The ‘the back story’ of hypertension 
might be expected to be even more complicated in oldest-age given the increased 
likelihood of co-morbidity and the increased time for exposure to external influences. 
As an example, one individual may have developed hypertension at age 40 years and 
had this treated with antihypertensive medication until age 80 when these were 
discontinued due to a risk of falls, with a degree of hypertension left purposefully 
untreated. If we compare this with another individual who developed hypertension at 
age 75 years and continues on antihypertensive treatment we can see that a 
response of ‘yes’ for previous hypertension can mean very different things. Using the 
same ‘yes/no’ hypertension variable to assess hypertension as a risk factor therefore 
has clear limitations in this age-group. In Chapter 4 we also note the potential 
beneficial effect of raised blood pressure in advanced old age; it may serve to maintain 
organ perfusion and therefore limit decline in the function of the organ system. It is 
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possible that such limitations have affected our findings and it reinforces the need to 
investigate these observed risk factor associations in more detail in future studies.  
A number of other factors considered in our studies are subject to similar complexities. 
Any of our health variables – including diabetes, cardiovascular disease, 
cerebrovascular disease – are likely to represent a diverse range of back-stories to 
their diagnosis. Variability in age at onset, duration, treatments, effectiveness of 
treatment, treatment compliance, disease complications and severity would be 
expected for all such factors. Different combinations of comorbidities between 
participants may also complicate the investigation of individual health variables in this 
age group, potentially making it more difficult to identify an association. Medication 
use – such as statins, which were observed to be associated with increased risk for 
dementia in Chapter 4 – will also have variability between persons. Age at 
commencement, severity of underlying disease, compliance and the exact type of 
drug used. Side effects of statins – such as confusion, weight loss and falls – are 
noted to be increased in oldest-old age; as a result, many of those who would have 
been prescribed this medication in earlier old age, will not be in advanced old age. 
This may give rise to differences in observed associations between statins and 
dementia in early old age and later old age.  
Lifestyle factors are also likely to have a wide range of different histories. If we 
consider ex-smoking then we can see why this might mean something very different 
for different individuals. One participant may have commenced smoking at age 15, 
and stopped at age 25; another may have started at age 20 and stopped the day 
before recruitment to LBC1921; and a third may have started at age 17, stopped at 
age 35, restarted at age 50 and stopped at age 70. One can see the potential in 
variability in age at smoking and duration of smoking, and this does not even take into 
account further potential variability including the number of cigarettes used, whether 
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cigarettes were hand rolled, and whether filters were used. The simplified 
categorisation of smoking used in our studies will therefore be subject to similar 
limitations as those noted for hypertension.  
By looking at variables in this simplified, binary way, there is a potential for missing 
an association, or revealing one that is not as simple as it first appears to be. If we 
chose to include additional variables that would describe many of these background 
features, we would introduce the possibility of a Type 1 error, through multiple 
hypothesis testing. We might therefore consider our analyses – with a simplified 
handling of variables – to be a basis for identifying ‘potential’ risk factors of interest in 
the cohort which should then be investigated in more detailed individual analyses.  
As discussed elsewhere in the thesis, other features of oldest-old age may complicate 
the study of this age group and thus give rise to limitations. In section 5.3 we note the 
overlap between features of declining fitness and features of frailty. Decreased 
walking speed and grip strength are both commonly reported features of frailty and 
investigating the association between such factors and dementia will therefore be 
complicated by the presence of frailty. Changes in cognition or memory can also form 
part of the frailty assessment and as such, frailty may also overlap with dementia, 
further complicating the assessment of associations between variables and cognitive 
outcomes.(Rockwood et al., 2005) Given the increased frequency of frailty with 
advancing age, frailty must be given due consideration as a potential limiting factor in 
studies of the oldest-old. 
Overall, it is clear that there are a number of factors that make the investigation of risk 
factors for dementia in the oldest-old more complicated. For this reason, further 
studies are required to complete a clearer picture of dementia risk factors in the 




8.4  Recommendations for future research 
Dementia ascertainment 
It is anticipated that the details and results of the dementia ascertainment in LBC1921 
will be of particular use to the researchers completing the planned dementia 
ascertainment in the LBC1936 – the larger (N=1091), younger, ‘sister’ cohort to 
LBC1921. It would be suggested that the LBC1936 dementia ascertainment method 
utilises those sources that proved valuable in this study, while exploring any additional 
data sources that may further reduce missed cases or add further evidence to support 
identified cases. In this study, both death records and hospital records were shown to 
yield useful information, and in particular, each identified cases that would have been 
missed by the other. The psychiatric records on the other hand, did not identify any 
cases that were not identified by other means. This is most likely the result of the 
migration of psychiatric records onto the general hospital system during the period of 
data collection. As such, it demonstrates that for any future dementia ascertainment 
procedures in this region (including the LBC1936), psychiatric records need not be 
consulted as they would provide little, if any, additional information.  
Three additional data sources that could be considered for future studies include 
national datasets, general practice records and prescribing data. The Scottish 
Morbidity Records from the Information Services Division of NHS Scotland provide 
lists of diagnostic codes following contacts with NHS services. While most dementia 
cases would likely overlap with those identified from hospital records, it is possible 
that any person with dementia whose treatment was provided outwith the study 
locality, and therefore not included on the regional computerised records, would be 
identified. This would be of particular use where participants were based over a larger 
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geographical area, or where movement out of the region was regular. In the LBC1936 
study, some SMR data are available and consideration should be given to expanding 
these to include more recent data. In older age, it is not uncommon for a change in 
residence to take place, whether it be to a residence with additional support, care or 
to simply downsize. When such moves take place, they may be out of the Lothian 
region, perhaps to be closer to family living elsewhere. SMR data might therefore 
provide data to assist in dementia ascertainment for these persons, for whom death 
certificates might be the only data source available.  
Given that dementia-specific drugs, such as Donepezil, are generally first prescribed 
by a specialist, prescribing data would also likely have significant overlap with the 
data gathered from hospital records. It is however possible that prescribing data would 
again identify a participant with dementia who was initially treated outwith the region 
covered by local hospital records. Accessing such records will therefore have similar 
benefits to the SMR data.  
While general practice records could also provide evidence for those who previously 
lived outwith the region, the records would also likely be rich with evidence that could 
support or oppose diagnoses listed in other sources. These data would therefore 
increase the possibility of both identifying dementia and dementia subtype 
classification. While we discuss these potential data sources with reference to the 
LBC1936 in particular, the rationale would be the same for other similar cohort studies 
in Scotland, or the United Kingdom. Rather than simply including all of these data 
sources in a dementia ascertainment methodology, it would be useful to perform an 
additional review or study to guide the inclusion and exclusion of such sources of 
data. While the systematic review detailed in Chapter 3 was valuable in designing the 
ascertainment method for LBC1921, there is the potential for gaining further 
information through an additional review. By focusing on studies of dementia 
incidence and/ or prevalence, the relative successes of different methodologies could 
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be more easily compared and contrasted as studies of this type would include specific 
numerical data on dementia ascertainment rates within populations or study cohorts. 
In order to gain the maximum benefit from such a review, studies completed both 
within and outwith the UK should be included. As noted within Chapter 3, European 
studies may be particularly informative. An additional option for obtaining further 
evidence for sources might be a study looking specifically at the concurrence of 
diagnoses within various data sources. For example, by using a cohort where 
dementia cases had been prospectively identified using accepted clinical assessment 
methods, one could obtain various types of records/ data sources and investigate 
whether dementia diagnoses were recorded and recorded accurately in each. The 
results of such a study might provide evidence of the most useful sources of existing 
data, and where overlap occurs between sources. Gathering a robust body of 
evidence on which dementia ascertainment methods using existing data could be built 
will be of particular value given the increasing use of existing electronic linked data. 
Both the review and study described above would be valuable to the LBC1936 and 
the wider field of dementia research.  
Once a method for dementia ascertainment in LBC1936 has been developed and 
completed, it would be recommended that researchers perform similar validation 
studies to those described within Chapter 4 to allow for reasoned judgements on the 
effectiveness of any additional evidence and the overall ascertainment findings. 
In addition to the possibility of adding new sources of evidence to the ascertainment 
methodology, there are features of the LBC1936 that might suggest that one would 
expect improved ascertainment rates from LBC1921, using the same methodology as 
described in Chapter 4. As LBC1936 is a younger cohort, there is more potential for 
performing clinical reviews where there is any suggestion of cognitive impairment on 
routine follow-up testing. This may lead to more cases being identified than would 
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have self-presented to health services for assessment, increasing diagnosis rates for 
the cohort. Unlike the LBC1921 participants, LBC1936 participants were consented 
for access to medical records and data linkage from recruitment and as such, there is 
the potential for more cases to be identified. Furthermore, such records are likely to 
reveal further detail on dementia diagnoses and this, together with the fact that the 
overall cohort is larger, may be sufficient to allow for analyses that consider the effects 
of different dementia subtypes.  
Risk factors 
The results obtained from the studies described in this thesis support the theory of a 
changed risk factor profile for dementia in the oldest old. While risk factors for 
dementia in earlier old age are not completely understood, there is a much larger body 
of evidence on which to draw conclusions. The same is required to allow the risk factor 
profile in the oldest-old to be better understood. Historically, recruitment and retention 
of participants of this age has been difficult, but improvements in life expectancy are 
likely to go some way to reduce this barrier to research. There is a particular 
requirement for further studies of potentially modifiable risk factors for dementia in the 
oldest-old. By demonstrating relationships that conflicted with previous findings, we 
reinforce the need for further study in this age-group in order to determine whether 
the findings were particular to this cohort or whether they might be observed in other 
study groups.  
The complexities of this population age group are described throughout the thesis. 
Such complexities will require the gathering of detailed background data for study 
participants, such that these complexities might be considered and addressed in the 
study of risk factors for dementia in oldest-old age. If we consider the ‘background’ to 
certain variables we can see that considerable detail is required for a single variable 
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of interest to reduce the possibility of confounding. The association between dementia 
and the use of a specific medication for example could be affected by a number of 
other variables, such as indication, duration of use, age at prescription and adherence 
to recommended regime. While our studies looked at potential risk factors as relatively 
‘simplified’ variables, further studies examining each variable in more detail may 
provide valuable additional information. Detailed data collection and considered 
design of analyses is therefore required to minimise such effects.(Power et al., 2015) 
In order to gather such detailed data, the size of studies may well continue to be 
limited in size. By completing further studies in smaller sized cohorts (like LBC1921 
and LBC1936), larger volumes of data for this age group can be produced. With larger 
volumes of evidence that is specific to this age-group, systematic reviews and meta-
analyses can be performed in order to evaluate the consistency in findings and report 
with increasing confidence the relevance and impact of such factors. While our 
studies are relatively small and may not be considered to be particularly impactful on 
their own, we hope that our data may be used in future meta-analyses in order to 
produce larger data sets with more conclusive findings. Given the similarities between 
the cohort demographics of LBC1921 and LBC1936, combining these data sets for 
future studies may be of particular value. Combining the data sets will result in a larger 
sample size, and include data from an earlier age as a result of the earlier-age 
recruitment of LBC1936.  
As noted previously, the size of our study cohort may have resulted in particular 
limitations which affected our findings. In particular, where we did not have sufficient 
numbers of cases for individual analyses – important associations could have been 
missed. Studies that are large enough to allow for the individual analyses of individual 
vascular factors for example, will be valuable in order to challenge or reinforce the 
findings of the 90+ Study. Similarly, we were limited by the number of dementia cases 
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and we were unable to classify each as having a probable aetiology. Larger studies 
that examine risk factors for specific dementia subtypes will be an extremely valuable 
addition to the literature. Given the results of previous studies relating DNA 
methylation to Alzheimer’s disease, it would be of particular value to repeat the study 
of DNA methylation-based measures of accelerated ageing and dementia in larger 
cohorts where the analyses could be repeated for individual subtypes of dementia.  
We note that there may be a valuable opportunity to examine risk factors for dementia 
in the LBC1936, addressing the limitations described above. In particular, a further 
study of potentially modifiable risk factors may be more informative given the larger 
size of the cohort, and the possibility of there being sufficient statistical power to 
investigate variables of interest. For example, where we did not have sufficient power 
to detect an association between diabetes and dementia, there may be a sufficient 
number of cases of diabetes in LBC1936 to provide adequate statistical power. We 
suggest that studies of the LBC1936 might consider performing analyses with 
‘simplified’ factors, before moving on to detailed investigation of individual factors. The 
larger cohort size and the availability of detailed clinical records for most participants 
may also mean that the LBC1936 is able to identify sufficient numbers of participants 
with specific types of dementia to allow for individual analyses. We would therefore 
suggest that a further study of DNA methylation-based measures of accelerated 
biological ageing be performed, using Alzheimer’s type dementia as a primary 
outcome, if there were a sufficient number of cases to allow for analyses. Given that 
the association between DNA methylation-based measures of accelerated ageing 
and dementia has not been described within the literature, except within LBC1921, 
we would suggest that this be investigated further in other study cohorts.  
Most existing studies of the oldest-old have been completed in Europe or Northern 
America and include predominantly Caucasian participants of relatively high socio-
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economic background and education. Historically, it was populations in these 
geographical areas that had the greatest life expectancy, and studies of this age 
group were therefore most relevant in these regions. As life expectancy improves out-
with these geographical areas, studies should also include populations residing in 
these areas. Future studies should therefore consider providing evidence that would 
be applicable to those from different populations.  
Preclinical dementia 
As we have done in our study of LBC1921 cognitive ageing studies (Chapter 7), we 
recommend that when dementia ascertainment is complete for LBC1936 that these 
cases are utilised in studies of cognitive ageing in this cohort to reduce the potential 
impact of preclinical or prodromal dementia on the findings. For existing studies, this 
could be done retrospectively as it was for LBC1921, while the data could also be 
used in future studies.  
Given the potential effect of preclinical dementia within the study cohort, it would be 
beneficial for future studies to be able to exclude any participant with a biomarker for 
preclinical dementia at baseline, thus limiting the potential for reverse causality. 
Similarly, such a marker could be used to identify any participant who had developed 
preclinical dementia during the study period, enabling accurate classification of 
disease development. As research studies improve the understanding of this early 
stage in the disease, identifying a marker that reliably identifies those persons who 
will develop the clinical dementia syndrome becomes increasingly possible. Dementia 
studies would undoubtedly benefit from the availability of such a marker.  
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8.5  Summary of findings 
This thesis had three primary aims: 1) to ascertain dementia cases in the Lothian Birth 
Cohort 1921 using existing data, 2) to investigate possible risk factors for dementia in 
his oldest-old cohort and whether these differ to the risk factors described in earlier 
old age, and 3) to examine whether preclinical dementia had affected previous 
findings for risk factors in non-pathological cognitive ageing. A dementia 
ascertainment method was developed using evidence gathered from a systematic 
review of similar methods. In an eligible cohort of n=489 participants, we identified 
that n=110 had developed probable dementia during the follow-up period, equating to 
approximately 22.5% of the cohort. Validation studies demonstrated that the methods 
were suitably effective.  
Three separate studies of potential risk factors for dementia were completed and the 
overall picture was of a changed risk factor profile for dementia in the oldest-old. In 
our first study of potentially modifiable risk factors, we found that a history of 
hypertension at age 79 years was associated with a decreased risk for dementia, 
while increased physical activity in adulthood was associated with an increased risk 
for dementia. Both results represented a change in direction of the associations 
reported in earlier old age. The results also suggested that a history of statin-use 
increased the risk for dementia. Previous studies in earlier old-age did not 
demonstrate any significant association between statins and dementia. We did 
however find that the presence of at least one APOE ɛ4 allele continued to be 
associated with an increased risk for dementia after age 79 years, while increased 
height reduced the risk for dementia. Our second study indicated that physical fitness 
– as measured by lung function, grip strength and walking speed – was not a risk 
factor for dementia after age 79 years. In our third study we did not find any consistent 
association between DNA methylation-based measures of accelerated ageing and 
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dementia, but the results did suggest that a history of never smoking may increase 
the risk for dementia. Despite many having been shown to be important in earlier old 
age, none of the other risk factors that we investigated were found to be associated 
with dementia after age 79 years. We do however recognise that some of the 
limitations of our study sample may have reduced our ability to detect all associations. 
Given the ongoing inconsistencies in the findings of studies investigating dementia in 
the oldest-old, the relatively small volume of literature describing the same, and the 
limitations of our studies, there is a clear requirement for further research in this area.  
The final study included in the thesis looked again at five previous studies of the 
LBC1921, aiming to determine the effect, if any, of preclinical or prodromal dementia 
on the original findings. The focus of these previous studies was to investigate four 
potential determinants of non-pathological (‘normal) cognitive ageing; within these 
previous studies, smoking, APOE ɛ4, reduced fitness and lower vitamin B12 had all 
been shown to be associated with poorer cognitive ageing. After excluding those 
participants who had gone on to develop dementia, the analyses were repeated in the 
same manner that they were originally conducted. The overall findings were 
unchanged from the original studies, with all four factors continuing to be associated 
with poorer cognitive ageing (p<0.05). These findings suggested that, in LBC1921, 
preclinical dementia did not impact the observed associations. The potential for some 
cases of dementia to remain unrecognised is acknowledged, but this was minimised 
as far as possible in this cohort. While excluding participants who went on to develop 
dementia did not affect the overall findings, the exclusion of those who died within the 
first 4 years after baseline testing did. Following these exclusions, only the association 
between physical fitness and cognitive ageing remained statistically significant. These 
findings suggested that so-called ‘terminal decline’ in the years preceding death might 
have influenced the original findings. We would note that the reduction in sample size 
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for these analyses reduced the statistical power to detect an association, but we 
would suggest that terminal decline is an important consideration in future studies of 
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Additional File 1: Medline Search Strategy 
Medline Search Strategy  
1. dementia/ or alzheimer disease/ or aphasia, primary progressive/ or primary 
progressive nonfluent aphasia/ or dementia, vascular/ or cadasil/ or dementia, multi-
infarct/ or diffuse neurofibrillary tangles with calcification/ or frontotemporal lobar 
degeneration/ or frontotemporal dementia/ or lewy body disease/ or "pick disease of 
the brain"/  
2. dementia*.mp.   
3. alzheimer*.mp.   
4. "primary progressive aphasia*".mp.  
5. "primary progressive non?fluent aphasia*".mp.   
6. (vascular adj2 dementia*).mp.   
7. cadasil.mp.   
8. "multi?infarct dementia".mp.  
9. "diffuse neurofibrillary tangles with calcification".mp.  
10. "fronto?temporal lobar degeneration".mp.  
11. (fronto?temporal adj2 dementia*).mp.   
12. ("lewy bod*" adj2 (dementia* or disease*)).mp.   
13. (pick* adj2 (dementia* or disease*)).mp.   
14. (presenile adj2 dementia*).mp.   
15. (senile adj2 dementia*).mp.  
16. (semantic adj2 dementia*).mp.   
17. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16  
18. great britain/ or england/ or northern ireland/ or scotland/ or wales/  
19. england.mp.   
20. english.mp.   
21. scotland.mp.   
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22. scottish.mp.   
23. wales.mp.   
24. welsh.mp.   
25. "northern ireland".mp.   
26. "n ireland".mp.  
27. ni.mp.   
28. "northern irish".mp.   
29. "n irish".mp.   
30. gb.mp.   
31. gbr.mp.  
32. "great britain".mp.   
33. britain.mp.   
34. british.mp.   
35. uk.mp.   
36. "united kingdom".mp.  
37. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 
32 or 33 or 34 or 35 or 36  
38. population surveillance/ or public health surveillance/ or sentinel surveillance/ or 
cohort studies/ or longitudinal studies/ or follow-up studies/ or prospective studies/ 
or retrospective studies/  
39. cohort*.mp.   
40. longitudinal.mp.   
41. surveillance.mp.   
42. follow?up.mp.   
43. prospective.mp.  
44. retrospective.mp.   
45. 38 or 39 or 40 or 41 or 42 or 43 or 44  
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Additional File 2 Table S1: Reasons for the Exclusion of Full-Text Articles, by Author 
 
Reasons for the Exclusion of Full-Text Articles  
First Author (n=297)  Second Author (n=297)  
a) Not UK (n=28)  
b) Non-English language (n=1)  
c) Self-referral/ other referral to studies 
(n=5)  
d) Response to census/ survey (n=0)  
e) Known neuropathological diagnosis 
(n=6)  
f) Direct referral (n=7)  
g) Recruited from hospital, clinics, 
referrals, other services (n=69)  
h) Existing register of cases, study, 
memory clinic patients, anticholinesterase 
users or carers (n=23)  
i) Dementia not the primary condition of 
interest (n=7)  
j) Animal models of dementia (n=0)  
k) Simulated cohorts (n=2)  
l) Ascertainment not for dementia (n=1)  
m) Not longitudinal or cohort study 
(n=42)  
n) Cases ascertained entirely through 
baseline and/ or prospective clinical 
assessment/ new data only (n=61)  
o) posters or abstracts (n=21)  
p) unclear/ errata/ additional duplicates 
(n=24)  
a) Not UK (n=5)  
b) Non-English language (n=1)  
c) Self-referral/ other referral to studies 
(n=0)  
d) Response to census/ survey (n=0)  
e) Known neuropathological diagnosis 
(n=0)  
f) Direct referral (n=13)  
g) Recruited from hospital, clinics, 
referrals, other services (n=33)  
h) Existing register of cases, study, 
memory clinic patients, anticholinesterase 
users or carers (n=41)  
i) Dementia not the primary condition of 
interest (n=9)  
j) Animal models of dementia (n=0)  
k) Simulated cohorts (n=0)  
l) Ascertainment not for dementia (n=3)  
m) Not longitudinal or cohort study 
(n=83)  
n) Cases ascertained entirely through 
baseline and/ or prospective clinical 
assessment/ new data only (n=42)  
o) posters or abstracts (n=44)  
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†: Was dementia ascertainment performed as the study outcome, or was dementia 
ascertainment performed in order to form a dementia cohort for which another 
outcome was determined.   
₸HAA: Hospital Activity Analysis; MHE: Mental Health Enquiry system; Körner: 
Korner Episode Statstics (hospital information systems).  
































1.Brayne C, Gao L, Dewey M, Matthews FE, Medical Research Council Cognitive F, 
Ageing Study I: Dementia before death in ageing societies--the promise 
of prevention and the reality. PLoS Medicine / Public Library of Science 
2006, 3(10):e397.  
2.Nicoll JAR, Savva GM, Stewart J, Matthews FE, Brayne C, Ince P, Med Res 
Council Cognitive F: Association between APOE genotype, 
neuropathology and dementia in the older population of England and 
Wales. Neuropathology and Applied Neurobiology 2011, 37(3):285-294.  
3.Valenzuela MJ, Matthews FE, Brayne C, Ince P, Halliday G, Kril JJ, Dalton MA, 
Richardson K, Forster G, Sachdev PS et al: Multiple biological pathways 
link cognitive lifestyle to protection from dementia. Biological Psychiatry 
2012, 71(9):783-791.  
4.Wharton SB, Brayne C, Savva GM, Matthews FE, Forster G, Simpson J, Lace G, 
Ince PG, Med Res Council Cognitive F: Epidemiological Neuropathology: 
The MRC Cognitive Function and Aging Study Experience. Journal of 
Alzheimers Disease 2011, 25(2):359-372.  
5.Brayne C, Richardson K, Matthews FE, Fleming J, Hunter S, Xuereb JH, Paykeld 
E, Mukaetova-Ladinska EB, Huppert FA, O'Sullivan A et al: 
Neuropathological correlates of dementia in over-80-year-old brain 
donors from the population-based Cambridge City over-75s Cohort 
(CC75C) study. Journal of Alzheimer's Disease 2009, 18(3):645-658.  
6.Perales J, Cosco TD, Stephan BC, Fleming J, Martin S, Haro JM, Brayne C, Study 
CC: Health-related quality of life in the Cambridge City over-75s Cohort 
(CC75C): development of a dementia-specific scale and descriptive 
analyses. BMC geriatrics 2014, 14:18.  
7.Clarke D, Morgan K, Lilley J, Arie T, Jones R, Waite J, Prettyman R: Dementia 
and 'borderline dementia' in Britain: 8-year incidence and post-
screening outcomes. Psychological Medicine 1996, 26(4):829-835.  
8.Morgan K, Lilley J, Arie T, Byrne J, Jones R, Waite J: Incidence of dementia: 
preliminary findings from the Nottingham Longitudinal Study of 
Activity and Ageing. Neuroepidemiology 1992, 11 Suppl 1:80-83.  
9.Morgan K, Lilley JM, Arie T, Byrne EJ, Jones R, Waite J: Incidence of dementia 




10.Morgan K, Lilley JM: RISK-FACTORS AMONG INCIDENT CASES OF 
DEMENTIA IN A REPRESENTATIVE BRITISH SAMPLE. International 
Journal of Geriatric Psychiatry 1994, 9(1):11-15.  
11.Imfeld P, Pernus YBB, Jick SS, Meier CR: Epidemiology, Co-Morbidities, and 
Medication Use of Patients with Alzheimer's Disease or Vascular 
Dementia in the UK. Journal of Alzheimers Disease 2013, 35(3):565-573.  
12.Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR: Risk of incident stroke in 
patients with Alzheimer disease or vascular dementia. Neurology 2013, 
81(10):910-919.  
13.Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR: Seizures in patients with 
Alzheimer's disease or vascular dementia: A population-based nested 
case-control analysis. Epilepsia 2013, 54(4):700-707.  
14.Newens AJ, Forster DP, Kay LDWK, Kirkup W, Bates D, Edwardson J: Clinically 
diagnosed presenile dementia of the Alzheimer type in the Northern 
Health Region: Ascertainment, prevalence, incidence and survival. 
Psychological Medicine 1993, 23(3):631-644.  
15.Kay DW, Forster DP, Newens AJ: Long-term survival, place of death, and 
death certification in clinically diagnosed pre-senile dementia in 
northern England: Follow-up after 8-12 years. The British Journal of 
Psychiatry 2000, 177:156-162.  
16.Newens AJ, Forster DP, Kay DW: Death certification after a diagnosis of 
presenile dementia. Journal of Epidemiology & Community Health 1993, 
47(4):293-297.  
17.Keenan TDL, Goldacre R, Goldacre MJ: Associations between primary open 
angle glaucoma, Alzheimer's disease and vascular dementia: Record 
linkage study. British Journal of Ophthalmology 2015, 99(4):524-527.  
18.Keenan TDL, Goldacre R, Goldacre MJ: Associations Between Age-Related 
Macular Degeneration, Alzheimer Disease, and Dementia: Record 
Linkage Study of Hospital Admissions. Jama Ophthalmology 2014, 
132(1):63-68.  
19.Wotton CJ, Goldacre MJ: Age at obesity and association with subsequent 




20.Goldacre R, Yeates D, Goldacre MJ, Keenan TDL: Cataract surgery in people 
with dementia: An English National Record linkage study. Journal of the 
American Geriatrics Society 2015, 63(9):1953-1955.  
21.Smolina K, Wotton CJ, Goldacre MJ: Risk of dementia in patients 
hospitalised with type 1 and type 2 diabetes in England, 1998-2011: a 
retrospective national record linkage cohort study. Diabetologia 2015, 
58(5):942-950.  
22.Sorahan T, Kheifets L: Mortality from Alzheimer's, motor neuron and 
Parkinson's disease in relation to magnetic field exposure: Findings 
from the study of UK electricity generation and transmission workers, 
1973-2004. Occupational and Environmental Medicine 2007, 64(12):820-
826.  
23.Sorahan T, Mohammed N: Neurodegenerative disease and magnetic field 
exposure in UK electricity supply workers. Occupational medicine 
(Oxford, England) 2014, 64(6):454-460.  
24.Staff RT, Murray AD, Ahearn T, Salarirad S, Mowat D, Starr JM, Deary IJ, 
Lemmon H, Whalley LJ: Brain volume and survival from age 78 to 85: the 
contribution of Alzheimer-type magnetic resonance imaging findings. 

























Additional File 4 Table S3: Quality Measure Result Breakdown  
 
  
1 2 3 4 5 6 7 Total 
Score 
Baker et al. (Baker, Cook, Arrighi, & Bullock, 
2011)  
C BII B A AI B A 9 
Brayne et al. (C. Brayne et al., 2006)  A AII A A AI A A 15 
Brayne et al. (C. Brayne et al., 2009)  A AII A A AI A A 15 
Chen et al. (L. Chen, Reed, Happich, Nyhuis, & 
Lenox-Smith, 2014)  
C BII B A AII B A 8 
Clarke et al. (Clarke et al., 1996b)  A AII A A AII A A 14 
Cook et al. (Cook et al., 2015)  C BII B A AI B A 9 
Crugel et al. (Crugel, Paton, Singh, Jeboda, & 
Treloar, 2012)  
D C B B AI A A 7 
Doll et al. (Doll, Peto, Boreham, & Sutherland, 
2000a)  
A C A A AII A A 11 
Dregan et al. (Dregan, Chowienczyk, & Gulliford, 
2015)  
A AII A A AII B A 13 
Goh et al. (Goh et al., 2015)  A AII A A AI B A 14 
Goldacre et al. (Goldacre et al., 2015)  D BII B B AI A A 8 
Grant et al. (Grant, Drennan, Rait, Petersen, & 
Iliffe, 2013)  
A AI B A AI B A 14 
Guthrie et al. (Guthrie, Clark, & McCowan, 2010)  A AII B A AI A A 14 
Heath et al. (Heath, Mercer, & Guthrie, 2015)  A AI A A AI A A 16 
Houttekier et al. (Houttekier et al., 2010)  A AII B A AI B A 13 
Imfeld et al. (Imfeld, Bodmer, et al., 2013a)  C BII B A AI B A 8 
Imfeld et al. (Imfeld, Bodmer, Schuerch, Jick, & 
Meier, 2013c)  
C BII B A AI B A 8 
Imfeld et al. (Imfeld, Pernus, et al., 2013)  C BII B A AI A A 9 
Karlinsky et al. (Karlinsky, Macdonald, & Berg, 
1992)  
B AII B A AII B B 10 
Kay et al. (Kay et al., 2000)  B AI B B AII A A 12 
Keenan et al. (Keenan et al., 2014)  A AII A A AII A A 14 
Keenan et al. (Keenan et al., 2015)  A AII A A AI A A 15 
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Kehoe et al. (Kehoe, Davies, Martin, & Ben-
Shlomo, 2013)  
C BII B A AI B A 9 
Lu et al. (N. Lu et al., 2014)  A AII A A AI B A 14 
Martinez et al. (Martinez, Jones, & Rietbrock, 
2013)  
C BII B A AI B A 9 
McCarthy et al. (McCarthy, AddingtonHall, & 
Altmann, 1997)  
C BII B A AII B A 8 
McGonigal et al. (McGonigal et al., 1993)  B AI B B AI A A 13 
Morgan et al. (G. S. Morgan et al., 2012)  A AI A A AI B A 15 
Morgan et al. (K. Morgan et al., 1992)  A AII A A AII B A 13 
Morgan et al. (K. Morgan et al., 1993)  A AII A A AII B A 13 
Morgan et al. (K. Morgan & Lilley, 1994)  A AII B A AII B A 12 
Newens et al. (Newens, Forster, Kay, et al., 
1993)  
B AI B B AI A A 13 
Newens et al. (Newens, Forster, & Kay, 1993)  D BII B B AI A A 8 
Nicoll et al. (Nicoll et al., 2011)  A AII A A B B B 11 
Palmer et al. (Palmer, Inskip, Martyn, & Coggon, 
1998)  
C BI B B B B A 7 
Pendlebury et al. (Pendlebury et al., 2015)  A AII A A AI B A 14 
Perales et al. (Perales et al., 2014)  A AII B A AI B A 13 
Perera et al. (G. Perera, Khondoker, Broadbent, 
Breen, & Stewart, 2014)  
C C B A AI B A 8 
Qizilbash et al. (Qizilbash et al., 2015)  A AII A A AII B A 13 
Rait et al. (Rait et al., 2010)  C BII B A AI A A 10 
Renvoize et al. (Renvoize, Hanson, & Dale, 
2011)  
B AI A B AII A A 13 
Reyniers et al. (Reyniers et al., 2015)  A BII B B AI B A 10 
Russ et al. (Russ et al., 2015)  A AI A A AI A A 16 
Ryan (D. H. Ryan, 1994)  A AII B A AI A A 14 
Sampson et al. (Sampson, Gould, Lee, & 
Blanchard, 2006)  
A AII A B AI B A 13 
Seshadri et al. (Seshadri et al., 2001)  A AII A A AI B A 14 
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Shah et al. (Shah, Carey, Harris, DeWilde, & 
Cook, 2012)  
A AI B A AII B A 12 
Sleeman et al. (Sleeman et al., 2014)  C BII B B AI B A 8 
Smolina et al. (Smolina et al., 2015)  A AII B A AI B A 13 
Sorahan et al. (Sorahan & Kheifets, 2007a)  A C A A AI A A 12 
Sorahan et al. (Sorahan & Mohammed, 2014)  A C A B AI B A 10 
Staff et al. (Staff et al., 2010)  A AI A A AI B A 15 
Stephens et al. (Stephens, Chikh, & Leufkens, 
2014)  
B BII B B AI B A 9 
Su et al. (Su et al., 2014)  A AII A A AI B A 14 
Valenzuela et al. (Valenzuela et al., 2012)  A AII A A AII B A 13 
De Vries et al. (Vries & Nowell, 2011)  A AII B A AII B A 12 
Whalley et al. (Whalley et al., 2012)  A AI A A AI B A 15 
Whalley et al. (Whalley et al., 2000)  A AI B A AI B A 14 
Wharton et al. (Wharton et al., 2011)  A C B A B C A 7 
White et al. (White & Montgomery, 2015)  A BII B A AII A A 11 
Wilcock et al. (Wilcock et al., 2013)  A BII B A AII B A 10 
Woodburn et al. (Woodburn & Johnstone, 1999)  B AI B B AI B A 12 
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Additional file 5: Table S4. Studies reporting a validation procedure. 
 
  
Article  Source/ Methodology  Validation/ Comparison 
Result  
Doll et al.(Doll et 
al., 2000a)  
Death Certificates:  
Dementia ‘mentioned’ on death 
certificate.  
-30% of dementia cases 
recorded on death 
certificates when compared 
to EURODEM statistics  
Guthrie et 
al.(Guthrie et al., 
2010)  
*SPICE-PC:  
Read codes for dementia,   
OR  
Prescription of acetylcholinesterase 
inhibitor.  
-prevalence approximately 
half of expected  
Heath et al.(Heath 
et al., 2015)  
Unnamed general practice research 
database:  
Read codes for dementia,  
OR  
Prescription of acetylcholinesterase 
inhibitor.  
-prevalence was close to 
middle of expected range  
Imfeld et 
al.(Imfeld, Pernus, 
et al., 2013)   
*GPRD:  
Stage I- read code for dementia, 
OR, prescription for 
acetylcholinesterase inhibitor.  
Stage II- algorithm for AD or VD 
(based on DSM-IV, NINCDS-
ADRDA, NINDS-AIREN, NICE & 
SIGN).  
-80% AD cases and 75% 
VD cases confirmed by GP 
questionnaire  
-incidence rates of AD 3-6 
times lower than previous 
studies   
McGonigal et 
al.(McGonigal et 
al., 1993)  
‡ISD Scotland Data for psychiatric 
hospitals & hospital records:  
Stage I: diagnostic codes for 
dementia in SMR,  
Stage II: NINCDS-ADRDA criteria 
and Hachinski score applied to 
records.  
-97% of participants with 
pre-senile dementia were 
cared for within psychiatric 
services  
-annual incidence of 
presenile dementia 
determined using hospital 
records comparable to 
annual incidence rates 
quoted by a national study.  
Newens et 
al.(Newens, 
Forster, Kay, et 
al., 1993)  
Electronic hospital information 
systems:  
Stage I: potential cases identified by 
ICD-9 codes from information 
systems, referrals for CT with 
dementing process, (and contact 
with services).  





Stage II: case notes for all 
examined for DSM-III-R criteria for 
dementia, then algorithm for pre-
senile AD  
Rait et al.(Rait et 
al., 2010)  
*THIN:  
Read codes for dementia.  
-incidence rates 
significantly lower than 
expected when compared 
with EURODEM and CFAS 
studies  
Renvoize et 
al.(Renvoize et al., 
2011)   
Computerised medical and social 
records:  
Stage I: discharge diagnosis of 
dementia in computer system,  
Stage II: “criteria for dementia” from 
notes (criteria not specified)  
-prevalence rate found to 
be consistent with previous 
studies  
Russ et al.(Russ 
et al., 2015)  
ISD Scotland data, death 
certificates, records for a nursing 
home medical practice:  
ICD-9 & 10 codes for dementia from 
SMR data and death certificates, 
and dementia status reported by a 
medical practice.  
-when compared to multiple 
sources, death certificates 
missed 16-18% of cases  
-general practice records 
did not identify all cases 
identified by record linkage  
Ryan et al.(D. H. 
Ryan, 1994)  
‡ISD Scotland data:  
ICD-8 & 9 codes for dementia.  
-validity rate of 84% quoted 
from a previous work by the 
same author  
Seshadri et 
al.(Seshadri et al., 
2001)  
*GPRD, GP records:  
Stage I: computer diagnosis of 
dementia,  
Stage II: records for each reviewed 
to confirm diagnosis based on 
NINCDS-ADRDA criteria  
-confirmed 48% of probable 
or possible AD cases 
according to NINCDS-
ADRDA  
-confirmed 83% of AD 
cases where there was 
adequate data for 
validation  
Shah et al.(Shah 
et al., 2012)  
*THIN:  
Read codes for dementia  
-prevalence noted to be 
lower than expected, based 
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Abstract
Background: With increasing numbers of people surviving beyond eighty years, this section of the population
demands attention to reduce the impact of dementia. In order to develop effective preventative strategies, it is
essential to understand age-specific risk factor profiles for dementia: do risk factors for dementia in those in their
sixties and seventies persist into oldest age? The aims of this study were to determine incident dementia and to
investigate the risk profile for dementia from age 79 to 95 years in a well-characterised cohort.
Methods: Participants underwent intelligence testing at age 11 and were followed-up from at 79 years of age.
Variables included: age, sex, age 11 IQ, APOE ɛ4, education, diabetes, hypertension, statin use, physical activity at
leisure and in occupation, symptoms of depression, height, number of teeth, body mass index, blood pressure,
cholesterol and HbA1c. Dementia cases were ascertained from death certificates, electronic patient records and
clinical reviews. Logistic regression analysis determined the degree of risk for dementia associated with each
variable. Analyses were completed both with and without the physical activity variables due to the significant
number of missing data for these variables.
Results: Of the eligible cohort, n = 410 participants remained dementia-free and n = 110 had developed probable
dementia. When logistic regression analyses contained all variables, complete data was available for n = 234 (n = 48
with dementia). Results demonstrated that positive APOE ɛ4 carrier status (OR: 2.15, 95% CI: 1.04, 4.42) and greater
lifetime physical activity (OR: 1.14, 95% CI: 1.02, 1.28) increased the risk for dementia. A reduction in risk for
dementia was seen for hypertension (OR: 0.47, 95% CI: 0.23, 0.98). When physical activity variables were excluded,
the number with complete data increased to n = 377 (n = 80 with dementia). APOE ɛ4 remained significant
(OR: 2.37; 95% CI: 1.37, 4.07), as did hypertension (OR: 0.55; 95% CI: 0.32, 0.93).
Conclusions: Dementia incidence was consistent with expected rates. The risk profile for dementia in this cohort of
participants aged 79–95 confirmed previous findings that risk factors differ for those over 79 years. Further evidence
is recommended in order that the risk profile for this age group can be accurately determined.
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Without clear means of prevention or cure, dementia is
recognised to be one of the greatest public health chal-
lenges facing the ageing global population. Dementia
rates are known to increase exponentially with age, from
5.5 per 1000 person-years in those aged 70–74, to 30.5
per 1000 person-years in those aged 80–84 [1]. With
increasing numbers of people surviving into the ninth
decade of life and beyond [2], this section of the popula-
tion demands attention in order to reduce the impact of
dementia [3]. Despite studies such as the 90+ Study [4].
(North America) and the Monzino 80-plus Study [5].
(Italy) the oldest in the population remain less well
represented in dementia research.
In order to develop effective preventative strategies
for dementia and ensure that these are directed
appropriately, it is essential to identify potentially
modifiable risk factors and understand whether these
persist into oldest age. Significant modifiable risk
factors for dementia demonstrated by replication
within the literature include: diabetes [6], hyperten-
sion [7], hypercholesterolaemia [8], depression [9],
smoking [10, 11], obesity [11]. and physical inactivity
[11–13]. Previous studies have proposed that the risk
factor profile for dementia changes with age, but the
evidence is not conclusive [14, 15].
The present study draws on prospectively collected
longitudinal data from the Lothian Birth Cohort 1921
(LBC1921). Participants were predominantly cognitively
normal at baseline (aged 79 years) and underwent de-
tailed follow-up to age 95 years. As a result, this study
can add further evidence to the literature regarding risk
factors for dementia in the oldest-old. Most participants
in this cohort had also taken part in childhood
intelligence testing at age 11 years. This is an unusual
and valuable feature of the data for a study cohort of the
oldest-old, given that lower childhood IQ has been
shown to be a putative risk factor for dementia [16]. and
is associated with several modifiable risk factors [17–19].
Dementia ascertainment had not previously been per-
formed in LBC1921 and, although a number of partici-
pants would have developed dementia during the study
period, there had not been any clear means of identifying
all such participants. Mini-Mental State Examination
(MMSE) [20]. was performed at each wave of follow-up
and a small number were seen for clinical review follow-
ing concerns raised regarding their cognitive function.
Some participants self-reported a new diagnosis of
dementia. This would have identified only a proportion
of cases. There was no previous follow-up regarding
dementia ascertainment for those who had died or left
the study. Given the likelihood that participants with in-
cident dementia were less likely to attend for follow-up,
death records would be a valuable source data for
dementia ascertainment, particularly where a diagnosis
of dementia failed to be recorded in the secondary care
records.
The primary aims of this study were: i) to determine
cases of incident dementia within the LBC1921 study
cohort from age 79–95, and ii) to investigate whether
recognised modifiable risk factors for dementia (diabetes,
hypertension, hypercholesterolaemia, depression, smok-
ing, physical inactivity, obesity) remained risk factors for
dementia in the ninth decade and beyond. These modifi-
able risk factors were considered together with key non-
modifiable factors including; age 11 IQ, APOE ɛ4 status,
and measures associated with socio-economic status.
The present study primarily drew on existing data
for dementia ascertainment. Given the variability in
methodology for using routinely collected data in the
literature, we aimed to quantify the effectiveness of




The LBC1921 is described in detail elsewhere [21], and
is outlined briefly here. Almost all Scottish school pupils
born in 1921 had their general intelligence tested at
age ~ 11 years as part of the Scottish Mental Survey
1932 [22]. Beginning in 1999, the LBC1921 was designed
in order to follow up some of the same participants in
later life with the primary aim of investigating non-
pathological cognitive ageing [23]. The LBC1921 in-
cludes 550 participants recruited from the Lothian area
of Scotland, as relatively healthy, community-dwelling
volunteers, most of whom had taken part in intelligence
testing in 1932. Lothian is an area in southeast Scotland
in which the largest settlement is the city of Edinburgh.
Participants underwent the first wave of testing at ap-
proximately 79 years of age. Those participants surviving
and continuing to consent to inclusion in the study were
re-tested at regular intervals, at mean ages of about 83,
87, 90 and 92 years of age. The data were collected by
questionnaire and one-to-one testing and included mea-
sures of socio-demographic, psychological, cognitive,
medical, physiological, and genetic factors. Those partic-
ipants self-reporting a history of dementia or scoring less
than 24 on the MMSE at baseline were excluded from
our study (n = 11), as were those who were missing
baseline MMSE data (n = 2). Deaths were ascertained
prospectively, with records for participants supplied by
the General Registrar’s Office, Scotland [24]. Ethical
approval was provided by the Lothian Research Ethics
Committee (test waves 1–3) and the Scotland A Re-
search Ethics Committee (test waves 4–5). Participants
attending from wave 4 provided written consent for data
linkage and access to health records.







Surviving participants who continued to take part in the
LBC1921 study were seen for routine follow-up as de-
scribed previously. Follow-up for the purposes of detect-
ing dementia diagnoses included the retrospective
collection of evidence from the sources described below,
from enrolment to age 95 years. Dementia cases were
determined at a final consensus meeting on 15th
December 2016. Death records for deceased participants
were examined for evidence of cognitive impairment or
dementia. Data from death records were collected from
those available by 30th June 2016. For consenting partic-
ipants, data were collected from medical and psychiatric
electronic patient records for services in Lothian. Pa-
tients were located in the system using their Community
Health Index (CHI) number, a unique number given to
each patient within Scotland, recorded at every health
service contact. Each hospital record accessed was read
in full and examined for evidence of dementia or cogni-
tive impairment since enrolment in the study. This in-
cluded gathering both recorded confirmed diagnoses
and evidence for diagnoses. Until 2014, general and
psychiatric records were held on separate systems (Trak
and PIMS respectively), but all records were subse-
quently incorporated into the Trak system. The final
date for data collection from this source was 16th May
2016. For 26 participants, additional information was
available as a result of clinical assessments undertaken
by the authors (JMS or TCR) in the NHS or research
setting. In the research setting, assessments were under-
taken when impairment or decline was noted during the
routine LBC1921 testing, or when a new diagnosis of
dementia was self-reported. Data from these sources
were collected until the consensus date.
Each case with evidence of cognitive impairment or
dementia was considered at a consensus meeting (RAS,
TCR, JMS) which included both a geriatrician and a
psychiatrist. The meeting agreed upon whether the
evidence supported a diagnosis of dementia and deter-
mined the subtype of dementia. Depending on the
strength of the evidence, the diagnosis and subtype were
deemed either ‘probable’ or ‘possible’. The criteria for
probable and possible diagnoses utilised by the consen-
sus are shown in Table 1. Any disagreement on diagnosis
was resolved through discussion.
Dementia subtype diagnoses were made on a similar
basis. Any dementia case with insufficient evidence to
make a subtype diagnosis was classified as ‘unknown’
subtype. In order to minimise the risk of misclassifica-
tion bias, probable dementia cases would be used as our
primary outcome and possible cases would be excluded
from the analyses. We would however repeat our
analyses including possible dementia cases and include
the results as supplementary information.
Variables
Modifiable risk factors assessed in the present study
were identified by matching those consistently reported
in the literature (diabetes, hypertension, depression,
hypercholesterolaemia, smoking, obesity, and physical
inactivity) [12]. with data collected at LBC1921 test
waves. We also included the following variables: age,
sex, APOE ɛ4 status, age 11 IQ, number of teeth (as a
post-retirement measure of socio-economic status [25]),
height, and years in full-time, formal education. The full
list of included variables is detailed in Additional file 1:
Table S1.
Age at baseline was calculated according to the num-
ber of days between birth date and date attending wave
1 testing. The presence of at least one APOE ɛ4 allele
was determined using genomic DNA isolated from ven-
ous blood [26]. Venous blood was also used to measure
total serum cholesterol and HbA1c [21]. Any previous
history of diabetes or hypertension, years in formal edu-
cation, use of statins, and smoking status (previous,
current or never) were self-reported by participants [26].
Body mass index (BMI) was calculated from height and
weight, measured using a SECA stadiometer and digital
SECA scales, respectively [27]. A trained research nurse
measured sitting blood pressures (systolic and diastolic)
using an Omron 705IT monitor [24]. Remaining teeth
were counted during the general physical assessment
[25]. Symptoms of depression were evaluated using the
self-reported Hospital Anxiety and Depression Scale
[28]. (HADS) at wave 1 [29]. Only the scores for the
depression sub-scale were considered. Physical activity
was self-reported by participants as part of a retrospect-
ive questionnaire at wave 2 follow-up (~age 83) [30].
Based on the methodology described by Hirvensalo and
colleagues [31], responses were scored on a six-item
scale according to increasing levels of physical activity.
Table 1 Consensus criteria for dementia case ascertainment
CONSENSUS CRITERIA FOR DEMENTIA CASE ASCERTAINMENT
PROBABLE DEMENTIA POSSIBLE DEMENTIA
ANY of the following
(without opposing evidence
from same/other source):
- dementia diagnosis on death
certificate (any part)
- dementia diagnosed on clinical
review (ICD-10/DSM-IV)
- dementia diagnosis in
electronic general medical
records (Trak)
- dementia diagnosis in
electronic psychiatric records
(PIMS)
- ICD-10 criteria for dementia
diagnosis met by data within
any existing records
ANY of the following
(without opposing evidence
from same/other source):
- recorded cognitive impairment
on death certificate
- cognitive impairment/decline
recorded in notes, but
incomplete evidence to meet
ICD-10 diagnostic criteria
- possibility of dementia
recorded in notes but no
formal diagnosis/incomplete
evidence to meet ICD-10 diag-
nostic criteria






Responses predominantly related to leisure based activ-
ity: necessary movement, walking, walking/outdoor exer-
cises, exercising until sweating, exercising several times
per week, keep fit/heavy exercise. Participants indicated
their perceived level of physical activity at three age
ranges: 20–35, 40–55 and 60–75 years [30]. A lifetime
score was calculated by the sum of the three scores. The
physical effort required in a participant’s previous occu-
pation was assessed using a single item [Q21] from the
Job Content Questionnaire (JCQ) by Karasek [32, 33].
which was included, with permission, in the wave 2
questionnaire.
Age 11 IQ was derived from the results of the Moray
House Test (MHT) no. 12, undertaken by participants in
1932 [26]. Following correction for age at testing, the
cohort MHT scores were converted to IQ scores, with a
standardised sample mean score of 100 and SD of 15
[26]. To demonstrate how the cohort IQ compares with
the general population, we consider the raw MHT
scores: 34.5 (SD: 15.5) was the mean score for Scotland,
37.3 (SD: 14.8) for those in Edinburgh schools, and 46.4
(SD: 12.1) for those recruited to LBC1921 [25].
Statistical analyses
Statistical analysis was performed using IBM SPSS Statis-
tics software version 21. The primary outcome of the
study was the development of dementia. The analyses
were completed for an outcome of probable dementia,
with possible cases excluded. Univariate analysis was com-
pleted for each predictor variable, using either the Pearson
chi-square or t-test. At this stage, a p value of <0.05 was
used to demonstrate significant difference between those
who developed dementia and those who did not. Binary
logistic regression analysis was used to determine the risk
for dementia associated with each predictor variable. For
the purposes of logistic regression, the data for height and
age 11 IQ were standardised so that a unit increase repre-
sented one standard deviation increase on the original
scale. The following logistic regression models were com-
pleted using the ‘backward conditional’ function. The in-
put for model 1 included all variables. The analyses for
model 2 included all variables except lifetime physical ac-
tivity and physical activity in occupation, which were ex-
cluded since data were missing for around one-third of
participants (33.3 to 39.0% missing, with zero to 14.2%
missing for all other variables). The analyses for models 1
and 2 were repeated to include both probable and possible
dementia in the outcome, and the results are made avail-
able in the supplementary information.
Results
Five hundred fifty participants recruited to the LBC1921
attended the first wave of data collection. We excluded 9
participants with an MMSE score of less than 24 at
baseline, 2 participants missing MMSE results at base-
line, 2 participants who self-reported a diagnosis of de-
mentia at baseline and 10 participants with no follow-up
data available. The eligible cohort (n = 527) included
305 (57.9%) females and 425 (80.6%) were known to be
deceased by the 30th of June 2016. The mean age in
years at wave 1 was 79.1 years (SD: 0.6). APOE ɛ4 carrier
status was available for 521 participants (98.9%), with
139 (26.4%) recorded as carriers. The mean (standar-
dised) age 11 IQ score was 100.1 (SD: 14.8), calculated
from the 473 scores available (89.8% of the eligible co-
hort). The mean MMSE score for the eligible cohort was
28.3 (SD: 1.5). Descriptive statistics for those eligible for
inclusion, and those excluded are shown in Table 2.
One hundred twenty nine participants were found to
have evidence of cognitive impairment or dementia in
their records. A consensus diagnosis of probable
dementia was agreed for 110 participants (38 probable
Alzheimer disease, 25 probable vascular dementia, 9
probable mixed-type dementia, 1 probable progressive
supra-nuclear palsy, 6 possible vascular dementia, 1
possible dementia in Parkinson’s disease, and 30 of
unknown subtype) and a diagnosis of possible dementia
was determined for 7 participants (1 possible vascular
dementia, 6 unknown subtype). The remaining 12 cases









Living 102 (19.4%) 11 (47.8%)
Deceased 425 (80.6%) 12 (52.2%)
Sex
Male 222 (42.1%) 12 (52.2%)
Female 305 (57.9%) 11 (47.8%)
Age at wave 1
Mean age in years 79.1 (SD: 0.6) 79.2 (SD: 0.5)
APOE ɛ4 carrier status
Carrier 139 (26.4%) 7 (30.4%)
Not carrier 382 (72.5%) 15 (65.2%)
Data missing 6 (1.1%) 1 (4.3%)
Age 11 IQ
Data available 473 (89.8%) 20 (87.0%)
Data missing 54 (10.2%) 3 (14.3%)
Mean age 11 IQ 100.1 (SD: 14.8) 97.8 (SD: 19.6)
MMSE
Data available 527 (100%) 21 (91.3%)
Data missing - 2 (8.7%)
Mean MMSE 28.3 (SD: 1.5) 25.2 (SD: 3.3)






considered had either insufficient information for
diagnosis or evidence contradictory to a diagnosis of
dementia (for example, the evidence supports a diagno-
sis of delirium rather than dementia). Figure 1 illustrates
the number of probable cases ascertained by each data
source, or combination of data sources. Almost two
thirds of cases of probable dementia (63.6%) were deter-
mined based on a single source of information with the
largest proportion of these single source diagnoses being
based on death certificate data (Fig. 1).
All 7 cases of possible dementia were identified based
on evidence from a single source (death certificate or
electronic medical record). Of the 12 cases that did not
meet the criteria for probable or possible dementia, 9
were determined based on a single data source, whilst
the remaining 3 used two sources. The sources were as
follows: 9 used evidence from the electronic medical re-
cords only, 1 used evidence from both the electronic
medical records and the electronic psychiatric records
and 2 used evidence from the electronic medical records
and from clinical review.
Univariate analysis demonstrated significant differ-
ences between the group with probable dementia and
the group without dementia for the following variables:
positive APOE ɛ4 carrier status (p < 0.001), lower BMI
at age 79 (p = 0.026) and current smoking status at age
79 (p = 0.039) (Table 3).
Following the exclusion of possible cases of dementia
(n = 7), n = 520 participants were included in the logistic
regression analyses, of which n = 110 had developed
probable dementia. The results for these analyses are
shown in Table 4. In both models the presence of an
APOE ɛ4 allele increased the risk of dementia (model 2
OR: 2.37, 95% CI: 1.37, 4.07). A history of hypertension
was associated with a decreased risk for dementia in
both models (model 2 OR: 0.55, 95% CI: 0.32, 0.93).
Increased height was associated with a decrease in risk
for incident dementia in model 2 (model 2 OR: 0.73,
95% CI: 0.56, 0.96) and the same relationship
approached significance in model 1 (model 1 OR: 0.71,
95% CI: 0.49, 1.01). A higher lifetime leisure-based phys-
ical activity score was associated with an increased risk
of dementia in model 1 (OR: 1.14, 95% CI: 1.02, 1.28).
Although current smoking was included in both models,
the relationship with dementia did not reach signifi-
cance. Age did not demonstrate an effect in any model,
as might be expected in this narrow-age cohort.
To investigate the relationship with physical activity fur-
ther, analysis for a third model was completed in which
three individual age groups scores (20–35, 40–55, 60–
75 years) replaced the lifetime physical activity score. All
other variables were also included. Increased physical
activity at age 20–35 years was significantly associated with
incident dementia (OR: 1.35, 95% CI: 1.06, 1.73). The re-
sults of this model are shown in Additional file 2: Table S2.
Results for logistic regression analyses (models 1 and 2),
repeated with possible cases included in the outcome, can
be seen in Additional file 3: Table S3.
Validation study
In order to validate our case ascertainment method
using existing data sources, we completed a validation
Fig. 1 Number of probable dementia cases ascertained, by data source






study comparing diagnoses extracted from existing data
with diagnoses made on clinical review. Clinical reviews
were performed for 26 participants. Of the 24 who were
diagnosed as having dementia on clinical review, 23 had
a diagnosis of dementia in at least one source of existing
data. This would suggest that we would miss 4% of cases
using existing data alone. Two participants seen for
clinical review were not diagnosed as having dementia,






p value (chi-square or t-test)
Age at wave 1 n = 410 n = 110
-mean age in years (SD) 79.1 (0.6) 79.0 (0.6) 0.610
Sex n = 410 n = 110
-% female 56.6 62.7 0.247
APOE ɛ4 carrier statusa n = 404 n = 110
-% carrier APOE ɛ4 22.5 40.9 <0.001
Age 11 IQ (standardised) n = 365 n = 102
-mean score (SD) 100.0 (14.5) 100.1 (16.1) 0.948
Teeth n = 410 n = 110
-mean number of teeth (SD) 9.2 (9.4) 9.6 (8.9) 0.706
Height n = 409 n = 107
-mean height in cm (SD) 163.6 (9.4) 162.1 (9.2) 0.144
Formal education n = 409 n = 109
-mean number of years (SD) 10.9 (2.4) 11.0 (2.7) 0.732
History of diabetes n = 410 n = 110
-% positive history 5.4 4.5 0.731
HbA1c n = 356 n = 98
-mean HbA1c (SD) 5.7 (0.8) 5.7 (0.5) 0.703
History of hypertension n = 406 n = 109
-% positive history 42.1 34.9 0.171
Systolic blood pressure n = 408 n = 109
-mean BP in mmHg (SD) 168.9 (27.3) 166.0 (24.8) 0.315
Diastolic blood pressure n = 408 n = 109
-mean BP in mmHg (SD) 83.1 (13.2) 81.8 (12.3) 0.352
Statin use n = 347 n = 99
-% positive history 7.5 11.1 0.250
Total serum cholesterol n = 401 n = 105
-mean (SD) 5.7 (1.1) 5.6 (1.1) 0.891
Depression (HADS) n = 409 n = 109
-mean depression score (SD) 3.5 (2.3) 3.5 (2.4) 0.966
BMI n = 409 n = 107
-mean kg/m2 (SD) 26.4 (4.2) 25.4 (4.0) 0.026
Smoking status n = 410 n = 109
-% current smoker 8.5 2.8 0.039
Lifetime physical activity n = 273 n = 74
-mean total lifetime score (SD) 8.7 (3.1) 9.5 (3.0) 0.058
Physical effort required in occupation n = 248 n = 69
-mean score (SD) 2.1 (0.8) 2.3 (0.8) 0.065
aOne or more alleles
Italicized results demonstrate significance of p<0.05






but both had a diagnosis of dementia in the electronic
medical records. This discrepancy might reflect the use of
different diagnostic criteria, or the use of clinical judge-
ment in clinical practice, particularly where evidence is
ambiguous. Despite this discrepancy, our method would
identify dementia in 88% of cases, with 4% being false
negatives and 8% being false positives. Of the 17 cases
identified as Alzheimer’s disease (AD) on clinical review,
14 (82%) had AD listed as a diagnosis within at least one
data source. Of the 14 cases, 5 (36%) also had a different
subtype diagnosis recorded in existing data, 7 (50%) also
had dementia of an unspecified subtype recorded, while 2
(14%) cases listed only AD. Of the 2 cases identified as
vascular dementia on clinical assessment, 1 had vascular
dementia listed as a diagnosis within the existing data. Of
the 3 cases identified as mixed Alzheimer’s and vascular
dementia on clinical assessment 1 had a diagnosis of
mixed dementia in the existing data. These findings dem-
onstrate the usefulness of accessing records to find
evidence that will support a subtype diagnosis based on
recognised criteria. Our finding that overall dementia
diagnoses were confirmed in 88% of cases is comparable,
if not better than, validation procedures performed for
other existing data sources or methodologies.
Discussion
This study found that 21.2% of eligible, initially cognitively
normal participants from the LBC1921 developed demen-
tia from age 79 to 95 years. At the time of this study, 420
of 520 eligible participants had died, including 89 who had
died with dementia. A total of 21 participants with
dementia were alive at age 95. Our analyses indicated that
the presence of an APOE ɛ4 allele and greater lifetime
leisure-based physical activity increased the risk for
dementia. A history of hypertension and increased height
were found to reduce the risk for dementia.
The results of this study reinforce the importance of
the APOE ɛ4 allele as a risk factor for the development
of dementia [34, 35]. A number of studies have
suggested a decline in the importance of APOE ɛ4 as a
risk factor for dementia with advancing age [34, 36].
Somewhat to the contrary, our study has determined
that APOE ɛ4 continues to be a significant risk factor for
incident dementia from age 79 to 95.
Our results also indicated that a history of hyperten-
sion by age 79 was associated with a reduction in risk
for dementia. This result supports the findings of previ-
ous studies that have demonstrated that the association
of hypertension with dementia changes towards later life
[37]. We might hypothesize that persons surviving and
remaining dementia-free at the ninth decade of life, are
no longer subject to any increased risk as a result of vas-
cular factors such as hypertension. In simple terms, such
risk factors have been used up and those with hyperten-
sion who were at the highest risk for dementia are more
likely to have died from hypertension-related diseases
prior to the onset of dementia. As a result, we might ex-
pect a paradoxical effect, much like that seen in this
study. This hypothesis is supported by the direction of
relationship for physical activity. Previous studies have
hypothesized that a reduction in blood pressure is a con-
sequence of the development of dementia and, although
this mechanism is not fully understood, several pro-
cesses have been proposed [37, 38]. Blood pressure may
decline in early dementia due to the direct effect of
neurodegeneration at the brainstem and hypothalamic
nuclei- where arterial pressure is regulated- or it may be
related to systemic changes such as weight loss, or any
disease effecting the ability of the cardiovascular system
to maintain perfusion pressures throughout the body
[38]. Another possible explanation for the reduced risk
is the potentially protective effect of antihypertensive
agents, particularly as it is reported that antihypertensive
use in hypertension is higher in older age [39–42].
The findings relating to physical activity were more
unexpected with higher levels of overall leisure activity
throughout adulthood being linked with an increased
risk of developing dementia. As a consequence of
missing data, the findings relating to physical activity
were obtained for a smaller sample size and we must
therefore be cautious in drawing inferences from these
findings, particularly as they contradict studies that have
previously indicated a link between midlife inactivity and
dementia [11, 13]. The discrepancy between our findings
and those of previous studies may be related to the
method of data collection for these variables. Self-
reporting physical activity levels throughout life at 79 years
is likely to be subject to recall bias and variability between
participants.
In this cohort, one standard deviation increase in
height corresponded to 9.3 cm which was associated
with an approximately 27% reduction in odds of possible
Table 4 Logistic regression results
Odds ratios (95% CI) for probable dementia
Model 1 (n = 234) Model 2 (n = 377)
APOE ɛ4 2.15 (1.04,4.42) 2.37 (1.37,4.07)
Height (z score) 0.71 (0.49, 1.01) 0.73 (0.56, 0.96)
Hypertension 0.47 (0.23,0.98) 0.55 (0.32,0.93)
Current smoking 0.18 (0.02, 1.41) 0.25 (0.06, 1.09)
Lifetime physical activity 1.14 (1.02,1.28) -
The variables entered into the analyses for each model were as follows:
Model 1- age, sex, APOE ɛ4 carrier status, age 11 IQ (z score), number of teeth,
height (z score), years in education, history of diabetes, HbA1c, history of
hypertension, systolic blood pressure, diastolic blood pressure, cholesterol, use
of statins, HADS depression score, BMI, smoking status, physical activity in
occupation, lifetime physical activity (‘backward conditional’ method);
Model 2- as model 1, but physical activity in occupation and lifetime physical
activity excluded (‘backward conditional’ method)






or probable dementia (OR: 0.73, 95% CI: 0.56, 0.96). Our
results are supported by the finding of a 2014 individual
participant meta-analysis, that increasing height was
related to a lower rates of death from dementia [43]. As
concluded by the authors, since height is regarded as a
marker of factors in early life, it may be these that are
related to risk of dementia [43]. Like APOE ɛ4, we have
demonstrated that decreased height continues to be a
significant risk factor for dementia in oldest age. By
demonstrating that certain recognised dementia risk
factors are unchanged in oldest age, we can be more
confident in our findings that the risk associated with
other factors is changed in oldest age.
Contrary to much of the existing literature, no other
factor considered in this study was found to be associ-
ated with dementia. We should consider however, that
the prevalence of some conditions, including diabetes
and depression, in our cohort was low and as a result,
we were unlikely to detect anything except large effects,
higher than those estimated by meta-analyses. [6, 9].
Power calculations determined that with binary logistic
regression, setting alpha = 0.05 and the group sizes fixed
at n = 410 (participants without dementia) and n = 110
(participants with dementia) with a base proportion of
5.4% (as for diabetes prevalence) in the n = 410, a mini-
mum prevalence of 14.1% would be required in the
n = 110 to detect a statistical difference with 80.0%
power. Further investigation using case-control studies
or much larger cohort studies are therefore required.
Moreover, given n = 110 people with dementia, the
number of participants with each subtype of dementia
was too few for analysis by individual subtype: combin-
ing cases of different aetiology may have affected the
analysis. As previously noted, some of the data collected
relied on recollection by the participant and was there-
fore subject to potential variability in reporting. The
associations between our variables may also have af-
fected our analyses. We attempted to minimise this as
far as possible, but such bias could not be eliminated
without excluding important variables. By examining
many different possible predictors for dementia, in more
than one model, there is also the potential for false posi-
tive findings. We limited the number of models in our
analyses to two to reduce the chance of such false find-
ings insofar as possible. A valuable strength of the study
cohort is the presence of an intelligence test score from
age 11 [16, 18, 21]. Each participant also underwent
careful background assessment and thorough follow-up,
providing a wealth of longitudinal data for the assess-
ment of modifiable risk factors. The LBC1921 is a
narrow-age cohort comprising ethnically, geographically
and culturally homogenous participants, which means
that we can rule out a number of potential confounding
effects. Follow-up data were available for a satisfactory
proportion of the original cohort to allow for analyses. The
cohort demographics for those excluded from the analyses
were similar to those included and it can therefore be as-
sumed that the eligible cohort was a successful representa-
tion of the whole cohort. With a mean baseline MMSE of
28.1 (SD: 1.7) for those participants who subsequently de-
veloped dementia, we can be confident that we have identi-
fied truly incident, as opposed to prevalent, cases.
To assess the effectiveness of our dementia detection
methodology, we sought to compare the incidence rate
found against the rates determined by previous studies.
Without knowing the age at diagnosis for a high
proportion of dementia cases, the expected overall
incidence over the study period had to be estimated (see
Additional file 4). Had all cases of dementia been ascer-
tained, we would have expected approximately 166 cases
(see Additional file 5: Table S4). The 110 cases of demen-
tia detected in this study therefore equates to 66.2% of the
estimated number of cases arising over the same time
period. This proportion is fairly consistent with a 2012
study of dementia diagnosis rates, which found that,
within Lothian (the Health Board where the LBC1921 is
resident), 68.3% of the expected cases of dementia had
received a diagnosis [44]. We also sought to establish
whether cases identified as possible dementia would be
confirmed with additional follow-up. Of the 7 possible de-
mentia cases, 5 were deceased at the time of the consen-
sus meeting and no further follow-up could be completed.
Electronic hospital records for the 2 other cases were
accessed on 10th January 2017 and both contained evi-
dence from that confirmed a formal diagnosis of demen-
tia. It should be noted that neither case was seen for
clinical review by ourselves and we did not therefore influ-
ence the diagnosis having been made.
This study has demonstrated the benefits of using mul-
tiple data sources for ascertainment. Our study returned
the greatest number of cases from death certificates,
which identified 68.2% of all cases of probable dementia,
and 84.3% of all deceased participants with probable
dementia. This finding would be in line with a previous
Scottish study that found 71.5% of patients who die with
dementia have the diagnosis on their death certificate [45].
Death certificates as a source of data benefit from their
availability, but it is clear that the potential for missed
cases remains. Many published UK studies utilising
existing data for dementia ascertainment use only a single
data source [46, 47]. As is the case with any dementia
ascertainment procedure, the emphasis must be on
achieving the most accurate representation of dementia
incidence or prevalence within the population. Where
possible, we would recommend that future studies con-
sider inconsistencies between sources on a case-by-case
basis. If there is reliable and consistent evidence in one
source, the absence of a diagnosis in another source






should not be assumed to equate to an absence of the dis-
ease. Where there is contradictory evidence, of similar
weighting, from two or more sources, external evidence
can be sought to clarify the diagnosis. This may take the
form of a clinical review. Where no external evidence is
available or possible, cases with contradictory evidence
should be classified as possible cases and excluded from
the analyses due to the risk of misclassification. Using
existing data offers savings in terms of researcher and par-
ticipant time and the associated financial costs. This
method also allows for large population studies, where
clinical diagnostic work-up is not feasible due to scale.
Conclusions
In summary, the results of this study suggest that the
presence of an APOE ɛ4 allele is a risk factor for incident
dementia from age 79–95. A previous diagnosis of
hypertension and increasing height were found to reduce
the risk of incident dementia in the same age group.
Increased leisure-based physical activity in adulthood
was found to increase the risk for incident dementia, but
including this variable in the analyses reduced the study
sample size and we must therefore be cautious in draw-
ing inferences from this finding, particularly as it contra-
dicts previous studies. Our findings would support the
hypothesis that the risk profile for dementia alters with
age, however, further evidence would be required before
the risk profile for the ninth decade of life and beyond
could be accurately described.
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Additional file 1: Table S1. LBC1921 data variables for inclusion in analyses   
 
LBC 1921 Data Elements Selected for Inclusion  
Age- from birth to wave 1 testing  
Sex  
Age 11 IQ score (standardised)  
Interview/ questionnaire measures:  
Years in full-time, formal education- self reported at wave 1  
Self-reported history of diabetes- at wave 1  
Self-reported history of hypertension- at wave 1  
Statin use- at wave 1  
Self-reported smoking status- at wave 1  
Physical activity at age 20-35, 40-55 and 60-75- self-reported at wave 2  
Physical effort required in occupation- self-reported at wave 2  
Symptoms of depression (HADS depression score)- at wave 1  
Physical measures:  
Number of teeth remaining- at wave 1  
Height- at wave 1  
Body mass index (BMI)- at wave 1  
Sitting systolic & diastolic blood pressure- at wave 1  
Blood measures:  
Total serum cholesterol- at wave 1  
HbA1c- at wave 1  


















Additional file 2: Table S2. Logistic Regression Analysis with Physical Activity Age 
Groups 
  
  Odds Ratios (95% CI) for Probable Dementia  
  Model 3 (n=234)  
APOE ɛ4  2.20 (1.07. 4.53)  
Height (z score)  0.69 (0.48, 1.00)  
Hypertension  0.46 (0.22, 0.96)  
Current smoking  0.16 (0.02, 1.29)  
Physical activity, age 20-35 
years  
1.35 (1.06, 1.73)  
  
Note. The variables entered into the analyses were as follows: age, sex, APOE ɛ4 
carrier status, age 11 IQ (z score), number of teeth, height (z score), years in 
education, history of diabetes, HbA1c, history of hypertension, systolic blood 
pressure, diastolic blood pressure, cholesterol, use of statins, HADS depression 
score, BMI, smoking status, physical activity in occupation, physical activity at age 
20-35, physical activity at age 40-55, physical activity at age 60-75 (‘backward 






















Additional file 3: Table S3. Logistic Regression Analyses for Probable and Possible 
Dementia  
 
  Odds Ratios (95% CI) for Probable and Possible 
Dementia  
  Model 1 (n=237)  Model 2 (n=382)  
APOE e4     2.24 (1.32,3.78)  
Height*    0.74 (0.57,0.96)  
Education  0.86 (0.74,1.00)    
Hypertension  0.57 (0.29,1.12)    
BMI    0.95 (0.89,1.01)  
Current smoker  0.31 (0.07,1.43)  0.37 (0.11,1.26)  
Lifetime physical 
activity  
1.13 (1.01,1.25)  -  
  
Note. The variables entered into the analyses for each model were as follows: 
Model 1- age, sex, APOE ɛ4 carrier status, age 11 IQ (z score), number of teeth, 
height (z score), years in education, history of diabetes, HbA1c, history of 
hypertension, systolic blood pressure, diastolic blood pressure, cholesterol, use of 
statins, HADS depression score, BMI, smoking status, physical activity in 
occupation, lifetime physical activity (‘backward conditional’ method); Model 2- as 
model 1, but physical activity in occupation and lifetime physical activity excluded 




















Additional file 4  
  
Estimated dementia incidence  
A European meta-analysis described annual incidence rates of dementia of 1.6% in 
those aged 75-79 years, 3.1% in those aged 80-84 years, 4.9% in those aged 85-89 
and 7% in those aged 90 and over.[1] In order to formulate the estimate, our 
calculations needed to take into consideration the number of participants who died 
in the preceding year, and the cohort size adjusted accordingly. Participants with a 
diagnosis of dementia at death were not counted as ‘deaths’ as expected cases had 
already been excluded from calculations for the following year as a result of a 
positive diagnosis. Taking the above values as the expected annual incidence rates, 
we would expect that of our eligible cohort of 520 participants (excluding those 
identified as possible dementia), 169 participants would have developed dementia 
by the conclusion of our study (additional table 3).    
The 110 cases of dementia ascertained in this study therefore equates to 66.2% of 
the estimated number of cases arising over the same time period. Given that our 
ascertainment method primarily relied on diagnosed cases of dementia, it is useful 
to consider the proportion detected in the context of diagnostic rates for the region. 
A 2012 study of dementia prevalence and diagnosis rates found that within Lothian 
68.3% of the expected cases of dementia had received a diagnosis.[2] We can be 
confident in our assumption that not all cases of dementia are diagnosed in the 
community, as in our cohort, cases of previously undiagnosed dementia were 
identified on clinical review, following concerns raised at routine follow-up. Overall, it 
can be seen that the number of cases of dementia ascertained in this study 
corresponded fairly closely to the predicted number of diagnosed cases for the 
same cohort. With the number of cases detected falling below the total estimate of 
166.1, it is unlikely that our ascertainment method has falsely identified any 
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participants without dementia, as having dementia. We expected incidence to be 
lower in our cohort, than the rates described for the general population, as a result 
of higher IQ and generally good health at baseline. Conversely, these participants 
are motivated to take part in research and therefore may be more likely to be 
motivated to access health services. Further to this, undergoing regular cognitive 
testing may have highlighted any issues with memory that might not have been 
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2. Alzheimer's Society. Mapping the Dementia Gap 2012: Progress on 
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Sample size at 











79  520  1  519  1.6%  8.3  
80  510.7  4  506.7  3.1%  15.7  
81  491  20  471  3.1%  14.6  
82  456.4  22  434.4  3.1%  13.5  
83  420.9  17  403.9  3.1%  12.5  
84  391.4  26  365.4  3.1%  11.3  
85  354.1  28  326.1  4.9%  16.0  
86  310.1  24  286.1  4.9%  14.0  
87  272.1  28  244.1  4.9%  12.0  
88  232.1  22  210.1  4.9%  10.3  
89  199.8  33  166.8  4.9%  8.2  
90  158.6  20  138.6  7%  9.7  
91  128.9  25  103.9  7%  7.3  
92  96.6  20  76.6  7%  5.4  
93  71.2  17  54.2  7%  3.8  
94  50.4  15  35.4  7%  2.5  
95   32.9  4  28.9  7%  2  
(*deduct 1)  
          Total= 166.1  
(*Less than half of the year studied, therefore 1 expected case from 2 was deducted 



















We contributed a paper on potential risk factors for dementia in the ninth decade of 
life and beyond.(Sibbett et al., 2017) Here we report some changes to the results 
owing to our having discovered that we did not have complete follow-up data for 31 
participants who were included in our original analyses (5.9% of our previously 
described eligible cohort). In view of this, we cannot be completely certain that these 
participants had not developed dementia and we have therefore repeated our 
analyses following the exclusion of these participants. The changes observed in the 
main findings are relatively minor. Dementia incidence in the cohort was only very 
slightly increased from that quoted in the original paper (22.5%). The proportion of 
expected cases identified was greater (73%). The main logistic analyses in the 
original analyses (models 1 and 2) demonstrated significant relationships with 
dementia for four variables: APOE ɛ4, height, history of hypertension and lifetime 
physical activity. In the updated main analyses, significant associations with 
dementia were observed for the same four variables with minimal changes in odds 
ratios. We also found an additional significant association between use of statin 
medication and increased risk for dementia, which we consider should be treated 
with caution given that it emerges with a minor decrease in the analytic sample.    
For clarity we detail the resulting changes in our main findings in updates of Tables 









 Tables:  
Table 2 (updated): Descriptive statistics for those included & excluded from the 
study  




from study  
(n=54)  
Deceased  
Living   
Deceased  
  
71 (14.3%)  
425 (85.7%)  
  
36 (75.0%)  





211 (42.5%)  
285 (57.5%)  
  
23 (42.6%)  
31 (57.4%)  
Age at wave 1  
Mean age in years  
  
79.1 (SD: 0.6)  
  
79.1 (SD: 0.5)  
APOE ɛ4 carrier status  
Carrier  
Not carrier  
Data missing  
  
132 (26.6%)  
358 (72.2%)  
6 (1.2%)  
  
14 (25.9%)  
39 (72.2%)  
1 (1.9%)  
Age 11 IQ  
Data available  
Data missing  
Mean age 11 IQ  
  
447 (90.1%)  
49 (9.9%)  
100.3 (SD: 14.9)  
  
46 (85.2%)  
8 (14.8%)  
97.3 (SD: 16.2)  
MMSE  
Data available  
Data missing  
Mean MMSE   
  
496 (100%)  
-  
28.3 (SD: 1.5)  
  
52 (96.3%)  
2 (3.7%)  





















Table 3 (updated): Univariate analyses: comparisons between groups with and 
without probable dementia  
Variable  
  





Group Comparison  
p value  
(chi-square or t-test)  
Age at wave 1   
-mean age in years (SD)  
n=379  
79.1 (0.6)  
n=110  











APOE ɛ4 carrier statusa  







Age 11 IQ 
(standardised)  
-mean score (SD)  
n=339  
100.2 (14.5)  
n=102  




-mean number of teeth 
(SD)  
n=379  
9.1 (9.3)  
n=110  
9.6 (8.9)  
  
0.635  
Height   
-mean height in cm (SD)  
n=378  
163.6 (9.5)  
n=107  
162.1 (9.2)  
  
0.140  
Formal education   
-mean number of years 
(SD)  
n=378  
10.9 (2.4)  
n=109  
11.0 (2.7)  
  
0.736  
History of diabetes  








-mean HbA1c (SD)  
n=329  
5.7 (0.8)  
n=98  




hypertension   









-mean BP in mmHg 
(SD)  
n=377  
168.6 (27.4)  
n=109  





-mean BP in mmHg 
(SD)  
n=377  
83.0 (13.4)  
n=109  
81.8 (12.3)  
  
0.401  
Statin use  








cholesterol   
-mean (SD)  
n=371  
5.6 (1.1)  
n=105  
5.6 (1.1)  
  
0.983  
Depression (HADS)  n=378  n=109    
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-mean depression score 
(SD)  
3.6 (2.3)  3.5 (2.4)  0.983  
BMI  
-mean kg/m2 (SD)  
n=378  
26.5 (4.2)  
n=107  
25.4 (4.0)  
  
0.027  
Smoking status  









-mean total lifetime score 
(SD)  
n=251  
8.7 (3.0)  
n=74  
9.5 (3.0)  
  
0.045  
Physical effort required 
in occupation  
-mean score (SD)  
n=229  
2.1 (0.8)  
n=69  




aOne or more alleles  





































Table 4 (updated): Logistic Regression Results 
  
  Odds Ratios (95% CI) for Probable Dementia  
  Model 1 (n=221)  Model 2 (n=355)  
APOE ɛ4  -  2.23 (1.29,3.86)  
Height (z score)  -  0.72 (0.55, 0.95)  
Hypertension  0.47 (0.23,0.98)  0.63 (0.36,1.08)  
Current smoking  0.14 (0.02, 1.17)  0.24 (0.05, 1.05)  
Lifetime physical activity  1.17 (1.04,1.32)  -  
Statin use  3.39 (1.04,11.02)  -  
Years in education  0.86 (0.73, 1.01)  -  
  
The variables entered into the analyses for each model were as follows: Model 1- 
age, sex, APOE ɛ4 carrier status, age 11 IQ (z score), number of teeth, height (z 
score), years in education, history of diabetes, HbA1c, history of hypertension, 
systolic blood pressure, diastolic blood pressure, cholesterol, use of statins, HADS 
depression score, BMI, smoking status, physical activity in occupation, lifetime 
physical activity (‘backward conditional’ method); Model 2- as model 1, but physical 































Additional Table S2 (updated): Logistic Regression Analysis with Physical Activity 
Age Groups  
  Odds Ratios (95% CI) for Probable Dementia  
  Model 3 (n=221)  
Years in education  0.86 (0.73, 1.01)  
Statin use  3.16 (0.98, 10.16)  
Hypertension  0.46 (0.22, 0.96)  
Current smoking  0.13 (0.02, 1.08)  
Physical activity, age 40-55 
years  
1.52 (1.12, 2.06)  
  
Note. The variables entered into the analyses were as follows: age, sex, APOE ɛ4 
carrier status, age 11 IQ (z score), number of teeth, height (z score), years in 
education, history of diabetes, HbA1c, history of hypertension, systolic blood 
pressure, diastolic blood pressure, cholesterol, use of statins, HADS depression 
score, BMI, smoking status, physical activity in occupation, physical activity at age 
20-35, physical activity at age 40-55, physical activity at age 60-75 (‘backward 






























Additional Table S3 (updated): Logistic Regression Analyses for Probable and 
Possible Dementia  
  Odds Ratios (95% CI) for Probable and Possible 
Dementia  
  Model 1 (n=227)  Model 2 (n=366)  
APOE ɛ4  -  2.18 (1.28, 3.70)  
Height (z score)  -  0.73 (0.56, 0.96)  
Statin use  3.09 (0.97, 9.92)  -  
Years in education  0.86 (0.74, 1.01)  -  
Hypertension  0.54 (0.27,1.09)  -  
BMI  -  0.94 (0.89, 1.01)  
Current smoking  0.29 (0.06, 1.39)  0.36 (0.10, 1.26)  
Lifetime physical activity  1.16 (1.03, 1.30)  -  
  
Note. The variables entered into the analyses for each model were as follows: 
Model 1- age, sex, APOE ɛ4 carrier status, age 11 IQ (z score), number of teeth, 
height (z score), years in education, history of diabetes, HbA1c, history of 
hypertension, systolic blood pressure, diastolic blood pressure, cholesterol, use of 
statins, HADS depression score, BMI, smoking status, physical activity in 
occupation, lifetime physical activity (‘backward conditional’ method); Model 2- as 
model 1, but physical activity in occupation and lifetime physical activity excluded 




































Sample size at 











79  489  1  488  1.6%  7.8  
80  480.2  4  476.2  3.1%  14.8  
81  461.4  20  441.4  3.1%  13.7  
82  427.7  22  405.7  3.1%  12.6  
83  393.1  17  376.1  3.1%  11.7  
84  364.4  26  338.4  3.1%  10.5  
85  327.9  28  299.9  4.9%  14.7  
86  285.2  24  261.2  4.9%  12.8  
87  248.4  28  220.4  4.9%  10.8  
88  209.6  22  187.6  4.9%  9.2  
89  178.4  33  145.4  4.9%  7.1  
90  138.3  20  118.3  7%  8.3  
91  110  25  85  7%  6  
92  79  20  59  7%  4.1  
93  54.9  17  37.9  7%  2.7  
94  35.2  15  20.2  7%  1.4  
95   18.8  4  14.8  7%  1  
(*deduct 0.5)  
          Total= 148.7  
  
(*Less than half of the year studied, therefore 0.5 expected cases from 1 was 

























1.Sibbett RA, Russ TC, Deary IJ, Starr JM: Risk factors for dementia in the ninth 
decade of life and beyond: a study of the Lothian birth cohort 1921. 


































Additional file 1: Table S4.1. LBC1921 data variables for inclusion in analyses   
 
LBC 1921 Data Elements Selected for Inclusion  
Age- from birth to wave 1 testing  
Sex  
Age 11 IQ score (standardised)  
Interview/ questionnaire measures:  
Years in full-time, formal education- self reported at wave 1  
Self-reported history of diabetes- at wave 1  
Self-reported history of hypertension- at wave 1  
Statin use- at wave 1  
Self-reported smoking status- at wave 1  
Physical activity at age 20-35, 40-55 and 60-75- self-reported at wave 2  
Physical effort required in occupation- self-reported at wave 2  
Symptoms of depression (HADS depression score)- at wave 1  
Physical measures:  
Number of teeth remaining- at wave 1  
Height- at wave 1  
Body mass index (BMI)- at wave 1  
Sitting systolic & diastolic blood pressure- at wave 1  
Blood measures:  
Total serum cholesterol- at wave 1  
HbA1c- at wave 1  

















Additional file 2: Table S4.2 (updated): Logistic Regression Analysis with Physical 
Activity Age Groups  
 
  Odds Ratios (95% CI) for Probable Dementia  
  Model 3 (n=221)  
Years in education  0.86 (0.73, 1.01)  
Statin use  3.16 (0.98, 10.16)  
Hypertension  0.46 (0.22, 0.96)  
Current smoking  0.13 (0.02, 1.08)  
Physical activity, age 40-55 
years  
1.52 (1.12, 2.06)  
  
Note. The variables entered into the analyses were as follows: age, sex, APOE ɛ4 
carrier status, age 11 IQ (z score), number of teeth, height (z score), years in 
education, history of diabetes, HbA1c, history of hypertension, systolic blood 
pressure, diastolic blood pressure, cholesterol, use of statins, HADS depression 
score, BMI, smoking status, physical activity in occupation, physical activity at age 
20-35, physical activity at age 40-55, physical activity at age 60-75 (‘backward 




















Additional file 3: Table S4.3 (updated): Logistic Regression Analyses for Probable 
and Possible Dementia  
  Odds Ratios (95% CI) for Probable and Possible 
Dementia  
  Model 1 (n=227)  Model 2 (n=366)  
APOE ɛ4  -  2.18 (1.28, 3.70)  
Height (z score)  -  0.73 (0.56, 0.96)  
Statin use  3.09 (0.97, 9.92)  -  
Years in education  0.86 (0.74, 1.01)  -  
Hypertension  0.54 (0.27,1.09)  -  
BMI  -  0.94 (0.89, 1.01)  
Current smoking  0.29 (0.06, 1.39)  0.36 (0.10, 1.26)  
Lifetime physical activity  1.16 (1.03, 1.30)  -  
  
Note. The variables entered into the analyses for each model were as follows: 
Model 1- age, sex, APOE ɛ4 carrier status, age 11 IQ (z score), number of teeth, 
height (z score), years in education, history of diabetes, HbA1c, history of 
hypertension, systolic blood pressure, diastolic blood pressure, cholesterol, use of 
statins, HADS depression score, BMI, smoking status, physical activity in 
occupation, lifetime physical activity (‘backward conditional’ method); Model 2- as 
model 1, but physical activity in occupation and lifetime physical activity excluded 

















Additional file 4  
  
 
Estimated dementia incidence  
A European meta-analysis described annual incidence rates of dementia of 1.6% in 
those aged 75-79 years, 3.1% in those aged 80-84 years, 4.9% in those aged 85-89 
and 7% in those aged 90 and over.[1] In order to formulate the estimate, our 
calculations needed to take into consideration the number of participants who died 
in the preceding year, and the cohort size adjusted accordingly. Participants with a 
diagnosis of dementia at death were not counted as ‘deaths’ as expected cases had 
already been excluded from calculations for the following year as a result of a 
positive diagnosis. Taking the above values as the expected annual incidence rates, 
we would expect that of our eligible cohort of 489 participants (excluding those 
identified as possible dementia), 148.7 participants would have developed dementia 
by the conclusion of our study (additional table S4.4).    
The 110 cases of dementia ascertained in this study therefore equates to 74% of 
the estimated number of cases arising over the same time period. Given that our 
ascertainment method primarily relied on diagnosed cases of dementia, it is useful 
to consider the proportion detected in the context of diagnostic rates for the region. 
A 2012 study of dementia prevalence and diagnosis rates found that within Lothian 
68.3% of the expected cases of dementia had received a diagnosis.[2] We can be 
confident in our assumption that not all cases of dementia are diagnosed in the 
community, as in our cohort, cases of previously undiagnosed dementia were 
identified on clinical review, following concerns raised at routine follow-up. Overall, it 
can be seen that the number of cases of dementia ascertained in this study 
corresponded fairly closely to the predicted number of diagnosed cases for the 
same cohort. With the number of cases detected falling below the total estimate of 
148.7, it is unlikely that our ascertainment method has falsely identified any 
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participants without dementia, as having dementia. We expected incidence to be 
lower in our cohort, than the rates described for the general population, as a result 
of higher IQ and generally good health at baseline. Conversely, these participants 
are motivated to take part in research and therefore may be more likely to be 
motivated to access health services. Further to this, undergoing regular cognitive 
testing may have highlighted any issues with memory that might not have been 
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Sample size at 











79  489  1  488  1.6%  7.8  
80  480.2  4  476.2  3.1%  14.8  
81  461.4  20  441.4  3.1%  13.7  
82  427.7  22  405.7  3.1%  12.6  
83  393.1  17  376.1  3.1%  11.7  
84  364.4  26  338.4  3.1%  10.5  
85  327.9  28  299.9  4.9%  14.7  
86  285.2  24  261.2  4.9%  12.8  
87  248.4  28  220.4  4.9%  10.8  
88  209.6  22  187.6  4.9%  9.2  
89  178.4  33  145.4  4.9%  7.1  
90  138.3  20  118.3  7%  8.3  
91  110  25  85  7%  6  
92  79  20  59  7%  4.1  
93  54.9  17  37.9  7%  2.7  
94  35.2  15  20.2  7%  1.4  
95   18.8  4  14.8  7%  1  
(*deduct 0.5)  
          Total= 148.7  
  
(*Less than half of the year studied, therefore 0.5 expected cases from 1 was 













Appendix 3. Supplementary material to Section 5.2  
  
Supplementary material for:  
Sibbett, RA et al. Physical fitness and dementia risk in the very old: a study of the 
Lothian Birth Cohort 1921. BMC Psychiatry 2017.  
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Additional file 1: Table S1. Group Comparison: Deceased and Living  
 







  Deceased  
(n=419)  
Not Deceased  
(n=69)  
Age  
-mean age in years (SD)  
n=419  
79.07 (0.59)  
n=379  
79.12 (0.58)  
  
0.51  
Dementia or no dementia  








-Mean height in cm (SD)  
n=415  
163.29 (9.30)  
n=69  
163.13 (10.08)  
  
0.90  
APOE ɛ4 carrier status  







Age 11 IQ (standardised)  
-Mean score (SD)  
n=381  
99.77 (15.18)  
n=59  




-mean rate in litres per second 
(SD)  
n=415  
1.84 (0.62)  
n=69  
2.03 (0.59)  
  
0.02  
Grip strength  
-mean strength in kilograms 
(SD)  
n=415  
26.26 (9.10)  
n=69  
26.75 (9.59)  
  
0.68  
6 metre walk time  
-mean time in seconds (SD)  
n=413  
4.88 (2.10)  
n=69  
4.21 (1.10)  
  
0.01  
Smoking status  







History of cardiovascular or 
cerebrovascular disease  







History of hypertension  







History of diabetes  
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Additional file 1: Figure S1. ICD-9 and ICD-10 codes relevant to dementia 
ascertainment   
 
ICD-9 Codes  
  
046.1 Creutzfeldt-Jakob disease  
290.0 Senile dementia, simple type  
290.1 Presenile dementia  
290.2 Senile dementia, depressed or 
paranoid type  
290.3 Senile dementia with acute 
confusional state  
290.4 Arteriosclerotic dementia  
290.8 Other senile and presenile organic 
psychotic conditions  
290.9 Unspecified senile and presenile 
organic psychotic conditions  
291.2 Other alcoholic dementia  
292.82 Drug induced persisting 
dementia  
294.0 Korsakov’s psychosis, alcoholic  
294.1 Dementia in conditions classified 
elsewhere  
294.8 Other organic psychotic conditions: 
Other  
294.9 Other organic psychotic conditions: 
Unspecified  
331.0 Alzheimer’s disease  
331.1 Pick’s disease  
331.2 Senile degeneration of the brain  
331.82 Dementia: Lewy body  
333.4 Huntington’s chorea  
797 Senility without mention of 
psychosis  
ICD-10 Codes  
  
F00 Dementia in Alzheimer’s disease  
F01 Vascular dementia  
F01.1 Multi-infarct dementia  
F02 Dementia in diseases classified 
elsewhere  
F02.0 Dementia in Pick’s disease  
F02.1 Dementia in Creutzfeldt-Jakob 
disease  
F02.2 Dementia in Huntington’s disease  
F02.3 Dementia in Parkinson’s disease  
F02.4 Dementia in HIV  
F03 Unspecified dementia  
F05.1 Delirium superimposed on 
dementia  
F06.7 Mild cognitive disorder  
G30 Alzheimer disease  
G30.0 Alzheimer disease with early onset  
G30.1 Alzheimer disease with late onset  
G30.8 Other Alzheimer disease  
G30.9 Alzheimer disease, unspecified  
G31.0 Circumscribed brain atrophy: 
Frontotemporal dementia, Pick disease, 
progressive isolated aphasia  
G31.1 Senile degeneration of the brain 
not classified elsewhere  
G31.8 Other specified degenerative 
diseases of nervous system: Grey-matter 
degeneration, Lewy 
body(dies)(dementia)(disease), subacute 
necrotising encephalopathy  







Additional file 2: Table S1: Logistic Regression Analyses Results for EEAA, IEAA, AgeAccelPheno and AgeAccelGrim  
 
  Odds Ratios (95% Confidence Interval)   
for Probable Dementia  
  Results for EEAA  Results for IEAA  Results for AgeAccelPheno  Results for AgeAccelGrim  
  Model 2  
(n=383)  
Model 3  
(n=382)  
Model 4  
(n=371)  
Model 2  
(n=383)  
Model 3  
(n=382)  
Model 4  
(n=371)  
Model 2  
(n=383)  
Model 3  
(n=382)  
Model 4  
(n=371)  
Model 2  
(n=383)  
Model 3  
(n=382)  
Model 4  
(n=371)  




























































































































-  -  0.01  
(-0.07, 
0.10)  
-  -  0.04  
(-0.03, 
0.12)  
-  -  0.06  
(-0.08, 
0.20)  
-  -  


























-  -  -0.43  
(-0.99, 
0.10)  
-  -  -0.42  
(-0.97, 
0.12)  
-  -  -0.42  
(-0.98, 
0.11)  





History of diabetes  -  -  0.31  
(-1.02, 
1.44)  
-  -  0.31  
(-1.02, 
1.43)  
-  -  0.31  
(-1.02, 
1.44)  







-  -  -0.33  
(-0.95, 
0.26)  
-  -  -0.34  
(-0.96, 
0.25)  
-  -  -0.33  
(-0.95, 
0.26)  






Additional file 3: Table S2.  Competing risk regression models for components of AgeAccelGrim  
 
  Component of AgeAccelGrim  
  DNAm ADM  DNAm B2M  DNAm 
CystatinC  





(0.98, 1.00)  
1.00  
(1.00, 1.00)  
1.00  
(1.00, 1.00)  
1.00  
(1.00, 1.00)  
1.00  
(1.00, 1.00)  
1.00  
(1.00, 1.00)  
1.00  
(1.00, 1.00)  
0.97  
(0.95, 0.99)  
Sex   
(female)  
1.33  
(0.82, 2.16)  
1.10  
(0.72, 1.70)  
1.07  
(0.68, 1.69)  
1.07  
(0.69, 1.66)  
0.86  
(0.39, 1.89)  
1.13  
(0.72, 1.77)  
1.04  
(0.67, 1.61)  
0.94  
(0.60, 1.47)  
APOE ɛ4   
(non-carrier)  
0.43  
(0.28, 0.65)  
0.43  
(0.28, 0.65)  
0.43  
(0.28, 0.66)  
0.44  
(0.29, 0.67)  
0.43  
(0.28, 0.66)  
0.43  
(0.28, 0.65)  
0.44  
(0.29, 0.67)  
0.46  















Additional file 4: Table S3. Logistic regression models for components of AgeAccelGrim  
  
  Component of AgeAccelGrim  
  DNAm ADM  
  















(-0.02, 0.00)  
-1.39  
(-3.85, 9.33)  
-6.94  
(-1.80, 3.44)  
-0.00  
(-0.00, 0.00)  
3.88  
(-6.45, 0.00)  
1.39  
(-1.94, 2.09)  
-0.00  
(-0.00, 0.00)  
-0.04  
(-0.06, -0.01)  
Sex   
(female)  
0.29  
(-0.27, 0.86)  
7.11  
(-4.26, 5.79)  
3.54  
(-4.67, 5.47)  
0.03  
(-0.47, 0.54)  
-1.95  
(-1.07, 0.68)  
9.58  
(-0.42, 0.62)  
-0.03  
(-0.54, 0.49)  
-0.12  
(-0.64, 0.41)  
APOE ɛ4   
(non-carrier)  
-0.97  
(-1.48, -0.46)  
-9.69  
(-1.47, -4.63)  
-9.70  
(-1.48, -4.64)  
-0.95  
(-1.45, -0.44)  
-9.58  
(-1.46, -0.45)  
-9.71  
(-1.48, -0.47)  
-0.96  
(-1.46, -0.45)  
-0.89  
(-1.40, -0.38)  
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Additional file 5: Table S4. Pearson correlations for epigenetic age acceleration 
measures in LBC1921  
 
  IEAA  EEAA  AgeAccelGrim  AgeAccelPheno  
IEAA  1  0.394*  0.259*  0.403*  
EEAA  0.394*  1  0.439*  0.424*  
AgeAccelGrim  0.259*  0.439*  1  0.416*  
AgeAccelPheno  0.403*  0.424*  0.416*  1  
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Supplementary File A: Supplementary Tables  
  
Note: This supplementary file contains seven tables that display the complete 
results for each main analysis, as described in the main text.  
  
Table S1. Main Analysis and Terminal Decline Analysis Results for APOE ɛ4 (paper 
1)  
  
  Main Sensitivity Results  Terminal Decline Results  
  F  Significance  Effect 
Size   
(ƞp2)  
F  Significance  Effect 
Size   
(ƞp2)  
Age 11 IQ  239.4  <0.001  0.40  200.47  <0.001  0.396  
Sex  4.76  0.03  0.013  2.63  0.106  0.009  
APOE ɛ4  4.27  0.039  0.012  1.30  0.255  0.004  
APOE 
ɛ4*Sex  





























    Main Sensitivity Results  Terminal Decline Results  
  Dependent Variable  F  Significance  Effect Size 
(ƞp2)  




Verbal Fluency score- age 79  0.19  0.664  0.001  0.59  0.443  0.002  
Ravens Matrices score- age 
79  
3.57  0.060  0.010  1.89  0.170  0.006  
Logical Memory score- age 79  8.16  0.005  0.022  2.95  0.087  0.010  
Sex  
Verbal Fluency score- age 79  0.52  0.470  0.001  0.04  0.845  <0.001  
Ravens Matrices score- age 
79  
10.92  0.001  0.030  2.41  0.122  0.008  
Logical Memory score- age 79  1.23  0.268  0.003  3.20  0.075  0.010  
Age 11 IQ  
Verbal Fluency score- age 79  26.49  <0.001  0.069  21.62  <0.001  0.066  
Ravens Matrices score- age 
79  
85.49  <0.001  0.194  69.31  <0.001  0.186  





Table S3. Main Analysis and Terminal Decline Analysis Results for Smoking  
  
  Main Sensitivity Results  Terminal Decline Results  
  F  Significance  Effect 
Size   
(ƞp2)  
F  Significance  Effect 
Size   
(ƞp2)  
Age 11 IQ  231.09  <0.001  0.391  191.49  <0.001  0.383  
Sex  3.12  0.078  0.009  1.89  0.170  0.006  
Smoker  3.67  0.026  0.020  1.97  0.141  0.013  







































Table S4. Main Analysis and Terminal Decline Analysis Results for Vitamin B-12  
 
  
    Main Sensitivity Results  Terminal Decline Results  




Significance  Beta  Beta SE  Standardised 
Beta  
Significance  
Model 1  
Age 11 IQ  0.585  0.045  0.584  <0.001  -  -  -  -  
B-12*  1.771  0.642  0.124  0.006  -  -  -  -  
Model 2  
Age 11 IQ  0.612  0.045  0.611  <0.001  0.569  0.046  0.609  <0.001  
Sex  -3.257  1.272  -0.115  0.011  -2.825  1.285  -0.108  0.029  
APOE ɛ4 status  1.884  1.505  0.056  0.211  0.394  1.553  0.012  0.800  
Smoking status  1.428  0.995  0.065  0.152  1.220  1.022  0.059  0.234  
Statin use  4.238  2.517  0.080  0.093  3.513  2.599  0.070  0.178  
Total number of 
drugs  
-0.947  0.281  -0.159  0.001  -1.072  0.284  -0.194  <0.001  
B-12*  1.535  0.624  0.110  0.014  1.127  0.631  0.087  0.075  
  






Table S5. Main Analysis and Terminal Decline Analysis Results for Physical Fitness  
 
  Main Sensitivity Results  Terminal Decline Results  
  R
2 




Beta  Significance  
R2 




Beta  Significance  
Age 11 
IQ  0.383  0.549  0.042  0.559  <0.001  0.385  0.534  0.044  0.558  <0.001  
Fitness 
trait  0.047  2.976  0.559  0.209  <0.001  0.048  2.851  0.602  0.203  <0.001  
Social 
class  0.18  
-
2.285  0.726  -0.136  0.002  0.013  
-
1.913  0.763  -0.116  0.013  
Sex  
0.08  -
2.535  1.135  -0.088  0.026  0.007  
-
2.335  1.170  -0.085  0.047  
  
  
Note. Smoking status and APOE ɛ4 carrier status did not enter the model (p>0.05).  
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Table S6. Multivariable Linear Regression Results: All main variables and Age 79 IQ 
Scores  
  
  R2 change  Beta  Beta SE  Standardised Beta  Significance  
Age 11 IQ  0.342  0.562  0.043  0.563  <0.001  
Fitness trait  0.058  3.658  0.620  0.255  <0.001  
Vitamin B-12*  0.021  2.507  0.735  0.147  0.001  
Sex  0.013  -3.284  1.226  -0.115  0.008  
Note. *Vitamin B-12 standardised as z-scores. Smoking status and APOE ɛ4 carrier 









































Table S7. Multivariate General Linear Modelling Results: All Main Variables and 
Verbal Fluency, Raven’s Matrices and Logical Memory Test Scores  
 




Verbal Fluency score- age 
79  
0.44  0.506  0.001  
Ravens Matrices score – age 
79  
1.85  0.175  0.006  
Logical Memory score- age 
79  
5.47  0.020  0.018  
Sex  
Verbal Fluency score- age 
79  
0.32  0.575  0.001  
Ravens Matrices score – age 
79  
13.27  <0.001  0.042  
Logical Memory score- age 
79  
1.15  0.284  0.004  
Age 11 IQ  
Verbal Fluency score- age 
79  
18.96  <0.001  0.059  
Ravens Matrices score – age 
79  
66.79  <0.001  0.182  
Logical Memory score- age 
79  
21.35  <0.001  0.066  
Smoking 
Status  
Verbal Fluency score- age 
79  
0.50  0.609  0.003  
Ravens Matrices score – age 
79  
0.84  0.432  0.006  
Logical Memory score- age 
79  
0.48  0.617  0.003  
Vitamin B-12*  
Verbal Fluency score- age 
79  
0.38  0.539  0.001  
Ravens Matrices score – age 
79  
3.82  0.052  0.013  
Logical Memory score- age 
79  
0.878  0.349  0.003  
Fitness  
Verbal Fluency score- age 
79  
12.28  0.001  0.039  
Ravens Matrices score – age 
79  
17.98  <0.001  0.056  
Logical Memory score- age 
79  
0.24  0.627  0.001  
  
Note. *Vitamin B-12 standardised as z-scores   
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  Supplementary File B: Risk Factor and Dementia Interactions  
 
Following each of the main individual analyses, we completed a subsequent 
analysis in which participants with probable dementia or no dementia were included. 
We excluded participants with possible dementia. Forming a between-groups 
variable (dementia or no dementia), we included an interaction term with the risk 
factor (e.g. dementia status*smoking status) to determine whether the effect of the 
risk factor varied as a function of the dementia group.  
APOE ɛ4 Paper 1: Moray House Test (MHT) score as outcome.(Ian J. Deary et al., 
2002)   
When we included those participants without dementia (n=363) and those with 
probable dementia (n=101)—a future diagnosis of probable dementia was 
associated with a lower standardised MHT score at age 79 (F1,456=8.13, p=0.005, 
ƞp2=0.018). The APOE ɛ4 carrier status by dementia status interaction was not 
significant (F1,456=1.10, p=0.30, ƞp2=0.002), demonstrating that the effect of APOE ɛ4 
was not significantly different between the two dementia groups. The mean MHT 
score (standardised) at age 79 (95% CI) for APOE ɛ4 carriers was 96.47 (92.88, 
100.06) for those with dementia and 98.89 (96.43, 101.35) for those without 
dementia. The mean MHT score at age 79 for APOE ɛ4 non-carriers was 96.48 
(93.70, 99.27) for those with dementia and 101.73 (100.43, 103.03) for those 
without dementia.  
APOE ɛ4 Paper 2: Logical Memory, Raven’s Matrices, and verbal fluency as 
outcomes.(I. Deary, Whiteman, Pattie, & Starr, 2004)  
When the analysis was repeated with the inclusion of probable dementia cases, a 
future diagnosis of dementia was found to contribute to Raven’s Matrices (F1,454= 
8.24, p=0.004, ƞp2 =0.018) and Logical Memory test scores (F1,454= 5.65, p=0.018, ƞp2 
=0.012) at age 79. The APOE ɛ4 carrier status by dementia status interaction was 
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associated with Raven’s Matrices test score at age 79 (F1,454= 7.75, p=0.006, ƞp2 
=0.017) but not Logical Memory (F1,454=0.49, p=0.484, ƞp2 =0.001) or Verbal Fluency 
test scores (F1,454= 0.20, p=0.66, ƞp2=<0.001). The effect of APOE ɛ4 on Raven’s 
Matrices test score was therefore different between those who developed dementia 
and those who did not, but no difference was noted for Logical Memory or Verbal 
Fluency. The mean (95% CI) Raven’s Matrices test score for APOE ɛ4 carriers was 
30.84 (29.19, 32.49) for those without dementia and 30.79 (28.45, 33.12) for those 
who developed dementia. For noncarriers, the mean test score was 32.65 (31.77, 
33.53) for those without dementia and 27.58 (25.71, 29.45) for those who developed 
dementia.  
Smoking  
Repeating the main analysis with the inclusion of participants who developed 
probable dementia (n=100) and participants who remained dementia free (n=367), 
we found that dementia was associated with age 79 IQ (F1,457=6.60, p=0.01, ƞp2 
=0.014). The smoking status by dementia status interaction was not associated with 
age 79 IQ (F2,457=0.513, p=0.599, ƞp2 =0.002). The effect of smoking was not 
therefore significantly different between the dementia groups. For those without 
dementia, the estimated marginal mean scores (95% CI) were 96.25 (92.24, 100.25) 
for current smokers, 101.28 (99.72, 102.85) for ex-smokers and 102.29 (100.43, 
104.14) for never-smokers. For those who developed probable dementia, the mean 
scores were 87.40 (74.87, 99.24) for current smokers, 97.61 (94.28, 100.93) for ex-
smokers and 96.53 (93.51, 99.54) for never-smokers.  
Vitamin B-12   
When we include only those participants with probable dementia (n=101) or no 
dementia (n=367), there was no significant association between the interaction term 
(dementia and vitamin B-12) and age 79 IQ (Sβ=-0.030, p=0.463). Future probable 
dementia was shown to be associated with age 79 IQ (Sβ=-0.141, p<0.001).  
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Physical Fitness  
Including in the analysis only those with probable dementia (n=97) or no dementia 
(n=359) – the interaction variable between dementia and fitness did not enter the 
model (p>0.05). Future probable dementia was again associated with age 79 IQ 
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Appendix 6. Abbreviations 
 
 
£   Pound Sterling 
AD   Alzheimer’s Disease  
ADM   Adrenomedullin 
AgeAccelGrim  Age acceleration measure based on GrimAge procedure  
AgeAccelPheno Age acceleration measure based on PhenoAge procedure  
APA   American Psychiatric Association  
APOE   Apolipoprotein E  
APP   Amyloid precursor protein  
B2M   Beta-2 microglobulin 
BBC   British Broadcasting Corporation 
BBSRC  UK Biotechnology and Biological Sciences Research Council 
BMI   Body mass index  
BP   Blood Pressure 
CC75C  Cambridge City over-75s Cohort  
CHI   Community health index  
CpG   Cytosine and guanine separated by only one phosphate 
group  
CPRD   Clinical Practice Research Database 
CRR   Competing risk regression 
CSF   Cerebrospinal fluid  
CSO   Chief Scientist Office 
DBP   Diastolic blood pressure 
DNA   Deoxyribonucleic Acid  
DNAm   DNA methylation  
DNAm GrimAge A DNA methylation-based measure of epigenetic age  
DNAm PhenoAge A DNA methylation-based measure of epigenetic age  
DSM   Diagnostic and Statistical Manual of Mental Disorders  
DSM-V  Diagnostic and Statistical Manual of Mental Disorders- version 
5 
EEAA   Extrinsic epigenetic age acceleration  
FEV1   Forced expiratory volume in 1 second  




GPRD   General Practice Research Database 
HAA   Hospital Activity Analysis 
HADS   Hospital anxiety and depression scale  
HDRUK  Health Data Research United Kingdom  
HR   Hazard Ratio  
ICD   International Classification of Diseases  
ICD 9 or 10  International Classification of Diseases version 9 or 10  
IEAA   Intrinsic epigenetic age acceleration  
IQ   Intelligence quotient  
ISD   Information Services Division 
LBC1921  Lothian Birth Cohort 1921  
LPA   Lasting Power of Attorney  
MCI   Mild cognitive impairment 
MMSE   Mini-Mental State Examination  
MHE   Mental Health Enquiry 
MHT   Moray House Test  
MRC   Medical Research Council UK 
MRC CFAS  Medical Research Council Cognitive Function and Ageing 
Study  
NHS   National Health Service  
NICE   National Institute of Clinical Excellence 
NINCDS-ADRDA National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association 
NINDS-AIREN National Institute of Neurological and Communicative 
Disorders and Stroke and Association pour la Recherché at 
l’Enseignement en Neurosciences 
NLSAA Nottingham Longitudinal Study of Activity and Ageing 
ONS Office for National Statistics 
OR   Odds Ratio  
PACKYRS  Smoking pack years 
PAI-1   Plasma activator-inhibitor 1 
PCR   Polymerase chain reaction  
PET   Positron emission tomography (scan) 
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PiMS Patient Information Management System (electronic patient 
record system)  
SBP Systolic blood pressure 
SD Standard deviation  
SIGN Scottish Intercollegiate Guidelines Network 
SMS1932 Scottish Mental Surveys 1932  
SPICE-PC Scottish Programme for Improving Clinical Effectiveness – 
Primary Care 
THIN The Health Improvement Network 
TIMP-1  Tissue inhibitor metalloproteinase 1  
Trak   TrakCare (electronic hospital patient records)  
UK   United Kingdom  
UK DRI  United Kingdom Dementia Research Institute  
UN   United Nations 
US$   American Dollars 
USA   United States of America  
VD   Vascular dementia 
WHO   World Health Organisation  
WISE   Women Cognitive Impairment Study of Exceptional Aging  
95% CI  Ninety-five percent confidence interval  
 
 
 
 
 
 
